Aaron, AM, 958(ab), 1027(ab)
Aaronson, RA, 116
Aas, M, 1100(ab)
Abbasy, M, 151
Abdel-Dayem, H, 919(ab)
Abdel-Nabi, H, 997(ab), 1052(ab), 1053(ab), 1058(ab), 1100(ab)
Abdul-Karim, F, 962(ab)
Abe, M, 1084(ab)
Abe, R, 1131(ab)
Aberle, D, 1061(ab)
Abitbol, C, 1085(ab)
Abou Khalil, B, 912(ab)
Abraham, S, 312
Abraham, SA, 969(ab), 1031(ab)
Abrams, M, 1050(ab)
Abrams, MJ, 849, 1099(ab)
Abrams, P, 1132(ab)
Abrass, IB, 940(ab)
Aburano, T, 961(ab), 1075(ab)
Acharyo, K, 1059(ab)
Achong, DM, 1912, 2275
Ackerman, Z, 924(ab)
Ackermann, RF, 911(ab)
Adachi, H, 1042(ab)
Adam, MJ, 1007(ab), 1092(ab)
Adam, W, 990(ab)
Adam, WE, 1053(ab)
Adams, HR, 1408
Adams, J, 1004(ab)
Adelstein, SJ, 116, 1082(ab)
Adkins, R, 1026(ab)
Adler, C, 960(ab)
Adler, LP, 1508, 962(ab), 1043(ab), 1140(ab)
Adler, SS, 58
Adyanthaya, A, 1039(ab)
Aegevaeren, WRM, 1538
Ahmad, M, 272, 851, 1050(ab)
Ahmad, MA, 1099(ab)
Ahn, CS, 1071(ab)
Ahonen, A, 988(ab)
Ahrendt, SA, 1836(ab)
Aigner, TG, 1408
Akabani, G, 830, 835
Akalin, S, 1106(ab)
Akamune, A, 1054(ab), 1055(ab)
Akers, MS, 2311, 919(ab)
Akiba, H, 1060(ab)
Akiyama, T, 1087(ab)
Akmal, M, 1010(ab)
Aktolun, C, 1429
Al Alwadhi, H, 973(ab)
Al-Aouar, Z, 1011(ab)
Alavi, A, 130, 136, 512, 856, 1261, 1422, 1777, 1897, 2079, 2299, 942(ab), 950(ab), 952(ab), 955(ab), 960(ab), 1007(ab), 1008(ab), 1020(ab), 1022(ab), 1046(ab), 1069(ab), 1072(ab), 1076(ab)
Alazo, NP, 978(ab)
Alazraki, N, 894(le), 1033(ab)
Alazraki, NP, 24N(6), 25N(3), 985(ab), 1006(ab), 1036(ab), 1080(ab)
Alberoni, M, 1022(ab)
Albert, R, 1084(ab)
Alberti, W, 961(ab)
Albro, J, 1048(ab)
Alderson, PO, 461
Aldrich, R, 1827(le)
Alexander, E, 1478
Alexander, E, III, 322
Alexander E, III, 933(ab)
Alexoff, DL, 1088(ab), 1094(ab)
Alexopoulos, D, 1032(ab)
Ali, A, 1513
Ali, MK, 1031(ab)
Alioth, C, 997(ab)
Al-Kaisi, N, 1508
Al-Kaisi, NL, 962(ab)
Allam, AH, 909(ab), 957(ab), 1038(ab)
Allan, R, 924(ab)
Allen, EW, 1130(ab), 1133(ab)
Allen, SJ, 1235
Allison, DJ, 968(ab)
Allman, K, 949(ab), 1028(ab), 1040(ab)
Allred, JF, 1091(ab)
Alpern, J, 1041(ab)
Alpert, N, 1934
Alpert, NM, 955(ab), 1014(ab)
Alspaugh, JP, 933(ab)
Altehoefer, C, 918(ab), 1037(ab)
Al-Tikriti, M, 979(ab), 1007(ab), 1071(ab)
Al-Tikriti, MS, 1754
Altman, DI, 1738
Alves, W, 950(ab), 960(ab), 1022(ab), 1072(ab)
Amat, F, 920(ab)
Ambrose, KR, 944(ab)
Ambrosio, A, 970(ab)
Amir, D, 1466(le)
Amman, W, 2241
Amundsen, T, 719
Ananth, J, 1076(ab)
Anderson, A-LJ, 89
Anderson, CJ, 925(ab)
Anderson, JH, 1464(le)
Anderson, LD, 915(ab), 1023(ab)
Anderson, P, 900(le)
Anderson, PJ, 1704, 954(ab)
Anderson, WHK, 914(ab)
Anderson, WL, 161
Andrich, MP, 1026(ab)
Andriole, DP, 1532
Anfossi, G, 940(ab)
Angelberger, P, 2132
Angello, DA, 193, 2027(le)
Anggelis, C, 978(ab)
Angrist, B, 1071(ab)
Anguenot, TJ, 1788
Ansari, AN, 1839(ab)
Ansari, MS, 1593, 961(ab), 1070(ab)
Anselmi, L, 1045(ab)
Antar, MA, 912(ab), 968(ab), 1133(ab), 1135(ab)
Antich, P, 1016(ab)
Antich, PP, 915(ab), 1081(ab)
Antonino, A, 1090(ab)
Antoniucci, D, 1501, 1844(ab)
Antuono, PA, 942(ab)
Anzai, Y, 1048(ab)
Appelbaum, FR, 1056(ab), 1843(ab)
Applebaum, DM, 924(ab)
Araki, N, 1070(ab)
Aras, T, 1977
Araujo, L, 955(ab)
Araujo, LI, 2169, 927(ab)
Arbit, E, 1021(ab)
Arbuck, S, 1052(ab)
Archer, C, 967(ab)
Archer, GE, 922(ab)
Arcomano, MA, 2278
Areeda, J, 1036(ab)
Argenyi, E, 1808
Arian-Schad, K, 1320
Arias, J, 1104(ab)
Arias, JM, 1270, 1048(ab), 1836(ab)
Arimizu, N, 686, 917(ab), 1048(ab)
Arista Mariani, A, 922(ab)
Aritake, S, 1044(ab)
Armstrong, PW, 1038(ab)
Arnal, C, 860
Arora, GD, 960(ab)
Arrighi, J, 938(ab)
Arroyo, A, 1467(le)
Artze, M, 1085(ab)
Asai, T, 1048(ab)
Ascoop, CAPL, 2071
Asenbaum, S, 991(ab), 1073(ab)
Ash, J, 237
Atcher, R, 1100(ab)
Athanasoulis, T, 255
Atkin, SD, 1090(ab)
Atkins, HL, 1840(ab)
Atochina, EN, 453
Aubry, F, 898(le)
August, D, 981(ab)
Aulet, M, 1105(ab)
Auringer, ST, 1614
Austin, MC, 1688
Austin, SM, 102
Axworthy, D, 1017(ab)
Axworthy, DB, 915(ab), 1020(ab)
Azuma, M, 1047(ab)

Babchyck, B, 1134(ab)
Babcock, EE, 1081(ab)
Babich, JW, 1681
Bacciottini, L, 1501, 1844(ab)
Bacharach, SA, 1661
Bacharach, SL, 1801, 938(ab), 994(ab), 1027(ab)
Backes, RJ, 929(ab)
Badenhorst, PN, 62, 2245
Badger, CC, 1843(ab)
Baew-Christow, T, 970(ab), 971(ab), 1053(ab)
Bai, L-Q, 994(ab), 1134(ab)
Baig, W, 1032(ab)
Baig, WM, 1031(ab), 1032(ab)
Bailey, DL, 360(le)
Bairey, CN, 796
Bajwa, N, 1611
Baker, F, 2281
Baker, JA, 1518
Baker, M, 1312(le)
Baker, RJ, 878
Bakke, AC, 2288
Bakker, WH, 1184, 1845, 981(ab), 1043(ab), 1084(ab)
Bakshi, S, 1052(ab)
Balasubramanian, PN, 915(ab), 1023(ab)
Baldwin, RM, 1754, 979(ab), 1007(ab), 1043(ab), 1071(ab)
Ballard, JG, 1136(ab)
Ballas, SK, 1617
Ballester, M, 1019(ab)
Ballou, B, 1836(ab)
Balon, H, 1231
Balseiro, J, 325, 1840(ab)
Ban, R, 1106(ab)
Ban, T, 673, 679, 1035(ab), 1039(ab)
Banks, LM, 968(ab)
Banks, RO, 933(ab)
Banks, W, 1841(ab)
Banks, WR, 1096(ab)
Banzo, I, 860
Baranczuk, RA, 1138(ab)
Baranowska-Kortylewicz, J, 1082(ab)
Barbagallo, S, 1668
Barbet, J, 940(ab)
Barcelo, J, 1054(ab)
Bardiès, M, 997(ab)
Bares, R, 918(ab), 1011(ab), 1052(ab)
Barkan, AL, 1011(ab)
Barker, W, 942(ab)
Barker, WW, 1725
Barnes, D, 1791
Barnett, CA, 1979
Barnhart, C, 959(ab)
Barnhart, CS, 958(ab), 1041(ab)
Baron, D, 785
Baron, E, 1873, 982(ab), 1045(ab)
Barrett, HH, 988(ab), 1135(ab)
Barrio, J, 1004(ab), 1025(ab)
Barrio, JR, 935(ab), 1010(ab)
Barron, BJ, 1129(ab)
Bartenstein, PA, 960(ab)
Bartlett, EB, 985(ab)
Bartzokis, T, 1038(ab)
Barzilai, D, 982(ab)
Basile, F, 919(ab)
Basmadjian, GP, 965(ab)
Bassand, JP, 1788
Bassano, DA, 1813
Basso, LV, 887
Basssingham, S, 924(ab)
Batalle, G, 930(ab)
Bateman, TM, 958(ab), 959(ab), 1041(ab)
Bauer, M, 1076(ab)
Baum, RP, 952(ab), 970(ab), 971(ab), 1053(ab)
Bavaria, G, 973(ab), 1103(ab)
Baxter, KG, 1130(ab), 1132(ab), 1137(ab), 1138(ab)
Baydush, AH, 936(ab)
Bayhan, H, 1429
Bayouth, J, 1059(ab)
Beanlands, R, 926(ab), 947(ab), 1028(ab)
Beatty, JD, 987(ab)
Beaumier, P, 915(ab), 1020(ab)
Beaumier, PL, 1445, 1056(ab)
Becker, C, 914(ab)
Becker, DM, 2324
Becker, DV, 1017(ab)
Becker, H, 914(ab)
Becker, LC, 782, 1968, 2253
Becker, W, 977(ab), 983(ab), 1002(ab)
Beckman, J, 1138(ab)
Beecher, D, 1838(ab)
Beekhuis, H, 1709, 1843(ab)
Beeley, NRA, 1842(ab)
Beer, S, 968(ab), 979(ab), 1031(ab), 1036(ab)
Behrens, R, 1026(ab)
Beierwaltes, WH, 1456, 1627
Beightol, RW, 1644(le)
Beilin, I, 1037(ab)
Bekdik, C, 1977, 1106(ab)
Belardinelli, L, 969(ab)
Belin, C, 971(ab)
Bell, RL, 961(ab)
Bell, SD, 362(le), 896(le), 954(ab)
Bellande, E, 925(ab)
Beller, GA, 957(ab), 958(ab), 1059(ab)
Bellon, EM, 1140(ab)
Bellotti, G, 1038(ab)
Belnavis, L, 947(ab)
Belzberg, AS, 1131(ab)
Benali, H, 898(le)
Benavides, J, 1078(ab)
Bendriem, B, 1062(ab), 1063(ab), 1067(ab)
Benevenia, J, 962(ab)
Ben-Haim, S, 1084(ab)
Benjamin, RS, 962(ab)
Bennett, LR, 1078(ab)
Bennett, R, 999(ab)
Benson, LN, 237
Berent, S, 912(ab)
Beresford, B, 350
Berger, H, 1005(ab), 1020(ab)
Berger, HJ, 785, 1005(ab)
Berger, KL, 966(ab), 1064(ab)

Aaron, AM, 958(ab), 1027(ab)
Aaronson, RA, 116
Aas, M, 1100(ab)
Abbasy, M, 151
Abdel-Dayem, H, 919(ab)
Abdel-Nabi, H, 997(ab), 1052(ab), 1053(ab), 1058(ab), 1100(ab)
Abdul-Karim, F, 962(ab)
Abe, M, 1084(ab)
Abe, R, 1131(ab)
Aberle, D, 1061(ab)
Abitbol, C, 1085(ab)
Abou Khalil, B, 912(ab)
Abraham, S, 312
Abraham, SA, 969(ab), 1031(ab)
Abrams, M, 1050(ab)
Abrams, MJ, 849, 1099(ab)
Abrams, P, 1132(ab)
Abrass, IB, 940(ab)
Aburano, T, 961(ab), 1075(ab)
Acharyo, K, 1059(ab)
Achong, DM, 1912, 2275
Ackerman, Z, 924(ab)
Ackermann, RF, 911(ab)
Adachi, H, 1042(ab)
Adam, MJ, 1007(ab), 1092(ab)
Adam, W, 990(ab)
Adam, WE, 1053(ab)
Adams, HR, 1408
Adams, J, 1004(ab)
Adelstein, SJ, 116, 1082(ab)
Adkins, R, 1026(ab)
Adler, C, 960(ab)
Adler, LP, 1508, 962(ab), 1043(ab), 1140(ab)
Adler, SS, 58
Adyanthaya, A, 1039(ab)
Aegevaeren, WRM, 1538
Ahmad, M, 272, 851, 1050(ab)
Ahmad, MA, 1099(ab)
Ahn, CS, 1071(ab)
Ahonen, A, 988(ab)
Ahrendt, SA, 1836(ab)
Aigner, TG, 1408
Akabani, G, 830, 835
Akalin, S, 1106(ab)
Akamune, A, 1054(ab), 1055(ab)
Akers, MS, 2311, 919(ab)
Akiba, H, 1060(ab)
Akiyama, T, 1087(ab)
Akmal, M, 1010(ab)
Aktolun, C, 1429
Al Alwadhi, H, 973(ab)
Al-Aouar, Z, 1011(ab)
Alavi, A, 130, 136, 512, 856, 1261, 1422, 1777, 1897, 2079, 2299, 942(ab), 950(ab), 952(ab), 955(ab), 960(ab), 1007(ab), 1008(ab), 1020(ab), 1022(ab), 1046(ab), 1069(ab), 1072(ab), 1076(ab)
Alazo, NP, 978(ab)
Alazraki, N, 894(le), 1033(ab)
Alazraki, NP, 24N(6), 25N(3), 985(ab), 1006(ab), 1036(ab), 1080(ab)
Alberoni, M, 1022(ab)
Albert, R, 1084(ab)
Alberti, W, 961(ab)
Albro, J, 1048(ab)
Alderson, PO, 461
Aldrich, R, 1827(le)
Alexander, E, 1478
Alexander, E, III, 322
Alexander E, III, 933(ab)
Alexoff, DL, 1088(ab), 1094(ab)
Alexopoulos, D, 1032(ab)
Ali, A, 1513
Ali, MK, 1031(ab)
Alioth, C, 997(ab)
Al-Kaisi, N, 1508
Al-Kaisi, NL, 962(ab)
Allam, AH, 909(ab), 957(ab), 1038(ab)
Allan, R, 924(ab)
Allen, EW, 1130(ab), 1133(ab)
Allen, SJ, 1235
Allison, DJ, 968(ab)
Allman, K, 949(ab), 1028(ab), 1040(ab)
Allred, JF, 1091(ab)
Alpern, J, 1041(ab)
Alpert, N, 1934
Alpert, NM, 955(ab), 1014(ab)
Alspaugh, JP, 933(ab)
Altehoefer, C, 918(ab), 1037(ab)
Al-Tikriti, M, 979(ab), 1007(ab), 1071(ab)
Al-Tikriti, MS, 1754
Altman, DI, 1738
Alves, W, 950(ab), 960(ab), 1022(ab), 1072(ab)
Amat, F, 920(ab)
Ambrose, KR, 944(ab)
Ambrosio, A, 970(ab)
Amir, D, 1466(le)
Amman, W, 2241
Amundsen, T, 719
Ananth, J, 1076(ab)
Anderson, A-LJ, 89
Anderson, CJ, 925(ab)
Anderson, JH, 1464(le)
Anderson, LD, 915(ab), 1023(ab)
Anderson, P, 900(le)
Anderson, PJ, 1704, 954(ab)
Anderson, WHK, 914(ab)
Anderson, WL, 161
Andrich, MP, 1026(ab)
Andriole, DP, 1532
Anfossi, G, 940(ab)
Angelberger, P, 2132
Angello, DA, 193, 2027(le)
Anggelis, C, 978(ab)
Angrist, B, 1071(ab)
Anguenot, TJ, 1788
Ansari, AN, 1839(ab)
Ansari, MS, 1593, 961(ab), 1070(ab)
Anselmi, L, 1045(ab)
Antar, MA, 912(ab), 968(ab), 1133(ab), 1135(ab)
Antich, P, 1016(ab)
Antich, PP, 915(ab), 1081(ab)
Antonino, A, 1090(ab)
Antoniucci, D, 1501, 1844(ab)
Antuono, PA, 942(ab)
Anzai, Y, 1048(ab)
Appelbaum, FR, 1056(ab), 1843(ab)
Applebaum, DM, 924(ab)
Araki, N, 1070(ab)
Aras, T, 1977
Araujo, L, 955(ab)
Araujo, LI, 2169, 927(ab)
Arbit, E, 1021(ab)
Arbuck, S, 1052(ab)
Archer, C, 967(ab)
Archer, GE, 922(ab)
Arcomano, MA, 2278
Areeda, J, 1036(ab)
Argenyi, E, 1808
Arian-Schad, K, 1320
Arias, J, 1104(ab)
Arias, JM, 1270, 1048(ab), 1836(ab)
Arimizu, N, 686, 917(ab), 1048(ab)
Arista Mariani, A, 922(ab)
Aritake, S, 1044(ab)
Armstrong, PW, 1038(ab)
Arnal, C, 860
Arora, GD, 960(ab)
Arrighi, J, 938(ab)
Arroyo, A, 1467(le)
Artze, M, 1085(ab)
Asai, T, 1048(ab)
Ascoop, CAPL, 2071
Asenbaum, S, 991(ab), 1073(ab)
Ash, J, 237
Atcher, R, 1100(ab)
Athanasoulis, T, 255
Atkin, SD, 1090(ab)
Atkins, HL, 1840(ab)
Atochina, EN, 453
Aubry, F, 898(le)
August, D, 981(ab)
Aulet, M, 1105(ab)
Auringer, ST, 1614
Austin, MC, 1688
Austin, SM, 102
Axworthy, D, 1017(ab)
Axworthy, DB, 915(ab), 1020(ab)
Azuma, M, 1047(ab)

Babchyck, B, 1134(ab)
Babcock, EE, 1081(ab)
Babich, JW, 1681
Bacciottini, L, 1501, 1844(ab)
Bacharach, SA, 1661
Bacharach, SL, 1801, 938(ab), 994(ab), 1027(ab)
Backes, RJ, 929(ab)
Badenhorst, PN, 62, 2245
Badger, CC, 1843(ab)
Baew-Christow, T, 970(ab), 971(ab), 1053(ab)
Bai, L-Q, 994(ab), 1134(ab)
Baig, W, 1032(ab)
Baig, WM, 1031(ab), 1032(ab)
Bailey, DL, 360(le)
Bairey, CN, 796
Bajwa, N, 1611
Baker, F, 2281
Baker, JA, 1518
Baker, M, 1312(le)
Baker, RJ, 878
Bakke, AC, 2288
Bakker, WH, 1184, 1845, 981(ab), 1043(ab), 1084(ab)
Bakshi, S, 1052(ab)
Balasubramanian, PN, 915(ab), 1023(ab)
Baldwin, RM, 1754, 979(ab), 1007(ab), 1043(ab), 1071(ab)
Ballard, JG, 1136(ab)
Ballas, SK, 1617
Ballester, M, 1019(ab)
Ballou, B, 1836(ab)
Balon, H, 1231
Balseiro, J, 325, 1840(ab)
Ban, R, 1106(ab)
Ban, T, 673, 679, 1035(ab), 1039(ab)
Banks, LM, 968(ab)
Banks, RO, 933(ab)
Banks, W, 1841(ab)
Banks, WR, 1096(ab)
Banzo, I, 860
Baranczuk, RA, 1138(ab)
Baranowska-Kortylewicz, J, 1082(ab)
Barbagallo, S, 1668
Barbet, J, 940(ab)
Barcelo, J, 1054(ab)
Bardiès, M, 997(ab)
Bares, R, 918(ab), 1011(ab), 1052(ab)
Barkan, AL, 1011(ab)
Barker, W, 942(ab)
Barker, WW, 1725
Barnes, D, 1791
Barnett, CA, 1979
Barnhart, C, 959(ab)
Barnhart, CS, 958(ab), 1041(ab)
Baron, D, 785
Baron, E, 1873, 982(ab), 1045(ab)
Barrett, HH, 988(ab), 1135(ab)
Barrio, J, 1004(ab), 1025(ab)
Barrio, JR, 935(ab), 1010(ab)
Barron, BJ, 1129(ab)
Bartenstein, PA, 960(ab)
Bartlett, EB, 985(ab)
Bartzokis, T, 1038(ab)
Barzilai, D, 982(ab)
Basile, F, 919(ab)
Basmadjian, GP, 965(ab)
Bassand, JP, 1788
Bassano, DA, 1813
Basso, LV, 887
Basssingham, S, 924(ab)
Batalle, G, 930(ab)
Bateman, TM, 958(ab), 959(ab), 1041(ab)
Bauer, M, 1076(ab)
Baum, RP, 952(ab), 970(ab), 971(ab), 1053(ab)
Bavaria, G, 973(ab), 1103(ab)
Baxter, KG, 1130(ab), 1132(ab), 1137(ab), 1138(ab)
Baydush, AH, 936(ab)
Bayhan, H, 1429
Bayouth, J, 1059(ab)
Beanlands, R, 926(ab), 947(ab), 1028(ab)
Beatty, JD, 987(ab)
Beaumier, P, 915(ab), 1020(ab)
Beaumier, PL, 1445, 1056(ab)
Becker, C, 914(ab)
Becker, DM, 2324
Becker, DV, 1017(ab)
Becker, H, 914(ab)
Becker, LC, 782, 1968, 2253
Becker, W, 977(ab), 983(ab), 1002(ab)
Beckman, J, 1138(ab)
Beecher, D, 1838(ab)
Beekhuis, H, 1709, 1843(ab)
Beeley, NRA, 1842(ab)
Beer, S, 968(ab), 979(ab), 1031(ab), 1036(ab)
Behrens, R, 1026(ab)
Beierwaltes, WH, 1456, 1627
Beightol, RW, 1644(le)
Beilin, I, 1037(ab)
Bekdik, C, 1977, 1106(ab)
Belardinelli, L, 969(ab)
Belin, C, 971(ab)
Bell, RL, 961(ab)
Bell, SD, 362(le), 896(le), 954(ab)
Bellande, E, 925(ab)
Beller, GA, 957(ab), 958(ab), 1059(ab)
Bellon, EM, 1140(ab)
Bellotti, G, 1038(ab)
Belnavis, L, 947(ab)
Belzberg, AS, 1131(ab)
Benali, H, 898(le)
Benavides, J, 1078(ab)
Bendriem, B, 1062(ab), 1063(ab), 1067(ab)
Benevenia, J, 962(ab)
Ben-Haim, S, 1084(ab)
Benjamin, RS, 962(ab)
Bennett, LR, 1078(ab)
Bennett, R, 999(ab)
Benson, LN, 237
Berent, S, 912(ab)
Beresford, B, 350
Berger, H, 1005(ab), 1020(ab)
Berger, HJ, 785, 1005(ab)
Berger, KL, 966(ab), 1064(ab)

Berger, P, 1139(ab)
Bergh, JR, 1132(ab)
Bergmann, SR, 10, 475, 2037, 937(ab), 1315(le), 1833(le), 1838(ab)
Bergström, K, 1070(ab)
Bergström, M, 610
Bergström, M, 2258
Berkovic, SF, 1688
Berlad, G, 1000(ab)
Berlangieri, SU, 1013(ab)
Berman, D, 929(ab), 959(ab), 978(ab), 1001(ab), 1006(ab)
Berman, DS, 447, 796, 950(ab), 958(ab), 1005(ab), 1006(ab), 1013(ab), 1036(ab), 1067(ab)
Berná, L, 550(le), 1019(ab), 2295
Berná, Ll, 1025(ab)
Bernard, L, 263
Bernard, YF, 1788
Bernbeck, J, 913(ab)
Bernstein, ID, 1843(ab)
Bernstein, RC, 956(ab), 1073(ab)
Bernstein, T, 946(ab)
Berridge, MS, 1043(ab), 1097(ab)
Berry, JJ, 1518, 1030(ab), 1034(ab)
Berry, JM, 1092(ab)
Bertrand, A, 221
Bertrand, SJ, 1573
Besser, GM, 1011(ab)
Best, M, 1134(ab)
Bestetti, A, 1136(ab)
Bethala, V, 1031(ab)
Betocchi, S, 1849
Bettinardi, V, 1022(ab)
Bevilacqua, G, 1082(ab)
Bflug, B, 952(ab)
Bhadkamaker, VA, 918(ab)
Bhadkamkar, V, 1326
Bhadkamkar, VA, 970(ab)
Bhatia, K, 929(ab), 1018(ab)
Bianco, JA, 1611, 892(le), 1047(ab), 1311(le), 2360(le)
Bice, AN, 1923, 923(ab), 986(ab), 1058(ab)
Bida, G, 1010(ab)
Biebuyck, JC, 1058(ab)
Biedermann, A, 1009(ab)
Biegon, A, 1140(ab)
Biersack, HJ, 388, 920(ab), 921(ab), 1044(ab), 1049(ab), 1051(ab), 1075(ab), 1076(ab), 1088(ab), 1106(ab), 1316(le)
Bietendorf, J, 929(ab), 1006(ab)
Biggi, A, 2064
Bigner, DD, 922(ab)
Billings, J, 964(ab), 1008(ab), 1069(ab), 1094(ab)
Billings, JJ, 339
Billington, D, 506
Billones, M, 1134(ab)
Bingham, D, 1070(ab)
Bingham, DR, 1063(ab)
Birnbaum, B, 1135(ab)
Bischof Delaloye, A, 941(ab)
Bischoff, H, 1138(ab)
Bishop, AJ, 1010(ab)
Bizais, Y, 923(ab), 962(ab)
Bjerkenstedt, L, 2043
Black, P, 912(ab)
Bladin, PF, 1688
Blahd, WH, 1266
Blair, HF, 1508, 962(ab)
Blanchard, H, 862
Blanco, R, 2295
Blank, G, 1837(ab)
Blasberg, RG, 1837(ab)
Bläuenstein, P, 1099(ab)
Blaufox, MD, 1297, 933(ab), 1103(ab)
Blechinger, JC, 1133(ab), 1835(ab)
Blinder, RA, 1840(ab)
Bloedow, D, 970(ab)
Blokland, JAK, 1129(ab)
Blomqvist, G, 2043
Bloomer, WD, 985(ab), 1100(ab)
Bloomfield, PM, 1838(ab)
Blower, PJ, 845
Blue, PW, 1465(le)
Blum, U, 1107(ab)
Blumenthal, RD, 1058(ab)
Blumhardt, R, 377, 2000, 749(le), 2025(le)
Bobeldijk, M, 1018(ab), 1078(ab), 1097(ab)
Bockisch, A, 388, 1044(ab), 1076(ab), 1088(ab)
Boden, J, 1842(ab)
Boden, R, 1842(ab)
Bodenheimer, MM, 293
Boeckmann, W, 970(ab), 1053(ab)
Boer, GJ, 1097(ab)
Boerman, OC, 1058(ab)
Boire, JY, 1037(ab), 1067(ab)
Boire, J-YP, 1573
Bois-Svensson, I, 1643(le)
Boja, JW, 1839(ab)
Bokisch, A, 921(ab)
Bol, A, 988(ab), 989(ab), 998(ab)
Bol, I, 1078(ab)
Boland, CJ, 970(ab)
Bolch, WE, 835
Bolgos, G, 1399
Bolomey, L, 1581
Boltwood, M, 1038(ab)
Bomanji, J, 1907, 973(ab), 992(ab), 1105(ab)
Bonafous, JF, 1573
Bonato, C, 1010(ab)
Bonavina, L, 436, 2027(le)
Bonazza, A, 1465(le)
Bonino, C, 970(ab)
Bonow, RO, 1801, 938(ab), 1027(ab)
Boothe, T, 1725
Borer, JS, 1801, 1835(ab)
Borges-Neto, S, 1918, 967(ab)
Borkon, AM, 1041(ab)
Bormans, G, 1016(ab)
Borsato, N, 436, 1036(ab), 2027(le)
Bossuyt, A, 399, 500, 952(ab), 1002(ab), 1826(le)
Bossuyt Piron, C, 952(ab)
Böttger, IG, 1077(ab)
Botvinick, EH, 998(ab), 1035(ab)
Boucher, CA, 969(ab), 1031(ab)
Boudjella, R, 971(ab)
Boudreau, FJ, 1545
Boudreau, RJ, 1089(ab), 1139(ab)
Bougas, C, 953(ab)
Bouillon, M, 931(ab)
Bouillon, R, 931(ab)
Boullais, N, 989(ab)
Boumal, D, 1788
Bourgeois, P, 549(le)
Bourgoignie, J, 934(ab)
Bourguet, P, 1051(ab)
Bourguignon, MH, 1067(ab)
Bousquet, V, 1067(ab)
Boutin, R, 1005(ab)
Bove, E, 1042(ab)
Bowen, WD, 1841(ab)
Bowsher, JE, 1285, 936(ab), 937(ab), 986(ab), 1066(ab)
Boyce, B, 1842(ab)
Boyd, CM, 1463(le)
Boyer, AL, 1059(ab)
Boyers, AS, 958(ab), 1027(ab)
Boyko, OB, 932(ab)
Braat, SH, 1036(ab)
Bradberry, C, 1071(ab)
Bradbury, VL, 940(ab)
Brady, F, 927(ab)
Brady, TJ, 1082(ab)
Brancato, R, 1050(ab)
Brandau, W, 901(le), 1077(ab), 1317(le), 1642(le)
Brandes, W, 1053(ab)
Brandt, J, 1079(ab)
Brandt, M, 862
Branscheid, D, 1138(ab)
Brateman, L, 777
Braun, A, 1841(ab)
Braunstein, G, 441
Bray, LA, 1090(ab)
Braziel, R, 2288
Brechbiel, MW, 1056(ab)
Breeman, WA, 1184
Breeman, WAP, 1043(ab), 1084(ab)
Breen, SL, 892(le), 997(ab)
Breisblatt, WM, 44
Brennan, KM, 974(ab)
Brenner, N, 1071(ab)
Bresnahan, DR, Jr, 1041(ab)
Breznock, E, 124
Brezovich, IA, 1162
Briele, B, 920(ab), 921(ab), 1044(ab), 1049(ab), 1051(ab), 1075(ab), 1088(ab), 1106(ab)
Brill, AB, 1042(ab), 1053(ab), 1100(ab)
Brinker, JA, 1033(ab)
Brinn, KA, 1840(ab)
Britton, KE, 940(ab), 973(ab), 992(ab), 1011(ab), 1102(ab), 1105(ab)
Broadhurst, P, 37
Brodack, JW, 1526, 1103(ab)
Brodie, JD, 1071(ab)
Broich, K, 1897, 1008(ab), 1022(ab), 1069(ab), 1076(ab)
Brooks, CE, 1391
Brooks, DJ, 960(ab), 1838(ab)
Brooks, K, 1092(ab)
Brooks, R, 1008(ab)
Brown, BG, 193, 2027(le)
Brown, BM, 1132(ab)
Brown, J, 1092(ab)
Brown, ML, 2162, 2332, 1003(ab), 1018(ab), 1033(ab), 1045(ab), 1082(ab), 1835(ab), 1843(ab)
Brown, PH, 48
Brown, R, 976(ab), 993(ab)
Brown, SJ, 1138(ab)
Brownell, A-L, 272, 981(ab), 1009(ab)
Brownell, GL, 981(ab), 1009(ab)
Brozena, S, 1041(ab)
Bruck, B, 1086(ab)
Bruck, CE, 1668
Brücke, T, 991(ab)
Brudin, LH, 1937
Brugge, WR, 1777
Brunberg, JA, 912(ab)
Bruner, J, 932(ab)
Brunken, R, 927(ab), 989(ab), 999(ab)
Brunken, RC, 665, 733, 2199, 926(ab), 938(ab), 946(ab), 969(ab), 998(ab)
Bruns, C, 1084(ab)
Brunt, E, 1005(ab)
Brust, P, 961(ab)
Bshara, I, 1836(ab)
Bubeck, B, 901(le), 1642(le)
Buccheri, G, 2064
Buchberger, R, 1036(ab)
Buchbinder, S, 186(le)
Buchegger, F, 1414, 941(ab)
Buchpiguel, CA, 1131(ab)
Buchsbaum, DJ, 1091(ab), 1095(ab)
Buck, A, 1950, 942(ab)
Buck, F, 994(ab)
Buckley, K, 777
Buckley, KR, 966(ab)
Budach, V, 961(ab)
Budd, JR, 1139(ab)
Budihna, N, 204, 1828(le)
Budinger, T, 955(ab)
Budinger, TF, 955(ab), 974(ab), 995(ab), 998(ab)
Budner, N, 753
Buell, U, 918(ab), 1011(ab), 1037(ab), 1052(ab), 1085(ab)
Bugelski, P, 1050(ab)
Buhé, T, 962(ab)
Büller, HR, 951(ab)
Bulteau, C, 1015(ab), 1841(ab)
Bunko, H, 1273, 2215
Bunn, PA, 970(ab)
Burch, L, 769
Burckhardt, D, 961(ab)
Burke, G, 934(ab)
Burman, KD, 1464(le)
Burmester, G, 983(ab)
Burmester, GR, 977(ab)
Burn, PR, 1105(ab)
Burn, HD, 1071(ab)
Burns, RJ, 919(ab), 929(ab), 1031(ab)
Burns, RS, 1015(ab)
Burr, G, 1022(ab)
Burrows, L, 1104(ab)
Burt, RW, 971(ab), 1074(ab)
Bushe, H, 1053(ab), 1100(ab)
Bushe, HS, 1042(ab)
Butler, J, 1836(ab)
Butler, R, 987(ab)
Butler, SP, 461, 2050, 951(ab), 993(ab)
Buxton, D, 2199, 909(ab), 989(ab)
Buxton, DB, 910(ab), 927(ab), 953(ab)
Buzdar, AU, 1326
Byars, A, 2079
Bye, R, 151
Byrne, CL, 936(ab)

Cabahug, C, 1840, 1866, 1022(ab), 1840(ab)
Cabaret, D, 971(ab)
Cabeen, M, 1137(ab)
Cahoon, JL, 995(ab)
Cahoon, KH, 1641(le)
Calame, W, 468
Caldwell, JH, 1028(ab)
Calenoff, E, 1005(ab)
Callahan, AP, 944(ab), 945(ab), 1089(ab), 1093(ab), 1098(ab)
Callahan, RJ, 851, 1029(ab), 1050(ab), 1099(ab)
Calmet, FH, 1046(ab), 1131(ab)
Calne, DB, 1246, 1007(ab)
Camargo, EE, 947(ab), 949(ab), 954(ab), 959(ab), 972(ab), 976(ab), 991(ab), 1007(ab), 1033(ab), 1035(ab), 1038(ab), 1046(ab), 1071(ab), 1077(ab), 1107(ab), 1836(ab)
Camera, L, 970(ab), 1055(ab), 1056(ab), 1057(ab), 1101(ab)
Camli, U, 1471
Cammilleri, S, 1841(ab)
Campeau, RJ, 2024(le)
Camps, JA, 814
Camps, JAJ, 468
Camrud, AR, 1029(ab)
Caner, B, 1977
Cantineau, R, 2266, 935(ab), 980(ab)
Cao, ZJ, 1066(ab)
Capelli, L, 1042(ab)
Cappa, SF, 1022(ab)
Cardot, JC, 1788
Carey, JE, 1096(ab)
Caride, VJ, 518
Carlson, KA, 1394
Carlsson, J, 2258
Carpi, A, 1045(ab)
Carrasquillo, JA, 1661,

970(ab), 978(ab), 1024(ab), 1055(ab), 1056(ab), 1057(ab), 1101(ab)
Carrera, GF, 963(ab)
Carrier, L, 1467(le)
Carril, JM, 860
Carrió, I, 2295, 550(le), 1019(ab), 1025(ab)
Carroll, FI, 1839(ab)
Carroll, M, 1105(ab)
Carroll, MJ, 1011(ab)
Carroll, P, 924(ab)
Carson, KJ, 1090(ab)
Carson, RE, 2206, 910(ab), 938(ab), 994(ab), 1008(ab)
Cartier, P, 934(ab)
Carton, EG, 999(ab)
Carvalho, PA, 322, 1206, 933(ab), 1022(ab)
Casati, R, 1050(ab)
Casey, ME, 2342
Casey, MJ, 2281
Cashion, D, 1070(ab)
Cashman, P, 37
Cassagnes, J, 1037(ab)
Cassel, D, 968(ab), 1031(ab), 1036(ab)
Castaigne, A, 998(ab)
Castelli, L, 970(ab)
Castronovo, FP, Jr, 1466(le)
Catz, Z, 921(ab)
Cauvin, JC, 1794, 1037(ab), 1067(ab)
Cave, V, 968(ab), 979(ab), 1031(ab), 1036(ab)
Cayla, J, 739
Cei, A, 1082(ab)
Cerqueira, MD, 928(ab), 940(ab)
Cesnik, H, 1320
Chak, SP, 2249
Chakraborty, PK, 1009(ab)
Chalandon, Y, 1414
Champailler, A, 1462(le)
Champman, JD, 1764
Chan, B, 1008(ab)
Chan, K, 997(ab)
Chan, SY, 665, 926(ab), 969(ab), 998(ab)
Chandarlapaty, SKC, 1135(ab)
Chang, J-Y, 1725
Chang, LS, 925(ab)
Chang, PC, 102
Chang, SL, 1000(ab)
Chang, W, 1838(ab)
Channing, MA, 1093(ab)
Chantarapitak, N, 1107(ab)
Chao, S, 958(ab)
Chapman, NJ, 2023(le)
Chapnick, J, 1135(ab)
Charkes, ND, 2176, 931(ab)
Charlebois, N, 934(ab)
Charlot V., 911(ab)
Charney, DS, 1754
Charnsangavej, C, 1000(ab)
Chatal, J-F, 221, 785, 940(ab), 941(ab), 984(ab), 997(ab), 1023(ab)
Chatrand, R, 1467(le)
Chatterton, BE, 878
Chauhan, D, 2026(le)
Chawluk, J, 942(ab)
Chen, B, 1555, 1016(ab)
Chen, BC, 2199, 920(ab), 926(ab), 953(ab), 981(ab), 1061(ab), 1062(ab)
Chen, BW, 982(ab)
Chen, C, 1071(ab)
Chen, CC, 1026(ab)
Chen, C-T, 707, 965(ab)
Chen, CW, 944(ab), 1041(ab)
Chen, F, 919(ab), 1005(ab)
Chen, GTY, 1478
Chen, J, 1135(ab)
Chen, K, 926(ab), 938(ab), 1003(ab)
Chen, W, 998(ab)
Chen, X, 1442
Cheng, KT, 1132(ab)
Cherif, A, 1093(ab)
Cherry, SR, 966(ab), 1062(ab), 1134(ab)
Chesin, R, 1466(le)
Chesney, M, 1038(ab)
Chetanneau, A, 221, 940(ab)
Cheung, NKV, 769, 1021(ab)
Chevres, A, 1138(ab)
Chew, FS, 556
Chiao, P, 946(ab), 1065(ab)
Chiariello, M, 1849
Chierchia, SL, 1039(ab)
Chierichetti, F, 436, 1036(ab), 2027(le)
Chilton, HM, 35N(4)
Chinen, L, 945(ab), 963(ab)
Chinol, M, 963(ab), 1842(ab)
Chiotellis, E, 1843(ab)
Chiou, PF, 1060(ab)
Chirico, A, 399
Chiron, C, 1015(ab), 1841(ab)
Chiti, A, 1136(ab)
Chiu, ML, 1992
Chiueh, CC, 894(le)
Cho, N, 1031(ab), 1032(ab)
Choi, Y, 733, 1555, 920(ab), 926(ab), 938(ab), 981(ab), 982(ab), 1004(ab), 1025(ab), 1838(ab)
Chouraqui, P, 447, 1005(ab), 1013(ab)
Chow, WC, 975(ab)
Chrem, Y, 1000(ab)
Christiaens, L, 2266, 935(ab)
Christian, PE, 1349, 955(ab), 1066(ab), 1836(ab), 1837(ab)
Chu, LS, 1000(ab), 1076(ab), 1088(ab)
Chu, TS, 958(ab), 1027(ab)
Chu, YK, 990(ab)
Chuang, K. S, 1060(ab)
Chugani, HT, 23
Chumpradit, S, 964(ab), 1069(ab)
Chung, CJ, 13, 1132(ab)
Chung, J-K, 1055(ab), 1056(ab), 1080(ab)
Ciarmiello, A, 1849, 1042(ab)
Ciarmiello, M, 1849
Cikrit, DF, 971(ab), 1074(ab)
Cinotti, L, 912(ab)
Civelek, AC, 947(ab), 949(ab), 959(ab), 1007(ab), 1033(ab), 1035(ab)
Claessens, R, 941(ab), 963(ab), 1854
1107(ab), 2195(le)
Claeys, K, 1026(ab)
Clague, J, 990(ab)
Clanton, JA, 1593
Clarke, K, 803
Clarke, LP, 1042(ab)
Clarke, S, 924(ab)
Clarke, SEM, 845, 1235
Clausen, M, 1053(ab)
Clemens, P, 399, 500
Cleto, EM, Jr, 1137(ab)
Cleynhens, B, 1016(ab)
Clinthorne, NH, 186(le), 946(ab), 1065(ab)
Clinthorne, NJ, 986(ab)
Closas, MG, 973(ab)
Coates, G, 729
Cody, R, 981(ab), 982(ab), 1011(ab)
Coenen, HH, 1225, 1338, 1888, 1009(ab)
Cogneau, M, 989(ab)
Cohen, AM, 649, 940(ab)
Cohen, P, 2359(le)
Cohen, RM, 1408
Cohen, S, 923(ab)
Cohen, SS, 1129(ab)
Colcher, DC, 1661
Cole, TJ, 325
Coleman, JS, 1020(ab), 1098(ab)
Coleman, R, 917(ab), 956(ab)
Coleman, RE, 527, 616, 1518, 42N(4), 932(ab), 936(ab), 942(ab), 986(ab), 1013(ab), 1016(ab), 1030(ab), 1034(ab), 1061(ab), 1065(ab), 1066(ab), 1067(ab), 1068(ab), 1077(ab), 1079(ab)
Colizzi, C, 1045(ab)
Collen, D, 2321
Collet, B, 1051(ab)
Collier, BD, 319, 1904, 942(ab), 963(ab)
Collins, J, 977(ab)
Colombo, F, 925(ab), 1007(ab), 1022(ab), 1039(ab)
Colsher, JG, 2342
Colt, HG, 1841(ab)
Comazzi, V, 925(ab)
Combs, MJ, 997(ab), 1046(ab)
Comino, A, 2064
Condorelli, M, 1849
Cone, L, 512
Connett, JM, 1054(ab)
Consigny, PM, 1081(ab)
Constantinescu, A, 915(ab), 1016(ab), 1081(ab)
Conti, PA, 954(ab)
Conti, PS, 623
Conway, J, 1017(ab)
Conway, JJ, 943(ab), 1085(ab)
Cook, SA, 2221, 968(ab), 1133(ab), 1135(ab)
Cooke, CD, 1006(ab), 1034(ab), 1036(ab), 1068(ab)
Coon, JS, 1641(le)
Coons, T, 1836(ab)
Cooper, AJL, 1835(ab)
Cooper, JA, 1002(ab)
Cooper, M, 1060(ab)
Cooper, MD, 707
Coppola, N, 1042(ab)
Corbelli, C, 424
Corbett, JR, 2311, 919(ab), 1006(ab), 1016(ab), 1068(ab)
Corbisiero, RM, 987(ab)
Cordes, M, 1027(ab), 1105(ab)
Cordon-Cardo, C, 1051(ab)
Corlija, M, 111, 1102(ab)
Cornblatt, B, 1076(ab)
Corne, R, 1559
Cornelius, E, 1827(le)
Cornu, P, 1608, 1078(ab)
Correia, JA, 955(ab), 1014(ab)
Corrigan, P, 953(ab)
Corstens, FHM, 27, 491, 941(ab), 1538, 1854, 963(ab), 1107(ab), 2195(le)
Costa, E, 1008(ab)
Costi, P, 1961
Counsell, RE, 495
Coupal, JJ, 1644(le)
Coupland, D, 1915
Coupland, DB, 930(ab)
Coveney, J, 1016(ab)
Covert, MA, 1090(ab)
Cowie, A, 1090(ab)
Cox, JL, 1031(ab)
Coxson, P, 955(ab)
Coxson, PG, 974(ab), 998(ab)
Crane, PD, 263, 957(ab)
Crawley, J, 37
Croft, BY, 1375, 997(ab)
Crouzel, C, 739, 1608, 989(ab), 998(ab), 1078(ab)
Cruz, J, 1022(ab)
Cullom, SJ, 166, 1001(ab), 1067(ab)
Culver, CM, 169
Cunningham, KM, 878
Cunningham, M, 957(ab), 1030(ab)
Cuocolo, A, 949(ab), 1044(ab)
Curtis, RL, 1089(ab)
Cutler, PD, 1134(ab)
Cygne, BV, 1018(ab)
Czech, T, 1073(ab)
Czernin, J, 927(ab), 989(ab), 998(ab), 999(ab)

Dadparvar, S, 1138(ab)
Dae, M, 998(ab)
Dae, MW, 1035(ab)
Daemen, BJG, 1587
Daghighian, F, 1021(ab), 1062(ab), 1837(ab)
Daher, S, 116
Dahlberg, ST, 910(ab)
Dahlbom, M, 1555, 920(ab), 926(ab), 966(ab), 981(ab), 982(ab), 1004(ab), 1025(ab), 1061(ab)
Daigneault, L, 919(ab)
Dalrymple, GV, 1132(ab)
Damhaut, P, 935(ab)
D'Amico, C, 942(ab)
Damjanov, I, 1021(ab)
D'Amore, J, 1089(ab)
Daniel, GB, 67, 1093(ab)
Danilov, SM, 453
Dann, R, 1020(ab)
Dannals, RF, 16, 76, 308, 954(ab), 961(ab), 980(ab), 1008(ab), 1062(ab), 1071(ab), 1077(ab), 1078(ab), 1079(ab)
Dansereau, RN, 548(le)
Das, C, 915(ab)
DasGupta, P, 967(ab)
Datz, F, 1104(ab)
Datz, FL, 881, 1270, 1349, 955(ab), 1048(ab), 1066(ab), 1836(ab), 1837(ab)
Daube-Witherspoon, ME, 2342, 994(ab)
Daugherty, A, 300
Daughtery, A, 925(ab)
Dauthieux, P, 971(ab)
Davidson, J, 967(ab)
Davidson, M, 1005(ab), 1013(ab)
Davis, K, 1076(ab)
Davis, RT, 912(ab), 913(ab), 1015(ab)
Day, D, 964(ab)
Day, DE, 945(ab), 1089(ab)
Dean, RT, 1842(ab)
Deblaton, M, 399, 500
Debongnie, JC, 1192
Debrand-Passard, A, 1105(ab)
Dec, GW, 1019(ab)
deCosta, BR, 1008(ab), 1841(ab)
Decostre, P, 897(le)
De Cristofaro, MTR, 1501, 1844(ab)
De Deyn, PP, 1619
de Deyn, PP, 1086(ab)
Deecke, L, 1675, 991(ab)
De Fabritis, A, 424
De Faucal, P, 785
Defer, G, 971(ab)
DeFulvio, J, 1021(ab), 1098(ab), 1836(ab)
De Gaudio, C, 1045(ab)
De Geeter, F, 1002(ab), 1826(le)
DeGrado, TR, 1888, 937(ab), 975(ab)
de Groot, TJ, 975(ab)
Degrossi, EB, 1826(le)
Degrossi, OJ, 1826(le)
Degueldre, C, 980(ab)
Dehdashti, F, 1526, 1532, 954(ab), 961(ab)
DeJesus, OT, 1004(ab), 1028(ab), 1070(ab), 1096(ab)
de Jong, M, 1184, 1084(ab)
de Klerk, JMH, 2057, 1082(ab), 1083(ab)
de Kraker, J, 921(ab)
de Kraku, J, 361(le)

Delaage, M, 940(ab)
de la Caffinière, H, 1015(ab)
de La Fourniere, L, 964(ab)
Delaloye, B, 941(ab)
de Lange, AH, 2245
Delforge, J, 739, 989(ab), 1004(ab)
DelMonte, M, 983(ab)
del Río, HG, 1826(le)
del Rosario, BB, 993(ab)
del Rosario, RB, 915(ab)
DeMaria, AN, 939(ab)
de Meeus, Y, 1192
Demirel, D, 1429
DeNardo, GL, 921(ab), 922(ab), 984(ab), 992(ab), 997(ab)
DeNardo, SJ, 921(ab), 922(ab), 984(ab), 992(ab), 997(ab)
Den Hollander, JA, 931(ab)
Denis, M, 911(ab), 990(ab)
Dennis, C, 1038(ab)
DePalatis, LR, 1020(ab), 1098(ab)
de Paulis, T, 1593, 961(ab), 1063(ab), 1070(ab)
DePuey, EG, 1199, 1559, 2012, 1006(ab), 1033(ab), 1036(ab)
DePuey, G, 1020(ab)
Derde, MP, 216
Derenzo, SE, 995(ab)
DeRidder, P, 1695
De Roo, M, 930(ab), 931(ab), 1016(ab), 1026(ab)
de Rooij, FWM, 1219
D'Errico, G, 1088(ab)
Derwanz, R, 1044(ab)
De Santi, S, 970(ab)
Deschamps, C, 1085(ab)
De Schepper, J, 216
de Silva, R, 2169
De Silva, R, 927(ab)
De Simone, A, 970(ab)
Desplanches, GG, 1573
Deutsch, E, 925(ab), 945(ab), 963(ab), 964(ab), 1007(ab), 1016(ab), 1089(ab), 1101(ab), 1102(ab), 1103(ab)
Deutsch, EA, 944(ab)
Deutsch, G, 941(ab)
Deutsch, K, 925(ab), 945(ab), 963(ab), 964(ab), 1089(ab)
DeVito, R, 1001(ab)
DeVito, RP, 343
DeVol, TA, 995(ab)
Devous, MD, Sr, 960(ab), 972(ab)
Devous MD, Sr, 951(ab)
deVries, DJ, 988(ab)
de Vries, JDM, 1107(ab)
Dewanjee, M, 934(ab), 1049(ab), 1085(ab)
Dewanjee, MK, 1048(ab), 1089(ab), 1092(ab)
Dewey, S, 960(ab), 1022(ab)
Dewey, SL, 993(ab), 1071(ab)
DeWoody, K, 1020(ab)
Dey, HM, 1043(ab)
de Yang, L, 796
D'Haenen, H, 952(ab)
Dhekne, R, 977(ab)
Dhillon, HK, 1649
Diamond, RH, 1422
Diaz-Cruz, C, 920(ab)
Di Chiro, G, 1346, 1008(ab)
Dienhart, DG, 970(ab)
Dierckx, R, 1086(ab)
Dierckx, RA, 1619
Digby, WM, 1134(ab)
Digennis, G, 1009(ab)
Diggles, L, 1017(ab), 1836(ab)
Dill, J, 1134(ab)
Dilmanian, FA, 1050(ab)
Dilsizian, V, 938(ab)
Dimitrakopoulou, A, 1548, 920(ab), 1083(ab), 1084(ab), 1138(ab)
Ding, Y-S, 993(ab)
Dinwiddie, R, 943(ab)
DiResta, GR, 1021(ab)
Diril, H, 475
DiRocco, RJ, 947(ab), 1001(ab)
Di Sacco, GL, 1010(ab)
DiStefano, R, 1082(ab)
Divgi, CR, 940(ab), 1051(ab)
Dixon, C, 990(ab)
DiZio, JP, 925(ab)
Dobbeleir, A, 364(le)
Dobbs, FR, 1009(ab)
Doerr, R, 1037(ab), 1052(ab), 1053(ab)
Doherty, FJ, 2275
Doll, J, 1138(ab)
Dom, L, 1086(ab)
Domnanovich, JR, 1513
Dondi, M, 369, 424
Dong, P, 1838(ab)
Donnal, JF, 932(ab)
Donohoe, KJ, 1046(ab)
Doo, E, 48
Doudet, DJ, 1408
Dowd, MT, 707, 1060(ab)
Dozono, H, 1102(ab)
Dragotakes, S, 953(ab)
Dramaix, JP, 930(ab)
Drew, HH, 972(ab)
Driedger, AA, 892(le), 1317(le)
Driscoll, E, 1030(ab)
Driussi, D, 1023(ab)
Du, L, 1050(ab)
Duara, R, 1725, 942(ab)
Duatti, A, 925(ab)
Dubois, F, 221
Dubois-Randé, JL, 998(ab)
Dubovsky, EV, 1821, 2061
Ducloux, G, 2194(le)
duCret, RP, 1545, 1139(ab)
Duda, RB, 1021(ab)
Dudzczak, R, 943(ab)
Duffy, GJ, 2281
Dulac, O, 1841(ab)
Duncan, JS, 960(ab)
Duncker, C, 949(ab), 959(ab), 1007(ab), 1019(ab), 1025(ab), 1033(ab)
Duncker, CM, 550(le)
Dunham, C, 952(ab)
Dunn, BB, 894(le)
Dunn, TJ, 1101(ab), 1103(ab)
Dupas, B, 785
Dupont, R, 992(ab)
Durack, LD, 923(ab), 986(ab), 1058(ab)
Duranceau, A, 930(ab), 1085(ab), 1310(le)
Durski, K, 947(ab), 949(ab), 959(ab), 1007(ab), 1033(ab), 1035(ab)
Durwen, HF, 388
Dutin, JP, 941(ab)
Dutta, AK, 1093(ab)
Duval, J, 1076(ab)
Dweck, E, 1046(ab)
Dworkin, H, 1075(ab)
Dworkin, HJ, 30, 169
Dysart, D, 1137(ab)

Earl, NL, 942(ab)
Eary, JF, 122, 923(ab), 986(ab), 1056(ab), 1058(ab), 1315(le), 1843(ab)
Eber, O, 1320, 1051(ab)
Eberl, S, 1382
Ebert, MH, 1593
Eckelman, WC, 1730
Edelbroek, MAL, 878
Edwards, S, 263
Efange, SMN, 1089(ab), 1092(ab), 1093(ab), 1139(ab)
Egbe, P, 929(ab)
Egglin, T, 556
Ehrenkaufer, RL, 1064(ab), 1094(ab), 1842(ab)
Ehrhardt, G, 964(ab)
Ehrhardt, GJ, 174, 1877, 925(ab), 945(ab), 1089(ab), 1090(ab)
Ehringer, H, 967(ab)
Eichstädt, H, 1105(ab)
Eindhoven, TU, 1018(ab)
Eisen, HJ, 130, 2024(le)
Eisenhofer, G, 102
Eisner, RL, 958(ab), 1027(ab)
Eitzman, D, 1011(ab)
Eklem, MJ, 48
Elder, GJ, 2273
Elder, RC, 1089(ab)
Elder, ST, 1094(ab)
Elger, CE, 388
Elger, Ch, 1076(ab)
Ell, PJ, 2193(le)
Eller, D, 917(ab)
Elliott, AT, 1771
Ellison, D, 940(ab)
Elmaleh, DR, 981(ab), 1009(ab), 1014(ab)
Elmendorf, SL, 1002(ab)
Elovich, RJ, 1090(ab)
Elsinga, PH, 1587
Elsworth, J, 1007(ab)
Embon, OM, 766
Emery, MF, 2025(le)
Emran, A, 1581, 1093(ab)
Emrich, D, 1019(ab)
Enas, JD, 965(ab)
Endo, K, 825, 978(ab), 1087(ab), 1099(ab)
Endo, M, 1061(ab)
Endou, K, 1047(ab)
Endres, CJ, 1004(ab), 1028(ab)
Engeler, CM, 1545
Englaro, EE, 963(ab), 1877
Englehart, JK, 1098(ab)
Ennow, K, 1837(ab)
Ensing, GJ, 468
Epperly, MW, 1100(ab)
Epperly, NW, 985(ab)
Erbas, B, 1106(ab)
Erbe, E, 964(ab)
Erbengi, G, 1977
Erdtsieck-Ernste, E, 1097(ab)
Ernstoff, M, 983(ab)
Erwin, WD, 1513
Eshima, D, 1021(ab), 1081(ab)
Eskridge, J, 971(ab)
Esparza, L, 1326
Esquerré, J-P, 1901
Essamri, B, 988(ab), 989(ab), 1012(ab)
Essamri, R, 998(ab)
Esser, PD, 1018(ab)
Essiambre, R, 919(ab)
Esterbrooks, D, 968(ab), 1012(ab), 1835(ab)
Estorch, M, 2295, 550(le), 1019(ab), 1025(ab)
Estrada, WN, 1910
Evans, AC, 154
Evans, K, 1704, 954(ab)
Evans, ML, 1439, 955(ab)
Evans, N, 1052(ab), 1053(ab)
Evans-Blumer, M, 1089(ab)
Even-Sapir, E, 1084(ab)
Everett, J, 943(ab), 1017(ab), 1085(ab)
Ezekiel, A, 1001(ab)

Faber, TL, 2311, 919(ab), 1006(ab), 1068(ab)
Fabian, C, 1138(ab)
Fahey, FH, 1923, 2086, 975(ab), 1136(ab)
Faivre, A, 1023(ab)
Fajman, WA, 1104(ab)
Falk, S, 259
Fallon, JT, 1019(ab)
Fand, I, 1058(ab)
Fang, M, 89
Fanti, S, 424
Farde, L, 934(ab)
Farinelli, MC, 2064
Farnsworth, AP, 1842(ab)
Farnsworth, RH, 1542
Farrell, E, 1052(ab), 1053(ab), 1058(ab), 1100(ab)
Fass, J, 1052(ab)
Faulhaber, PJ, 707
Fawwaz, RA, 461, 984(ab), 993(ab), 1091(ab)
Fazio, F, 925(ab), 1007(ab), 1010(ab), 1022(ab), 1039(ab), 1050(ab), 1832(le)
Fedio, VA, (9)N11, 11N(2)
Feenstra, MGP, 1097(ab)
Feenstra, O, 1491
Feindendegen, LE, 909(ab), 926(ab)
Feine, U, 2209
Feinendegen, C, 1037(ab)
Feinendegen, LE, 1225, 1353, 1063(ab)
Feitsma, HIJ, 468
Felix, R, 1027(ab), 1105(ab)
Fendly, B, 1837(ab)
Ferguson, D, 999(ab)
Ferlin, G, 1036(ab), 2027(le)
Fernandes, V, 1382
Fernandez-Ulloa, M, 1605
Ferrarese, C, 1008(ab)
Ferrieri, RA, 1094(ab)
Ferrigno, D, 2064
Ferrone, S, 993(ab)
Ferry, D, 1387
Fessler, JA, 946(ab)
Fetterman, RC, 759, 909(ab)
Feyerabend, AJ, 970(ab), 1025(ab)
Fiaschi, R, 925(ab)
Ficke, DC, 1838(ab)
Ficken, VJ, 1130(ab), 1133(ab)
Fields, M, 1907
Fig, LM, 1011(ab)
Figulla, HR, 1019(ab)
Fila, G, 1465(le)
Fink-Bennett, D, 803, 1231, 1695, 923(ab), 1073(ab)
Finn, R, 769
Finn, RD, 1661, 940(ab), 1021(ab), 1051(ab)
Finn, RT, 1408
Firnau, G, 729
Fischer, C, 912(ab)
Fischman, AJ, 272, 483, 851, 2351, 928(ab), 955(ab), 969(ab), 1014(ab), 1029(ab), 1031(ab), 1050(ab), 1057(ab), 1099(ab), 1101(ab), 1105(ab)
Fish, DR, 960(ab)
Fishbein, M, 1005(ab), 1013(ab)
Fisher, C, 2241
Fisher, DR, 1055(ab)
Fisher, P, 124
Fisher, RA, 1605, 933(ab)
Fisher, RS, 651, 2176
Fisher, S, 993(ab), 1011(ab), 1020(ab), 1043(ab)
Fitzner, J, 915(ab), 1020(ab)
Fitzner, JN, 1445, 1017(ab)
Fitzpatrick, J, 1041(ab)
Fleishaker, J, 1009(ab)
Fleisher, T, 970(ab)
Fleishman, MJ, 984(ab), 1091(ab)
Fleming, RM, 1239
Fletcher, B, 1837(ab)
Floyd, CE, Jr, 1285, 986(ab), 1066(ab), 1068(ab)
Floyd, JL, 805
Floyd CE, Jr, 936(ab), 937(ab)
Foged, C, 934(ab)
Fogelman, I, 913(ab), 924(ab)
Folks, R, 953(ab), 1103(ab)
Folks, RD, 1006(ab), 1068(ab)
Fonouni-Fard, M, 1018(ab)
Foon, KA, 1052(ab)
Ford, KA, 1140(ab)
Forman, AD, 962(ab)

Formiconi, AR, 1501
Forster, A, 967(ab)
Forstrom, LA, 1029(ab), 1082(ab)
Fosella, F, 918(ab)
Foss, F, 970(ab)
Foster, ED, 1002(ab)
Foster, NL, 942(ab)
Fournier, D, 989(ab)
Fowler, J, 1022(ab)
Fowler, JS, 960(ab), 993(ab), 1071(ab), 1088(ab), 1094(ab)
Fox, K, 2299
Fox, TH, 985(ab)
Frackowiak, RSF, 960(ab)
Fragasso, G, 1039(ab), 1832(le)
France, G, 922(ab)
Franceschi, M, 1022(ab)
Francesconi, L, 924(ab), 1094(ab)
Franchi, R, 369
Francis, I, 1882
Francis, IR, 1086(ab)
Franck, G, 980(ab)
Frank, JA, 938(ab)
Frank, TL, 1968, 2253
Frankel, TL, 1442
Freedman, N, 994(ab), 1027(ab)
Freedom, RF, 237
Freeman, DA, 495
Freeman, I, 293
Freeman, LM, 972(ab)
Freeman, M, 919(ab)
Freeman, MR, 1038(ab)
Freitas, JE, 1387, 1882
Frenkel, A, 766, 974(ab)
Freund, L, 1070(ab), 1096(ab)
Frey, EC, 937(ab), 946(ab), 1065(ab), 1136(ab)
Frey, KA, 1399, 912(ab), 942(ab), 980(ab), 994(ab)
Frick, M, 1835(ab)
Frick, MP, 35N(4), 994(ab), 1012(ab), 1039(ab), 1134(ab)
Friden, A, 920(ab)
Friedberg, C, 1011(ab)
Friede, J, 919(ab)
Friedman, A, 2227
Friedman, J, 929(ab), 950(ab), 958(ab), 959(ab), 978(ab), 1001(ab), 1006(ab)
Friedmann, G, 931(ab)
Friedrich, B, 932(ab)
Friman, L, 186(le)
Frincke, J, 970(ab)
Fritz, B, 1014(ab)
Fritzberg, AR, 1445, 915(ab), 1017(ab), 1020(ab), 1102(ab)
Frohn, J, 259
Froment, JC, 912(ab)
Front, D, 766, 1157, 974(ab), 982(ab), 1084(ab)
Frost, JJ, 651, 980(ab), 1062(ab), 1078(ab), 1079(ab)
Fruhling, J, 549(le)
Fucello, AJ, 483
Fuchs, HE, 922(ab)
Fujibayashi, Y, 819, 825, 974(ab), 978(ab), 1034(ab)
Fujii, R, 1622, 1097(ab)
Fujii, T, 1054(ab), 1055(ab)
Fujikawa, K, 928(ab)
Fujimori, K, 1055(ab)
Fujimoto, Y, 1044(ab)
Fujita, H, 991(ab), 1069(ab), 1074(ab)
Fujita, M, 228
Fujita, S, 1075(ab)
Fujita, T, 991(ab), 1000(ab), 1047(ab), 1073(ab), 1084(ab)
Fujiwara, Y, 1496, 1040(ab)
Fukiita, H, 911(ab)
Fukuchi, M, 1087(ab)
Fukuda, H, 1040(ab), 1061(ab)
Fukui, H, 924(ab), 1047(ab)
Fukumura, T, 1655, 1015(ab), 1079(ab)
Fukunaga, M, 825, 978(ab)
Fukuyama, H, 991(ab)
Fulham, M, 1008(ab)
Fumoleau, P, 221
Fung, A, 919(ab)
Fung, AY, 930(ab)
Fung, P, 1005(ab), 1013(ab)
Furukawa, T, 825, 978(ab)
Fusamoto, H, 924(ab), 1047(ab)

Gabor, FV, 1836(ab), 1837(ab)
Gad, M, 1025(ab), 1087(ab)
Gagne, G, 2126
Gagnon, A, 1103(ab)
Gal, R, 959(ab)
Galie, E, 447
Galster, J, 915(ab), 1020(ab)
Galt, J, 953(ab)
Galt, JR, 166, 985(ab), 1067(ab), 1080(ab)
Gambhir, S, 927(ab)
Gambhir, SS, 733, 987(ab), 1134(ab)
Gan, MP, 1078(ab)
Gansow, OA, 1056(ab)
Gantet, P, 1901
Ganz, W, 920(ab), 934(ab), 1005(ab), 1013(ab), 1049(ab), 1085(ab), 1138(ab)
Ganz, WI, 1047(ab), 1089(ab), 1092(ab)
Garada, B, 933(ab)
Garbe, L, 1841(ab)
Garcia, E, 953(ab), 1001(ab), 1103(ab)
Garcia, EV, 166, 1199, 749(le), 1006(ab), 1034(ab), 1036(ab), 1067(ab), 1068(ab)
Garg, PK, 922(ab), 984(ab), 1030(ab)
Garg, S, 922(ab), 984(ab), 986(ab)
Garland, D, 1026(ab)
Garreau, B, 1015(ab), 1086(ab)
Garrett, K, 1684
Garty, I, 2227
Garza, D, 1581, 1039(ab)
Gasparini, D, 2092
Gaston-Perry, D, 1668
Gatanash, H, 1649
Gáti, I, 2258
Gatley, SJ, 58, 993(ab), 1088(ab), 1094(ab)
Gautherot, E, 940(ab)
Geatti, O, 2092
Gelbard, AS, 1835(ab)
Geltman, EM, 245, 2037, 1833(le)
Gemayel, N, 1105(ab)
Gemmell, H, 967(ab)
Gennarelli, T, 1022(ab)
Gentili, A, 1140(ab)
Georgi, K, 952(ab)
Georgiou, M, 934(ab), 1085(ab)
Gerdes, JM, 965(ab)
Germá, JR, 2295, 1025(ab)
Germain, L, 2288
Germano, G, 2199, 953(ab), 1062(ab)
Gestin, JF, 984(ab), 1023(ab)
Gewirtz, H, 2009, 930(ab)
Ghafouripour, AK, 1089(ab), 1092(ab)
Ghazal, ME, 1391
Ghosh, PR, 11N(5), 15N(1), 17N(3), 27N(5), 28N(4)
Gibbons, JF, 929(ab), 1018(ab)
Gibbons, RJ, 2162, 929(ab), 1033(ab), 1835(ab), 2023(le)
Gibson, R, 1071(ab)
Gibson, T, 913(ab)
Gijsemans, M, 952(ab)
Gilardi, MC, 1022(ab), 1039(ab)
Gilbert, FI, Jr, 411, 1642(le), 2360(le)
Gilbert, S, 48
Gilday, D, 237
Gildersleeve, DL, 1399, 994(ab), 1096(ab)
Gilland, DR, 527, 986(ab), 1067(ab)
Gillen, GJ, 1771
Gillespie, D, 1593
Gillespie, H, 980(ab)
Gilman, S, 912(ab)
Gilmore, B, 1771
Gilmore, IT, 506
Gilmore, MP, 910(ab)
Gilvydas, R, 1387
Giorgi, MCP, 1038(ab)
Gips, S, 982(ab)
Giudicelli, R, 1841(ab)
Gjedde, A, 154, 692, 910(ab), 961(ab)
Glaspy, J, 1555, 981(ab), 982(ab), 1838(ab)
Glazebrook, GA, 921(ab)
Glenn, SD, 970(ab), 1089(ab)
Glick, SJ, 917(ab)
Glover, DK, 957(ab)
Glowniak, JV, 242, 1025(ab), 1087(ab)
Go, RT, 912(ab), 968(ab), 1133(ab), 1135(ab)
Go, S, 1017(ab)
Gobuty, AH, 922(ab)
Goddard, AW, 1043(ab)
Goeckeler, WF, 174, 1058(ab)
Goedemans, WTh, 468
Goldenberg, DM, 1024(ab), 1051(ab), 1052(ab), 1053(ab), 1054(ab), 1058(ab), 1098(ab), 1101(ab)
Goldenberg, G, 991(ab)
Goldfine, SM, 1835(ab)
Goldrosen, M, 1052(ab)
Goldsmith, SJ, 1861, 15N(11), 933(ab), 962(ab), 963(ab), 976(ab), 1003(ab), 1013(ab), 1044(ab), 1049(ab), 1083(ab), 1104(ab), 1842(ab)
Goldstein, DS, 102
Goldstein, HA, 1831(le)
Goldstein, RA, 606, 1315(le)
Gona, J, 1052(ab)
Gonazlez, P, 1467(le)
Gonzalez, JA, 1387
Gonzalez, R, 970(ab)
Goodenberger, DM, 961(ab)
Goodman, MM, 965(ab), 1093(ab)
Goodman, W, 1004(ab)
Goodwin, DA, 750(le)
Goomer, NC, 1016(ab)
Gora, G, 803
Gordon, I, 1649, 1704, 362(le), 900(le), 943(ab), 954(ab)
Gordon, L, 13, 1132(ab)
Gordon, R, 1695
Gore, S, 506
Gorenberg, M, 982(ab)
Goris, ML, 887
Goroon, DG, 969(ab)
Gossens, I, 1011(ab)
Gotoh, M, 2291
Gottfried, HW, 1053(ab)
Gotti, PR, 1081(ab)
Gottlieb, G, 952(ab)
Gottlieb, SF, 1840(ab)
Gottschalk, A, 950(ab)
Gould, KL, 1, 58, 161, 579, 1581, 1039(ab)
Gould, L, 938(ab), 1040(ab)
Gould, R, 548(le)
Grafton, S, 1004(ab), 1062(ab)
Graham, K, 1056(ab)
Graham, MC, 1021(ab)
Graham, MM, 404, 1439, 2149, 955(ab)
Grandin, C, 988(ab), 998(ab), 1012(ab)
Granier, P, 1901
Granneman, B, 951(ab)
Granowska, M, 940(ab)
Grant, C, 980(ab)
Grant, I, 992(ab)
Grant, MF, 1452
Grant, SF, 1080(ab)
Gratz, KF, 729
Gravili, S, 1465(le)
Gray, B, 1092(ab)
Grayson, R, 961(ab), 1008(ab)
Green, JD, 1837(ab)
Green, MA, 475, 937(ab), 944(ab), 1139(ab)
Green, MV, 1801, 1064(ab)
Greenberg, D, 919(ab)
Greenberg, ID, 1559, 2306
Greenberg, J, 1072(ab)
Greenberg, JH, 1064(ab), 1070(ab)
Greene, R, 2069
Greene, RW, 1071(ab)
Greenspan, BS, 989(ab)
Greenwell, ML, 1641(le)
Greer, KL, 527, 956(ab), 986(ab)
Grehl, O, 1052(ab)
Gremillet, E, 1462(le)
Grenier, R, 553(le), 1059(ab)
Grierson, JR, 955(ab)
Griffeth, LK, 1532, 954(ab), 961(ab)
Griffin, T, 1100(ab)
Griffin, TW, 1053(ab)
Griffiths, GL, 1024(ab), 1098(ab), 1101(ab)
Grimmel, S, 1085(ab)
Grobmann, K, 909(ab)
Groch, MW, 1513
Grønvald, F, 934(ab)
Gropler, RJ, 10, 245, 475, 1315(le), 1833(le)
Groshar, D, 766, 974(ab)
Gross, K, 913(ab), 977(ab)
Gross, M, 949(ab)
Gross, MD, 1882
Grossman, M, 1072(ab)
Grossman, SA, 954(ab)
Grothe, RA, Jr, 552(le)
Grover-McKay, M, 1808
Gruaz-Guyon, A, 940(ab)
Gruenwald, F, 1076(ab)
Grummon, G, 925(ab), 964(ab)
Grundman, M, 1471
Grunwald, AM, 293
Grünwald, F, 388, 1075(ab), 1316(le)
Grzonka, R, 1054(ab)
Guadagni, A, 1082(ab)
Guarneri, L, 1136(ab)
Guerra, G, 934(ab)
Guerreau, D, 997(ab)
Guhlke, S, 1009(ab)
Guidotti, A, 1008(ab)
Guidry, GW, 2158
Guillaume, M, 2266, 935(ab), 980(ab)
Guillon, JM, 990(ab)
Guiney, TE, 969(ab), 1031(ab)
Gullberg, GT, 916(ab), 937(ab), 946(ab), 955(ab), 956(ab), 1066(ab), 1837(ab)
Gullion, CM, 951(ab)
Gumerlock, MK, 1137(ab)
Gupta, N, 1835(ab)
Gupta, NC, 968(ab), 1012(ab), 1039(ab), 1134(ab)
Gupta, RK, 1089(ab)
Gupta, SM, 2249
Gurll, NJ, 1358
Gvozdanovic, D, 967(ab)
Gyobu, T, 1075(ab)

Gyulai, L, 1076(ab)
Gzesh, D, 960(ab)

Haag, D, 1548, 1083(ab)
Haapanen, A, 988(ab)
Haaparanta, M, 938(ab), 988(ab)
Haberkorn, U, 1485, 1548, 920(ab), 1083(ab), 1084(ab), 1138(ab)
Hademenos, G, 917(ab)
Hagan, WK, 1140(ab)
Hagenfeldt, L, 2043
Haim, N, 1084(ab)
Ha-Kawa, SK, 2233
Halama, J, 1017(ab), 1085(ab)
Hales, CA, 950(ab)
Halkar, RK, 953(ab), 1103(ab)
Hall, H, 934(ab)
Hall, JN, 1135(ab)
Halldin, C, 2043, 934(ab), 994(ab), 1095(ab)
Haller, J, 719
Hallgring, E, 1206, 1022(ab)
Halpern, S, 992(ab)
Ham, HR, 1294, 364(le)
Hamamoto, K, 1496, 911(ab), 991(ab), 1027(ab), 1040(ab), 1054(ab), 1055(ab), 1066(ab), 1069(ab), 1074(ab), 1106(ab)
Hamazaki, K, 1047(ab)
Hamet, P, 973(ab)
Hamill, J, 1001(ab)
Hamill, JJ, 343
Hammar, RJ, 1090(ab)
Hammeke, TA, 942(ab)
Handy, DM, 1836(ab)
Hanrath, P, 1037(ab)
Hansen, CL, 1041(ab)
Hansen, H, 953(ab), 1024(ab)
Hansen, HJ, 1052(ab), 1054(ab), 1098(ab), 1101(ab)
Hansen, K, 934(ab)
Hansen, S, 1837(ab)
Hanson, C, 942(ab)
Hanson, H, 909(ab)
Hanson, MW, 616, 1518, 932(ab), 1016(ab), 1077(ab), 1079(ab)
Hantraye, P, 1004(ab)
Haot, J, 1192
Hara, M, 1102(ab)
Harada, K, 1102(ab)
Harata, Y, 1059(ab), 1068(ab)
Harcke, HT, 1140(ab)
Hardman, N, 1414, 941(ab)
Hardoff, R, 1157, 1873, 982(ab), 1045(ab)
Harker, J, 1078(ab)
Harkness, B, 2086
Harkness, BA, 1136(ab)
Härkönen, R, 988(ab)
Harnish, G, 957(ab)
Harper, PV, 1239
Harrell, LE, 941(ab)
Harrington, CK, 1058(ab)
Harris, CC, 932(ab)
Harris, G, 991(ab)
Harris, JM, 1080(ab)
Hartiala, J, 988(ab)
Hartman, J, 2037
Hartman, NG, 1131(ab)
Hartmann, A, 971(ab)
Harvey, EB, 1162
Hasan, A, 1091(ab), 1095(ab)
Hasegawa, Y, 228, 1029(ab)
Hashimoto, S, 993(ab), 1056(ab), 1059(ab), 1068(ab)
Hatabu, H, 2098
Hatahet, MA, 1073(ab)
Hatano, K, 713
Hatazawa, J, 699, 713, 1069(ab)
Hathaway, R, 913(ab)
Hattner, RS, 1782, 1831(le), 1833(le), 2024(le)
Hattori, A, 865
Hauptmann, St, 1052(ab)
Hauser, MM, 1099(ab)
Hauw, JJ, 1608, 1078(ab)
Havlik, S, 965(ab)
Hawes, DR, 1358
Hawk, TC, 1030(ab)
Hawkins, L, 992(ab)
Hawkins, RA, 733, 1555, 2199, 35N(4), 920(ab), 926(ab), 938(ab), 946(ab), 953(ab), 981(ab), 982(ab), 1004(ab), 1025(ab), 1061(ab), 1062(ab), 1838(ab)
Hawkins, WG, 141, 1442, 916(ab), 994(ab)
Hay, RV, 1239
Hayashi, K, 1060(ab)
Hayashida, K, 1333, 1008(ab)
Hayford, C, 1132(ab)
Haynie, M, 1
Haynie, MP, 1039(ab)
Haynie, TP, 932(ab), 962(ab), 970(ab)
Hayostek, RJ, 2332, 1018(ab)
Hays, JT, 948(ab), 979(ab)
Haze, K, 1012(ab), 1030(ab)
He, Z-X, 1794
Heal, AV, 1042(ab), 1054(ab)
Healy, S, 977(ab)
Heaton, R, 992(ab)
Hebben, N, 1206, 1022(ab)
Heberle, J, 204, 1828(le)
Hebert, CB, 948(ab)
Heelan, R, 1132(ab)
Hegeman, IM, 210
Heggie, JCP, 840
Heikkinen, J, 926(ab)
Heim, A, 1019(ab)
Heimberger, K, 1675
Heindel, W, 931(ab)
Heinrich, MM, 1353, 2361(le)
Heiss, W-D, 1338, 931(ab), 932(ab)
Heller, SL, 972(ab)
Hellman, RS, 319, 1904, 942(ab), 963(ab)
Hellstrom, I, 922(ab)
Hellstrom, KE, 922(ab)
Helvie, M, 982(ab)
Heminway, SJ, 957(ab)
Henderson, B, 990(ab)
Heneghan, W, 983(ab)
Heninger, GR, 210, 1754
Henkes, H, 1027(ab)
Henkin, R, 447
Henley, M, 967(ab)
Hennemann, P, 1836(ab)
Hennerici, M, 1063(ab)
Henrich, MM, 909(ab), 926(ab)
Henry, TR, 912(ab)
Henze, E, 1053(ab)
Heo, J, 968(ab), 979(ab), 1031(ab), 1036(ab)
Hepner, A, 949(ab), 1011(ab)
Herberhold, W, 920(ab)
Herholz, K, 1338, 931(ab), 932(ab)
Hermann, WH, 988(ab)
Hermanne, JP, 980(ab)
Hero, AO, 946(ab)
Herrera, J, 1076(ab)
Herrera, L, 1053(ab)
Herrero, P, 937(ab)
Herrmann, G, 970(ab)
Herrold, EM, 1835(ab)
Herron, KG, 1452
Herscheid, JD, 986(ab)
Herscovitch, P, 102, 910(ab), 994(ab)
Hertel, A, 952(ab), 970(ab), 971(ab), 1053(ab)
Hertzberg, VS, 963(ab), 1877
Herzog, H, 1225, 1353, 909(ab), 926(ab), 1063(ab)
Hess, MJ, 1
Heuchemer, T, 1053(ab)
Heuchert, T, 2209
Heusser, C, 941(ab)
Hewitt, KA, 1246
Heyl, B, 2000, 947(ab), 948(ab), 1029(ab)
Heymsfield, S, 983(ab), 1104(ab), 1105(ab)
Heyndrickx, GR, 998(ab), 1012(ab)
Heyns, ADP, 2245
Heyns, AdP, 62
Hiam, J, 11N(3), 20N(6), 22N(2), 22N(5), 29N(5), 47N(4)
Hichwa, RD, 2342, 1063(ab)
Hicklin, OA, 13, 1132(ab)
Hicks, R, 565, 949(ab)
Hicks, RJ, 524, 988(ab)
Hidaka, A, 2098
Hiemish, H, 453
Hierholzer, J, 1027(ab), 1105(ab)
Higano, CS, 1047(ab)
Higashi, S, 1074(ab)
Higashino, H, 1027(ab), 1040(ab), 1074(ab)
Higgenbotham, C, 1102(ab)
Higley, B, 967(ab)
Hijdra, A, 382
Hille, N, 1382
Hilleman, D, 968(ab), 1012(ab), 1835(ab)
Hilson, AJW, 973(ab)
Himelman, R, 998(ab)
Himi, T, 1039(ab), 1040(ab)
Hines, J, 1100(ab)
Hinge, D, 967(ab)
Hinnefeld, JD, 1018(ab)
Hirakawa, K, 1097(ab)
Hirano, M, 1084(ab)
Hirasawa, Y, 1059(ab), 1087(ab)
Hirata, K, 673, 1035(ab), 1039(ab)
Hirata, M, 1091(ab)
Hirner, A, 1049(ab)
Hironaka, FH, 1038(ab)
Hirsch, H, 1605, 933(ab)
Hisada, K, 1273, 2215, 2284, 961(ab), 1074(ab), 1075(ab), 1079(ab)
Hitchens, RE, 2342
Hitzemann, R, 960(ab), 1022(ab)
Hiyama, T, 228
Hnatowich, DJ, 750(le), 1014(ab), 1053(ab), 1098(ab), 1100(ab)
Ho, LCY, 33
Ho, PJ, 1011(ab)
Hochberg, FH, 955(ab)
Hodge, M, 942(ab)
Hodson, EM, 1542
Hoefnagel, CA, 361(le), 921(ab)
Hoehn-Saric, R, 991(ab)
Hoekstra, OS, 986(ab)
Hoffer, PB, 210, 1506, 1754, 979(ab), 1007(ab), 1043(ab)
Hoffman, EJ, 1923, 2342, 966(ab), 1062(ab), 1134(ab)
Hoffman, JM, 616, 1518, 932(ab), 942(ab), 1015(ab), 1061(ab), 1077(ab), 1079(ab)
Hoffman, TJ, 1102(ab)
Hoffmann, G, 1026(ab)
Hoffmann, RG, 942(ab)
Hofland, LJ, 1084(ab)
Hoh, C, 1555, 1838(ab)
Hoh, CK, 920(ab), 926(ab), 938(ab), 946(ab), 981(ab), 982(ab), 1004(ab), 1025(ab), 1061(ab)
Holanders, E, 1904
Holburn, G, 1070(ab)
Holdeman, K, 1015(ab)
Holden, JE, 966(ab), 1004(ab), 1007(ab), 1028(ab), 1070(ab), 1096(ab)
Hollister, L, 980(ab)
Hollister, MS, 1047(ab)
Holman, BL, 322, 1206, 1475, 1478, 899(le), 933(ab), 1022(ab)
Holmes, DR, 1029(ab)
Holmes, GL, 912(ab)
Holmes, RA, 111, 1102(ab), 1137(ab)
Holthoff, VA, 912(ab), 980(ab)
Holvoet, P, 2321
Honda, N, 1106(ab)
Hong Tai Eng, F, 919(ab)
Hood, C, 947(ab)
Hood, JT, 1838(ab)
Hoop, B, 890
Hoory, S, 293
Hör, G, 259, 952(ab), 970(ab), 971(ab), 1053(ab)
Hori, M, 1037(ab)
Horn, J, 1018(ab)
Horneff, G, 977(ab), 983(ab)
Hornof, WJ, 124, 547(le)
Hornykiewicz, O, 1675
Horowitz, M, 878
Horstmann, K, 918(ab)
Hortobagyi, GN, 1326
Horwich, D, 1897
Hoshi, H, 1785
Hoskinson, JJ, 67
Hosono, M, 1087(ab), 1099(ab)
Hossein-Foucher, C, 2194(le)
Hotze, A, 388, 920(ab), 921(ab), 1044(ab), 1049(ab), 1051(ab), 1076(ab), 1088(ab)
Houghton, AN, 1051(ab)
Houser, WD, 1070(ab), 1096(ab)
Hovaguimian, H, 1025(ab)
Hriso, E, 1471
Hsia, T, 1038(ab)
Hsieh, KS, 944(ab), 1041(ab)
Hsu, CY, 975(ab)
Hsu, JJ, 1045(ab)
Hsu, L-C, 1048(ab)
Hu, S, 1026(ab)
Huang, G, 1838(ab)
Huang, H, 994(ab), 1134(ab)
Huang, HC, 1003(ab)
Huang, SC, 733, 2199, 909(ab), 910(ab), 926(ab), 927(ab), 938(ab), 953(ab), 987(ab), 994(ab), 1004(ab), 1025(ab), 1062(ab)
Huang, ZH, 939(ab)
Hubner, KF, 35N(4), 1093(ab)
Huda, W, 1312(le)
Hudgins, PA, 985(ab)
Huesman, R, 955(ab)
Huesman, RH, 995(ab), 998(ab)
Hufnagel, A, 1076(ab)
Hughes, JMB, 927(ab)
Hughes, T, 943(ab)
Hughey, BJ, 1096(ab)
Huijgens, PC, 986(ab)
Hume, SP, 1838(ab)
Humen, D, 919(ab)
Humeres, P, 1467(le)
Huneidi, AHS, 992(ab)
Huneke, R, 1056(ab)
Hung, G-L, 913(ab), 1026(ab), 1105(ab)
Hung, JC, 2162, 2332, 1018(ab), 1835(ab), 1843(ab), 2023(le)
Hung, L, 924(ab)
Hur, S, 983(ab)
Hurley, JR, 1017(ab)
Hurm, KD, 1046(ab)
Hurtig, H, 960(ab)
Hurwitz, RA, 1086(ab)
Hutchins, B, 1837(ab)
Hutchins, G, 926(ab),

982(ab), 988(ab), 1012(ab), 1028(ab), 1040(ab)
Hutchins, GD, 1950, 926(ab), 928(ab), 946(ab), 974(ab)
Hutchinson, RJ, 362(le), 943(ab), 1086(ab)
Huth, CJ, 1605, 933(ab)
Hutton, BF, 360(le)
Huysmans, DA, 27
Hwang, D-R, 1730, 1841(ab)
Hyödynmää, S, 1837(ab)

Iadicicco, RA, 1098(ab)
Ichihara, T, 1273, 1059(ab), 1068(ab), 1079(ab)
Ichiya, Y, 1655, 1015(ab), 1079(ab)
Ido, T, 95, 713, 1622, 2118, 1069(ab), 1083(ab), 1097(ab), 1844(ab)
Ii, M, 1075(ab)
Iida, H, 1931, 2169, 988(ab), 1003(ab)
Iida, Y, 2098
Iimura, O, 865, 2291
Iinuma, T, 1061(ab)
Iio, A, 1040(ab), 1074(ab)
Iio, M, 1432
Iizuka, M, 1432
Ike, D, 978(ab)
Ikekubo, K, 1034(ab)
Iles, S, 919(ab)
Ilo, A, 1027(ab)
Imahori, Y, 1622, 1097(ab)
Imaoka, S, 228
Imazeki, K, 686
Imazeki, S, 917(ab)
Inagaki, S, 1042(ab)
Inagaki, Y, 1039(ab), 1040(ab)
Ind, PW, 990(ab)
Infante-Rivard, C, 1467(le)
Innis, RB, 1754, 979(ab), 1007(ab), 1043(ab), 1071(ab)
Inoue, S, 1061(ab)
Inoue, T, 911(ab), 991(ab), 1040(ab), 1068(ab), 1074(ab)
Inoue A, 228
Intenzo, CM, 328, 2026(le)
Ironson, G, 1038(ab)
Isacson, O, 981(ab), 1009(ab)
Ishida, Y, 1037(ab)
Ishigami, S, 228
Ishiguro, S, 228
Ishii, K, 1079(ab)
Ishiwata, K, 95, 713, 2118, 1069(ab), 1083(ab), 1844(ab)
Ish-Shalom, S, 1157
Isitman, AT, 319, 1904
Iskandrian, AS, 1966, 968(ab), 979(ab), 1031(ab), 1036(ab)
Israel, O, 1157, 974(ab), 982(ab), 1084(ab)
Itami, J, 686, 917(ab)
Ito, T, 1100(ab)
Itoh, A, 1030(ab)
Itoh, K, 1137(ab)
Itoh, M, 713, 1069(ab), 1081(ab)
Ivanovic, M, 1866, 916(ab), 980(ab), 1022(ab), 1840(ab)
Iwao, H, 1079(ab)
Iwasaki, Y, 991(ab), 1073(ab)
Iwata, R, 95, 1069(ab)
Izaki, M, 1038(ab)

Jabir, AM, 1130(ab), 1135(ab)
Jabour, B, 920(ab)
Jackson, GA, 993(ab)
Jacobs, A, 1002(ab)
Jacobs, E, 1838(ab)
Jacobs, MP, 990(ab)
Jacobson, AF, 330, 518, 1047(ab)
Jagoda, EM, 1057(ab)
Jagust, WJ, 955(ab)
Jain, D, 938(ab), 939(ab), 1038(ab)
Jain, S, 965(ab)
Jamitzky, T, 1044(ab)
Janicek, MJ, 913(ab)
Janier, M, 739
Janik, M, 944(ab)
Janssens, J, 931(ab)
Jaros, R, 1695
Jarry, M, 919(ab)
Jarvi, K, 1425
Jaszczak, R, 917(ab)
Jaszczak, RJ, 527, 956(ab), 986(ab), 1065(ab), 1067(ab), 1068(ab)
Jatene, AD, 1038(ab)
Jay, M, 2139
Jeffery, PJ, 951(ab)
Jeffries, K, 1063(ab)
Jelinek, JJ, 1464(le)
Jeng, FS, 1088(ab)
Jensen, JL, 1266
Jeong, JM, 1024(ab), 1055(ab), 1056(ab), 1057(ab), 1101(ab)
Jerushalmi, J, 1157
Jessa, Z, 1049(ab)
Jewell, WR, 1138(ab)
Jewett, DM, 1010(ab)
Jewkes, R, 1907
Jia, W, 964(ab)
Jimenez, H, 920(ab)
Jingu, K, 1655
Joensuu, H, 1211
Johansen, K, 252, 1641(le)
Johansson, L, 1837(ab)
John, CS, 1090(ab)
John, E, 1021(ab), 1098(ab)
Johnson, DK, 940(ab)
Johnson, EW, 1754
Johnson, G, 934(ab), 1085(ab)
Johnson, J, 1399
Johnson, JE, 963(ab)
Johnson, KA, 1206, 1475, 1478, 1022(ab), 1098(ab)
Johnson, LL, 2012, 929(ab), 1018(ab)
Johnson, SH, 1030(ab)
Johnson, TK, 970(ab)
Johnson G, III, 948(ab)
Johnson, VE, 937(ab)
Johnston, DJ, 1063(ab)
Johnston, GS, 1139(ab)
Johnston, RE, 1136(ab)
Jolles, PR, 1131(ab), 1132(ab)
Jonas, D, 970(ab)
Jonckheer, MH, 216
Jones, AL, 1024(ab), 1101(ab)
Jones, FDL, 1078(ab)
Jones, HA, 927(ab)
Jones, LA, 1098(ab)
Jones, M, 953(ab), 1103(ab)
Jones, ME, 1199, 985(ab), 1104(ab)
Jones, PD, 1945
Jones, RH, 1918, 967(ab)
Jones, T, 1937, 2169, 927(ab)
Jonker, N, 1014(ab)
Joyce, MJ, 1508, 962(ab)
Jülicher, F, 909(ab)
Jung, Y-W, 974(ab), 994(ab), 1096(ab)
Juni, J, 923(ab)
Juni, JE, 956(ab), 999(ab), 1073(ab), 1075(ab)
Justin, EP, 1358
Juweid, M, 1057(ab), 1101(ab)
Jyawook, S, 1050(ab)

Kaarndikar, NS, 1043(ab)
Kabalka, GW, 965(ab), 1093(ab)
Kader, KL, 461
Kaendler, SH, 952(ab)
Kagaya, A, 1039(ab), 1040(ab)
Kahn, D, 934(ab)
Kahn, SE, 940(ab)
Kaila, PK, 1080(ab)
Kainer, G, 1542
Kaiser, GA, 1048(ab)
Kaiser, HJ, 1037(ab)
Kaiser, W, 920(ab), 921(ab)
Kalaigian, H, 918(ab)
Kalasinski, LA, 1394
Kalden, JR, 977(ab)
Kalff, V, 1090(ab)
Kalloo, AN, 976(ab), 1046(ab)
Kalnins, RM, 1688
Kamada, T, 924(ab), 1037(ab), 1047(ab)
Kamano, T, 1106(ab)
Kambara, H, 673, 679, 2152, 1034(ab), 1035(ab), 1039(ab)
Kamdar, N, 1134(ab)
Kamen, Y, 1050(ab)
Kaminski, MS, 1043(ab), 1314(le)
Kammerhuber, F, 1320
Kanaya, K, 1060(ab)
Kanaya, S, 1044(ab), 1060(ab)
Kanazawa, S, 1000(ab)
Kanke, M, 928(ab)
Kanke, M., 1254
Kanno, I, 1931, 1003(ab)
Kanter, L, 1011(ab)
Kanvinde, MH, 965(ab)
Kao, CH, 944(ab), 975(ab), 1041(ab)
Kao, PF, 976(ab), 1026(ab)
Kapadvanjwala, M, 1048(ab)
Kaphan, G, 1841(ab)
Kaplan, DA, 1020(ab), 1098(ab)
Kaptein, EM, 1010(ab)
Kapucu, Ö, 1106(ab)
Karanauskas, S, 1086(ab)
Karesh, SM, 447
Karh, G, 1491
Kärkkinen, A, 1837(ab)
Karp, A, 1070(ab)
Karp, JS, 2342, 995(ab)
Kasagi, K, 2098
Kasahara, A, 924(ab), 1047(ab)
Kashigawa, T, 924(ab)
Kashiwagi, T, 1037(ab), 1047(ab)
Kasi, LP, 918(ab), 970(ab), 1000(ab), 1059(ab)
Kasina, S, 1445, 915(ab), 1017(ab), 1020(ab), 1102(ab)
Kasliwal, R, 970(ab)
Kassira, W, 934(ab), 1085(ab)
Kassis, AI, 116, 1751, 1082(ab)
Katada, K, 1080(ab)
Katayama, M, 1056(ab)
Kato, H, 1034(ab)
Kato, M, 1015(ab)
Katsume, H, 1042(ab)
Katti, KV, 1102(ab)
Katz, BP, 1394
Katz, PM, 972(ab)
Katzenellbogen, JA, 1526
Katzenellenbogen, JA, 81, 1532, 925(ab), 975(ab), 995(ab)
Katznelson, D, 944(ab)
Kaufman, HS, 1836(ab)
Kaul, S, 2115
Kawada, TK, 1839(ab)
Kawai, C, 673, 679, 2152, 1034(ab), 1035(ab), 1039(ab)
Kawai, K, 819
Kawakami, K, 1059(ab), 1087(ab)
Kawamoto, M, 2152, 1000(ab), 1034(ab), 1035(ab), 1039(ab)
Kawashima, K, 713
Kearfott, KJ, 985(ab)
Keeling, C, 887
Keenan, A, 1020(ab)
Kegeles, L, 1104(ab)
Keilp, J, 1076(ab)
Keim, SG, 777
Keiser, HR, 1044(ab)
Keith, D, 1837(ab)
Keller, E, 1107(ab)
Kelly, MJ, 1090(ab)
Kelsen, D, 1051(ab)
Kemeny, N, 1051(ab)
Kemp, B, 1108(ab)
Kempner, KM, 1064(ab)
Kenemans, P, 941(ab)
Kengen, RA, 1709
Kengen, RAM, 1843(ab)
Kennedy, A, 968(ab)
Kennedy, EJ, 963(ab)
Kersjes, W, 388
Kertzman, C, 1064(ab)
Keske, U, 1027(ab), 1105(ab)
Kessler, RM, 1593, 912(ab), 961(ab), 1008(ab), 1015(ab), 1063(ab), 1070(ab)
Ketch, RB, 1136(ab)
Ketring, AR, 174, 985(ab), 1023(ab), 1090(ab), 1102(ab)
Keyes, JW, 875, 885
Keyes, JW, Jr, 2086
Keyser, A, 1105(ab)
Khalili-Varasteh, M, 1004(ab)
Khaw, BA, 272, 312, 867, 1254, 1742, 977(ab), 987(ab), 992(ab), 1005(ab), 1019(ab), 1029(ab), 1050(ab), 1082(ab)
Khazaeli, MB, 1162, 1052(ab)
Khelifa, F, 1841(ab)
Kho, GS, 1845
Kiat, H, 929(ab), 950(ab), 959(ab), 978(ab), 1001(ab), 1006(ab), 1036(ab)
Kiesewetter, D, 1008(ab)
Kiesewetter, DO, 894(le)
Kiessler, C, 1052(ab)
Kiewel, LJ, 1081(ab)
Kijewski, MF, 899(le), 988(ab)
Kikegawa, T, 1060(ab)
Kilbourn, M, 1043(ab)
Kilbourn, MR, 974(ab), 980(ab), 994(ab), 1009(ab), 1010(ab), 1095(ab), 1097(ab)
Kilroy, A, 1015(ab)
Kim, AS, 919(ab)
Kim, CH, 1045(ab)
Kim, CK, 1861, 933(ab), 962(ab), 976(ab), 1003(ab), 1013(ab), 1044(ab), 1049(ab), 1083(ab)
Kim, EE, 1233, 918(ab), 932(ab), 962(ab), 970(ab), 1093(ab)
Kim, H-J, 333, 1923
Kim, S, 961(ab)
Kim, SE, 1080(ab)
Kim, SM, 328, 2026(le)
Kimura, K, 924(ab), 1037(ab), 1047(ab)
Kimura, Y, 911(ab), 1054(ab), 1055(ab), 1066(ab), 1069(ab), 1074(ab), 1106(ab)
Kinahan, PE, 1064(ab)
King, DW, 1668
King, HF, 964(ab), 1007(ab)
King, L, 1471
King, MA, 917(ab), 936(ab)
King, WA, 1684
Kingston, JE, 992(ab)
Kinoshita, R, 1102(ab)
Kinuya, K, 1074(ab), 1079(ab)
Kinuya, S, 961(ab), 1024(ab), 1055(ab),

1057(ab), 1090(ab)
Kioumehr, F, 1078(ab)
Kippenhan, S, 942(ab)
Kir, KM, 942(ab)
Kir, M, 1429
Kirchner, P, 429
Kirchner, PT, 934(ab), 946(ab)
Kirkeeide, RL, 1039(ab)
Kirkwood, R, 151
Kirsch, C-M, 1365, 931(ab), 1014(ab)
Kirsch, M, 1011(ab)
Kirsh, R, 1050(ab)
Kitabatake, A, 1037(ab)
Kitakata, Y, 1048(ab)
Kitani, H, 1087(ab)
Kitani, K, 1079(ab)
Kitapçi, M, 1977
Kitz, P, 1675
Kizukuri, T, 1137(ab)
Kjøller, E, 139
Klauser, AG, 931(ab)
Klein, E, 1076(ab)
Klein, G, 955(ab)
Klein, HA, 1371, 1310(le), 1645(le)
Klein, J., 958(ab)
Klein, JL, 1442, 749(le)
Klein, WP, 1135(ab)
Klepzig, H, Jr, 971(ab)
Kletter, K, 943(ab)
Klibanov, A, 1742, 992(ab)
Klieger, P, 1866
Klimpfinger, M, 1320
Kling, GA, 1137(ab)
Kling, P, 1338
Klinkowstein, RE, 1096(ab)
Kloiber, R, 919(ab)
Klonecke, AS, 1713
Kloppenborg, PW, 27
Knapp, FF, Jr, 945(ab), 1089(ab), 1093(ab), 1098(ab)
Knapp FF, Jr, 944(ab)
Knesaurek, K, 1839(ab)
Knight, LC, 785, 2176, 931(ab)
Knopp, M, 920(ab), 1083(ab), 1084(ab)
Knopp, MV, 1485, 1138(ab)
Knuuti, J, 938(ab), 988(ab)
Koblik, PD, 124, 547(le)
Kodaira, S, 2194(le)
Koeppe, RA, 1399, 912(ab), 942(ab), 980(ab)
Koga, S, 1080(ab), 1137(ab)
Koh, C-S, 1055(ab), 1080(ab)
Koh, WJ, 955(ab)
Koivisto, VA, 938(ab)
Koizumi, T, 1047(ab)
Kojima, A, 1102(ab)
Kojima, J, 228
Kollath, J, 259
Koller, E, 2132
Koller, F, 2132
Kolodny, GM, 1157, 1046(ab), 1084(ab)
Kolozsi, WZ, 1695
Kolsky, KL, 945(ab)
Kolthoff, B, 1002(ab)
Komai, S, 1137(ab)
Komtebedde, J, 124
Kondo, RL, 987(ab)
Konietzko, N, 961(ab)
Konings, AWT, 1587
Konishi, J, 673, 679, 819, 2098, 2152, 974(ab), 991(ab), 1000(ab), 1034(ab), 1035(ab), 1039(ab), 1047(ab), 1064(ab), 1073(ab), 1084(ab), 1087(ab), 1099(ab), 1313(le)
Kooij, PPM, 1184, 1219, 1043(ab), 1084(ab)
Koolbergen, DR, 1018(ab)
Koong, SS, 1055(ab)
Koper, JW, 1184, 1084(ab)
Kopin, IJ, 102
Koral, KF, 1291, 186(le), 916(ab)
Koray, Z, 1106(ab)
Kosaka, N, 1432, 1002(ab), 1077(ab)
Kostakoglu, L, 918(ab)
Koster, K, 210
Kotler, DP, 1050(ab)
Kotlyarov, EV, 1139(ab)
Kotts, C, 1837(ab)
Kotzé, HF, 62
Kowada, M, 726
Kozeni, K, 1432
Kozuka, T, 924(ab), 1037(ab), 1047(ab)
Kral, JG, 1104(ab)
Kramer, B, 970(ab)
Kramer, E, 1132(ab), 1135(ab)
Kramer, EL, 1140(ab)
Kramer, HH, 2361(le)
Kramer, W, 970(ab)
Krasnow, A, 319
Krasnow, AZ, 1904, 942(ab), 963(ab)
Krawczynska, EG, 1033(ab), 1034(ab)
Krebs, D, 1051(ab)
Krenning, EP, 1184, 1845, 981(ab), 1043(ab), 1084(ab)
Kreuzer, H, 1019(ab)
Krevsky, B, 2176, 923(ab), 931(ab)
Krichner, PT, 1808
Krishna, L, 1138(ab)
Krishnamurthy, GT, 48, 976(ab)
Krishnamurthy, S, 976(ab)
Krishnan, L, 1138(ab)
Krishnan, S, 1105(ab)
Krivokapich, J, 927(ab)
Kroger, LE, 922(ab)
Krohn, KA, 122, 1169, 955(ab), 1028(ab), 1140(ab), 1843(ab)
Krom, RF, 999(ab)
Kronauge, JF, 1992, 957(ab)
Kroon, D, 483
Kropp, J, 921(ab), 1049(ab), 1106(ab)
Krubsack, AJ, 1830(le)
Krystal, JH, 210
Kuang, L-R, 1093(ab)
Kubo, A, 993(ab), 1056(ab), 1059(ab), 1068(ab), 2194(le)
Kubo, S, 1000(ab), 1047(ab), 1084(ab)
Kubodera, A, 819
Kubota, K, 95, 2118, 1083(ab), 1844(ab)
Kubota, M, 865, 2291
Kubota, R, 95, 2118, 1083(ab), 1844(ab)
Kuczynski, B, 947(ab)
Kuczynski, BL, 1001(ab)
Kudo, M, 1177
Kuhar, MJ, 1069(ab), 1839(ab)
Kuhl, DC, 1108(ab)
Kuhl, DE, 524, 912(ab), 942(ab), 980(ab), 994(ab), 1096(ab)
Kuhle, W., 2199, 909(ab), 927(ab), 953(ab)
Kuhle, WG, 926(ab), 938(ab)
Kuhn, JA, 987(ab)
Kuikka, JT, 1225, 1353, 926(ab), 1070(ab)
Kulkami, PV, 915(ab)
Kulkarni, PV, 1016(ab), 1081(ab)
Kumamoto, M, 1061(ab)
Kumar, A, 952(ab)
Kumar, D, 1105(ab)
Kumita, S, 1012(ab), 1030(ab), 1035(ab)
Kumita, S-I, 1333
Kung, HF, 339, 924(ab), 974(ab), 1008(ab), 1069(ab), 1091(ab), 1094(ab)
Kung, MP, 339, 964(ab), 1008(ab), 1069(ab), 1091(ab), 1094(ab)
Kuni, CC, 1545, 1139(ab)
Kunz, A, 1024(ab)
Kunz, LL, 1056(ab)
Kupfer, S, 1104(ab)
Kurata, C, 417
Kurihara, S, 1060(ab)
Kurogane, H, 1718
Kurowski, CJ, 1059(ab)
Kurtz, I, 953(ab)
Kusagai, H, 228
Kusakabe, K, 1044(ab), 1060(ab)
Kushner, BH, 769
Kusic, Z, 1017(ab)
Kuwabara, H, 692, 910(ab)
Kuwabara, Y, 1655, 1015(ab), 1079(ab)
Kuwert, T, 1225, 1063(ab)
Kuyama, J, 917(ab)
Kuzel, TM, 1021(ab)
Kvols, LK, 1018(ab)
Kwekkeboom, DJ, 981(ab), 1845
Kwiatkowski, M, 925(ab), 1007(ab)

Laarman, GJ, 2071
Labar, D, 988(ab)
Labarre, PG, 1573
Laberge, J-M, 862
Labontiaqe, C, 919(ab)
Labontè, C, 919(ab), 1085(ab)
Lacy, JL, 2158
Lafont, A, 2221
Lafontaine, E, 1085(ab)
LaFrance, N, 1035(ab)
Lahiri, A, 36, 967(ab)
Laitinen, R, 1425
Lalibertè, RJ, 957(ab)
Lalonde, L, 919(ab)
Lalush, DS, 936(ab), 937(ab), 1066(ab)
Lambert, C, 1842(ab)
Lambert, CR, 1093(ab)
Lambert, R, 1961, 919(ab), 973(ab), 1085(ab)
Lamberts, SW, 1184
Lamberts, SWJ, 1845, 981(ab), 1043(ab), 1084(ab)
Lamborn, KR, 992(ab)
Lamçon, J-P, 739
Lamer, O, 1063(ab)
Laméris, JS, 1184
Lamki, LM, 1326, 962(ab), 970(ab)
Lammertsma, AA, 1838(ab)
Lamoureux, F, 919(ab)
Lamoureux, G, 992(ab)
LaMuraglia, GM, 1427
Lan, JA, 972(ab)
Landais, P, 912(ab)
Landmeir, B, 962(ab)
Landoni, C, 1039(ab), 1050(ab)
Landress, L, 2227
Landress, LJ, 1046(ab), 1131(ab)
Lang, EV, 1041(ab), 1049(ab)
Lang, JH, 1049(ab)
Lang, L, 1023(ab)
Lang, W, 991(ab)
Langen, KJ, 1225, 2193(le)
Langer, R, 1027(ab)
Langlois, Y, 973(ab)
Långström, B, 610, 2258, 1095(ab)
Lanigan, JP, 1089(ab)
Länsimies, E, 1070(ab)
Lantto, EH, 2029
Lantto, T, 1425
Lantto, TJ, 2029
La Pidus, AS, 1006(ab), 1104(ab)
Lapointe, D, 1028(ab)
Laquaglia, M, 769
Larcos, G, 2101, 2144, 1003(ab), 1033(ab)
Larson, S, 1189, 1132(ab)
Larson, SM, 287, 769, 1661, 918(ab), 940(ab), 970(ab), 1021(ab), 1051(ab)
Larsson, SA, 1837(ab)
Lartigue, S, 923(ab)
Laruelle, M, 979(ab), 1071(ab)
Laruelle, MA, 1754
Lasher, JC, 749(le), 1029(ab)
Lastoria, S, 970(ab)
Lathrop, KA, 1239
Latour, Y, 1961
Lattimer, JC, 945(ab), 1089(ab)
Lauer, E, 914(ab)
Laulamaa, V, 1070(ab)
Laurin, NR, 1317(le)
Lavender, JP, 1014(ab)
Lavender, P, 990(ab)
Lawhorn, S, 1130(ab)
Laws, DE, 1235
Lawton, RG, 915(ab)
Layne, WW, 2158
Lazarus, C, 924(ab)
Lazarus, CR, 1235
Lazewatsky, J, 263
Lazzari, S, 922(ab)
Le, N, 1055(ab), 1056(ab), 1057(ab)
Lear, JL, 1957, 911(ab), 970(ab), 1025(ab)
Le Bars, D, 912(ab)
Lec, A, 1082(ab)
Lechner, P, 1320, 1051(ab)
Le Cloirec, J, 1051(ab)
LeDoussal, JM, 940(ab)
Lee, DS, 1055(ab), 1080(ab)
Lee, HB, 933(ab), 1103(ab)
Lee, HK, 1076(ab)
Lee, J, 1764, 1081(ab)
Lee, K, 1028(ab)
Lee, KS, 942(ab), 966(ab), 988(ab), 1064(ab), 1072(ab), 1841(ab)
Lee, MC, 1055(ab), 1080(ab)
Lee, RE, 1054(ab)
Lee, SD, 990(ab), 1088(ab)
Lee, SL, 2275
Lee, SO, 976(ab), 1013(ab), 1049(ab)
Lee, SP, 1047(ab)
Lefebvre, B, 930(ab)
Lehr, P, 992(ab)
Lehur, PA, 940(ab)
Leichner, PK, 141, 1442, 916(ab), 994(ab)
Leidholdt, EM, Jr, 1979
Leisure, G, 1508
Leisure, GP, 962(ab), 1043(ab)
Lelord, G, 1086(ab)
Lemaire, C, 2266, 935(ab), 980(ab)
Lemieux, RJ, 934(ab)
Lemlek, J, 979(ab)
Lennon, SE, 1041(ab)
Lensing, AWA, 951(ab)
Lentle, BC, 1915, 2241, 2359(le)
Lenzi, GL, 1022(ab)
Leon, AR, 958(ab), 1027(ab)
Leonard, JC, 965(ab)
Leone, A, 2064
Leong, H, 1067(ab)
Leong, HC, 1013(ab)
Lepage, R, 934(ab)
Leppo, JA, 2012, 910(ab)
Lerakis, S, 1031(ab)
Leskinen-Kallio, S, 1211
Leslie, WD, 2306
Levasseur, M, 1078(ab)
Leveillé, J, 1961, 919(ab), 973(ab), 1103(ab)
Levenson, H, 1010(ab)
Lever, JR, 964(ab)
Levin, DP, 862
Levin, V, 932(ab)
Levine, D, 930(ab)
Levine, RL, 925(ab)
Levine, S, 1836(ab)
Levorato, M, 424
Levy, NB, 921(ab)

Levy, WC, 940(ab)
Lewellen, TK, 2342, 923(ab), 955(ab)
Lewis, CA, 973(ab)
Lewis, DH, 2149, 971(ab)
Lewis, J, 967(ab)
Lewis, JP, 921(ab)
Li, J, 956(ab)
Li, Q-S, 1968
Li, SR, 2132
Liang, Z, 917(ab)
Liao, SQ, 944(ab), 975(ab), 1041(ab)
Liau, C-S, 1254
Lich, LL, 1738
Lidgi, S, 974(ab)
Lieberman, L, 944(ab)
Ligon, RW, 959(ab)
Lillemoe, KD, 1836(ab)
Lim, P, 1139(ab)
Lim, S-M, 978(ab), 1057(ab)
Lima, J, 976(ab)
Limburg, M, 382
Limes, BJ, 972(ab)
Limonetti, P, 369
Lin, J, 193
Lin, KN, 1076(ab)
Lin, MS, 975(ab)
Lin, Q, 987(ab)
Lin, WY, 975(ab)
Lind, P, 1320, 1051(ab)
Linder, KE, 947(ab), 1001(ab)
Line, B, 1020(ab)
Linfante, I, 1008(ab)
Link, JM, 1140(ab)
Links, J, 1077(ab)
Links, JM, 1252, 2253, 2342
Liotta, F, 1026(ab)
Liow, J-S, 966(ab)
Lippman, HR, 325
Lisic, E, 945(ab)
Lisic, EC, 1102(ab)
Liss, R, 1014(ab)
Lister-James, J, 1842(ab)
Liu, A, 81
Liu, B, 1094(ab)
Liu, B-L, 339
Liu, CK, 972(ab)
Liu, H, 1836(ab)
Liu, HC, 1076(ab)
Liu, P, 298
Liu, Q, 1051(ab)
Liu, RS, 975(ab), 990(ab), 1000(ab), 1060(ab), 1076(ab), 1088(ab)
Liu, TP, 1052(ab)
Liu, WY, 1000(ab)
Liu, XJ, 967(ab)
Liu, Y, 1838(ab)
Livingston, GK, 1018(ab)
Livni, E, 1009(ab), 1014(ab)
Ljungberg, M, 1278, 916(ab), 917(ab)
Llace, S, 1000(ab)
Llinas, EJ, 1107(ab)
Lloyd, D, 1063(ab)
Lloyd, J, 1730
Lloyd-Smith, R, 2241
Loats, HA, 16
Loats, HL, 1063(ab)
Loats, S, 16
LoBuglio, A, 1052(ab)
LoBuglio, AF, 1162
Loc'h, C, 739, 1004(ab), 1015(ab)
Loeffler, J, 933(ab)
Loeffler, JS, 322, 1478
Loew, MH, 333
Loewenstein, D, 1725, 942(ab)
Logan, J, 960(ab), 1071(ab)
Logan, KW, 1137(ab)
Lohman, PHM, 814
Lollo, C, 970(ab)
Lombroso, CT, 912(ab)
London, ED, 1071(ab)
Long, WB, 1261
Longford, CPD, 1093(ab)
Loomer, R, 2241
Lord, RS, 1382
Lorenz, WJ, 1083(ab)
Losinno, F, 424
Lötter, MG, 62, 2245
Loudenslager, DM, 1442
Lowe, JL, 972(ab)
Lu, J, 1092(ab)
Lu, JY, 1035(ab)
Lubowski, DZ, 1668
Lucchesi, B, 1030(ab)
Luciani, L, 1045(ab)
Lucignani, G, 1039(ab), 1050(ab), 1832(le)
Luck, D, 1471
Lüders, H, 912(ab)
Luedtke, RR, 1842(ab)
Lufkin, R, 920(ab)
Lund, EC, 1104(ab)
Lundberg, PO, 610
Lupattelli, G, 2132
Lusson, JR, 1037(ab)
Luthra, SK, 927(ab), 960(ab)
Luurtsema, G, 975(ab)
Luyama, J, 686
Luyten, PR, 931(ab)
Lyle, M, 969(ab)
Lyons, KP, 1266
Lyss, AP, 1526

Maas, KW, 1140(ab)
Macapinlac, H, 1021(ab), 1132(ab)
MacDonald, J, 925(ab)
MacDonald, JR, 1101(ab)
MacDougall, ML, 1452
Macey, D, 1000(ab)
Macey, DJ, 922(ab), 997(ab), 1059(ab)
Mach, JP, 1414, 941(ab)
Mach, RH, 1094(ab), 1842(ab)
Machac, J, 1031(ab), 1032(ab)
Machida, K, 1106(ab)
MacIntyre, WJ, 912(ab), 968(ab), 1133(ab), 1135(ab)
Mackensen, D, 915(ab)
Mackey, DWJ, 1945
Mackie, TR, 1001(ab)
Macklis, RM, 350
MacSweeney, JE, 968(ab)
Madary, J, 991(ab)
Maddahi, J, 447, 1555, 35N(4), 920(ab), 929(ab), 953(ab), 959(ab), 981(ab), 982(ab), 1001(ab), 1005(ab), 1006(ab), 1013(ab), 1025(ab), 1036(ab), 1061(ab), 1067(ab)
Madden, JA, 1042(ab), 1136(ab)
Maddens, MD, 1073(ab)
Maddock, SW, 921(ab), 970(ab)
Maddox, AF, 878
Madelmont, J-C, 1573
Maden, HA, 1429
Madras, BK, 981(ab), 1009(ab)
Madsen, MT, 1808, 946(ab)
Maeda, H, 1080(ab)
Magata, Y, 673, 679, 2152, 1000(ab), 1034(ab), 1039(ab), 1064(ab), 1084(ab), 1091(ab)
Magid, NM, 1835(ab)
Magnani, B, 369
Magnani, P, 1010(ab), 1050(ab)
Magoun, S, 913(ab), 977(ab)
Maguire, G, 1135(ab)
Maguire, RT, 1052(ab)
Mahé, M, 997(ab)
Mahmarian, JJ, 948(ab), 969(ab), 979(ab), 1030(ab)
Mahoney, DK, 987(ab), 1134(ab)
Maiello, L, 369
Mainguet, P, 1192
Maini, RN, 1907
Maisey, MN, 1235
Maizels, M, 943(ab)
Makino, M, 1044(ab), 1060(ab)
Makj, M, 1044(ab)
Makler, PT, Jr, 1313(le)
Makley, JT, 1508, 962(ab)
Maler-Borst, W, 920(ab)
Malessa, S, 1675
Malison, R, 1007(ab)
Malison, RT, 1754
Mallette, S, 943(ab)
Mallette, SA, 1086(ab)
Malmud, LS, (9)N16, 22N(12)
Maltby, PJ, 506
Mamiya, T, 1106(ab)
Manaiwski, PJ, 909(ab)
Mandell, GA, 1140(ab)
Maneval, DC, 1837(ab)
Manglos, SH, 1813, 1839(ab)
Mangner, T, 926(ab), 1028(ab)
Mangner, TJ, 1950, 1072(ab)
Maniawski, PJ, 871, 957(ab)
Mann, P, 1021(ab)
Mann, RB, 805
Mannan, RH, 1764
Manning, RG, 1593, 961(ab), 1063(ab), 1070(ab)
Mannting, F, 949(ab)
Mansfield, P, 279
Manspeaker, HF, 1042(ab)
Mantil, J, 1841(ab)
Maor, D, 1000(ab)
Maquet, P, 980(ab)
Marbach, P, 1084(ab)
Marcaggi, X, 1037(ab)
Marchandise, X, 2194(le)
Marchetta, F, 424
Marchi, A, 925(ab)
Marcille, BM, 997(ab)
Marcus, CS, 808, 1836(ab)
Marcus, M, 429
Mardirossian, G, 1053(ab), 1098(ab), 1100(ab)
Margouleff, D, 1910, 1134(ab)
Mariani, G, 1082(ab)
Marien, P, 1619
Markham, J, 937(ab)
Marlatt, SW, 518
Marmion, M, 925(ab)
Marmion, ME, 1101(ab)
Marmor, A, 939(ab)
Maros, S, 1051(ab)
Marshall, ET, 1090(ab)
Marshall, RC, 1979
Martin, CC, 999(ab)
Martin, GV, 1028(ab)
Martin, M, 940(ab)
Martin, NL, 1138(ab)
Martin, RH, 1791
Martin, SE, 958(ab)
Martin, TE, 1027(ab)
Martino, J, 1135(ab)
Maruno, H, 686, 917(ab)
Maruyama, Y, 928(ab), 1084(ab)
Marwick, T, 1133(ab)
Marwick, TH, 2221, 968(ab)
Masaki, M, 699
Masatoshi, I, 699
Mascalchi, M, 1501
Masdeu, JC, 1471
Maseri, A, 2169
Masière, B, 989(ab)
Mason, G, 1017(ab)
Mason, NS, 1063(ab), 1070(ab)
Mason, RP, 1081(ab)
Mason, S, 961(ab)
Massey, MD, 2286
Massuger, L, 941(ab)
Mastrostamatis, S, 1843(ab)
Masuda, K, 1655, 928(ab), 1015(ab), 1079(ab)
Masuda, Y, 1039(ab), 1040(ab)
Masuo, M, 1432
Masure, MC, 911(ab)
Mather, SJ, 940(ab)
Mathias, CH, 944(ab)
Mathias, CJ, 81, 475, 1526, 1730
Mathis, CA, 955(ab), 965(ab), 974(ab)
Mathog, RH, 1137(ab)
Matoba, N, 991(ab), 1073(ab)
Matsuda, H, 1074(ab), 1075(ab), 1079(ab)
Matsudaira, M, 1273
Matsueda, GR, 1254
Matsumoto, K, 974(ab), 1097(ab)
Matsumoto, T, 1061(ab)
Matsumura, K, 76
Matsunari, I, 1273
Matsuzawa, T, 1069(ab)
Mattera, JA, 759, 939(ab)
Maublant, JC, 1794, 1037(ab), 1067(ab)
Mauguière, F, 912(ab)
Maul, FD, 952(ab), 971(ab)
Maurat, JP, 1788
Maurea, S, 938(ab), 1027(ab), 1044(ab)
Maurer, A, 1041(ab)
Maurer, AH, 2176, 923(ab), 931(ab)
Mausner, LF, 945(ab), 1023(ab), 1840(ab)
Maussier, ML, 1088(ab)
Maxon, HR, 1045(ab)
Maxon, HR, III, 1877, 933(ab)
Maxon, J, 963(ab)
Mayaud, C, 990(ab)
Mayberg, HS, 951(ab), 1062(ab), 1078(ab), 1079(ab)
Mayer, J-C, 221
Mayeur, S, 930(ab)
Mayfield, G, 1018(ab)
Mazariegos, M, 1104(ab)
Mazière, B, 1004(ab), 1015(ab), 1841(ab)
Mazière, M, 1004(ab)
Mazoyer, B, 989(ab), 998(ab), 1063(ab)
Mazoyer, BM, 911(ab), 1086(ab)
Mazziotta, J, 1004(ab)
Mazziotta, JC, 46N(4), 1062(ab)
McAfee, JG, 2126, 1090(ab)
McBride, D, 1684
McCallum, RW, 1375, 997(ab), 1046(ab)
McCandless, BK, 1002(ab)
McCartney, JE, 1005(ab)
McCutcheon, A, 992(ab)
McDermott, K, 940(ab)
McDevitt, M, 1021(ab), 1098(ab)
McDonald, RJ, 1266
McDougall, IR, 1713
McElgin, W, 1008(ab), 1069(ab)
McEwan, AJB, 918(ab), 921(ab)
McGee, S, 1140(ab)
McGivney, WT, 660
McGuire, AH, 1526, 1532, 954(ab), 961(ab)
McKay, WJ, 1688
McKenzie, AT, 1139(ab)
McKusick, KA, 955(ab), 969(ab), 1031(ab)
McLean, RG, 1668
McLellan, CA, 1408
McLeod, DR, 991(ab)
McMahan, CA, 377, 2025(le)
McNamara, D, 934(ab)
McPherson, DW, 944(ab), 1093(ab)
Meares, C, 984(ab)
Meares, CF, 475
Mease, RC, 984(ab), 1023(ab), 1842(ab)
Meertsuk, FE, 453
Megibow, A, 1135(ab)
Meguro, K, 713
Mehringer, CM, 1684
Mehta, VD, 1081(ab)
Meier, DA, 30

Meignan, M, 990(ab)
Meijer, S, 1709, 1843(ab)
Meinken, GE, 984(ab), 1023(ab), 1840(ab), 1842(ab)
Meis, DM, 934(ab)
Mejia, AA, 699
Mekhmandarov, S, 944(ab)
Meldolesi, U, 1501
Melega, W, 1004(ab)
Melin, JA, 988(ab), 989(ab), 998(ab), 1012(ab)
Melis, K, 1086(ab)
Mena, I, 1684, 972(ab), 1021(ab), 1076(ab)
Mendelson, J, 1206, 1022(ab)
Menequetti, JC, 1038(ab)
Meng, XJ, 1093(ab)
Mengel, CE, 2026(le)
Mercer, JR, 1764
Meredith, R, 1052(ab)
Meredith, RF, 1162
Merhige, M, 1581
Merhige, ME, 1039(ab), 1130(ab)
Merlet, P, 989(ab), 998(ab)
Merrick, MV, 1642(le)
Mertens, J, 952(ab)
Mesko, L, 1643(le)
Messa, C, 1555, 1838(ab)
Metcalfe, DD, 1026(ab)
Metz, CE, 1646, 1646(le)
Meyer, B, 2245
Meyer, E, 910(ab)
Meyer, G-J, 729
Meyer, M, 942(ab)
Meyers, L, 1882
Meyniel, G, 1573
Miale, A, 1840(ab)
Miceva, S, 973(ab)
Michelot, JM, 1573
Michelson, RH, 1089(ab), 1092(ab), 1093(ab)
Michigishi, T, 961(ab)
Middelheim, AZ, 2027(le)
Miketic, L, 983(ab)
Miki, H, 991(ab)
Milčinski, M, 204, 1828(le)
Miletich, RS, 1008(ab)
Miley, A, 2288
Millaire, A, 2194(le)
Millar, K, 1842(ab)
Miller, B, 972(ab), 1021(ab)
Miller, DD, 2000, 947(ab), 948(ab), 1028(ab), 1029(ab)
Miller, GA, 1394
Miller, J, 934(ab)
Miller, TR, 534, 552(le), 985(ab)
Millican, A, 1842(ab)
Mills, BJ, 913(ab), 939(ab)
Mills, SL, 965(ab), 1130(ab)
Mills, SN, 921(ab)
Minami, C, 1836(ab)
Minamiji, K, 1718
Mineura, K, 726
Mingiardi, AM, 951(ab)
Minkin, E, 1071(ab)
Minoshima, S, 686, 917(ab), 966(ab), 1048(ab)
Mintun, M, 1028(ab)
Mintun, MA, 1526, 966(ab), 1064(ab), 1072(ab)
Miraldi, F, 1508, 962(ab), 1043(ab)
Miron, SD, 1140(ab)
Mirzadeh, S, 945(ab), 1089(ab)
Miser, J, 1086(ab)
Misra, S, 1072(ab)
Mita, A, 1045(ab)
Mitani, I, 1333
Mitchell, B, 977(ab)
Mitchell, DG, 1081(ab)
Mitsutani, N, 1047(ab)
Miura, S, 1931, 1003(ab)
Miyagawa, M, 1027(ab), 1040(ab), 1066(ab), 1106(ab)
Miyake, H, 1408
Mochizuki, T, 1496, 999(ab)
Modorati, G, 1050(ab)
Moerlein, SM, 300, 1762, 925(ab), 935(ab), 1096(ab)
Mogami, H, 1066(ab), 1106(ab)
Mohapatra, SM, 1133(ab)
Mohiuddin, S, 968(ab), 1012(ab), 1835(ab)
Moi, MK, 915(ab)
Moinnereau, M, 1051(ab)
Moisan, A, 1051(ab)
Mojsiak, JZ, 1052(ab)
Moka, D, 975(ab)
Mokka, R, 1425
Mol, BW, 1018(ab)
Molinoff, PB, 1842(ab)
Momose, T, 1432, 952(ab), 1002(ab), 1072(ab), 1077(ab)
Monaghan, P, 1945
Mondor, H, 971(ab)
Mondorf, U, 971(ab)
Monetti, N, 369, 424
Mong, DP, 1464(le)
Monnens, LAH, 1107(ab)
Monroe, L, 977(ab)
Montane, B, 934(ab), 1085(ab)
Mooibroeck, J, 1587
Moon, RE, 1079(ab)
Moon, S, 1030(ab), 1043(ab)
Moore, BA, 1135(ab)
Moore, JG, 1349
Moore, R, 188
Moore, RH, 851, 953(ab), 987(ab), 1105(ab)
Moore, SC, 899(le), 988(ab)
Moore, W, 977(ab)
Moore, WH, 1133(ab)
Moore, WV, 1452
Moran, EM, 1266
Mordenti, J, 1837(ab)
Moreau, M-FC, 1573
Morefield, LD, 1133(ab)
Moreira, LFP, 1038(ab)
Moretti, JL, 971(ab)
Morgan, GF, 399, 500
Morgan, HT, 871, 955(ab), 1066(ab)
Morgan, MG, 949(ab)
Morguet, AJ, 1019(ab)
Mori, T, 1718
Mori, Y, 1059(ab), 1087(ab)
Moriarty, JA, 1015(ab)
Morita, M, 1785
Morita, R, 928(ab)
Moritan, T, 1432
Moriyama, Y, 1622
Moroney, DA, 1094(ab)
Morozumi, T, 1037(ab)
Morris, AI, 506
Morris, G, 940(ab)
Morris, HH, 912(ab)
Morris, KDW, (9)N11, 11N(2)
Morrish, DW, 921(ab)
Morrison, D, 1072(ab)
Morrison, KS, 1246
Mortelmans, JL, 967(ab)
Mortelmans, L, 1026(ab)
Morton, KA, 1270, 1048(ab), 1104(ab), 1836(ab), 1837(ab)
Mosca, F, 1082(ab)
Moscatelli, G, 922(ab)
Moser, E, 1107(ab)
Moser, R, 932(ab)
Moses, WW, 995(ab)
Moskwa, J, 1028(ab)
Moskwa, JJ, 1072(ab)
Motomura, N, 1068(ab)
Moulton, J, 963(ab)
Moulton, JS, 1605, 1877
Mountz, JM, 941(ab), 1080(ab)
Moyes, J, 992(ab)
Mozley, D, 1008(ab), 1069(ab)
Mozley, PD, 952(ab)
Mu, D, 1030(ab)
Muddiman, B, 1008(ab)
Mudgett, EE, 1086(ab)
Mudgette, EE, 943(ab)
Muehllehner, G, 2342
Mueller, B, 999(ab)
Mueller, SP, 899(le), 988(ab)
Mueller-Gaertner, HW, 980(ab), 1062(ab), 1079(ab)
Muhr, C, 610, 2258
Muirhead, K, 1092(ab)
Mujoo, K, 279
Mukai, T, 991(ab)
Mukherjee, J, 1060(ab)
Mulder, RU, 997(ab)
Mulholland, GK, 942(ab), 974(ab), 994(ab), 1010(ab), 1095(ab)
Mullani, N, 1, 58, 938(ab), 980(ab), 1040(ab)
Mullani, NA, 161, 551(le)
Müller, SP, 961(ab)
Müller-Lissner, SA, 931(ab)
Müller-Schauenburg, W, 2209
Müller-Suur, R, 1643(le)
Muls, E, 931(ab)
Mulshine, JL, 970(ab)
Mumper, RJ, 2139
Munda, R, 1605
Munley, MT, 936(ab), 986(ab), 1066(ab)
Munz, DL, 1002(ab), 1019(ab), 1052(ab)
Murakami, K, 1091(ab)
Murakami, M, 1931, 1003(ab)
Murakami, N, 1785
Murali, D, 1096(ab)
Muramori, A, 1273
Murase, K, 1496, 911(ab), 991(ab), 1027(ab), 1040(ab), 1054(ab), 1066(ab), 1069(ab), 1074(ab), 1106(ab)
Murphy, JG, 1029(ab)
Murphy, PH, 1133(ab)
Murphy, SN, 1060(ab)
Murray, IPC, 1945
Murray, JL, 279, 1326, 970(ab)
Murthy, S, 1054(ab)
Musachio, JL, 964(ab)
Muswick, GJ, 1043(ab), 1065(ab)
Muz, J, 1137(ab)
Muzik, O, 909(ab), 926(ab), 947(ab), 1012(ab), 1028(ab)
Muzykantov, VR, 453
Myers, MJ, 968(ab)
Myers, R, 1838(ab)

Nagaraj, N, 1907
Nagata, H, 1075(ab)
Nagata, S, 1333
Nagel, AA, 1841(ab)
Nagel, JS, 322
Nagle, CE, 1075(ab)
Nagle, K, 967(ab)
Någren, K, 1211, 1095(ab)
Nair, N, 364(le)
Naitoh, Y, 417
Najafi, A, 1017(ab)
Nakagawa, I, 1102(ab)
Nakagawa, K, 1039(ab), 1040(ab)
Nakagawa, M, 1042(ab)
Nakagawara, J, 1073(ab)
Nakahashi, H, 1622, 1097(ab)
Nakai, T, 1087(ab), 1099(ab)
Nakajima, K, 739, 1273, 2215, 961(ab)
Nakamura, J, 1073(ab)
Nakamura, K, 993(ab), 1056(ab), 2194(ie)
Nakamura, T, 699
Nakane, K, 1080(ab)
Nakano, K, 1044(ab)
Nakano, N, 1029(ab)
Nakano, S, 228
Nakashima, Y, 952(ab)
Nakata, S, 1040(ab)
Nakata, T, 865, 2291
Nakayama, M, 1102(ab)
Nakhleh, RE, 1545
Namavari, M, 935(ab)
Nanda, A, 1100(ab)
Nang, G-J, 1022(ab)
Nardin, R, 1206, 1022(ab)
Nariai, T, 1097(ab)
Narra, RK, 947(ab), 1001(ab)
Naruki, Y, 1084(ab)
Narula, J, 312, 867, 1019(ab)
Natali, P, 922(ab)
Natarajan, AT, 814
Natarajan, TK, 308, 1008(ab), 1071(ab)
Naudé, H, 2245
Nedelman, M, 1005(ab), 1013(ab), 1030(ab)
Nedelman, MA, 1005(ab)
Need, JL, 932(ab)
Negrin, J, 1100(ab)
Negrin, JA, 1910
Nelp, WB, 1056(ab), 1843(ab)
Nelson, AD, 1043(ab), 1065(ab)
Neptune, M, 2227, 2079
Nerad, S, 959(ab)
Neto, VR, 1131(ab)
Neubauer, RA, 1840(ab)
Neumann, DR, 912(ab), 968(ab), 1133(ab), 1135(ab)
Neumann, R, 1057(ab)
Neumann, RD, 1661, 970(ab), 1024(ab), 1044(ab), 1055(ab), 1056(ab), 1057(ab), 1090(ab), 1101(ab)
Neumann, W, 925(ab)
Neumann, WL, 944(ab), 1103(ab)
Neumeyer, JL, 1069(ab)
Neuringer, L, 1081(ab)
Newell, D, 971(ab)
Newell, JB, 1742
Ng, CK, 910(ab), 927(ab)
Nguyen, N, 1950, 926(ab), 947(ab), 1028(ab)
Nguyen, T, 968(ab), 979(ab), 1031(ab), 1036(ab)
Nichols, KJ, 796
Nickels, RJ, 1001(ab)
Nickles, RJ, 925(ab), 999(ab), 1070(ab), 1072(ab), 1091(ab), 1096(ab)
Nicol, PD, 977(ab)
Niewiarowski, T, 923(ab)
Nimmon, CC, 973(ab), 992(ab), 1105(ab)
Nishibori, T, 1039(ab), 1040(ab)
Nishikawa, J, 1432, 952(ab), 1002(ab), 1072(ab), 1077(ab)
Nishimura, S, 948(ab), 969(ab), 979(ab), 1030(ab)
Nishimura, T, 1333, 1012(ab), 1030(ab), 1035(ab)
Nishino, H, 1622
Nishino, M, 1084(ab)
Nishizawa, S, 991(ab)
Nissenson, A, 1004(ab)
Nissoff, N, 1082(ab)
Nitahara, KS, 946(ab)
Nitzsche, E, 1107(ab)
Niwayama, H, 1039(ab), 1040(ab)
Noguchi, M, 1084(ab)
Noguchi, S, 1785
Nohara, N, 1061(ab)
Nohara, R, 673, 679, 2152, 1034(ab), 1035(ab), 1039(ab)
Noirclerc, M, 1841(ab)
Nonogi, H, 1012(ab), 1030(ab)
Nonomura, A, 2284, 961(ab)
Noon, GP, 255
Nordyke, RA, 411, 1642(le), 2360(le)

Normandin, L, 1085(ab)
Normolle, D, 1399
Normolle, DP, 1086(ab)
Northover, JMA, 940(ab)
Nosco, D, 925(ab), 1016(ab)
Nossiff, N, 1742, 992(ab), 1050(ab)
Nossiff, ND, 1005(ab)
Noto, T, 865
Novak, S, 1048(ab)
Novak-Hofer, I, 1099(ab)
Nowak, DJ, 946(ab)
Nowak, PA, 1094(ab), 1842(ab)
Noz, M, 1132(ab), 1135(ab)
Noz, ME, 1140(ab)
Nuechterlein, P, 803
Nuechterlein, PM, 956(ab), 1073(ab)
Nugeh, EA, 1641(le)
Nuguyen, T, 979(ab)
Nunn, A, 948(ab)
Nunn, AD, 1988, 925(ab), 947(ab), 1001(ab)
Nürnberger, N, 943(ab)
Nusynowitz, ML, 1363, 552(le)
Nuutila, P, 938(ab), 988(ab)
Nybäck, H, 1095(ab)
Nyedvwiecki, D, 918(ab)

Oates, E, 2275
Obara, T, 1044(ab)
Oberdorfer, F, 1548, 920(ab), 1138(ab)
Obrador, D, 1019(ab)
O'Brien, K, 1791
Ochi, K, 911(ab), 991(ab), 1027(ab), 1054(ab), 1055(ab), 1069(ab)
Ochsenkühn, R, 1053(ab)
O'Connell, RA, 1471
O'Connor, MK, 2332, 999(ab), 1018(ab), 1045(ab)
Oda, K, 1079(ab)
Odom-Maryon, T, 796
O'Donnell, S, 992(ab), 1082(ab)
O'Donnell, SM, 1742, 1005(ab)
O'Driscoll, CM, 2281
Odugbesan, O, 252
Oehr, P, 1009(ab), 1051(ab)
Oei, HY, 1845, 981(ab)
Oertel, WH, 1014(ab)
Ogawa, K, 1718, 1059(ab), 1068(ab)
O'Grady, LF, 921(ab), 922(ab)
Ogushi, A, 1061(ab)
Oh, DJ, 958(ab)
Oh, H, 1048(ab)
Oh DJ, 1027(ab)
Ohmomo, Y, 924(ab), 1091(ab), 1094(ab)
Ohnishi, T, 1785
Ohno, T, 2215
Ohta, S, 910(ab)
Ohta, Y, 1044(ab)
Ohtake, T, 1432, 1002(ab)
Ohtani, H, 673, 679, 987(ab), 1029(ab), 1035(ab), 1313(le)
Okada, H, 1064(ab)
Okada, J, 686, 917(ab), 1048(ab)
Okada, RD, 948(ab)
Okada, S, 924(ab)
O'Keefe, JH, Jr, 958(ab), 959(ab), 1041(ab)
Oku, S, 1432
Okunieff, P, 1081(ab)
Oldendorf, WH, 1229
Olea, N, 395
Ollinger, JM, 994(ab), 1060(ab)
O'Malley, JP, 1107(ab)
Onay-Basaran, S, 1056(ab), 1057(ab)
O'Neill, LJ, 1130(ab)
Ono, K, 1084(ab)
Onsel, C, 942(ab)
Ooie, Y, 1066(ab)
Oosterhuis, HW, 975(ab)
Ooya, T, 1084(ab)
Opperman, RW, 1068(ab)
Oppermann, H, 1005(ab)
Oratz, R, 1135(ab)
Ordu, Y, 1026(ab)
Orebaugh, SL, 990(ab)
Oreton, M, 1704
Orlandi, C, 263, 957(ab)
O'Rourke, RA, 2000, 947(ab)
Orr, R, 1052(ab)
Orr, RA, 1162
Orton, M, 943(ab), 954(ab)
Osieka, R, 918(ab)
Ostella, F, 1024(ab), 1098(ab), 1101(ab)
Oster, ZH, 1569
Ostertag, A, 1485
Ostertag, H, 1084(ab)
Ota, Y, 1051(ab)
Otake, T, 952(ab), 1072(ab), 1077(ab)
Otani, H, 928(ab)
Othmer, JP, 1137(ab)
Otsuka, M, 1655, 1015(ab), 1079(ab)
Otsuka, S, 1084(ab)
Otto, AC, 2245
O'Tuama, LA, 16, 912(ab), 913(ab), 1015(ab)
Ouhayoun, E, 1901
OuYang, X, 965(ab)
Overbeck, B, 921(ab), 1044(ab), 1049(ab), 1075(ab)
Owen, J, 461
Owens, DS, 1104(ab)
Oyama, M, 1079(ab)
Oyen, WJG, 1854, 963(ab), 2195(le)
Ozaki, Y, 924(ab)
Ozawa, S, 1039(ab)
Özdemir, T, 1106(ab)
Ozguven, M, 947(ab), 949(ab), 959(ab), 1007(ab), 1033(ab), 1035(ab)

Paans, AMJ, 1587
Paas, M, 961(ab)
Pace, L, 1661, 1849, 949(ab), 1042(ab)
Paganelli, G, 1007(ab), 1010(ab), 1050(ab)
Paik, C, 1057(ab)
Paik, CH, 1024(ab), 1055(ab), 1056(ab), 1057(ab), 1090(ab), 1101(ab)
Pais, SO, 1139(ab)
Palac, RT, 193, 2027(le)
Palacios, I, 1019(ab)
Palatianos, GM, 1048(ab)
Palestro, CJ, 1861, 933(ab), 962(ab), 976(ab), 1003(ab), 1013(ab), 1044(ab), 1049(ab), 1083(ab)
Palevsky, HI, 512, 950(ab)
Palmas, W, 929(ab), 950(ab), 978(ab)
Palmer, L, 1092(ab)
Pan, T, 1065(ab)
Pan, T-S, 1061(ab)
Pang, IW, 1135(ab)
Pang, RHL, 1005(ab)
Panyachotipun, C, 964(ab)
Panzer, DE, 1046(ab), 1131(ab)
Papadpoulos, M, 1843(ab)
Papapoulos, SE, 1129(ab)
Papisov, M, 1082(ab)
Papon, JM, 1573
Pappas, N, 1022(ab)
Pappata, S, 1608, 1078(ab)
Paradis, K, 862
Paradise, A, 980(ab)
Parekh, JS, 2324
Parisi, MT, 1782
Park, CH, 328, 1617, 2026(le)
Park, H-M, 1640(le)
Parker, D, 1842(ab)
Parker, JA, 1046(ab)
Parker, LN, 1266
Parkey, RW, 1016(ab)
Parkinson, D, 935(ab), 1096(ab)
Parry, DF, 1573
Parsons, SM, 1089(ab), 1092(ab)
Pascal, S, 1725, 942(ab)
Paserio, E, 1640(le)
Pasqualini, R, 925(ab)
Patch, G, 1048(ab), 1104(ab)
Patch, GG, 1270, 1836(ab)
Pate, BD, 1246, 966(ab), 1007(ab)
Patel, N, 319
Patel, NC, 963(ab)
Patel, R, 328
Patrick, ST, 242, 1025(ab)
Patterson, J, 2086
Patterson, L, 2023(le)
Patterson, RE, 958(ab), 1027(ab)
Patton, CS, 67
Patton, DD, 1135(ab)
Paulesu, E, 1022(ab)
Pauwels, EKJ, 468, 814, 1129(ab)
Pauwels, S, 1192
Payan, JM, 13
Payne, JK, 972(ab)
Pearlson, GD, 991(ab)
Pedersen, F, 139
Pedley, B, 1842(ab)
Pedraza, V, 395
Peeters, T, 931(ab)
Pēlegrin, A, 1414, 941(ab)
Pelizzari, CA, 1478
Peller, PJ, 1129(ab)
Pellerin, SL, 969(ab)
Peltier, P, 221, 785, 941(ab), 967(ab)
Peng, FK, 1000(ab)
Penix, LR, 1078(ab)
Penney, BC, 936(ab)
Pentlow, KS, 1021(ab)
Peracchia, A, 436, 2027(le)
Perani, D, 1022(ab)
Pereira-Barreto, AC, 1038(ab)
Perentesis, P, 970(ab)
Perlman, SB, 925(ab), 999(ab), 1070(ab)
Perlmutter, JS, 935(ab)
Perlmutter, NS, 193, 2027(le)
Peroutka, SJ, 965(ab)
Perper, EJ, 2107
Perri, JL, 1050(ab)
Perrone-Filardi, P, 938(ab), 1027(ab)
Perry, AD, 954(ab)
Perry, DJ, 961(ab)
Perry, JR, 946(ab)
Peshock, RM, 2311
Pesser, JW, 975(ab)
Petegnief, Y, 898(le)
Peters, AM, 1649, 362(le), 896(le), 900(le), 954(ab), 968(ab), 990(ab), 1014(ab)
Peters, J, 1106(ab)
Peters, WP, 1013(ab)
Petrillo, EW, Jr, 1730
Petry, N, 947(ab), 1028(ab), 1030(ab)
Petry, NA, 2278, 1072(ab)
Petti, AR, 1844(ab)
Peycelon, P, 1037(ab)
Pfeiffer, N, 1008(ab), 1069(ab)
Phelps, M, 989(ab), 999(ab), 1004(ab)
Phelps, ME, 23, 665, 733, 1555, 2199, 35N(4), 909(ab), 920(ab), 926(ab), 927(ab), 935(ab), 938(ab), 953(ab), 969(ab), 981(ab), 982(ab), 987(ab), 998(ab), 1004(ab), 1010(ab), 1025(ab), 1061(ab), 1062(ab), 1134(ab), 1838(ab)
Philbrick, JT, 2324
Phillips, PC, 16
Phillips, RKS, 940(ab)
Phillips, WT, 377, 749(le), 2025(le)
Philpott, GW, 1054(ab)
Picard, D, 1467(le)
Picard, M, 919(ab), 1467(le)
Pidlich, J, 2132
Pieper, KS, 1518, 1034(ab)
Piepsz, A, 216, 1294, 364(le)
Pieralli, S, 1050(ab)
Pieri, P, 312, 851
Piers, DA, 1709, 1843(ab)
Pierson, RN, Jr, 983(ab), 1050(ab), 1104(ab), 1105(ab), 25N(12)
Pieters, H, 62
Pietrelli, L, 945(ab)
Pietrzyk, U, 931(ab)
Pike, MC, 483, 2034
Pileggi, F, 1038(ab)
Pina, V, 938(ab), 1040(ab)
Pinotti, HW, 1131(ab)
Pinsky, CM, 1051(ab), 1052(ab), 1054(ab)
Pinson, A, 2324
Pipes, DW, 1089(ab)
Pippin, G, 1056(ab)
Pirotte, R, 399
Pirro, J, 947(ab)
Pisani, T, 1097(ab)
Pisani, TL, 964(ab), 974(ab), 994(ab), 1096(ab)
Piscani, K, 1022(ab)
Piscione, F, 1849
Pison, CF, 862
Pitt, HA, 1836(ab)
Piwnica-Worms, D, 1992, 957(ab)
Planchon, B, 785
Plankey, MW, 1375
Plati, EL, 1318
Platts, SH, 263
Plenevaux, A, 2266, 935(ab), 980(ab)
Pless, J, 1084(ab)
Pleus, RC, 994(ab)
Plott, G, 1052(ab)
Plott, WE, 1162
Pochis, WT, 1904
Podoloff, D. A., 1233, 1326, 918(ab), 932(ab), 962(ab), 970(ab)
Podreka, I., 1675, 991(ab), 1073(ab)
Polansky, A, 1162
Polepalle, CS, 1046(ab)
Poline, JB, 1063(ab)
Pollak, JS, 1601, 1047(ab)
Pollard, KR, 923(ab), 1058(ab)
Pollock, DK, 914(ab)
Pomper, MG, 1532
Ponce, YZ, 1092(ab)
Ponto, LL, 1063(ab)
Ponto, RA, 956(ab)
Pooley, RA, 1004(ab), 1028(ab)
Porenta, G, 909(ab), 927(ab), 989(ab), 998(ab), 999(ab)
Port, S, 553(le)
Port, SC, 939(ab), 959(ab), 1032(ab), 1059(ab)
Porter, AT, 918(ab), 997(ab)
Poston, JW, 830
Poston, JW, Sr, 835
Potts, JM, 1918, 967(ab)
Pounds, BK, 1133(ab)
Powe, JE, 997(ab)
Powers, WJ, 1738
Pozniakoff, T, 929(ab)
Prados, MD, 955(ab)
Pralet, D, 1084(ab)
Prapansiri, V, 964(ab)
Prato, FS, 1108(ab)
Pratt, JP, 970(ab)
Prellwitz, J, 1134(ab)
Prellwitz, JA, 1039(ab)
Prenant, C, 1608, 1078(ab)
Prenen, JA, 2057
Preslar, J, 429, 1808
Press, OW, 1843(ab)
Preston, DF, 1452, 1130(ab),

1132(ab), 1137(ab), 1138(ab)
Price, JC, 1062(ab)
Prigent, F, 1067(ab)
Primeau, M, 1961
Prince, JR, 1133(ab), 1835(ab)
Prokop, EK, 518
Provan, I, 1945
Provenzale, JA, 366
Puchnina, EA, 453
Pupi, A, 1501, 1844(ab)
Purnell, GL, 1131(ab), 1132(ab)
Pyzalski, RA, 999(ab)

Quadri, SM, 1442
Quaife, RA, 919(ab), 1006(ab)
Quaranta, M, 2064
Quinn, RJ, 2050, 2273, 951(ab)
Quirce, R, 860
Quirijnen, JMSP, 1082(ab)

Raat, A, 1192
Rabé, WLR, 2245
Rabito, CA, 272, 953(ab), 973(ab)
Rabitsch, H, 1491
Racz, JC, 1046(ab)
Radesca, L, 1841(ab)
Rae, JR, 1791
Raffel, DM, 1004(ab), 1028(ab)
Raftery, E, 37
Raftery, EB, 967(ab)
Rajagopalan, R, 1016(ab), 1103(ab)
Rajashekharrao, B, 364(le)
Rajeevan, N, 936(ab)
Rajur, SB, 1081(ab)
Ramanna, L, 441, 917(ab)
Ramsay, SC, 33, 1382
Randive, GN, 985(ab), 1100(ab)
Ranger, N, 154, 955(ab), 1008(ab), 1069(ab)
Ranger, NT, 1060(ab)
Rao, MG, 2026(le)
Rao, PS, 1043(ab)
Rao, S, 913(ab)
Rao, TN, 1445, 915(ab), 1017(ab), 1102(ab)
Rasey, JS, 955(ab), 1028(ab)
Rashidi-Nezami, S, 2288
Raskin, JB, 1046(ab), 1131(ab)
Ratib, O, 927(ab)
Rattner, Z, 1062(ab)
Raubitchek, A, 1661
Raubitschek, A, 970(ab)
Rauh, DA, 2227
Raval, U, 967(ab)
Ravert, H, 1071(ab)
Ravert, HT, 16, 308, 961(ab), 980(ab), 1008(ab), 1062(ab), 1071(ab), 1078(ab), 1079(ab)
Ray, S, 1014(ab)
Raynaud, C, 911(ab), 1015(ab), 1086(ab), 1841(ab)
Raynaud, L, 998(ab)
Rayne, D, 1099(ab)
Read, RC, 1132(ab)
Reba, RC, 333, 1923, 1024(ab), 1090(ab), 1139(ab)
Reddy, D, 1132(ab)
Reddy, RV, 1074(ab)
Redlhammer, DE, 1046(ab), 1131(ab)
Reece, C, 1042(ab)
Reese, L, 1108(ab)
Regelmann, WE, 1139(ab)
Rehder, JG, 1129(ab)
Reiber, C, 920(ab)
Reiche, W, 1011(ab)
Reid, C, 1382
Reid, R, 918(ab)
Reigber, Ch, 1083(ab)
Reijs, AEM, 1043(ab)
Reilley, J, 1076(ab)
Reiman, RE, 932(ab), 1061(ab), 1077(ab), 1079(ab)
Reinartz, R, 1052(ab)
Reiners, C, 961(ab)
Reinprecht, B, 1073(ab)
Reinsberg, J, 1051(ab)
Reiser, M, 920(ab)
Reisser, C, 1548
Reivich, M, 942(ab), 960(ab), 1070(ab), 1072(ab), 1094(ab), 1842(ab)
Renkin, J, 1012(ab)
Reno, J, 1020(ab)
Reno, JM, 1445, 1017(ab), 1102(ab)
Resche, I, 962(ab)
Reske, SN, 918(ab), 1085(ab)
Resnick, L, 1725
Reubi, J-C, 1184, 981(ab), 1084(ab)
Reuland, P, 2209
Revenaugh, JR, 1028(ab)
Revol, M, 912(ab)
Rexinger, D, 483
Rexworthy, CG, 930(ab)
Reynolds, JC, 1661, 970(ab), 978(ab), 1055(ab), 1056(ab), 1057(ab)
Reynolds, JC(ab)
Rezai, K, 429
Rhind, SK, 1842(ab)
Rhodes, BA, 1021(ab), 1836(ab)
Rhodes, CG, 1937, 2169, 927(ab)
Ricciardelli, B, 949(ab)
Rice, KC, 1008(ab), 1841(ab)
Rich, KM, 954(ab)
Riekkinen, P, 1070(ab)
Rifkin, MD, 1081(ab)
Rigo, P, 1036(ab)
Riley, S, 990(ab)
Ringert, R-H, 1052(ab)
Ritchie, JL, 928(ab)
Riva, N, 922(ab)
Riva, P, 922(ab)
Rivera-Luna, H, 949(ab), 972(ab), 991(ab), 1071(ab), 1107(ab), 1836(ab)
Rizzo, G, 1050(ab)
Robbins, C, 923(ab)
Robbins, MS, 242
Robbins, T., 1231
Roberts, J, 982(ab)
Roberts, R, 2158
Robeson, W, 1134(ab)
Robinson, E, 1084(ab)
Robinson, RA, 1358
Robinson, RG, 1130(ab), 1132(ab), 1137(ab), 1138(ab)
Rocco, TP, 200
Rocque, PA, 975(ab)
Rodney, RA, 929(ab), 1018(ab)
Rodrigues, JG, 1131(ab)
Rogé, C, 962(ab)
Rogers, KJ, 1162
Rogers, P, 946(ab)
Rogers, WL, 186(le), 936(ab), 986(ab), 1065(ab)
Rogic, MM, 1101(ab), 1103(ab)
Rohlfing, J, 1104(ab)
Rojas-Burke, J, 11N(7), 13N(6), 16N(7), 17N(6), 11N(10), 24N(11), 13N(12), 21N(12)
Roland, J, 2027(le)
Romahan, J, 1485
Ronga, G, 1640(le), 1645(le)
Roodt, JP, 62
Roosen, N, 1225
Roper, SN, 1684
Roque, C, 1840(ab)
Rosanowski, F, 920(ab)
Roschmann, P, 1133(ab)
Rose, E, 967(ab)
Rosebrough, SF, 1098(ab)
Rosen, C, 1026(ab)
Rosen, JM, 993(ab)
Rosen, ST, 1021(ab)
Rosen, T, 1841(ab)
Rosenberg, AR, 1542
Rosenberg, DJ, 1777
Rosenblum, MG, 279, 1326
Rosenschein, U, 1034(ab)
Rosenspire, K, 948(ab)
Rosenthall, L, 1391
Rosenzweig, HS, 985(ab), 1100(ab)
Roser, CA, 1102(ab)
Ross, CA, 1078(ab)
Ross, DS, 2181
Rossetti, C, 925(ab), 1007(ab), 1039(ab)
Rossleigh, M, 1542
Rosso, J, 990(ab)
Roth, D, 934(ab)
Roth, GM, 136
Roth, R, 1071(ab)
Roth, RH, 1007(ab)
Rothstein, RD, 1422
Rothstein, RM, 856
Rotman, M, 1661, 970(ab)
Roumanas, P, 962(ab), 1049(ab)
Rousseau, J, 2194(le)
Rowe, CC, 1688
Rowe, RK, 1135(ab)
Rowe, RW, 1581
Roy, S, 1042(ab), 1053(ab)
Rozanski, A, 796, 958(ab), 959(ab)
Rubin, RH, 483, 1014(ab), 1050(ab), 1057(ab), 1101(ab)
Ruck, P, 2209
Rudat, V, 1548
Rudolf, J, 1338
Ruiz, M, 957(ab)
Ruiz de Almodóvar, JM, 395
Ruiz-Garcia, J, 395
Rump, C, 1107(ab)
Rumsey, WL, 947(ab), 948(ab)
Ruotsalainen, U, 1211, 938(ab), 988(ab)
Rusch, V, 1132(ab)
Rusckowski, M, 750(le), 1014(ab), 1053(ab), 1098(ab)
Rush, AJ, 951(ab)
Russell, C, 1052(ab)
Russell, CD, 1162, 1821, 2061
Russell, M, 983(ab), 1050(ab)
Russolillo, E, 1849
Ruth, TJ, 1246, 966(ab), 1007(ab)
Ryals, CJ, 1133(ab)
Ryan, JW, 1239
Ryan, PJ, 913(ab)
Ryo, UY, 2139, 913(ab), 939(ab), 977(ab), 1641(le)
Rysavy, JA, 994(ab)
Ryvlin, P, 912(ab)

Saalmann, A, 969(ab)
Saari, MA, 939(ab)
Saccavini, JC, 1051(ab)
Sacchetti, E, 1136(ab)
Sackellares, JC, 912(ab)
Sacker, D, 1866
Sacker, DF, 1022(ab)
Sacknoff, R, 1318
Sadato, N, 991(ab)
Sadzot, B, 980(ab), 1077(ab)
Saenger, EL, 1018(ab)
Saerens, J, 1619
Saga, T, 825, 978(ab), 1087(ab), 1099(ab)
Saha, G, 912(ab), 968(ab)
Saha, GB, 1133(ab)
Sai-Maurel, C, 997(ab)
Saito, T, 1742
Saitoh, M, 917(ab)
Saitta, B, 436, 1036(ab), 2027(le)
Saji, H, 819, 1064(ab)
Sakahara, H, 1087(ab), 1099(ab)
Sakaki, S, 911(ab), 991(ab), 1069(ab), 1074(ab)
Sakakibara, T, 865
Sakata, K, 417
Salcedo, EE, 2221
Saleh, MN, 1162
Salimi, A, 1100(ab)
Saling, M, 1688
Salk, D, 1132(ab)
Salk, RD, 808
Salmon, E, 980(ab)
Salmon, Y, 897(le)
Salter, MM, 1162
Saltzman, HA, 950(ab)
Salusky, I, 1004(ab)
Salvadori, P, 1082(ab)
Salvatore, M, 1849, 949(ab), 970(ab), 1042(ab)
Samaan, NA, 962(ab)
Samaratunga, R, 1877, 963(ab)
Samaratunga, RC, 1045(ab)
Samoszuk, MK, 89
Samson, Y, 1608, 1078(ab)
Samuelson, E, 1021(ab)
Sanchez, A, 1048(ab)
Sanchez-Urdazpal, L, 999(ab)
Sanderson, JA, 1445, 1017(ab), 1102(ab)
Sanderson, L, 1017(ab)
Sandler, D, 998(ab)
Sandler, ED, 1782
Sandrock, D, 1002(ab), 1019(ab), 1052(ab)
Sanford, EJ, 1054(ab)
Sanger, J, 1135(ab)
Sanger, JJ, 1140(ab)
Saptogino, A, 983(ab), 1002(ab)
Saraste, M, 988(ab)
Sarnoski, J, 939(ab), 959(ab), 1032(ab)
Sarti, G, 922(ab)
Sasajima, T, 726
Sasaki, M, 1077(ab)
Sasaki, T, 1079(ab)
Sasaki, Y, 228, 1432, 2124, 952(ab), 1002(ab), 1072(ab), 1077(ab)
Sasayama, S, 2152, 991(ab), 1039(ab)
Sasayama, T, 1064(ab)
Sassaman, MB, 1841(ab)
Sasso, NL, 1052(ab)
Sato, J, 1057(ab)
Sato, K, 1073(ab)
Sato, T, 2118, 1083(ab)
Satter, MR, 1072(ab)
Satyamurthy, N, 935(ab), 1004(ab), 1010(ab), 1025(ab)
Satz, P, 1078(ab)
Savas, V, 1950
Savill, J, 1014(ab)
Sawle, GV, 960(ab)
Sayman, HB, 1700
Scaible, T, 785
Scates, S, 1837(ab)
Scatton, B, 1608
Schaab, KM, 1090(ab)
Schaefer, RF, 1132(ab)
Schaible, T, 967(ab), 1020(ab)
Schauwecker, DS, 1394
Scheff, A, 1313(le)
Scheffel, U, 76, 964(ab), 1069(ab)
Scheibe, PO, 1169
Schelbert, H, 927(ab), 989(ab), 999(ab)
Schelbert, HR, 665, 733, 2199, 909(ab), 910(ab), 926(ab), 927(ab), 938(ab), 953(ab), 969(ab), 998(ab)
Schiepers, C, 1004(ab)
Schiepers, CW, 982(ab), 1025(ab)
Schifter, T, 932(ab)
Schijf, C, 941(ab)
Schildhauer, T, 913(ab)
Schlake, H-P, 1077(ab)
Schlom, J, 1051(ab), 1052(ab)
Schlyer, D, 993(ab)

Schmarkey, LS, 958(ab), 1027(ab)
Schmelter, R, 1052(ab)
Schmidbauer, M, 991(ab)
Schmidt, D, 961(ab), 1070(ab)
Schmidt, DE, 1593
Schmidt, DH, 1059(ab)
Schmidt, H, 1106(ab)
Schmidt, S, 1051(ab)
Schneider, H, 963(ab)
Schneider, HJ, 1877
Schneider, PM, 1133(ab)
Schneider, RF, 2126
Schnell, PO, 1837(ab)
Schnobrich, KE, 940(ab)
Schnur, W, 982(ab)
Schober, B, 2359(le)
Schober, O, 1077(ab), 1317(le)
Schoeps, K-O, 994(ab)
Schold, SC, 616, 932(ab), 1077(ab)
Scholm, J, 1661
Schreiber, G, 1057(ab)
Schroder, L, 963(ab)
Schroder, LE, 1877
Schroettle, W, 1365
Schröttle, W, 931(ab)
Schubiger, PA, 1099(ab)
Schuldes, H, 970(ab)
Schultz, SJ, 969(ab)
Schumacher, J, 981(ab), 1009(ab)
Schumpelick, V, 1052(ab)
Schunck, BG, 936(ab)
Schuster, B, 1073(ab)
Schuster, DP, 719
Schuster, JM, 922(ab)
Schwaiger, M, 565, 1950, 926(ab), 947(ab), 949(ab), 988(ab), 994(ab), 1011(ab), 1012(ab), 1013(ab), 1028(ab), 1030(ab), 1034(ab), 1040(ab)
Schwartz, AN, 404
Schwartz, JG, 377, 2025(le)
Schwartz, M, 1313(le)
Schwartz, RB, 322, 1478, 933(ab)
Schwartz, RS, 940(ab), 1029(ab)
Schwartz, Z, 1466(le)
Schwarz, J, 1014(ab)
Schwarz, SS, 1054(ab)
Schweitzer, J, 1684
Schwetlick, G, 1027(ab)
Sciammarella, M, 1039(ab)
Scott, JA, 188, 366, 367, 903, 1469, 2363
Scott, JW, 1821
Scott, MD, 1614
Scott, P, 993(ab)
Scripko, JG, 1842(ab)
Seabold, J, 967(ab)
Seabold, JE, 1358
Sease, D, 1581, 1039(ab)
Sebastian, JL, 319
Seccamani, E, 922(ab), 970(ab)
Seeger, L, 1025(ab)
Segall, GM, 2107, 1038(ab), 1041(ab), 1049(ab)
Sehgal, VJ, 977(ab)
Seibyl, J, 979(ab)
Seibyl, JP, 1754, 1043(ab)
Seiffert, E, 920(ab)
Seiler, C, 938(ab), 1040(ab)
Seitz, J, 1073(ab)
Seitz, JP, 1075(ab)
Sekela, ME, 255
Seki, C, 1071(ab)
Sekine, H, 1087(ab)
Sela, J, 1466(le)
Seldin, DW, 929(ab), 1018(ab)
Selmer, J, 2318
Senda, M, 1079(ab)
Senneff, MJ, 2037
Seo, IS, 983(ab)
Seo, S, 713
Serafini, A, 934(ab), 1049(ab), 1085(ab), 1138(ab)
Serafini, AN, 2227, 920(ab), 1048(ab), 1089(ab), 1092(ab)
Serano, J, 860
Setyono-Han, B, 1084(ab)
Sexsmith, GP, 930(ab)
Sfakianakis, G, 920(ab), 934(ab), 1049(ab), 1085(ab)
Sfakianakis, GN, 2227, 1046(ab), 1048(ab), 1089(ab), 1092(ab), 1131(ab)
Shafique, I, 1077(ab)
Shah, A, 983(ab), 1074(ab)
Shani, J, 1466(le)
Shanker, R, 1129(ab)
Shannon, K, 1015(ab)
Shao, L, 995(ab), 1008(ab), 1064(ab), 1069(ab)
Shapiro, B, 524, 1882, 362(le), 943(ab), 1011(ab), 1086(ab), 1313(le), 2092
Sharkey, RM, 1054(ab), 1058(ab)
Sharma, S, 1031(ab), 1032(ab)
Shaw, A, 805
Shaya, E, 961(ab), 964(ab), 1008(ab), 1071(ab)
Shea, CE, 1094(ab)
Shealy, D, 1005(ab)
Shefer, RE, 1096(ab)
Sheinfeld, M, 1873, 1045(ab)
Sheldon, J, 1725
Shelton, S, 1070(ab), 1096(ab)
Shemesh, E, 944(ab)
Shen, YH, 939(ab), 959(ab), 1032(ab), 1059(ab)
Shepard, HM, 1837(ab)
Shereff, MJ, 963(ab)
Sherman, P, 1097(ab)
Sherman, PS, 964(ab), 974(ab), 994(ab), 1096(ab)
Sheth, K, 1092(ab)
Shibahara, N, 1059(ab)
Shibasaki, H, 991(ab)
Shigeta, A, 1044(ab)
Shih, WJ, 913(ab), 977(ab), 1644(le)
Shikama, N, 1039(ab), 1040(ab)
Shima, F, 1015(ab)
Shimada, T, 1059(ab), 1087(ab)
Shimamoto, K, 2291
Shimonagata, T, 1012(ab), 1030(ab), 1035(ab)
Shindledecker, G, 967(ab)
Shindo, M, 1035(ab)
Shishido, F, 726
Shiue, C-Y, 1012(ab), 1039(ab)
Shiue, GG, 994(ab), 1134(ab)
Shlue, C-Y, 994(ab), 1134(ab)
Shoji, T, 865
Shore, RM, 1297
Shoup, TM, 965(ab)
Shryock, MS, 1641(le)
Shuke, N, 961(ab), 1075(ab)
Shulkin, BL, 2278, 943(ab), 1086(ab)
Sibbitt, R, 1081(ab)
Sibbitt, W, 1081(ab)
Siddiqui, A, 1086(ab)
Siegal, BA, 1532
Siegel, BA, 245, 1526, 954(ab), 961(ab), 1054(ab), 1833(le)
Siegel, JA, 2176, 931(ab), 1836(ab)
Siegel, ME, 1010(ab), 1839(ab)
Siegel, S, 926(ab)
Sigal, SL, 759
Signore, A, 1640(le), 1645(le)
Sigurdson, ER, 649
Silagan, G, 959(ab), 1001(ab), 1036(ab)
Silber, H, 929(ab), 950(ab), 978(ab), 1067(ab)
Silberstein, EB, 982(ab), 1018(ab)
Silbiger, ML, 1042(ab), 1136(ab)
Silfen, D, 1261, 2299, 1046(ab)
Silverman, L, 20N(10)
Silverman, PM, 2086
Silvestri, R, 958(ab)
Simon, H, 1353
Simon, HE, 1133(ab)
Simpkin, DJ, 1001(ab)
Simpson, JR, 954(ab)
Simpson, SG, 951(ab)
Sinclair, I, 1014(ab)
Singer, F, 1004(ab)
Singh, J, 845, 2025(le)
Singh, PR, 985(ab)
Singletary, SE, 1326
Sinha, S, 927(ab)
Sinow, R, 1836(ab)
Sinusas, A, 939(ab)
Sinusas, AJ, 909(ab), 957(ab)
Sinzinger, H, 2132
Sirotta, PS, 900(le)
Sisler, J, 2241
Sisson, JC, 1399, 362(le), 943(ab), 1086(ab)
Sitomer, J, 1013(ab), 1040(ab)
Siwko, R, 910(ab)
Sjögren, I, 2043
Skrade, B, 1059(ab)
Skretting, A, 1837(ab)
Sladen, GE, 924(ab)
Slamon, D, 1555, 981(ab), 1837(ab)
Slinkin, MA, 453, 1742
Slizofski, WJ, 1138(ab)
Sloof, TJJH, 963(ab), 2195(le)
Smallhorn, JF, 237
Smalling, RW, 1
Smart, RC, 1668
Smets, L, 361(le)
Smith, A, 1099(ab)
Smith, BD, 956(ab)
Smith, CB, 102
Smith, E, 1007(ab)
Smith, EO, 210, 1754, 979(ab), 1043(ab)
Smith, FW, 967(ab)
Smith, GT, 1093(ab)
Smith, H, 1877, 963(ab)
Smith, HE, 1593
Smith, LR, 1918
Smith, MF, 1068(ab)
Smith, P, 967(ab)
Smith, QR, 16
Smith, W, 1048(ab)
Smith, WH, 958(ab), 1059(ab)
Smits, P, 1538
Smoak, W, 942(ab)
Sńchez-Roa, PM, 308
Snow, BJ, 1246, 966(ab)
Soares, J, Jr, 1038(ab)
Sobczak, M, 1059(ab)
Sobel, BE, 300, 925(ab)
Sobezak, M, 958(ab)
Sobue, T, 228
Söderborg, B, 186(le)
Soil, A, 1000(ab)
Solanki, K, 992(ab)
Solanki, KK, 1011(ab), 1102(ab), 1105(ab)
Sold, G, 1019(ab)
Solomon, HF, 548(le)
Solot, G, 1968
Som, P, 1569
Somayaji, VV, 1764
Sood, VK, 1024(ab)
Sorandes, T, 1139(ab)
Sørensen, SS, 139
Sorrentino, S, 1042(ab)
Soskolne, WA, 1466(le)
Sostman, HD, 616
Sostre, S, 972(ab), 976(ab), 991(ab), 1046(ab), 1071(ab), 1077(ab), 1107(ab), 1836(ab)
Souder, E, 942(ab)
Soufer, R, 759
Southern, J, 1019(ab)
Southern, JF, 312
Spaulding, M, 1052(ab)
Specht, HD, 2288
Spencer, RP, 207, 1182, 2249, 1641(le), 1828(le)
Spencer, SA, 1162
Spencer, WR, 1100(ab)
Sperling, M, 1045(ab)
Spicer, JA, 1138(ab)
Spicer, KM, 1132(ab)
Spiegler, EH, 976(ab), 1046(ab)
Spies, SM, 1021(ab)
Spies, WG, 1021(ab)
Spieth, ME, 1839(ab)
Spinelli, A, 922(ab)
Spittka, G, 1020(ab)
Spittka, GA, 1058(ab)
Spitz, J, 914(ab), 1026(ab)
Splinter, TAW, 1845
Split, A, 1018(ab)
Squire, P, 1056(ab)
Srinivasan, A, 1445, 915(ab), 1017(ab), 1020(ab)
Srivastava, PC, 1091(ab), 1095(ab)
Srivastava, SC, 945(ab), 984(ab), 1023(ab), 1840(ab), 1842(ab)
Stabin, M, 1661, 1017(ab)
Stabin, MG, 808
Stadalnik, RC, 1169, 1177
Staker, BL, 1439
Stamey, TA, 1713
Stamos, JA, 986(ab)
Standke, R, 952(ab)
Stanford, W, 429
Stapleton, J, 945(ab)
Stark, VJ, 1239
Starksen, N, 998(ab)
Stassinopoulou, C, 1843(ab)
Stathis, M, 964(ab)
Steel, C, 927(ab)
Steele, LS, 1101(ab)
Steele, RT, 1090(ab)
Stein, PD, 950(ab)
Stein, S, 1064(ab)
Steinert, CL, 1069(ab)
Steingart, RM, 753
Steinmetz, A, 944(ab)
Steplewski, Z, 984(ab), 1023(ab), 1842(ab)
Stepniak-Biniakiewicz, D, 1016(ab)
Stern, M, 960(ab)
Stern, S, 1559, 1312(le)
Stevens, JS, 2286
Stevick, CA, 1041(ab)
Stewart, CA, 913(ab), 1026(ab), 1105(ab)
Stewart, RE, 2000, 947(ab), 948(ab), 1028(ab), 1029(ab)
St. George, JK, 1601, 1047(ab)
Stinson, RL, 1442
Stipp, V, 913(ab)
Stöcklin, G, 1225, 1338, 1888, 937(ab), 1009(ab)
Stoecklin, G, 918(ab)
Stolz, B, 1084(ab)
Stone, CK, 1611, 925(ab), 999(ab)
Stoneburner, LK, 1058(ab)
Stone-Elander, S, 994(ab)
Stowell, JG, 1139(ab)
Strand, M, 1056(ab)
Strand, RD, 556
Strand, S-E, 1278, 916(ab)
Stratton, JR, 928(ab), 940(ab)
Straub, RF, 1840(ab)
Strauer, BE, 909(ab)
Strauss, A, 1017(ab)
Strauss, HW, 272, 483, 851, 1254, 1742, 2351, 2356, 3A(1), 3A(2), 3A(3), 3A(4), 3A(5), 3A(6), 3A(7), 3A(8), 3A(9), 3A(10), 3A(11),

3A(12), 928(ab), 955(ab), 969(ab), 987(ab), 992(ab), 1005(ab), 1014(ab), 1019(ab), 1029(ab), 1031(ab), 1050(ab), 1057(ab), 1082(ab), 1099(ab), 1101(ab), 1105(ab)
Strauss, J, 1085(ab)
Strauss, LG, 623, 1485, 1548, 920(ab), 1083(ab), 1084(ab), 1138(ab)
Stricke, P, 1031(ab)
Strickland, A, 1021(ab)
Stringham, LM, 1090(ab)
Stritzke, P, 1076(ab)
Stritzke, PH, 1104(ab)
Strother, SC, 966(ab)
Stubbs, CC, 1375
Stubbs, JB, 1375
Stulmuller, JE, 946(ab)
Stulzaft, O, 1004(ab)
Sturiale, C, 922(ab)
Stutte, H-J, 259
Stuttle, A, 990(ab)
Su, CH, 1000(ab)
Su, F-M, 915(ab), 1020(ab)
Subramanian, G, 2126
Subramanian, KM, 480
Suehiro, M, 1087(ab)
Suematsu, K, 1073(ab)
Suess, E, 1675
Sugarbaker, P, 1661
Sugihara, H, 1042(ab)
Sugii, A, 1102(ab)
Sugiyama, Y, 1075(ab)
Sukahara, T, 1061(ab)
Sullivan, BW, 915(ab), 1023(ab)
Sullivan, K, 1132(ab)
Sumiya, H, 1074(ab), 1079(ab)
Summer, TE, 1614
Sunderland, JJ, 994(ab), 1039(ab), 1134(ab)
Sures, T, 1063(ab)
Sutton, RT, 1003(ab)
Suzuki, T, 928(ab)
Svendsen, TL, 139
Swahn, C-G, 934(ab), 1095(ab)
Swailem, FM, 186(le)
Sweetlove, MA, 62
Swyer, AJ, 962(ab), 1861, 1003(ab), 1013(ab), 1049(ab)
Sy, WM, 983(ab)
Sybirska, E, 979(ab), 1007(ab), 1071(ab)
Sybirska, EH, 1754
Sychra, JJ, 987(ab)
Syrota, A, 739, 1608, 911(ab), 989(ab), 998(ab), 1004(ab), 1015(ab), 1062(ab), 1063(ab), 1067(ab), 1078(ab), 1086(ab), 1841(ab)
Szabo, Z, 964(ab), 991(ab), 1071(ab), 1077(ab), 1836(ab)
Szego, T, 1131(ab)

Tabbarah, M, 1021(ab)
Tachibana, K, 1087(ab)
Tada, M, 2118, 1083(ab)
Taguchi, T, 417
Tahara, T, 1655
Taher, MA, 1640(le)
Taillefer, R, 1961, 919(ab), 930(ab), 967(ab), 1085(ab), 1103(ab), 1310(le)
Tait, JF, 928(ab)
Tajiri, H, 924(ab)
Tajiri, J, 1785
Takahashi, H, 235
Takahashi, M, 928(ab), 1102(ab), 1137(ab)
Takahashi, N, 2152, 1000(ab), 1034(ab), 1035(ab), 1039(ab), 1084(ab)
Takahashi, T, 95, 1069(ab), 1106(ab)
Takashima, T, 2284
Takayama, K, 1042(ab)
Takayama, T, 961(ab)
Takeda, R, 1073(ab)
Takemoto, K, 978(ab)
Takemoto, KA, 929(ab), 950(ab)
Takeshita, G, 1080(ab)
Takeuchi, A, 1080(ab), 1137(ab)
Taki, J, 1273, 2215, 2284, 961(ab)
Taki, W, 1073(ab)
Takishima, T, 1106(ab)
Tally, NA, 1668
Tam, FWK, 990(ab)
Tamaki, N, 673, 679, 2152, 991(ab), 1000(ab), 1034(ab), 1035(ab), 1039(ab), 1064(ab), 1073(ab), 1313(le)
Tamaru, M, 1785
Tamminga, C, 1008(ab), 1063(ab)
Tanada, S, 1496, 911(ab), 991(ab), 1027(ab), 1040(ab), 1055(ab), 1066(ab), 1069(ab), 1074(ab), 1106(ab)
Tanaka, C, 1091(ab)
Tanaka, S, 228, 2291
Tanaka, Y, 2233
Tancredi, L, 980(ab)
Tang, Z, 1024(ab), 1098(ab)
Tani, A, 1037(ab)
Taniguchi, M, 2215
Taniwaki, T, 1015(ab)
Tansey, LW, 1093(ab)
Tarolo, GL, 1136(ab)
Tartagni, F, 369
Tarter, R, 1074(ab)
Tateno, Y, 1039(ab), 1040(ab), 1061(ab)
Tates, AD, 814
Tatsch, K, 1365, 931(ab), 1014(ab)
Taube, RA, 116
Tauxe, WN, 1496, 999(ab)
Taviani, M, 2064
Tawarahara, K, 417
Taylor, A, 953(ab), 1103(ab)
Taylor, CB, 1038(ab)
Taylor, SF, 966(ab)
Teates, CD, 1375, 997(ab)
Teefey, SA, 1047(ab)
Teixeira, JP, 1002(ab)
Temponi, M, 993(ab)
ten Cate, JW, 951(ab)
tenKate, C, 483
ten Kroode, NFJ, 1082(ab)
Tenorio, L, 1054(ab)
Teoh, SK, 1206, 1022(ab)
Ter, S, 2079
Teraoka, S, 1035(ab)
Teräs, M, 1211, 938(ab), 988(ab)
Ter-Pogossian, MM, 1838(ab)
Terris, AH, 1097(ab)
Terris, MK, 1713
Terry, JA, 916(ab), 946(ab)
Terzis, A, 184(ab)
Teule, GJJ, 986(ab)
Tewson, T, 1581, 2197
Tewson, TJ, 1009(ab)
Thakur, ML, 1021(ab), 1081(ab), 1098(ab), 1836(ab)
Thédrez, P, 997(ab)
Theobald, AE, 1102(ab), 1105(ab)
Thien, T, 1538
Thomas, C, 1005(ab), 1013(ab)
Thomas, FD, 1813, 1839(ab)
Thomas, JR, 1092(ab), 1093(ab)
Thomas, S, 963(ab)
Thomas, SR, 1877, 1045(ab)
Thompson, CJ, 154
Thompson, NW, 1882
Thoolen, MJ, 263, 957(ab)
Thornback, JR, 399, 500, 506, 968(ab)
Thornton, J, 1105(ab)
Thronton, J, 983(ab)
Tian, Z, 1838(ab)
Tibben, C, 941(ab)
Tiel-van Buul, MMC, 951(ab)
Tierney, AR, 1050(ab)
Tikofsky, RS, 942(ab)
Tilbury, R, 1093(ab)
Tilbury, RS, 932(ab)
Tillisch, J, 989(ab)
Tilyou, SM, 11N(2), 15N(4), 21N(3), 34N(4)
Tittel, K, 914(ab)
Tobin, JN, 753
Todd-Pokropek, A, 362(le)
Todd-Pokropek, AT, 1000(ab)
Toivio, I, 1425
Tomiguchi, S, 1102(ab)
Tonami, N, 2284, 961(ab), 1075(ab)
Tong, J, 1021(ab)
Toni, MG, 1045(ab)
TonThat, T, 919(ab), 930(ab), 1085(ab)
Toorongian, SA, 928(ab), 994(ab)
Topchik, S, 920(ab)
Topol, EJ, 1034(ab)
Torchilin, VP, 1742, 992(ab), 1082(ab)
Torres, G, 2295, 1019(ab), 1025(ab)
Touchon-Danguy, H, 927(ab)
Tourassi, GD, 936(ab), 986(ab), 1066(ab)
Touze, M-D, 785
Tow, DE, 1071(ab)
Toxey, J, 1912
Toyama, H, 1079(ab), 1080(ab), 1137(ab)
Toyama, S, 1099(ab)
Toyoshima, K, 1087(ab)
Tracey, KP, 921(ab)
Tran, HD, 1129(ab)
Trebossen, R, 1063(ab)
Tremblay, J, 973(ab)
Trepashko, D, 987(ab)
Tresgallo, ME, 929(ab), 1018(ab)
Treves, ST, 912(ab), 913(ab), 1015(ab)
Trimarco, B, 949(ab)
Tromholt, N, 2318
Troutner, D, 1092(ab)
Troutner, DE, 985(ab), 1023(ab)
Trudeau, WL, 1169, 1177
Trzepacz, P, 1074(ab)
Tsai, D, 803, 1231
Tse, N, 1555
Tsen, O, 1017(ab)
Tsuchihashi, N, 928(ab)
Tsuda, T, 865, 2291
Tsui, BMW, 186(le), 916(ab), 936(ab), 937(ab), 946(ab), 1065(ab), 1066(ab), 1136(ab)
Tu, JI, 1057(ab)
Tubergen, K, 111
Tucker, P, 915(ab)
Tune, L, 961(ab), 1079(ab)
Tung, CH, 955(ab), 1066(ab)
Turkington, TG, 986(ab)
Turley, JD, 1133(ab)
Turner, A, 1842(ab)
Turner, DA, 1513
Turner, FE, 242
Turton, DR, 1838(ab)
Tyson, IB, 1042(ab), 1054(ab), 1136(ab)
Tzen, KY, 976(ab), 1026(ab)
Tzourio, N, 911(ab), 1086(ab)

Uchida, Y, 917(ab), 1048(ab)
Ueda, S, 1622, 1097(ab)
Uehara, T, 272, 1333, 1012(ab), 1030(ab), 1035(ab)
Uesaka, Y, 726
Uğur, Ö, 1977
Ulanski, J, 912(ab)
Ulanski, JS, 913(ab), 1015(ab)
Underwood, DA, 2221, 968(ab)
Ungersböck, K, 1675
Uno, H, 1070(ab), 1096(ab)
Uno, K, 686, 917(ab), 1046(ab), 1048(ab)
Uno, Y, 16, 76
Urbain, JL, 930(ab), 931(ab), 1026(ab)
Urgancioglu, I, 1700
Urion, DK, 1015(ab)
Urita, Y, 1084(ab)
Urman, M, 2241

Vaalburg, W, 1587, 975(ab)
Vaccarino, R, 929(ab)
Vaghaiwalla-Mody, F, 998(ab)
Valance, J, 1076(ab)
Valdès Olmos, RA, 921(ab)
Valenza, V, 1088(ab)
Valenzuela, GA, 1375
Valette, H, 998(ab), 1067(ab)
Valind, SO, 1937
Valk, PE, 955(ab), 998(ab)
Vallabahn, R, 948(ab)
Vallabhajosula, S, 1861, 963(ab), 1031(ab), 1104(ab), 1842(ab)
Vallar, G, 1022(ab)
Vallois, J-M, 739
Vanarthos, W, 1138(ab)
van Beek, EJR, 951(ab)
van Blankenstein, M, 1219
van Breemen, B, 1078(ab)
VanBrocklin, HF, 81, 1532, 975(ab)
VanBrocklin, JF, 995(ab)
Vanbutsele, R, 988(ab), 989(ab), 998(ab)
Vancutsem, E, 931(ab)
van Dam, FJ, 814
Van den Abbeele, AD, 116, 1082(ab)
van den Berg, JWO, 1219
Van den Broeck, M, 216
Van Den Broeck, P, 500
Vandenbroeck, P, 399
van den hazel, SJ, 1078(ab)
Vandenmaegdenbergh, V, 931(ab)
Vanderheyden, JL, 915(ab), 1020(ab)
van der Meer, JWM, 491, 1854, 963(ab), 2195(le)
van der Wall, EE, 814
Van der Wall, H, 1945
Vandevivere, J, 1619, 1086(ab)
van Dijk, A, 1082(ab), 1083(ab)
van Dongen, A, 951(ab)
Van Dort, ME, 1399, 928(ab), 964(ab), 994(ab), 1096(ab)
van Eijck, CHJ, 981(ab)
van Furth, R, 468
Van Heertum, RL, 1471
van het Schip, AD, 2057, 1082(ab), 1083(ab)
van Horn, JR, 963(ab), 2195(le)
van Kaick, G, 1485, 1548, 1084(ab), 1138(ab)
van Kroonenburgh, M, 1036(ab)
van Lingen, A, 986(ab)
Van Nerom, C, 1016(ab)
Van Ness, P, 912(ab)
Vanoli, G, 1007(ab)
Vanoverschelde, JL, 989(ab), 998(ab), 1012(ab)
Vanregemorter, J, 1826(le)
van Rijk, PP, 2057, 1082(ab), 1083(ab)
van Royen, EA, 382, 951(ab), 1018(ab), 1078(ab), 1097(ab)

van Royen, N, 1078(ab)
Vansant, J, 1103(ab)
VanThiel, D, 1074(ab)
van Tilburg, AJP, 1219
Van Train, K, 959(ab), 1001(ab), 1006(ab), 1036(ab), 1067(ab)
Vantrappen, G, 931(ab)
Van Tricht, L, 1002(ab)
Vardi, Y, 974(ab)
Vargas-Cuba, R, 2227
Varvalho, PA, 1478
Varvarigou, A, 1843(ab)
Vasquez, S, 308
Vasta, M, 1134(ab)
Vasta, MC, 1039(ab)
Vavouraki, H, 1843(ab)
Vecchietti, G, 922(ab)
Vekemans, MC, 930(ab)
Velaquez, M, 719
Velchik, M, 1046(ab)
Velchik, MG, 136, 2079
Venavides, J, 1608
Venizelos, N, 2043
Venkatesan, PP, 1843(ab)
Vera, DR, 1169, 1177
Verani, MS, 255, 2158, 948(ab), 969(ab), 979(ab), 1030(ab)
Verbanac, KM, 1058(ab)
Verbeeten, B, Jr, 382
Verbruggen, A, 1016(ab)
Vergara, E, 970(ab)
Verha, M, 1002(ab)
Verhagen, A, 975(ab)
Verheij, LF, 1129(ab)
Verhoeff, NPLG, 1018(ab), 1078(ab), 1097(ab)
Verhulst, A, 1078(ab)
Verma, RC, 1078(ab)
Vermaut, G, 1026(ab)
Vermeersch, PHMJ, 2071
Verrey, B, 1062(ab), 1063(ab)
Verslegers, W, 1619
Verzijlbergen, JF, 2071
Vesselle, J-M, 1097(ab)
Vester, E, 1353, 909(ab)
Vetter, RJ, 1018(ab)
Vetterlein, D, 1837(ab)
Veyre, A, 1794, 1037(ab), 1067(ab)
Veyre, AJ, 1573
Viglietti, A, 2064
Villanueva, FS, 2115
Villanueva-Meyer, J, 972(ab), 1017(ab), 1021(ab), 1076(ab)
Villari, B, 1849
Villemagne, VL, 308
Villeneuve, J-P, 1467(le)
Vinitski, S, 1081(ab)
Virgolini, I, 2132
Visser, FC, 986(ab)
Visser, TJ, 1184, 1043(ab), 1084(ab)
Vita, NA, 938(ab)
Vitols, PJ, 909(ab), 957(ab)
Vitti, R, 1041(ab)
Vitti, RA, 2176, 931(ab)
Voderholzer, W, 931(ab)
Vogel, M, 237
Voges, J, 931(ab)
Voipio-Pulkki, L-M, 938(ab), 988(ab), 1027(ab)
Volk, S, 952(ab)
Volkert, EW, 1089(ab)
Volkert, WA, 111, 174, 985(ab), 1102(ab)
Volkow, ND, 58, 1866, 960(ab), 980(ab), 993(ab), 1022(ab), 1062(ab), 1071(ab)
vom Dahl, J, 949(ab), 988(ab), 1011(ab), 1012(ab), 1013(ab)
von der Lohe, E, 1353
Vonorta, K, 1049(ab)
Vorne, M, 1425, 2029
Voslar, AM, 942(ab)
Votaw, JR, 961(ab), 1008(ab), 1063(ab), 1070(ab)
Voûte, PA, 361(le), 921(ab)
Vreim, CE, 950(ab)
Vriesendorp, HM, 1442
Vuillez, J-P, 221

Wackers, FJ, 909(ab)
Wackers, FJT, 1538, 938(ab), 939(ab), 957(ab)
Wackers, FJTh, 759, 871, 1038(ab)
Wada, K, 974(ab)
Wade, K, 1101(ab)
Wade, PW, 1139(ab)
Wagner, AJ, 1162
Wagner, HN, 951(ab), 1107(ab), 1839(ab)
Wagner, HN, Jr, 16, 76, 308, 561, 905, 1968, 11N(8), 947(ab), 949(ab), 954(ab), 959(ab), 961(ab), 964(ab), 972(ab), 976(ab), 980(ab), 991(ab), 1007(ab), 1008(ab), 1033(ab), 1035(ab), 1046(ab), 1062(ab), 1071(ab), 1077(ab)
Wagner, U, 1051(ab)
Wahl, RL, 2278, 362(le), 915(ab), 981(ab), 982(ab), 993(ab), 1011(ab), 1020(ab), 1043(ab), 1314(le)
Wahner, HW, 2101, 2144
Wainwright, P, 942(ab)
Wakasugi, S, 1029(ab)
Wakita, K, 1097(ab)
Waldman, DL, 989(ab)
Walker, BM, 1945
Walker, WP, 1358
Wallace, S, 1093(ab)
Wallis, JW, 534, 552(le), 985(ab), 1462(le)
Walsh, SJ, 2328
Waltman, A, 2056
Wands, JR, 235
Wang, F, 959(ab)
Wang, FP, 929(ab), 1006(ab)
Wang, G-J, 1569, 960(ab)
Wang, H, 956(ab), 1065(ab)
Wang, J, 983(ab), 1050(ab), 1104(ab), 1105(ab)
Wang, SH, 944(ab)
Wang, SJ, 975(ab), 1041(ab)
Wang, TST, 461, 984(ab), 993(ab), 1091(ab)
Wang, X, 916(ab), 936(ab)
Wang, Y, 1837(ab)
Wang, YL, 944(ab), 1041(ab)
Wang, YP, 944(ab)
Ward, R, 1910
Wargovich, TJ, 777
Warhoe, KA, 922(ab)
Warren, FD, 1005(ab)
Wartofsky, L, 1464(le)
Wassertheil-Smoller, S, 753
Wasterlain, C, 1078(ab)
Watanabe, K, 1785
Watanabe, M, 1064(ab)
Watanabe, T, 1432, 952(ab), 1002(ab), 1069(ab), 1072(ab), 1077(ab)
Watanabe, Y, 2284, 961(ab)
Watanuki, S, 699, 713
Watkins, GL, 1063(ab)
Watkinson, JC, 1235
Watson, DD, 957(ab), 958(ab), 1059(ab)
Watson, EE, 808
Waxman, A, 441
Waxman, AD, 917(ab)
Webb, D, 1014(ab)
Webber, DI, 1021(ab)
Weber, A, 862
Weber, DA, 1569, 1866, 916(ab), 1022(ab), 1050(ab), 1840(ab)
Weber, R, 952(ab), 1016(ab)
Weber, U, 1027(ab)
Webster, EW, 903
Weg, JG, 950(ab)
Wegelius, U, 988(ab)
Wegener, WA, 136, 2079
Wei, YH, 1043(ab)
Weigand, H, 914(ab)
Weinberger, D, 1841(ab)
Weiner, RE, 1099(ab), 1100(ab)
Weinheimer, CJ, 937(ab)
Weinmann, HJ, 1831(le)
Weinmann, P, 971(ab)
Weinstein, D, 1026(ab)
Weinstein, J, 1057(ab)
Weinstein, JN, 1055(ab)
Weintraub, S, 962(ab)
Weintraub, WS, 978(ab)
Weisman, HF, 1005(ab)
Weiss, D, 130, 2079
Weiss, R, 429
Weiss, S, 943(ab), 1017(ab), 1085(ab)
Weiss, SB, 1014(ab)
Weissleder, R, 1082(ab)
Welch, MJ, 81, 300, 475, 1526, 1532, 1730, 1762, 44N(4), 925(ab), 937(ab), 975(ab), 995(ab), 1054(ab), 1096(ab)
Wellens, HJJ, 1036(ab)
Weller, R, 1053(ab)
Weller, S, 2209
Welsh, MW, 942(ab)
Wen, MD, 1057(ab)
Wendel, MJ, 707
Wendt, RE, III, 1133(ab)
Wenger, S, 991(ab)
Werner, RK, 1089(ab), 1092(ab)
Wester, DW, 1090(ab)
Wexler, J, 753
Wheeler, R, 1052(ab)
Wheeler, RH, 1162
Wheelwright, EJ, 1090(ab)
Whetsell, WO, 961(ab)
White, DL, 1831(le)
White, J, 967(ab)
White, TA, 1135(ab)
Whybrow, P, 1076(ab)
Wiebe, LI, 1764
Wiegmann, TB, 1452
Wieland, D, 1040(ab)
Wieland, DM, 1399, 362(le), 914(ab), 928(ab), 964(ab), 994(ab), 1096(ab)
Wienhard, K, 1338
Wieringa, AR, 1587
Wierzbinski, B, 913(ab), 977(ab)
Wiesel, FA, 2043
Wiesner, RF, 999(ab)
Wiggins, JR, 1831(le)
Wijns, W, 988(ab), 989(ab), 998(ab), 1012(ab)
Wilbur, DS, 279
Wilken, T, 259
Wilkins, GE, 1131(ab)
Wilkinson, R, 483, 928(ab), 1029(ab)
Wilkinson, RA, 1050(ab)
Willenbrock, R, 973(ab)
Willerson, JT, 269, 606
Williams, C, 963(ab)
Williams, CC, 1877
Williams, CM, 777
Williams, KA, 1239
Williams, LE, 987(ab)
Williams, RP, 1508, 962(ab)
Williams, WG, 237
Wilmanns, C, 279
Wilson, AA, 16, 76, 308, 954(ab), 961(ab), 980(ab), 1008(ab), 1062(ab), 1071(ab), 1078(ab), 1079(ab), 1839(ab)
Wilson, DA, 1133(ab)
Wilson, LA, 987(ab)
Wilson, ME, 2162, 1835(ab), 1843(ab)
Wilson, MW, 1080(ab)
Wilson, PD, 1008(ab)
Wilson, R, 1015(ab)
Wilson, RA, 193, 2027(le)
Winker, KH, 2209
Winn, HR, 971(ab)
Winston, S, 1071(ab)
Wiseman, GA, 1056(ab)
Witt, RM, 971(ab), 1074(ab)
Wlodkowski, TJ, 1052(ab)
Woldring, VM, 814
Wolf, AP, 960(ab), 993(ab), 1022(ab), 1062(ab), 1071(ab), 1088(ab), 1094(ab)
Wolf, F, 977(ab), 983(ab), 1002(ab)
Wolfangel, RG, 242
Wolfe, E, 988(ab), 1040(ab)
Wolpers, G, 926(ab)
Wolpers, HG, 1950
Wong, C, 1866
Wong, CTC, 1022(ab), 1840(ab)
Wong, DF, 308, 961(ab), 964(ab), 1008(ab), 1071(ab), 1839(ab)
Wong, FCL, 1008(ab), 1839(ab)
Wong, FP, 950(ab)
Wong, PJ, 974(ab)
Wong, WH, 2342, 965(ab)
Woodhouse, NJY, 252
Woods, SW, 210, 1754, 979(ab), 1043(ab)
Worley, G, 1016(ab)
Worsley, DF, 930(ab), 1131(ab)
Wortsman, J, 1882
Wouda, S, 975(ab)
Woulfe, S, 925(ab)
Woulfe, SR, 1101(ab)
Wright, K, 1000(ab)
Wright, L, 929(ab)
Wright, SJ, 994(ab)
Wu, C, 1098(ab)
Wu, LC, 990(ab), 1060(ab)
Wu, S-y, 1266
Wyatt, R, 1408
Wyeth, P, 2025(le)
Wynsen, JC, 1904

Xu, EZ, 161

Yagle, AE, 1061(ab)
Yahav, Y, 944(ab)
Yamada, M, 1066(ab), 1106(ab)
Yamada, S, 2118, 1083(ab), 1844(ab)
Yamagami, H, 1037(ab)
Yamamoto, I, 928(ab)
Yamamoto, K, 1000(ab), 1047(ab), 1084(ab)
Yamamoto, T, 1087(ab)
Yamamoto, Y, 2169, 927(ab)
Yamamoto, YL, 1622
Yamamuro, T, 1099(ab)
Yamasaki, T, 1061(ab)
Yamashita, J, 1074(ab)
Yamashita, K, 673, 679, 1000(ab), 1039(ab), 1073(ab)
Yamashita, T, 1064(ab)
Yamazaki, N, 417
Yamazaki, T, 928(ab)
Yan, Y, 994(ab), 1064(ab)
Yanai, K, 308, 1069(ab)
Yang, D, 1093(ab)
Yang, DJ, 932(ab)
Yang, L, 1038(ab)
Yang, N-C, 141, 1442, 916(ab), 994(ab)
Yang, Y, 1094(ab)
Yang, Y-Y, 339
Yano, J, 1005(ab), 1013(ab)
Yao, J, 988(ab)
Yaoita, H, 272, 928(ab), 1057(ab)
Yasmeen, S, 973(ab)
Yasuda, T, 1254, 1019(ab)
Yeates, MG, 33, 1382
Yeates, P, 1382
Yeh, SDJ, 769, 918(ab), 1021(ab)
Yeh, SH, 944(ab), 975(ab), 990(ab), 1000(ab), 1041(ab), 1043(ab), 1060(ab), 1076(ab), 1088(ab)
Yen, C-K, 124
Yen, TC, 1043(ab)

Yester, MV, 1162
Yki-Järvinen, H, 938(ab)
Yokoyama, A, 819, 825, 974(ab), 978(ab), 1064(ab)
Yokoyama, I, 1432
Yokoyama, K, 1661, 2284, 961(ab), 1075(ab)
Yokoyama, M, 1106(ab)
Yonekura, S, 2291
Yonekura, Y, 673, 679, 819, 2152, 974(ab), 991(ab), 1000(ab), 1034(ab), 1035(ab), 1039(ab), 1047(ab), 1064(ab), 1073(ab), 1084(ab), 1313(le)
Yonts, SR, 1641(le)
Yoshida, H, 228
Yoshida, K, 1, 938(ab), 1039(ab), 1040(ab)
Yoshida, Y, 1718
Yoshii, F, 1725
Yoshikai, T, 1655, 1015(ab), 1079(ab)
Yoshikawa, E, 1064(ab)
Yoshikawa, K, 686
Yost, F, 1057(ab)
Young, G, 1140(ab)
Young, JB, 255
Young, W, 524
Yu, CC, 1071(ab)
Yu, DC, 994(ab), 1004(ab)
Yu, SL, 975(ab)
Yudd, A, 1471
Yung, A, 932(ab)

Zagni, P, 424
Zalutsky, MR, 922(ab), 984(ab), 1030(ab)
Zanca, M, 1067(ab)
Zanco, P, 436, 1036(ab), 2027(le)
Zandberg, AR, 1107(ab)
Zanzi, I, 1910, 1134(ab)
Zanzonico, P, 1835(ab)
Zanzonico, PB, 1017(ab)
Zardi, L, 922(ab)
Zaret, BL, 909(ab), 938(ab), 939(ab), 957(ab), 1038(ab)
Zasadny, K, 982(ab), 1043(ab), 1314(le)
Zasadny, KR, 916(ab), 1086(ab)
Zeeberg, BR, 333, 1923
Zeffiro, TA, 1064(ab)
Zeiger, LS, 1836(ab)
Zelman, AL, 22N(7)
Zeman, RK, 2086
Zeng, GL, 916(ab), 955(ab), 956(ab), 1066(ab)
Zeng, Gl, 946(ab)
Zhang, D-Y, 1979
Zhao, XD, 937(ab), 946(ab)
Ziegler, S, 1548, 1083(ab)
Zierz, S, 1075(ab)
Ziessman, HA, 2086, 975(ab), 1107(ab)
Ziffer, J, 1033(ab)
Ziffer, JA, 978(ab), 1006(ab), 1034(ab), 1036(ab), 1068(ab), 1104(ab)
Zilbovicius, M, 911(ab), 1086(ab)
Zilleruelo, G, 1085(ab)
Zimmer, AM, 1021(ab)
Zimmer, W, 1648
Zimmerman, RE, 322, 1478
Zimmermann, RC, 1754
Zinn, K, 964(ab)
Zito, F, 1007(ab), 1050(ab)
Zoghbi, S, 979(ab), 1007(ab)
Zoghbi, SS, 1754, 1071(ab)
Zöller, G, 1052(ab)
Zonnenberg, BA, 1082(ab), 1083(ab)
Zubal, G, 1043(ab)
Zubal, IG, 210
Zu'bi, SM, 151
Zuccalá, A, 424
Zukiwiski, A, 1326
Zwinderman, AH, 814, 1129(ab)
Zygas, P, 1002(ab)

A

Abbreviations, suggestions for journal style, 885
Abdomen
fast diagnosis of infections and inflammations, Tc-99m HMPAO labeled leukocytes, 2029
scintigraphy, protein-losing enteropathy, Tc-99m human serum albumin, 924(ab)
tissue glucose utilization, noninvasive method, input function, 1432
tumors, PET total body imaging, FDG, 982(ab)
Abscess, aortic ring, prosthetic valve endocarditis, gallium-SPECT, 1791
ACE, -inhibited renal scintigraphy, 1104(ab)
Acetazolamide
-enhanced SPECT evaluation, cerebral perfusion, carotid endarterectomy, 971(ab)
Tc-99m HMPAO
carotid artery disease, 1074(ab)
cerebral blood flow reserve, carotid endarterectomy, 1385
Tc-99m HMPAO SPECT
brain perfusion reserve, 1074(ab)
cerebral blood flow, cerebrovascular disease, 1073(ab)
vascular reserve, brain diseases, 1074(ab)
Acetylcholine, molecular medicine, from science to service, 16N(8)
Acquired immunodeficiency syndrome (AIDS)
asymptomatic seropositive HIV-1 patients, metabolic asymmetries, disease onset and MRI findings, 1725
depletion of body cell mass, not bone mineral, 1050(ab)
malnutrition and depletion of body cell mass, potassium and nitrogen losses, 1050(ab)
PET, CT/MRI and neuropsychological testing, 1078(ab)
prominence of nuclear medicine, 16N(7)
role of nuclear medicine, algorithms, 1138(ab)
Acromegaly, active, bone mineral density, dual-photon absorptiometry, 1011(ab)
Actin, In-111 labeled mRNA probes, 1089(ab)
Actinomycosis, pulmonary, Tc-99m MIBI and Tl-201 uptake, 1429
Acyl hypofluorites, structural effect, fluorination, L-m-tyrosine, 935(ab)
Adenocarcinoma
esophageal, pericardial fistula, hepatobiliary scintigraphy, 518
recurrence after radical prostatectomy, bone scans, PSA levels, 1713
refractory, Y-90 B72.3 monoclonal antibody, 1021(ab)
Adenoma, pituitary, clinical evaluation, PET, 610
Adenosine
coronary hyperemia
critical stenosis, Tl-201 and Tc-99m sestamibi, 947(ab)
SPECT, remote Q-wave myocardial infarction, 979(ab)
teboroxime SPECT, 1036(ab)
detection of ischemic/stunned myocardium, thrombolytic therapy, 1012(ab)
dipyridamole and, vasodilatory action, PET scanning of heart, 969(ab)
exercise thallium imaging, moderate coronary stenosis, 1031(ab)
infusion
feasibility, low-level treadmill exercise, 1031(ab)
maximal myocardial blood flow, intravenous dipyridamole, 969(ab)
intravenous, dipyridamole for myocardial infusion, Tc-99m MIBI, 1027(ab)
lung Tl-201 uptake and left ventricular dilation, coronary artery disease, 1030(ab)
regional and global tumor cerebral blood flow, PET, 932(ab)
SPECT
single vessel CAD, jeopardized myocardium, 969(ab)
Tl-201 and, reinjection technique, 979(ab)
SPECT and exercise SPECT Tl-201 imaging, multi-center trial, 968(ab)
thallium-201 myocardial scintigraphy
compared to IV dipyridamole, 969(ab)
risk reduction, severe arrhythmia, 978(ab)
safety in the elderly, 978(ab)
thallium scintigraphy
asymmetric renal uptake, renovascular disease, 1104(ab)
increased lung uptake, coronary artery disease, 979(ab)
vs. exercise SPECT thallium, coronary artery disease, elderly patients, 968(ab)
Adrenal cortex, medulla and, imaging, 1627
Adrenal gland, clinical significance of solitary functioning, 1882
Adrenoceptors, *alpha*-1, I-125 heat binding, tissue kinetics, 927(ab)
Adriamycin, cardiomyopathy, systemic adrenergic hyperactivity, 1029(ab)
Aebersold Award, Robert N. Beck, 27N(5)
Aerosol, scintigraphy, therapy for cystic fibrosis, 1139(ab)
Aging
adenosine Tl-201 myocardial imaging, 978(ab)
body composition, 1105(ab)
coronary artery disease, adenosine *vs.* exercise SPECT thallium, 968(ab)
L-methionine uptake, cerebral cortex, 16
moderate, noninvasive delineation, myocardial perfusion, 2037
quantification of muscarinic cholinergic receptors, Alzheimer's disease, 942(ab)
Akathisia, metoclopramide-induced, gastric emptying imaging, 1644(le)
Albumin
galactose-bound human serum, suppression of uptake by hepatocytes and renal cells, radiolabeled antibody, 1054(ab)
labeled microspheres, specific linker technology, radiation synovectomy, 964(ab)
proteinuria and, Tc-99m MAG_3 clearance, effective renal plasma flow, 1709
Alcohol
brain metabolic response, benzodiazepines, 1022(ab)
dependence, I-123 SPECT, 1075(ab)
Aldosterone, endocrine imaging, 1627
Algorithms
circular harmonic transform, SPECT, 141
cone beam reconstruction, perpendicular orbits, 956(ab)
dependence of bias and variation, art, multiplicative art and E-M algorithm, 986(ab)
depth-of-interaction measurement information, PET data acquisition, 995(ab)
detection and correction of gradual or abrupt heart motion, Tl-201 SPECT, myocardial perfusion images, 947(ab)
diagnostic role of nuclear medicine in AIDS, 1138(ab)
experimental evaluation, cross-plane scattering correction method, 995(ab)
fully 3-D reconstruction, multi-slice PET scanners, 966(ab)
iterative reconstruction
multigrid implementation, PET, 1061(ab)
spatially-variant regularization, emission tomography, 936(ab)
motion-correction
bicycle and treadmill radionuclide angiocardiography, 1918
Tl-201 SPECT, 1007(ab)
preconditioned iterative, improved convergence rates, tomographic reconstruction, 1065(ab)
resolution-dependent noise improvements, maximum likelihood reconstruction, 966(ab)
SPECT, energy-distance principle, 916(ab)
N1-Alkyl-2-iodo-lyseric acid diethylamide derivatives, radioiodinated, ligands, serotonin receptors, 964(ab)
Allografts
femoral, evaluation in spine, bone SPECT, 913(ab)
pediatric renal, abnormal cortical appearances, 1542
Alumina, trapping and decomposition, F-18 fluormethane, 1094(ab)
Alzheimer's disease
cerebrovascular responsiveness to hypercapnia, PET, 1079(ab)
dementia, severity and onset, Tc-99m HMPAO perfusion patterns, 1076(ab)
quantification of muscarinic cholinergic receptors, aging, 942(ab)
sensitivity and specificity, SPECT and PET, 942(ab)
typical FDG-PET scan pattern, 942(ab)
Xe-133 CBF profiles, Tc-99m HMPAO SPECT, 941(ab)
American College of Nuclear Physicians (ACNP)
consideration of appeal, NRC quality management rule, 20N(10)
petition in federal court, NRC's increased user fees, 35N(11)
SNM and
government relations update, 11N(2)
revisions to CLIA, 28N(1)
strategic planning, 22N(12)
Society of Nuclear Medicine and, government relations update, 11N(9)
Amino acids
increased transport into brain tumors, L-(2-^{18}F)fluorotyrosine PET, 1338
neurotransmission, F-18 FTCP PET, 1008(ab)
study of I-123 L-AMT transport, 819
uptake saturation by human brain tumor, SPECT, 1229
L-Amino acids, brain uptake, L-3-I-123 iodo-α-methyl tyrosine, 1225
Amphetamine, -induced dopamine release, competition, I-123 IBZM binding to D2 receptors, 1007(ab)
Anemia, sickle cell, severe hypoxemia, acute sternal infarction, 1617
Anger, effect on left ventricular function, 1038(ab)
Angiocardiography, bicycle and treadmill radionuclide, 967(ab), 1918
Angiography

blood-pool radionuclide, Novacor left ventricular assist device, 255
gated radionuclide, multicrystal gamma camera, special high resolution collimation, 1059(ab)
pulmonary, before and after ventilation perfusion lung scan, 1139(ab)
radionuclide, contrast ventriculography and, left ventricular diastolic function, 1849
scintigraphic, acute gastrointestinal hemorrhage, 1601
visual assessment of quantitative 3-D displays, stress Tl-201 tomograms, 1006(ab)
Angiomatosis, skeletal, limitation to hand, radiography and scintigraphy, 1912
Angioplasty
cerebral, regional brain blood flow, SPECT, 971(ab)
coronary, prediction of restenosis, Tl-201 scintigraphy, 959(ab)
Angiosarcoma, metastatic, thrombocytopenia, intratumoral In-111 platelet deposition, 2278
Angiotensin-converting enzyme
inhibition, renal scintigraphy, Tc-99m MAG_3, 424
positron-labeled inhibitor, F-18 fluorocaptopril, 1730
pulmonary uptake of radiolabeled monoclonal antibody, reduction by endotoxin, 453
Animal models
performance and design features, new PET system, 1134(ab)
small laboratory, high resolution pinhole sequence imaging, 987(ab)
studies, performance characteristics, PET, 1064(ab)
validation of techniques, liver blood flow, 999(ab)
Annexin-V, *in vivo* thrombus labeling, activated platelets, 928(ab)
Antibiotics, synthetic vascular graft infection, In-111 leukocyte scan, 13
Antimyosin, myocarditis simulating MI, 312
Antimyosin antibody
imaging and histopathology of myocardial infarction, 867
risk of rejection-related complications, heart transplantation, 1019(ab)
scintigraphy, myocarditis, 1019(ab)
severity of myocardial damage, doxorubicin, 1019(ab)
Antimyosin FAB, negative charge-modified monoclonal antibody, gamma imaging, synthetic polymers, 1742
Anxiety, panic disorders and, Tc-99m HMPAO brain SPECT, 1136(ab)
Aorta
right arch, first-pass and multigated radionuclide ventriculography, 1904
sclerosis, bone mineral measurements, dual-photon absorptiometry, 259
Apallic syndrome, Tc-99m HMPAO brain imaging, 1077(ab)
Appendix, "hot", Tc-99m monoclonal antibodies against granulocytes, 1049(ab)
Arrhythmias, severe, risk reduction, adenosine thallium-201 myocardial scintigraphy, 978(ab)
Arteriography
contrast, peripheral vascular disease, whole body scintigraphy, 1041(ab)
sequential tomographic myocardial perfusion imaging, Tc-99m teboroxime, 919(ab)
Arteriopathy, orthotopic heart transplant, exercise SPECT Tl-201, 1041(ab)
Arteriovenous malformations, before and after embolization, quantification, blood flow, 968(ab)
Artery
carotid, *see* Carotid artery
coronary, *see* Coronary artery
global extraction, cerebral blood flow, I-123 IMP SPECT, 1080(ab)
great, congenitally-corrected transposition, thallium myocardial scintigraphy, 1611
hepatic, temporary segmental hepatic venous occlusion, 1000(ab)
input curve, cerebral blood flow, Tc-99m HMPAO SPECT, 1501
input function
dipyridamole, PET perfusion imaging, 1040(ab)
simple one image, PET perfusion imaging, 938(ab)
left coronary, anomalous origin from pulmonary artery, isotopic findings, 1788
lower extremity peripheral arterial disease, muscle perfusion, Tc-99m MIBI, 1700
mammary, with and without bypass, sternal viability after sternotomy, 1025
moderate coronary stenosis, adenosine, exercise thallium imaging, 1031(ab)
Arthroplasty, infected joint, In-111 immunoglobulin G scintigraphy, 963(ab)
Artifacts, count loss, magnitude and causes, SPECT, 1771
ASPECT, Tc-99m HMPAO, brain perfusion abnormality, cocaine-dependent polydrug users, 1206
Assays
immunoradiometric
metallic radionuclide labeled IgG, 978(ab)
metallic radionuclides, 825
Astatine-211 monoclonal antibody, experimental human neoplastic meningitis, 922(ab)
Astrocytoma, PET cancer evaluations with FDG, 1555
Atherosclerosis, imaging of lesions with I-123 SP-4, 1842(ab)
Atrial fibrillation, left ventricular function curve, gated blood pool scintigraphy, 1042(ab)
Atrial natriuretic factor, receptor imaging with I-123 ANF, 973(ab)
Attenuation correction
cardiac SPECT reconstruction, geometric point response correction, 916(ab)
geometric mean *vs.* left anterior oblique, half emptying time, lag time, 931(ab)
nonuniform
acquired transmission data, SPECT, 1067(ab)
SPECT bulls-eye analysis, myocardium, 1839(ab)
transmission and CT data, SPECT, 1839(ab)
optimization of transmission source collimation, SPECT, planar imaging, 986(ab)
PET performance standards, 2342
quantitative measurements, radioacitivity in conjugate counting, SPECT, 1136(ab)
scatter and
SPECT, analytical scatter functions, 916(ab)
SPECT, sources in nonhomogenous object, 1278
Tc-99m sestamibi SPECT, myocardial distributions, 1067(ab)
segmented, PET, 161
truncated transmission scan, 1066(ab)
variance improvement, reconstruction-reprojection, PET, 1060(ab)
Autism, childhood, rCBF, SPECT, 1086(ab)
Autonomic nerve, abnormality, animal models of diabetes, iodinated MIBG, 928(ab)
Autoradiography
dosimetry of radioactive simulated grains, 996(ab)
evaluation of monoclonal antibodies, 2-deoxyglucose distribution in xenografts, human ovarian carcinoma, 993(ab)
monoclonal anti-CEA antibodies, tumor uptake, 1052(ab)
quantitative, beta camera, 1059(ab)
Tc-99m compounds, quantitation of radioactivity, computed radiography, 1060(ab)
whole-body, pharmacokinetics, I-125 murine monoclonal antibody, 1837(ab)
Avidin, quantitation, pharmacokinetics and analysis, 1098(ab)
Axilla, staging, breast carcinoma, FDG PET, 981(ab)

B

Back, chronic low pain, bone scintigraphy, SPECT, 913(ab)
Background Equivalent Radiation Time: *see* BERT unit
Bayesian analysis, utility of In-111 OC 125 immunoscintigraphy, diagnosis, ovarian cancer, 941(ab)
B cells, malignancies, I-131 Lym-1, immunophoresis, 921(ab)
Beck, Robert N., to receive Aebersold Award, 27N(5)
Below Regulatory Concern, moratorium on enactment, 14N(9)
Benedict Cassen Memorial Fund, receipt of $1.25 million bequest, 20N(6)
Benperidol, 3-N-ω-[F-18]fluoroalkylated, mapping CNS dopaminergic receptors, PET, 935(ab)
Benzamides, iodinated, high affinity dopamine D2 receptor radioligands, 1593
Benzodiazepines
brain metabolic response, normals and alcoholics, 1022(ab)
receptor binding, regional glucose metabolism, refractory temporal lobe epilepsy, 912(ab)
BERT unit
equivalent exposure to small ionizing radiation amounts, public understanding of exposure, 26N(1)
proposed companion unit ERNIE, 900(le)
Beta camera, quantitative autoradiography, 1059(ab)
Bicarbonate, stability of gallium-transferrin complex, 1439
Bile, leak, elective laparoscopic cholecystectomy, 1777
Bile duct
clearance, radionuclide injection, Sphincter of Oddi dysfunction, 975(ab)
common stones, hepatobiliary imaging, impact on management, 1046(ab)
gallstones, hepatobiliary imaging, 1261
pattern of obstruction reversed by naloxone, analgesic narcotics, hepatobiliary imaging, 1270
Biliary atresia, congenital, hepatobiliary scintigraphy after surgical treatment, 1047(ab)
Biliary tree, laparoscopic cholecystectomy, postoperative complications, scintigraphy, 1910
Biologic response modifiers, imaging tumors, Tc-99m tumor necrosis factor, 1021(ab)

Biotin
derivatized polylysine, pre-targeting, streptavidin conjugates, 993(ab)
indium-labeled, tumor imaging, 750(le)
quantitation, pharamcokinetics and analysis, 1098(ab)
Bis-trimethylsilylsulfate, simplified recovery and purification, F-18 fluoride, 1095(ab)
Blood
blood vessels and, absorbed dose calculations, internally deposited radionuclides, 830
loss estimate, hematochezia, Tc-99m red blood cells, 923(ab)
Blood-brain barrier, permeability measurement, I-123 IMP/Tc-99m HMPAO/Tc-99m ECD, compartment analysis and dynamic SPECT, 911(ab)
Blood flow
cerebral
absolute quantitation, Tc-99m HMPAO single scan, 1506
acetazolamide, Tc-99m HMPAO SPECT in cerebrovascular disease, 1073(ab)
acute closed-head injury, Tc-99m HMPAO SPECT and CT, 1684
acute neurological disorders, childhood, 943(ab)
adenosine effects, PET, 932(ab)
alterations, unipolar depression, 951(ab)
arterial input curve, Tc-99m HMPAO SPECT, 1501
before and after cerebral angioplasty, SPECT, 971(ab)
brain infarction, outcome prediction with SPECT, 382
comparison, Tc-99m MAG_3 brain clearance, 1844(ab)
complex visual reasoning stimulus, CERETEC SPECT, 1137(ab)
evaluation of brain death, DTPA and HMPAO, 1839(ab)
focal cerebral ischemia, Tc-99m ECD, 1070(ab)
glucose metabolism, brain tumors, 1077(ab)
I-123 IMP SPECT, global extraction between artery and internal jugular vein, 1080(ab)
kinetic behavior of Tc-99m HMPAO, dynamic SPECT, 1069(ab)
non-steady state conditions, PET, 910(ab)
obsessive-compulsive disorders, Xe-133, 1076(ab)
optimal scan time, O-15 water, 1931
optimization, PET, 1934
refractory unipolar depression, Tc-99m HMPAO SPECT, 951(ab)
regional distribution in childhood, Tc-99m HMPAO SPECT, 1080(ab)
residual effect of physiological stimulation, O-15 water PET, 1072(ab)
ROER and RCBF/RCBV ratio, acute stroke, 960(ab)
Tc-99m HMPAO, carotid endarterectomy, 1382
Tc-99m HMPAO distribution, visual cortex, 210
values measured on predetermined ROIs, Xe-133 in children, 1841(ab)
variations during mental imagery task, low and high imagers, 911(ab)
Xe-133 and Tc-99m HMPAO SPECT, Alzheimer's disease, 941(ab)
convection-diffusion-uptake model, glomerular filtration rate, renal studies, 1104(ab)
deuterium NMR measurement, wash-in technique, murine tumors, 1081(ab)
hepatic, hepatic binding receptor, Tc-99m DTPA-galactosyl-HSA, 2233
hepatic arterial, N-13 ammonia, dynamic PET, 2199
liver, validation of techniques, animal model, 999(ab)
maximal myocardial, adenosine infusion, intravenous dipyridamole, 969(ab)
myocardial
estimation and optimal SPECT collimator resolution, side information effects, 946(ab)
N-13 ammonia, reoriented dynamic PET, 909(ab)
N-13 ammonia and dynamic PET, simplified quantification, 926(ab)
N-13 ammonia and O-15 water, quantification, 926(ab)
region of interest size, PET, 1027(ab)
retention of Tc-99m teboroxime, 947(ab)
simultaneous measurement in same animal, Tc-96 sestamibi and Tl-201, 947(ab)
uptake of C-11 acetate, indirect estimate, 245
quantification, systemic arteriovenous malformations, embolization, 968(ab)
rate pressure product, remote myocardium, acute infarction, 989(ab)
renal
N-13 ammonia, dynamic PET and 2-compartment model, 953(ab)
vascular mean transit time, visual assessment in transplant patients, 1103(ab)
resting cerebral, dual-isotope SPECT, cerebrovascular reserve, 972(ab)
Tc-99m TEBO and Tl-201 extraction and retention, heart, 1979
temporal lobe SPECT/IMP abnormalities, rapid cycling bipolar disorder, 1076(ab)
Blood-pool imaging
cardiac, 480
scintigraphy, rats and hamsters, 851
copper-62, 475
dual isotope In-111 antimyosin/Tl-201 SPECT, right ventricular infarction, 1018(ab)
multigated, use of heart sounds, 1513
Tc-99m RBC gastrointestinal bleeding study, significance, intensity of delayed activity, 2249
validity of left ventricular ROI, 954(ab)
Body composition, sex, age, and race, 1105(ab)
Bone
bone marrow scan and, pattern, osteomyelofibrosis, 1085(ab)
density, spinal cord injury, 1026(ab)
four-phase scan with Tc-99m MDP, electric burns, 1026(ab)
imaging agent therapeutic trial, Sm-153 EDTMP, 918(ab)
long-term scintigraphy, parathyroidectomy, chronic renal osteodystrophy, 983(ab)
mass changes, optimal monitoring, densitometry, 1129(ab)
mestatic disease, palliation of pain, Re-186 HEDP, 1088(ab)
metabolic rates, F-18 fluoride ion and PET, 1004(ab)
metabolism in hyperparathyroidism, thyrotoxicosis, *in vivo* SPECT quantitation, 1157
metastases, Re-186(Sn)HEDP treatment, 1877
mineral content
aortic sclerosis, dual-photon absorptiometry, 259
depletion of body cell mass, AIDS malnutrition, 1050(ab)
forearm, dual-energy X-ray absorptiometry, 2101
lumbar spine, children, 216
mineral density
dual-photon absorptiometry, active acromegaly, 1011(ab)
lumbar spine and femoral neck, GnRH-agonists, 1026(ab)
mineral loss, regional variations, dual-photon and dual X-ray absorptiometry, 1025(ab)
nuclear medicine imaging, anthropomorphic thoracic phantom, Scandinavia, 1837(ab)
osseous metastases, pain palliation, tin-111m(4+)DTPA, 1840(ab)
painful metastases, Re-186 HEDP, metastatic prostate or breast cancer, 1082(ab)
radiation absorbed dose calculations, Sm-153 EDTMP, 840
remodeling, scintimetric evaluation, physiologic and pathophysiologic factors, 914(ab)
scan
clinical benefit, polytraumated patients, 914(ab)
early assessment, nasal bone graft viability, 33
scan results in skeletal metastases, prostate-specific antigen, prostate cancer, 1082(ab)
scans in conjunction with PSA levels, recurrence of adenocarcinoma, after radical prostatectomy, 1713
scintigram/MRI/osteomedullar biopsy comparison, metastases detection, small cell lung cancer, 962(ab)
scintigraphy
art of, technical aspects, 2332
chronic low back pain, SPECT, 913(ab)
evaluation, talar dome fractures, 2241
In-111 leukocytes and Tc-99m MDP, vertebral osteomyelitis, 1861
prostate-specific antigen, prostate cancer follow-up, 1387
spectrum of lymphoma presentations, 1129(ab)
serial bone scintigraphy, duration, etidronate effect, 1782
serial scanning, systemic mastocytosis, 1026(ab)
soft tissue thickness and fat, measurements, dual photon absorptiometry, 983(ab)
SPECT, evaluation of femoral allograft, spine, 913(ab)
SPECT and 3-D reconstruction, hip-head-necrosis, pedicled pelvic bone graft, 1027(ab)
systematic reactions to fracture, scintigraphic evaluation, 914(ab)
Tc-99m MDP, stage IV renal cell carcinoma, 983(ab)
three-phase scan, muscular sarcoidosis, 1829(le)
three-phase scintigraphy, In-111 chloride, osteomyelitis, 67
total body skeletal imaging, F-18 ion and PET, 1025(ab)
tracers *vs.* vascular tracers, staging, reflex sympathetic dystrophy syndrome, 1026(ab)
turnover and loss, hyperparathyroidism, scintigraphy, 982(ab)
Bone marrow
autologous transplantation, Tc-99m sulfur colloid, granulocyte colony-stimulating factor, 1013(ab)
dosimetry in rats, direct tissue counting, radiodinated monoclonal antibodies or $F(ab')_2$ fragments, 1414
immunoscintigraphy, superiority to scintigraphy, skeletal metastases in prostatic and renal carcinoma, 1052(ab)
radioimmune imaging, 549(le)

reconversion, pattern, femur, 1013(ab)
regeneration, hormonal therapy, bone metastases from prostate carcinoma, 2295
regeneration after hormone therapy, antigranulocyte scans, bone metastases from prostatic carcinoma, 1025(ab)
scan identification of "diffuse" skeletal metastases, equivocal super bone scan, 1083(ab)
transplantation
delay in gallbladder visualization, absence of acute cholecystitis, 1047(ab)
serum thymidine kinase, marker for effect of transplant, 1087(ab)
Bone neoplasms, metastatic, pharmacokinetics, Re-186 and Re-186 HEDP, 1083(ab)
Book reviews
Annals of the ICRP: ICRP Publication 61, 2363
Atlas of Roentgenographic Measurement, Sixth Edition, 1318
Brain Imaging: Applications in Psychiatry, 903
Chemistry of Fluorine-18, The, 2197
Cross Currents: The Promise of Electromedicine, The Perils of Electropollution, 188
Envisioning Information, 188
Introduction to Radiobiology, 1469
IRPA Guidelines on Protection Against Ionizing Radiation, 2363
Language of Fractures, The, 367
Learning Medical Terminology, 1318
Magnetic Resonance Imaging of the Pediatric Brain: An Anatomical Atlas, 556
MRI Atlas of the Brain, 366
MRI of the Musculoskeletal System, Second Edition, 556
NCRP Report No. 108, 2363
Obsessive-Compulsive Disorders, 2nd Edition, 366
Radiation Protection. A Guide For Scientists and Physicians, Third Edition, 903
Radiology of the Liver, Biliary Tract, Pancreas and Spleen, 556
Radiology Review Manual, 1648
Visible Human Body: An Atlas of Sectional Anatomy, The, 1648
Bowel, inflammatory bowel disease, management, role of scintigraphy, 856
Brain
abnormal perfusion, cocaine-dependent polydrug users, Tc-99m HMPAO SPECT, 1022(ab)
activation, O-15 water PET, 58
acute cerebral injury, Tc-99m glucarate, 272
AIDS and nuclear medicine, 16N(7)
animal, radioiodinated pindolol, 1140(ab)
asymptomatic crack abuse subjects, distribution and clearance, I-123 IMP, 1022(ab)
basal ganglia hypometabolism, movement disorders, 1015(ab)
binding of muscarinic cholinergic receptors, I-123 IDEX, 1097(ab)
biological background subtraction, improved scintigraphy, subsequent antigen injection, 2318
C-11 epinine, neuronal marker, heart sympathetic neurons, 994(ab)
cerebral activation changes in Stroop test, Tc-99m HMPAO SPECT, 991(ab)
cerebral blood flow, *see* Blood flow, cerebral
cerebral cortex, finite resolution effects in SPECT, use of MR images, 985(ab)
cerebral cortex and cerebellum, system resolution, SPECT, 1080(ab)
cerebral cortex L-methionine uptake, maturation, infancy to old age, 16
cerebral oxygen extraction fraction, brief inhalation method, PET, 1738
cerebral oxygen metabolic rate, parametric imaging, dynamic PET and on-line plasma separator, 1062(ab)
cerebral uptake and retention, C-11 alprazolam PET, 1009(ab)
cerebral uptake of radiolabelled MIBG, adrenergic receptors, 992(ab)
changes in regional perfusion, total sleep deprivation, major depression, 952(ab)
charting, 18N(9)
chemistry of, 18N(10)
clearance of Tc-99m MAG_3, compared to rCBF, 1844(ab)
computed tomographic scans and SPECT, accurate correlation, 1080(ab)
computer-assisted superimposition of MRI, SPECT, 1478
death
coma, F-18 FDG PET, 1077(ab)
evaluation, DTPA and HMPAO, 1839(ab)
diffusion of neuroreceptor ligand into synapse, effect, binding kinetics, 1008(ab)
dopamine D2 receptors
hemi-Parkinsonism, I-123 IBZM, 1070(ab)
-specific binding
C-11 YM-09151-2, PET, 713
dopamine receptors, density calculation, raclopride effects, 961(ab)
drug effects on binding, F-18 GBR, 1097(ab)
dual-isotope SPECT, dementia/stroke, I-123 IMP, 1073(ab)
early and delayed SPECT, Tc-99m ECD *vs.* I-123 IMP, subacute stroke, 971(ab)
energy-dependent accumulation of Tc-99m D,L-HMPAO, rats, 1071(ab)
geography and, representation on flat paper, cortex, 1826(le)
glioma, direct intralesional injection, radiolabeled monoclonal antibody, 922(ab)
global cerebral glucose metabolism, influence, cerebral regions, 1077(ab)
glucose transport, F-18 carbohydrate analogs of glucose, 1093(ab)
histamine H1 receptors, C-11 pyrilamine, 308
HMPAO uptake, test-retest results, 991(ab)
imaging
human development with PET, 23
structural features, metal-based tracers, 1139(ab)
increased basal ganglia contrast in PET scans, 6-^{18}F-DOPA, postinjection L-phenylalanine, 1408
increased striatal dopamine uptake, normal glucose metabolism, idiopathic dystonia, 1015(ab)
increases in cerebellar metabolism, secondary to THC administration, 980(ab)
infarction, regional cerebral blood flow, outcome prediction with SPECT, 382
injury, SPECT, hyperbaric oxygen therapy, 1840(ab)
intracerebral kinetics of Tc-99m ECD, dynamic brain SPECT, 991(ab)
intracranial mass lesions, multiple radiotracers, PET, 954(ab)
I-123 IMP SPECT, redistribution, effects of visual stimulation, 1866
I-123 SPECT, severe carotid artery stenosis, transient ischemic attacks, 972(ab)
kinetic analysis, *N*-isopropyl-p-iodoamphetamine, 991(ab)
mapping, echolalia and palilalia, Tc-99m HMPAO SPECT, 1619
mapping of histamine H-1 receptors, C-11 pyrilamine, 1069(ab)
medically intractable temporal lobe epilepsy, Tc-99m HMPAO SPECT, 388
metabolic activity during different stages, cocaine withdrawal, 960(ab)
metabolic response, benzodiazepines, normals and alcoholics, 1022(ab)
metastases, non-CNS neoplasms, preliminary FDG-PET evaluation, 954(ab)
molecular medicine, from science to service, 14N(8)
monkey, C-11 methyl-2-carbomethoxy-3-phenyl tropane, 1009(ab)
neural activation foci, Cu-62 PTSM, 1072(ab)
neural network subserving picture comprehension, PET activation studies, 1072(ab)
new tomograph ECAT 953B/31, 1063(ab)
non-oxidative glycolysis in tumors, FDG-PET and H-MRS, 931(ab)
normal and malignant, lumped constant and glucose metabolic rate, PET, 1837(ab)
opthalmoplegia plus, Tc-99m HMPAO SPECT, 1075(ab)
O-15 water PET, input function, dynamic neck scan, 1003(ab)
perfusion
after long-term cocaine abuse, Xe-133 rCBF and Tc-99m HMPAO, 1021(ab)
Tc-99m MRP20, 500
Tc-99m MRP20 SPECT, 399
ultra-high-resolution SPECT, 3-head rotating gamma camera, 1079(ab)
perfusion abnormality, cocaine-dependent polydrug users, Tc-99m HMPAO SPECT, 1206
perfusion reserve, acetazolamide test, Tc-99m HMPAO SPECT, 1074(ab)
perfusion SPECT, double injection, Tc-99m HMPAO, 1073(ab)
PET, C-11 nicotine preparation, metabolite studies, 1095(ab)
post-mortem studies, extrastriatal dopamine D2 receptors, 961(ab)
primate, *in vivo* imaging, sigma receptors, 1071(ab)
quantification of muscarinic cholinergic receptors, I-123 4-iododexetimide SPECT, 980(ab)
quantitative localization and clearance properties, Tc-99m HMPAO and I-123 IMP, crack users and normals, 1840(ab)
recurrent tumor
detection, Tl-201 and F-18 deoxyglucose, 955(ab)
histologic findings, F-18 FDG PET, 932(ab)
regional cerebral blood flow variations
mental imagery task, low and high imagers, 911(ab)
refractory unipolar depression, Tc-99m HMPAO SPECT, 951(ab)
unipolar depression, 951(ab)
reproducibility of striatal uptake, F-18 L-6-fluorodopa PET, 1246
scattered focal cortical defects, Tc-99m HMPAO SPECT, 1840(ab)
simulated imaging, patterns of head movement, normal subjects, 1064(ab)
SPECT
chronic vestibular dysfunction, 1075(ab)
simultaneous dual-tracer, Tc-99m HMPAO and I-123 IMP, 956(ab)
simultaneous emission data acquisition,

1066(ab)
sustained attention, schizophrenia, 1076(ab)
stationary 3D SPECT system, 1135(ab)
striatal dopamine nerve terminals in primates, β-fluoromethylene-m-tyrosine PET, 1070(ab)
surface MR image, planar mapping, three-dimensional images, 1002(ab)
Tc-99m HMPAO, brain death, apallic syndrome and agonal cerebral dysfunction, 1077(ab)
Tc-99m HMPAO SPECT
anxiety and panic disorders, 1136(ab)
bilateral subdural hematomas, 1915
convulsions and fever, 1086(ab)
temporal lobe SPECT/IMP abnormalities, rapid cycling bipolar disorder, 1076(ab)
three-dimensional physical phantom, mathematical model, 3-D SPECT, 1923
transport and metabolic rate constants, fluorodeoxyglucose and glucose, 911(ab)
tumors
cerebral blood flow, glucose metabolism, 1077(ab)
clinical application, PET, 616
glutathione content, Tc-99m HMPAO, 1675
increased amino acid transport, L-(2-^{18}F)fluorotyrosine PET, 1338
PET radiopharmaceuticals, 1346
saturation of amino acid uptake, SPECT, 1229
SPECT thallium index, 1138(ab)
uptake of iodo-alpha-methyl-tyrosine, 2193(le)
tyrosine transport, L-[1-^{11}C]tyrosine PET, 2043
uptake of L-3-I-123 iodo-α-methyl tyrosine, competition, natural L-amino acids, 1225
vascular reserve in disease, acetazolamide, Tc-99m HMPAO SPECT, 1074(ab)
Breast cancer, *see also* Carcinoma, breast
advanced metastatic, I-131 chimeric monoclonal antibody, radioimmunotherapy, 922(ab)
chemohormonotherapy, sequential assessment, FDG PET, 982(ab)
circulating c-*erb*B-2 protooncogene products, serum thymidine kinase, marker for effect of transplant, 1087(ab)
detection and staging, In-111 B72.3 monoclonal antibody, 1326
detection by imageable estradiol, clinical results, 1138(ab)
metastatic, painful bone metastases, Re-186 HEDP, 1082(ab)
PET total body imaging, FDG and F-18 ion, 981(ab)
scintigraphic radiologic and clinical correlation, CA 15-3 RIA, 1132(ab)
Bremsstrahlung, spatial and energy distribution, Monte Carlo simulation, beta point sources in water, 1001(ab)
BRL 34778, F-18 benzamide derivatives, 1842(ab)
4-Bromo-acetamido cyclohexyl EDTA, bifunctional chelating agents, 1023(ab)
Buckyballs, high hopes for Technegas, 24N(11)
Burns, electric, four-phase bone scan, Tc-99m MDP, 1026(ab)

C

CA 15-3
radioimmunoassay, scintigraphic radiologic and clinical correlation, breast cancer, 1132(ab)
serum levels in hepatoma and chronic hepatitis, 1088(ab)
Caffeine, false-negative dipyridamole-Tl-201 myocardial imaging, 1538
Calcium, bone mineral measurements, aortic sclerosis, dual-photon absorptiometry, 259
Calcium channel, blockade, human intestinal transit, 923(ab)
Camera
-based method, calculation, Tc-99m MAG_3 clearance, 953(ab)
high resolution pinhole sequence imaging, small laboratory animals, 987(ab)
Canada, nuclear sites, no increased leukemia, 26N(10)
Cancer, *see also* specific type
findings hotly disputed, Oak Ridge National Laboratory, 11N(7)
PET evaluations with FDG, 1555
radioactive discharges and, 1827(le)
therapy, F-18 FDG PET, 1655
Candidal infections, F-18 fluconazole PET in rabbits, 1014(ab)
Captopril
enhanced renal scintigraphy, Tc-99m MAG_3, renal artery stenosis and renovascular hypertension, 934(ab)
pre post, Tc-99m MAG_3 renography, renal angiography and plasma renin activity, 934(ab)
renal scintigraphy
angiotensin-converting enzyme, Tc-99m MAG_3, 424
simple visual criteria, 933(ab)
renography, noninvasive screening test, hypertension secondary to renal artery stenosis, 1107(ab)
β-Carbolines, F-18 6-(4′-fluorobenzylamino)-3-ethocycarbonyl-β-carboline, PET, 1094(ab)
Carbon-11
-derived rabiolabel, myocardial clearance rates, oxidative metabolism, 1957
sn-1,2- and *sn*-1,3-diacylglycerols, no-carrier-added, C-11 propyl ketene method, 1622
Carbon-11 acetate
myocardial oxidative reserve, PET, 988(ab)
myocardial uptake, indirect estimate, blood flow, 245
recirculation, myocardial oxygen consumption, PET, 1950
regional myocardial perfusion, 665
tracer for myocardial oxidative metabolism, 910(ab)
Carbon-11 alprazolam, PET, cerebral uptake and retention, 1009(ab)
Carbon-11 amphetamine, synthesis, D-2 receptor binding, 994(ab)
α-Carbon-11 amphetamine, synthesis from C-11 nitroalkanes, 994(ab)
1-Carbon-11 arachidonic acid, radiosynthesis, 1093(ab)
Carbon-11 benzovesamicols, mapping of heart cholinergic innervation, 974(ab)
Carbon-11 carazolol, imaging β-adrenergic receptors, 1097(ab)
Carbon-11 carfentanil
epilepsy, 651
on being a guinea pig, 12N(10)
PET
opiate *mu* receptor binding, Alzheimer's disease, 1079(ab)
opiate *mu* receptors, depression, 1078(ab)
Carbon-11 CGP 12177, PET, myocardial *beta* receptors, 927(ab)
Carbon-11 cocaine, F-18 NMS and, robotic assay, metabolites in plasma, 1088(ab)
1,2-Carbon-11 diacylglycerols, PET, phosphatidylinositol turnover, 1097(ab)
Carbon-11 diprenorphine
epilepsy, 651
generalized absence seizures, 960(ab)
Carbon-11 epinine, neuronal marker for heart sympathetic neurons, 994(ab)
Carbon-11 flumazenil
kinetics, differentiation, ligand delivery and binding, 980(ab)
PET, benzodiazepine receptor binding parameters, 1062(ab)
Carbon-11 HED, regional myocardial sympathetic neuronal function, acute myocardial infarction, 1040(ab)
Carbon-11 MET, quadruple-tracer study, radiotherapy monitoring, 1083(ab)
Carbon-11 methionine
application in multicellular spheroid system, 258
fluorodeoxyglucose and, non-Hodgkin's lymphoma, PET, 1211
Carbon-11 L-methionine, PET, diagnosis, gliomatosis cerebri, 726
Carbon-11 methyl-ABV, cholinergic presynaptic tracer, 1095(ab)
Carbon-11 methyl-2-carbomethoxy-3-phenyl tropane, preparation and *in vivo* imaging, monkey brain, 1009(ab)
Carbon-11 nicotine, preparation, metabolite studies, brain PET, 1095(ab)
Carbon-11 nitroalkanes, synthesis, α-C-11 amphetamine and α-C-11 phenethylamine, 994(ab)
Carbon-11 NNC756, dopamine D1 receptor ligand for PET, 934(ab)
Carbon-11 NMSP, dopamine and serotonin BMAX, unified estimation procedure, 1008(ab)
Carbon-11 pergolide, dopamine receptor agonist for PET, 934(ab)
α-Carbon-11 phenethylamine, synthesis from C-11 nitroalkanes, 994(ab)
Carbon-11 PK 11195
PET, peripheral type benzodiazepine sites, glioblastoma, 1608
total and specific *in vivo* binding, human glioblastoma, 1078(ab)
Carbon-11 propyl ketene, no-carrier-added C-11-labeled *sn*-1,2- and *sn*-1,3-diacylglycerols, 1622
Carbon-11 PT, primate model of Huntington's disease, glucose utilization, 981(ab)
Carbon-11 pyrilamine
imaging in living brain, histamine H1 receptors, 308
mapping of histamine H-1 receptors, brain, 1069(ab)
PET, factor analysis, histamine H-1 receptors, 1071(ab)
Carbon-11 raclopride, PET, quantitation in striatum, 1838(ab)
Carbon-11 serotonin, extraction in man, lung, noninvasive measurement, 729
Carbon-11 Thd, quadruple-tracer study, radiotherapy monitoring, 1083(ab)
Carbon-11 threo-MHED, kinetic properties, dog myocardium, 928(ab)
Carbon-11 tyrosine
PET
hyperthermia-induced suppression, protein synthesis, 1587
transport into human brain, 2043
Carbon-11 YM-09151-2, D2 dopamine receptor-specific binding, brain, PET, 713
Carbon-14 leucine, PET, myocardial protein synthesis, 1835(ab)

Carbon-14 methionine, tracer feasibility, monitoring tumor radiotherapy, 2118
Carbon-14 urea, breath test, quantification of *Helicobacter pylori*, gastritis and ulcer disease, 1192
Carcinoembryonic antigen
anti-CEA immunoscintigraphy, primary and recurrent colorectal carcinoma, 1319
anti-CEA monoclonal antibodies, three-step tumor targeting, medullary thyroid carcinoma, 1010(ab)
hapten-chelate constructs, improved stability through modification, linker, 1023(ab)
immunoscintigraphy, Tc-99m antibody fragment, colorectal cancer, 1051(ab)
prospective immunoscintigraphy, chimeric I-123 anti/CEA monoclonal antibody, 941(ab)
Carcinoid neoplasms, endocrine imaging, 1627
Carcinoma, adrenocortical, clinical significance of solitary functioning, adrenal gland, 1882
Carcinoma, bladder
prospective staging, In-111 and Tc-99m anti-CEA antibody SPECT, 970(ab)
Tc-99m anti-CEA-MAK, 1053(ab)
Carcinoma, breast, *see also* Breast cancer
detection of progestin receptors, 21-[^{18}F]fluoro-16α-ethyl-19-norprogesterone PET, 1532
16α-[^{18}F]-fluoro-17β-estradiol uptake, metastases, PET, 1526
scintigraphic radiologic and clinical correlation, CA 15-3 RIA, 1132(ab)
staging of axilla, FDG PET, 981(ab)
Carcinoma, bronchial, ROC analysis of tumor detection ability, Tc-99m MIBI and Tl-201, 961(ab)
Carcinoma, colonic, *see also* Colon cancer
xenograft, anti-CEA antibody uptake, vascular and immunologic factors, 1055(ab)
Y-90 and In-111 macrocycle chimeric B72.3 conjugates, comparative biodistributions, 1842(ab)
Carcinoma, colorectal, *see also* Colorectal cancer
advanced, In-111 anti-colorectal carcinoma monoclonal antibody, 1054(ab)
detection of hepatic metastases, In-111 monoclonal antibody, 940(ab)
In-111 low molecular weight bivalent hapten, dual specificity monoclonal antibody conjugate, 940(ab)
metastatic, radioimmunotherapy, I-131 monoclonal antibody CC49, 1051(ab)
monoclonal anti-CEA antibodies, tumor uptake, autoradiography, 1052(ab)
primary and recurrent, anti-CEA immunoscintigraphy, 1319
refractory, Phase I trial, Y-90 CYT-103 monoclonal antibody, 1052(ab)
routine application, Tc-99m PR1A3 monoclonal antibody, 940(ab)
Carcinoma, hepatocellular, *see also* Liver cancer
hepatobiliary scintigraphic agent, evaluation, distant metastases, 1137(ab)
poor prognosis, 235
Tc-99m PMT uptake, relationship to prognosis, 228
tumor markers, 1088(ab)
Carcinoma, insular, distinct thryoid carcinoma, I-131 localization, 1358
Carcinoma, lung, *see also* Lung cancer
non-small cell, fusion of Tc-99m NR-LU-10 monoclonal antibody, CT, 1132(ab)
Carcinoma, medullary thyroid, three-step tumor targeting, anti-CEA monoclonal antibodies, 1010(ab)
Carcinoma, ovarian
advanced, improved survival, immunoscintigraphy and induction of anti-idiotypic antibodies, 1051(ab)
2-deoxyglucose distribution in xenografts, monoclonal antibodies, 993(ab)
diagnosis of, Bayesian analysis, In-111 OC 125 immunoscintigraphy, 941(ab)
dosimetric estimations, uptake and retention kinetics, In-111 OC 125, 997(ab)
immunotherapy for improved survival, 16N(11)
suspicion of, immunoscintigraphy, Tc-99m OV-TL 3 Fab′, 941(ab)
Carcinoma, papillary thyroid, radioiodide dosage, chronic ambulatory peritoneal dialysis, 1010(ab)
Carcinoma, parathyroid, lymph node metastasis, Tl-201 scintigraphy, 1044(ab)
Carcinoma, prostatic, *see also* Prostatic cancer
histologic Gleason scores, correlation, serum PSA and PAP measurements, 977(ab)
Carcinoma, prostatic
bone metastasis
bone marrow regeneration, hormone therapy, 1025(ab)
hormonal therapy, bone marrow regeneration, 2295
dose estimation, strontium-89 radiotherapy, 997(ab)
skeletal metastases, superiority, bone marrow scintigraphy, 1052(ab)
Carcinoma, renal cell
pre-operative radiotherapy, Sm-153 activatable glass microspheres, 1089(ab)
skeletal metastases, superiority, bone marrow scintigraphy, 1052(ab)
stage IV, Tc-99m MDP bone scan, 983(ab)
Carcinoma, squamous cell
pharmacokinetics and biodistribution, Tc-99m(V)dimercaptosuccinic acid, animal tumor model, 1235
Tl-201 chloride, planar and SPECT, malignant ENT-tumors, 920(ab)
Carcinoma, thyroid, *see also* Thyroid cancer
anaplastic, differentiation, 1363
differentiated
follow-up, Tl-201, 921(ab)
post-surgical follow-up, I-131 whole-body scan, 1826(le)
post-surgical follow-up, 1640(le)
serum thyroglobulin, whole-body I-131 scan, 1645(le)
endocrine imaging, 1455
insular carcinoma, I-131 localization, 1358
malignant transformation of Hürthle cell tumor, 1266
new IRMA, serum human thyroglobulin, 1088(ab)
post-therapy I-131 imaging, gallbladder visualization, 2275
recurrent medullary, localization, Tc-99m MIBI scintigraphy, 2281
Carcinomatoses, peritoneal, radiation absorbed dose, I-131 B72.3, 1661
Cardiomyopathy
Adriamycin, systemic adrenergic hyperactivity, 1029(ab)
dilated-phase hypertrophic, damage assessment, In-111 antimyosin Fab myocardial scintigraphy, 1333
hypertrophic
coronary flow reserve, dipyridamole N-13 ammonia PET, 1040(ab)
glucose loading, FDG PET, 1039(ab)
myocardial uptake rate in scintigraphy, I-123 MIBG and Tl-201 chloride, 1040(ab)
hypertrophic and postpartum, myocardium accumulation, monoclonal antimyosin Fab, 2291
ischemic, myocardial viability, PET, 130
Cardiomyoplasty, evaluation with radionuclide ventriculography, 1038(ab)
Cardiopulmonary bypass, heparinized surface and iloprost infusion, platelet thrombus quantitation, oxygenator and arterial filter, 1048(ab)
Cardioscint, miniature nuclear probe system, cardiac function and ST-segment, 37
Carditis, Tc-99m HMPAO labeled WBC scan, 1041(ab)
Carotid artery
acetazolamide, Tc-99m HMPAO, 1074(ab)
endarterectomy
cerebral perfusion, acetazolamide-enhanced SPECT, 971(ab)
Tc-99m HMPAO, changes in cerebral blood flow reserve, 1382
severe stenosis with I-123 IMP brain SPECT, carotid territory transient ischemic attacks, 972(ab)
CDTA, -In-111 anti-CEA F(ab′)$_2$ immunoconjugates, improved biodistribution, nude tumor mice, 1023(ab)
Cellobiose, -tyramine radioiodination of antibody, improved treatment, leukemia, 1843(ab)
Cellulose acetate, hemodialyzers, comparative loss, In-111 PMN granulocyte, 1048(ab)
Central nervous system
mapping of dopaminergic receptors, 3-N-ω-[F-18]fluoroalkylated benperidol, 935(ab)
primary tumors, FDG-PET, 932(ab)
Cerebrospinal fluid
leak
intestinal activity, radionuclide cisternography, 151
scintigraphic localization, benefit of tomography, 2149
Cerebrovascular disease, Tc-99m ECD and I-123 IMP, SPECT, 1073(ab)
Cesium, environmental radiation, fallout in firewood, 28N(10)
Cesium iodide, miniature nuclear probe system, cardiac function and ST-segment, 37
CGP 12177
cardiac β-adrenergic receptor density, 739
vs. I-125 CYP, beta adrenergic receptors, heart, 1028(ab)
Chelating agents
bifunctional, triamenedithiol ligands, Tc-99m and Re-186, 985(ab)
iron, alternation of biodistribution, In-111 ZCE025, 1056(ab)
hapten-chelate constructs, improved stability through modification, linker, 1023(ab)
4-isothiocyanato- and 4-bromo-acetamido cyclohexyl EDTA, preparation of radiometal immunoconjugates, 1023(ab)
Mo-99/Tc-99m generated eluate contaminants, N_2S_2 and N_3S amide thiolate, 1102(ab)
phenylenediamine Schiff base bifunctional, radiolabeling proteins, 1023(ab)
preformed, Tc-99m radiolabeling, antibody Fab fragment, 1445
Chemistry, computational, applications, radiopharmaceutical design, 1139(ab)
Chemohormonotherapy, sequential assessment, FDG PET, breast cancer, 982(ab)
Chemotactic peptide
analogs, In-111 labeling, bacterial infection imaging, 483

new locomotion for imaging of infection, 491
Chemotherapy
effects, malignant lymphoma, F-18 FDG PET, 918(ab)
response monitored by I-131 MIBG scintigraphy, malignant pheochromocytoma, 1044(ab)
Chernobyl
radiation exposure four years later, physical and biological evidence, 1018(ab)
U.S. and IAEA delegations assess radiation effects, 11N(3)
Cholecystectomy
elective laparoscopic, bile leak, 1777
laproscopic, postoperative complications, scintigraphy, 1910
Cholecystitis
absence of, delay in gallbladder visualization, bone marrow transplantation, 1047(ab)
acute, In-111 leukocyte, 803
Cholecystokinin
cholescintigraphy
abnormal gallbladder motor function, chronic acalculous gallbladder disease, 1695
combined visual and quantitative method, sphincter of Oddi dysfunction, 1046(ab)
necessity to separate normal from CBD obstruction, prompt gallbladder filling but no bowel filling, 976(ab)
various infusion rates, gallbladder ejection fraction, 975(ab)
Cholescintigraphy
bronchobiliary fistula, 136
clinical significance of non-visualization, gallbladder, choledochal cyst, 976(ab)
delayed kinetics, sphincter of Oddi dysfunction, 976(ab)
morphine-augmented, detection, acute cholecystitis, 1231
Cholestasis, intrahepatic, reliability of diagnosis, Tc-99m mebrofenin, 976(ab)
Choline
3-I-125 BP for mapping, 1093(ab)
neuron marker 5-iodobenzovesamicol, preclinical studies, 1096(ab)
presynaptic tracer, C-11 methyl-ABV, 1095(ab)
Chromatography, antiidiotypic affinity, purification, radiolabeled antibody, 993(ab)
Chromium-51, reference values, red cell survival times, 2245
CHX-DTPA, synthesis, α-particle radioimmunotherapy, Rauscher leukemia virus, 1056(ab)
Cigarette smoking, neutrophil margination in the lung, platelet activating factor, 990(ab)
Cimetidine, -enhanced Tc-99m pertechnetate, visualization, Meckel's diverticulum, 1422
Cirrhosis
after liver transplantation, reversal of intrapulmonary shunting, 862
chronic biliary, shunt fraction estimation, I-123 IMP and Tc-99m pertechnetate, 124
liver uptake with phytate colloid, 1467(le)
Clean Air Act, two-year exemption from regulations, 14N(2)
Clebopride, F-18 benzamide derivatives, 1842(ab)
Clinical Laboratory Improvement Amendments (CLIA), 1988, no final regulations yet, 11N(9)
Clorgyline, radioiodinated analogs, mapping MAO-A activity, brain SPECT, 1091(ab)
Cobalt, ligands for labeling antibodies for PET, 1842(ab)
Cocaine
carrier-free radioiodinated, synthesis, animal biodistribution, 965(ab)
crack users, localization and clearance properties, Tc-99m HMPAO and I-123 IMP, 1840(ab)
-dependent polydrug users, abnormal brain perfusion, Tc-99m HMPAO SPECT, 1022(ab), 1206
-induced global and regional myocardial ischemia, 1569
long-term abuse, brain perfusion, Xe-133 rCBF and Tc-99m HMPAO, 1021(ab)
withdrawal, different stages, regional brain metabolic activity, 960(ab)
Collimator
clinical gamma camera high penetration parallel hole, I-131 scattering and septal penetration, 1058(ab)
compensation of attenuation and divergence, 3D model, SPECT image reconstruction, 917(ab)
high-energy, planar imaging at 511keV, 986(ab)
high-resolution pinhole sequence imaging, small laboratory animals, 987(ab)
parallel-hole, combined cone-beam, SPECT data, 956(ab)
parallel-hole/fan beam/cone beam, myocardial defect detection, Tl-201 SPECT, 946(ab)
pinhole, cardiac blood-pool scintigraphy, rats and hamsters, 851
special high-resolution, multicrystal gamma camera, gated radionuclide angiography, 1059(ab)
table position and, cardiac phantom comparison, gamma camera SPECT, 1136(ab)
Colloid, negative scans, residual spleen, denatured red blood cell scan, 2286
Colon
transit of nondigestible solids in man, noninvasive assessment, 1375
transit scintigraphy, comparison, I-131 cellulose and In-111 DTPA, 1668
Colon cancer, *see also* Carcinoma, colonic
fate of 5-[I-125]iodo-2′-deoxyuridine, intratumoral injection, 1082(ab)
Colony-stimulating factor, granulocyte, Tc-99m sulfur colloid, autologous bone marrow transplantation, 1013(ab)
Colorectal cancer, *see also* Carcinoma, colorectal
CEA immunoscintigraphy, Tc-99m antibody fragment, 1051(ab)
In-111 transferrin scintigraphy, 1084(ab)
occult metastases, Tc-99m anti-CEA Fab′ fragments, 1052(ab)
recurrent, fluorodeoxyglucose PET, radiotherapy, 1485
suspected recurrent, In-111 CYT-103 monoclonal antibody, 1053(ab)
Coma, brain death and, F-18 FDG PET, 1077(ab)
Compton scatter
correction
current status, 1291
regularized energy-spectral fitting-deconvolution method, 916(ab)
dual-window correction, region of interest selection, scatter multiplier, 186
free imaging, Klein-Nishina based energy factors, 1000(ab)
maximum-likelihood, expectation-maximization reconstructions, SPECT, 1285
Computed tomography (CT)
AIDS, 1078(ab)
cone-beam transmission, nonuniform attenuation compensation, SPECT, 1813
fusion of functional SPECT images, 1135(ab)
fusion of Tc-99m NR-LU-10 monoclonal antibody, non-small cell lung carcinoma, 1132(ab)
maximum-likelihood estimation, mathematical model, quantitation in nuclear medicine, 898(le)
reprojection method, automatic removal, streak artifacts, 996(ab)
SPECT and, accurate correlation, brain scans, 1080(ab)
Tc-99m HMPAO SPECT and, cerebral blood flow, acute closed-head injury, 1684
three-dimensional display, 534
ultrafast, right ventricular ejection fraction, 429
Computers
-based interactive educational technique, PET, 1134(ab)
present and future directions, Tenth Annual SNM Mid-Winter Meeting, 24N(1)
Computers, software, symbolic interactive modeling package, learning environment, 987(ab)
Cone beam
parallel-hole collimation SPECT data, 956(ab)
reconstruction algorithm, perpendicular orbits, 956(ab)
straight line tomography, SPECT cardiac imaging, 956(ab)
Congress, debate of states' right to override BRC policy, 30N(1)
Contrast
enhancement of lung MR imaging, 1081(ab)
negative oral, magnetic resonance imaging, 1081(ab)
Convulsions, fever and, Tc-99m HMPAO SPECT, brain, 1086(ab)
Copper-62, blood-pool agents, 475
Copper-62 PTSM
detection of neural activation foci, 1072(ab)
myocardial flow tracer, 1028(ab)
PET, quantification, myocardial perfusion, 937(ab)
retention mechanism, 974(ab)
Copper-67 BAT-Lym-1 monoclonal antibody, B cell lymphoma, 984(ab)
Copper(II)-bis-(N^4-substituted)thio semicarbazone, protein complexes, stability of, 944(ab)
Copper pyruvaldehyde thiosemicarbazone, myocardial uptake, N-13 ammonia, PET, 999(ab)
Coronary artery
bypass graft, bull's-eye subtraction polar map, perfusion, 1035(ab)
gated SPECT, 2311
In-111 platelet deposition, porcine restenosis model, 1029(ab)
occlusion, myocardial glucose metabolism, FDG-PET, 909(ab)
stenosis, regional myocardial Tc-99m SQ30217 clearance rate, 1037(ab)
Coronary artery disease (CAD)
abnormal wall motion, improvement with hyperventilation, 939(ab)
accuracy and reproducibility of VEST measurements, left ventricular ejection fraction, 796
adenosine SPECT and Tl-201, reinjection technique, 979(ab)
adenosine *vs.* exercise SPECT thallium, elderly patients, 968(ab)
advanced, clinical outcome, PET viability studies, 1011(ab)
clinical role of PET, cardiology, 606
comparison between Tc-99m teboroxime, Tl-201 dipyridamole imaging, 919(ab)

decrease of ejection fraction, occurrence at rest, 1038(ab)
detection, optimal efficiency, PET perfusion, 1130(ab)
dipyridamole Tc-99m-2-MIBI tomoscintigraphic imaging, compared to Tl-201 stress-rest study, 369
dipyridamole-thallium imaging, safety in high risk patients, 2107, 2115
effect of anger, left ventricular function, 1038(ab)
FDA approval of new technetium-labeled cardiac agents, alternative to exercise, stress-thallium studies, 11N(5)
increased lung uptake, adenosine Tl-201 scintigraphy, 979(ab)
left bundle branch block detection, 1033(ab)
lung Tl-201 uptake
exercise emission computed tomography, 417
left ventricular dilation, adenosine and exercise, 1030(ab)
nuclear cardiology, PET perfusion imaging, 579
nuclear exercise testing, 753
reinjection of Tl-201, compared to 4-hour redistribution images, 948(ab)
single vessel, adenosine and exercise Tl-201 SPECT, jeopardized myocardium, 969(ab)
Tc-99m MIBI and Tl-201 reinjection, detection of viable myocardium, 949(ab)
Tc-99m sestamibi myocardial perfusion, 1961, 1966
Tc-99m teboroxime and Tl-201 planar myocardial perfusion, 919(ab)
Tl-201 redistribution, facilitation by ribose, 193
Tl-201/Tc-99m teboroxime/Tc-99m sestamibi, comparison of perfusion agents, 919(ab)

Crack
asymptomatic users, distribution and clearance, I-123 IMP, 1022(ab)
quantitative localization and clearance properties, Tc-99m HMPAO, I-123 IMP, 1840(ab)

Creatinine
clearance, radionuclide GFR, non-insulin dependent diabetes mellitus, 1105(ab)
clearance and Tc-99m DMSA, discrepancy of renal uptake, drug-induced nephrotoxicity, 1106(ab)

Credentialing, delineation of privileges, 190

Cushing's syndrome, endocrine imaging, 1627

CX-1 tumor model
binding of IgG and Fab forms of CC49 to TAG-72, biodistribution, 1098(ab)
I-125 IgG, F(ab)′$_2$ and Fab forms, TAG-72 antigen, 1020(ab)

Cycloheximide, application of (methyl-^{11}C)-methionine, multicellular spheroid system, 2258

α-Cyclohextrin, new usage in radionuclide labeling, 1091(ab)

Cyclosporine, radioimmunoassay, prediction of nephrotoxicity, heart transplant, 977(ab)

Cyclotron
negative ion *vs.* positive ion, 23N(4)
vertical beam facility, irradiation, molten targets, 1091(ab)

Cystic disease, hepatobiliary scintigraphy, 944(ab)

Cystic fibrosis, therapy, aerosol scintigraphy, 1139(ab)

Cytochrome P-450, mediated defluorination, non-β-oxidizable ω-[F-18]fluoro long chain fatty acid, 975(ab)

D

Dementia
AIDS, 16N(7)
Alzheimer and Binswanger, cerebrovascular responsiveness to hypercapnia, PET, 1079(ab)
Alzheimer's disease, severity and onset, Tc-99m HMPAO perfusion patterns, 1076(ab)
I-123 IMP and Tc-99m HMPAO, brain SPECT, 1073(ab)
neuropsychological test, SPECT/IMP, 942(ab)
stroke and, Xe-133 rCBF SPECT, Tc-99m HMPAO SPECT, 972(ab)

Densitometry, optimal monitoring, bone mass changes, 1129(ab)

Deoxyglucose, uridine uptake and, ischemic myocardium, 928(ab)

2-Deoxyglucose, distribution in xenografts, autoradiographic evaluation of Mab, ovarian carcinoma, 993(ab)

Department of Energy (DOE)
appropriations for FY 1991, 13N(2)
approves grant for NBTF feasibility study, 17N(3)
isotope supply tenuous, federal funding at issue, 13N(12)
medical applications program, 12N(9)
National Biomedical Tracer Facility, 13N(2), 12N(9)
three American distributors of radiopharmaceuticals and, study of domestic Moly-99 production, 32N(6)
Y-90 for cancer therapy studies, government and commercial suppliers, 16N(2)

Department of Transportation (DOT), Hazardous Materials Transportation Act passed, 14N(2)

Depression
5-HT2 receptor imaging, 2-I-123 ketanserin, 952(ab)
late onset before and after treatment, semi-quantitative I-123 SPECT, 952(ab)
major, total sleep deprivation, changes in regional brain perfusion, 952(ab)
opiate *mu* receptors, PET and C-11 carfentanil, 1078(ab)

Desipramine, heart uptake and metabolism, 6-F-18 FDA and FNE, 993(ab)

Deuterium, NMR measurement of blood flow, wash-in technique, murine tumors, 1081(ab)

Diabetes
animal models, cardiac autonomic nerve abnormality, I-123 MIBG, 928(ab)
clinical role of metabolic imaging of heart, PET, 565
feet, osteomyelitis, In-111 leukocytes, 1003(ab)
gastroparesis, long-term oral erythromycin, blood glucose control, 931(ab)
non-insulin dependent, endogenous creatinine clearance, radionuclide GFR, 1105(ab)
pedal osteomyelitis, diagnostic efficacy, In-111 WBC imaging, 963(ab)
quality of myocardial tissue viability studies, insulin substitution, FDG-PET, 988(ab)

Diamide dimercaptide, chelating agent, kit development, preformed chelate Tc-99m radiolabeling, 1445

Diarrhea, selenium-75 homocholic acid taurine test reevaluated, 1219

Diet, AIDS malnutrition, depletion of body cell mass, 1050(ab)

Dietary fat, *see also* Fat
pre-load effect on gastric emptying, normal healthy male subjects, 1046(ab)

Dipyridamole
alteration of arterial input function, PET perfusion imaging, 1040(ab)
delayed Tl-201 myocardial SPECT, normalization of stress, normal reference area, 1901
exercise stress imaging and, myocardial and plasma Tl-201 kinetics, exercise type, 1031(ab)
inadequate exercise, suboptimal imaging, Tl-201 myocardial perfusion, 2071
infusion, increased thallium lung uptake, significance, 1031(ab)
infusion thallium scan, mechanisms, transient myocardial perfusion defects, 1030(ab)
intravenous
maximal myocardial blood flow, adenosine infusion, 969(ab)
vs. IV adenosine thallium myocardial scintigraphy, 969(ab)
intravenous adenosine
myocardial perfusion, Tc-99m MIBI, 1027(ab)
vasodilatory action, PET scanning of heart, 969(ab)
myocardial kinetics of Tc-99m teboroxime, canine stenosis model, 948(ab)
myocardial perfusion imaging, exercise supplementation, 1564
N-13 ammonia PET, coronary flow reserve, hypertrophic cardiomyopathy, 1040(ab)
noninvasive delineation, effects of moderate aging, myocardial perfusion, 2037
nuclear cardiology, PET perfusion imaging, 579
packaging of intravenous Persantine, 2023(le)
PET, left ventricular mass, myocardial perfusion, 2221
stress Tl-201 myocardial perfusion scintigraphy, role of 24 hour imaging, Tl-201 re-injection, 1129(ab)
Tc-99m-2-MIBI tomoscintigraphic imaging, Tl-201 stress-rest comparison, diseased coronary vessels, 369
-thallium imaging
quality, exercise supplementation, 1559
safety in high risk patients, coronary artery disease, 2107, 2115
Tl-201
false-negative and caffeine infusion, myocardium, 1538
lung uptake, ejection fraction in peripheral vascular disease, 967(ab)
Tl-201 SPECT, left bundle branch block, 1033(ab)
tomographic myocardial perfusion imaging, Tc-99m teboroxime, 1968

Diuresis
renography
evaluation of hydronephrosis, newborns, 943(ab)
standardized protocol in neonates, hydronephrosis, 943(ab)

Diving, decompression accidents, neurologic sequelae, F-18 FDG PET, 1079(ab)

DNA, pharmacokinetics of single-chain antibody fragments, systemic and regional delivery, 1020(ab)

DNA, mitochondrial, radiation effect, respiratory functions, rat, 1043(ab)

Dobutamine
myocardial oxidative and contractile reserve, 989(ab)
pharmacologic cardiac stress, thallium myocardial perfusion studies, 1130(ab)
Tl-201 tomography, suspected coronary artery

disease, 979(ab)

Dopamine
amphetamine-induced release, competition, I-123 IBZM binding to D2 receptors, 1007(ab)
endogenous
F-18 N-methylspiroperidol binding, 1071(ab)
H-3 WIN-35,428, binding to dopamine release sites, 1069(ab)
function, I-123 IDDE, potential radiotracer, 1092(ab)
increased uptake in striatum, normal glucose metabolism, idiopathic dystonia, 1015(ab)
nerve terminals, F-18 6-fluoro-MDL-72394, rats and monkeys, 1096(ab)
serotonin BMAX, C-11 NMSP, unified estimation procedure, 1008(ab)
transporter, X-ray affinity labeling, photoaffinity ligands, 1839(ab)

Dosimetry
absorbed dose calculations, blood and blood vessels, internally deposited radionuclides, 830
absorbed doses in humans, F-18 fluorodeoxyglucose PET, 699
activity selection, gastrointestinal transit, Er-171 and Sm-153 labeled hydrogel beads, 997(ab)
alteration of biodistribution, I-131 B72.3, 1052(ab)
bone marrow, direct tissue counting, radioiodinated monoclonal antibodies or $F(ab')_2$ fragments, 1414
clinical PET scanning, F-18 6-fluorodopamine, 102
enhancement of radioiodine therapy, hyperthyroidism, 1017(ab)
estimation in Sr-89 radiotherapy, metastasized prostatic carcinoma, 997(ab)
estimation of weighted effective dose, Tc-99m radiopharmaceuticals, 1835(ab)
I-123 Tyr-3-octreotide, 1018(ab)
organ, monoclonal antibody procedures, 1130(ab)
radioactive simulated grains, autoradiography study, 996(ab)
radioimmunotherapy, body activity correction method, 997(ab)
terminal portion of tumor time-activity curve, radioimmunotherapy, 1314(le)
uptake and retention kinetics, In-111 OC 125 antibody, ovarian carcinoma, 997(ab)
whole blood doses from I-131, thyroid cancer, 1045(ab)

Doxorubicin, severity of myocardial damage, antimyosin monoclonal antibody, 1019(ab)

DTPA
long-term biodistribution of In-114m, 1100(ab)
metabolism of In-111 monoclonal antibody, 1055(ab)

Dual-energy X-ray absorptiometry, forearm bone mineral measurement, 2101

Dual-photon absorptiometry (DPA)
assessment by OHTA, 12N(2)
bone mineral density, active acromegaly, 1011(ab)
bone mineral measurements, aortic sclerosis, 259
dual X-ray absorptiometry and, regional variations, bone mineral loss, 1025(ab)
measurement of response to nonhormonal therapy, osteoporosis, 982(ab)
reassessment by Office of Health Technology Assessment, 11N(9)

Duodenogastroesophageal reflux, modified scintigraphic method, 2027(le)

DuP753, renal effects, renovascular hypertension, 1103(ab)

Dystonia, idiopathic, increased striatal dopamine uptake, normal glucose metabolism, 1015(ab)

E

Echocardiography, gated PET FDG imaging, parameter estimation, cardiac geometry, 927(ab)

Echolalia, brain mapping, Tc-99m HMPAO SPECT, 1619

Editorials
additional useful information, myocardial washout characteristics, teboroxime, 1988
advantage of protecting antigen-binding site, antibody labeling, 122
antimyosin imaging and histopathology, myocardial infarction, 867
application of SPECT, *in vivo* measurement, benzodiazepine potency, 1762
applications of PET in clinical oncology, 649
autonomously functioning thyroid nodule, 30
biologic characterization of melanoma tumors, antigen-specific targeting, radiolabeled anti-tumor antibodies, 287
cardiac blood-pool tracers, 480
chemotactic peptides, new locomotion, infection imaging, 491
chronic prosthetic vascular graft infection, visualization with Ga-67, 1427
compensatory splenic growth, 207
considerations for accurately measuring gastric emptying, 881
constraints on sensitivity and specificity, "logically" merged test results, 1646
continuous radionuclide monitoring, left ventricular function, 44
correction for patient Compton scattering, current status, 1291
decision analysis approach to treatment of suspected pulmonary emboli, 2056
detection of acute myocardial infarcts, infarct-avid imaging, 269
development and application, mathematical models, nuclear medicine, 2206
diagnostic accuracy and deep venous thrombosis, biostatistician's perspective, 2328
differential myocardial washout, Tc-99m teboroxime, mechanism and significance, 2009
differentiating anaplastic thyroid carcinomas, 1363
dipyridamole/thallium-201 imaging, safety of, 2115
exercise supplementation, dipyridamole, myocardial perfusion imaging, 1564
glomerular filtration rate in children, 1297
HIV encephalopathy, 1475
imaging human brain development with PET, 23
imaging of inflammatory sites in the 1990s, new horizons, 2034
immunoscintigraphy for lung cancer detection, reality testing, 2069
immunoscintigraphy of thrombi, 2321
improving esophageal transit scintigraphy, 1371
infiltrated radiopharmaceutical injection, risk considerations, 890
influence of positioning, accuracy and precision, emission tomography, 1252
in vivo assay, receptor-ligand binding, 1182
monitoring tumor radiotherapy, 2124
morphine injection, scintigraphic detection, acute cholecystitis, 1233
myocardial viability, 10
optimization of regional cerebral blood flow, PET, 1934
optimizing antibodies, use in nuclear medicine, 1751
PET cancer evaluations with FDG, 1555
prognosis of hepatocellular carcinoma, 235
quantitation of renal function using MAG_3, 2061
radionuclide ventriculography, 782
radiopharmaceutical, imaging of venous thrombosis, 791
receptors on tumors, radionuclide scintigraphy, 1189
redistribution, importance, sestamibi myocardial imaging, 1966
relationship between myocardial clearance rates, C-11-derived radiolabel, oxidative metabolism, 1957
saturation of amino acid uptake, human brain tumor, SPECT, 1229
small coordination complexes, tumor imaging, 849
SPECT and artifacts, in search of imaginary lesion, 875
symbiotic developments in PET and SPECT, myocardial tomography, 166
Tc-99m HMPAO, retention and uptake, role of glutathione, 1681
Tc-99m sestamibi, window on myocardial viability, 298
Tl-201 chloride, detection, viable myocardium, 200
toward absolute quantitation, cerebral blood flow, Tc-99m HMPAO single scan, 1506
which PET radiopharmaceuticcal for brain tumors, 1346
year's end, 2356

EDTA, administration effect, biodistribution, In-111 monoclonal antibodies, 1100(ab)

Effusion, sympathetic, Tc-99m MDP uptake, 325

Ejection fraction
cardiac function and ST-segment, miniature nuclear probe system, 37
episodes of fall, occurrence at rest, coronary artery disease, 1038(ab)
first pass, rest/treadmill exercise Tc-sestamibi, 929(ab)
gallbladder, various infusion rates, cholecystokinin, 975(ab)
left ventricular
accuracy and reproducibility of measurements, VEST system, 796
non-imaging miniature probe, 1038(ab)
list mode ECG-gated first pass, accuracy with single crystal gamma camera, Tc-99m perfusion agents, 939(ab)
peripheral vascular disease, lung uptake, dipyridamole Tl-201, 967(ab)
right, scintigraphic methods, ultrafast computed tomography, 429

Electrocardiography
ambulatory, stress redistribution thallium scintigraphy, patient population factors, 958(ab)
-gated first pass LVEF, accuracy with single crystal gamma camera, Tc-99m perfusion agents, 939(ab)
-gated imaging with Tc-99m Sestamibi, quantitative assessment, regional myocardial thickening, 957(ab)

Electroencephaloengram, localization of foci in childhood-onset epilepsy, HMPAO SPECT,

912(ab)
Emboli
arteriovenous malformations, quantification, blood flow, 968(ab)
pulmonary, *see* Pulmonary embolism
Emission computed tomography
exercise, lung Tl-201 uptake, 417
spatially-variant regularization, iterative reconstruction algorithm, 936(ab)
Emitters, therapeutic radionuclides, 174
Enalaprilat, ^{99m}Tc-MAG$_3$, scintigraphy, renovascular hypertension, 934(ab)
Encephalomyelitis, acute disseminated, HMPAO-SPECT and MRI, 1897
Encephalopathy
Binswanger type, regional water content, PET, 1079(ab)
hepatic, I-123 IMP SPECT, 1074(ab)
human immunodeficiency virus, SPECT, 1471, 1475
Endarterectomy
carotid
cerebral perfusion, acetazolamide-enhanced SPECT, 971(ab)
Tc-99m HMPAO, changes in cerebral blood flow reserve, 1382
Endocarditis
prosthetic valve, aortic ring abscess, gallium-SPECT, 1791
suspected subacute bacterial, immunoscintigraphy, monoclonal Tc-99m anti-granulocyte antibody, 1019(ab)
Endocrine
imaging
management, goiter and thyroid nodules, 1455
parathyroid, adrenal cortex and medulla, 1627
Endotoxin, reduction of specific pulmonary uptake, radiolabeled monoclonal antibody, angiotensin-converting enzyme, 453
Energy, deposition patterns in spheres, estimates, beta absorbed fractions, 835
Environmental Protection Agency (EPA)
Clean Air Act, 14N(2)
Clean Water Act, 20N(9)
postponement of NESHAPS rule, 29N(6)
Resource Conservation Recovery Act, 20N(9)
White House involvement, 20N(9)
Eosinophilia myalgia syndrome, gallium uptake, 2026(le)
Eosinophils
degranulated, radioimmunodetection, Hodgkin's disease, 89
tryptophan-related pulmonary disease, gallium uptake, 328
Epilepsy
childhood-onset, HMPAO SPECT, EEG localization of foci, 912(ab)
extratemporal, PET, 912(ab)
intractable focal, preoperative evaluation, F-18 FDG PET, 912(ab)
localization of foci, Tc-99m HMPAO, childhood, 913(ab)
PET, 651
presurgical diagnosis, magnetic resonance tomography, compared to HMPAO SPECT, 1076(ab)
refractory temporal lobe, regional glucose metabolism, benzodiazepine receptor binding, 912(ab)
temporal lobe
interictal SPECT, Tc-99m HMPAO, 1688
MRI T2 increased signal, PET interictal hypometabolism, 912(ab)
Tc-99m HMPAO SPECT, 388
Epitopes, melanoma-associated antigens, human malignant melanoma, 1056(ab)
Equilibrium dissociation constants, receptor binding ligands, 1004(ab)
Erbium-171, labeled hydrogel beads, activity selection and dosimetry, gastrointestinal transit, 997(ab)
Erythrocytes, *in vivo* labeling technique, factors which influence effectiveness, 1090(ab)
Erythromycin
contraction of prairie dog gallbladder, 1836(ab)
long-term oral, gastric emptying and blood glucose control, diabetic gastroparesis, 931(ab)
Esophagus
adenocarcinoma, pericardial fistula, hepatobiliary scintigraphy, 518
columnar-lined, Tc-99m pertechnetate scintigraphy, 930(ab)
emptying
body posture effects, semi-solid bolus test meal, 930(ab)
bolus viscosity, 1045(ab)
motility disorders, multiple swallow test, 1365
radionuclide transit study, usefulness, 1310(le)
scintigraphy, manometry, multiple swallow investigations, 931(ab)
transit scintigraphy, 1371
Estradiol, imageable, clinical results, breast cancer detection, 1138(ab)
Estrogen
receptor stimulation, fluorodeoxyglucose uptake, feasibility study, 1011(ab)
responsive tumors, synthesis and evaluation, polyunsaturated 17α-iodovinylestradiols, 965(ab)
17α-Ethynyl-16β-[F-18]fluoro-11β-methoxy-estradiol, control of metabolism, target tissue uptake, 974(ab)
Etidronate disodium, duration of effect, serial bone scintigraphy, 1782
European Association of Nuclear Medicine Congress, scientific highlights of Congress 1991, 15N(11)
European Economic Community (EEC), international state of PET, 33N(4)
Exercise
bicycle and treadmill, comparison, radionuclide angiocardiography, 967(ab)
inadequate, suboptimal imaging, Tl-201 myocardial perfusion, 2071
low-level treadmill, feasibility, adenosine infusion, 1031(ab)
lung Tl-201 uptake and left ventricular dilation, coronary artery disease, 1030(ab)
markedly positive tests, myocardial perfusion scintigraphy, 1035(ab)
nuclear testing, coronary artery disease, 753
peak power, cardiac contractile reserve in man, 939(ab)
rest/treadmill, Tc-99m Sestamibi first pass ejection fraction, normal limits, 929(ab)
SPECT Tl-201
adenosine SPECT, multi-center trial, 968(ab)
arteriopathy, orthotopic heart transplant, 1041(ab)
supplementation
dipyridamole, myocardial perfusion imaging, 1564
dipyridamole Tl-201 image quality, 1559
thallium imaging, adenosine, moderate coronary stenosis, 1031(ab)
Tl-201 SPECT, left bundle branch block, 1033(ab)
treadmill stress, myocardial FDG uptake, PET, 1039(ab)
type, myocardial and plasma Tl-201 kinetics, dipyridamole and exercise stress imaging, 1031(ab)

F

Fab fragments
antibody, kit development, preformed chelate Tc-99m radiolabeling, 1445
bone marrow dosimetry, direct tissue counting, 1414
immunohistochemical localization, CX-1 tumor model, I-125 IgG, 1020(ab)
pharmacokinetics of single-chain antibody fragments, systemic and regional delivery, 1020(ab)
Fasting, simple quantification, regional myocardial uptake, F-18 deoxyglucose, 2152
Fat, *see also* Dietary fat
gastric emptying, measurement with Tc-99m(V)thiocyanate, 878
measurements with dual photon absorptiometry, soft tissue thickness, 983(ab)
Fatty acids
-glucose cycle, human heart, PET, 938(ab)
long-chain, myocardial utilization, F-18 FTHA, 1888
utilization in myocardium, 14(*R,S*)-[F-18] fluoro-6-thia-heptadecanoic acid, 937(ab)
Fc fragment, selective iodination, preservation of immunoreactivity, monoclonal antibody, 1100(ab)
F-DOPA, PET, various graphical analyses, estimation of influx constant, 1004(ab)
Fenoldopam, diagnosis of renal artery stenosis, 933(ab)
Fermi Award, bestowed upon Robley Evans, 23N(2)
Ferritin
exchange of In-111 between IgG and lactoferrin, transferrin, 1099(ab)
Ga-67 binding, influence of conditions, 1100(ab)
Fetus, radiation dosimetry, I-131 administration, hyperthyroidism, 808
Fever
convulsions and, Tc-99m HMPAO SPECT, brain, 1086(ab)
unknown origin, muscular sarcoidosis, Ga-67 imaging, 319
Fibrin, -specific monoclonal antibody, localization, pulmonary emboli, 1254
Fibrosis, differentiation from viable mediastinal Hodgkin's disease, semiquantitative method, SPECT, 918(ab)
Filters
energy-weighted acquisition, determination, weighting functions, 343
noise suppression in image sequences, 987(ab)
Fine-needle aspiration, solitary nodule, thyroid scan, preoperative diagnosis, 1045(ab)
Fistula
bronchobiliary, cholescintigraphy, 136
pericardial, hepatobiliary scintigraphy, 518
Flow cytometry, glucose uptake and cell proliferation, 1548
Fluorine-18
carbohydrate analogs of glucose, glucose transport, brain, 1093(ab)
electrophilic, spectroscopic identification, 1010(ab)
fluoroalkylated analogues of raclopride,

mapping cerebral D2 receptors, PET, 1095(ab)
fluorination/carbonylation, new route to aryl [F-18]fluorides, 1009(ab)
6-(4′-fluorobenzylamino)-3-ethocycarbonyl-β-carboline, PET, 1094(ab)
labeling, release of updated monograph by National Research Council, 28N(1)
5-HT subtype 3 receptor antagonist, 1841(ab)
Fluorine-18 altanserin
PET
radiolabeling, *in vivo* biologic behavior in rats, 2266
serotonin S2 receptor imaging, 980(ab)
Fluorine-18 amphetamine, analogs, synthesis, D-2 receptor binding, 994(ab)
Fluorine-18 antimyosin antibody, tracer for PET myocardial imaging, 1030(ab)
Fluorine-18 aryl precursors, kryptofix-free "dry" synthesis, ion exchange, 1010
Fluorine-18 benzamide derivatives, based on clebopride and BRL 34778, 1842(ab)
Fluorine-18 deoxyglucose
metabolic activity in areas of new fill-in, Tl-201 reinjection, 673
N-13 ammonia and, effect of metabolic milieu, cardiac PET imaging, 1518
15-(ortho-^{123}I-phenyl)-pentadecanoic acid uptake and, Tl-201 tomography, myocardial infarction, 1353
PET
advanced head and neck cancer, 920(ab)
glucose uptake, tumor proliferation, 1083(ab)
radiation or chemotherapy effects, malignant lymphoma, 918(ab)
thoracic oncology, 1138(ab)
regional myocardial uptake, fasting condition, 2152
Tl-201 and, detection, recurrent brain tumor, 955(ab)
Fluorine-18 DOG, PET, glucose uptake, resting myocardial perfusion defects, 1037(ab)
6-Fluorine-18 DOPA, increased basal ganglia contrast in PE scans, postinjection L-phenylalanine, 1408
6-Fluorine-18 FDA, 6-F-18 FNE and, heart uptake, metabolism and effect of desipramine, 993(ab)
Fluorine-18 fluconazole, PET, candidal infections, rabbits, 1014(ab)
Fluorine-18 fluoride
F-18 fluorination/carbonylation, 1009(ab)
PET, bone metabolic rates, 1004(ab)
simplified recovery and purification, bis-trimethylsilylsulfate, 1095(ab)
Fluorine-18 fluorine, high affinity progestin, receptor-mediated uptake, uterine and mammary tumor tissue, 975(ab)
Fluorine-18 fluormethane, trapping and decomposition of alumina, 1094(ab)
Fluorine-18 fluoroacylated biotin, fast localization of tumors with PET, 1009(ab)
Fluorine-18 fluoroazomycin acyclonucleoside, PET imaging of hypoxic tumors, 1095(ab)
4-Fluorine-18 fluorobenzyl-ABV, marker for central cholinergic presynaptic sites, 994(ab)
Fluorine-18 fluorocaptopril, ACE inhibitor, 1730
Fluorine-18 fluorodeoxyglucose, *see also* Fluorodeoxyglucose
development of, 22N(5)
H-3 FMISO uptake and, low-flow ischemia, 1028(ab)
intravenous administration, absorbed doses in humans, PET, 699
myocardial metabolic rate of glucose, parametric images, dynamic cardiac PET, 732
nonuniformity in myocardial accumulation, normal fasted humans, 1832(le)
PET
coma and brain death, 1077(ab)
evaluation, parenchymal liver disease, 1000(ab)
histologic findings, recurrent brain tumors, 932(ab)
memory circuits in man, 1022(ab)
neurologic sequelae, decompression accidents, 1079(ab)
preoperative evaluation, intractable focal epilepsy, 912(ab)
radiotherapy response, pancreatic cancer, 1084(ab)
response to cancer therapy, 1655
Rb-82, identification of viable myocardium, 968(ab)
radiation dose to bladder wall, adult humans, 707
removal of 2.2.2 cryptand, cation exchange, 1094(ab)
tissue glucose utilization, thoracic and abdominal organs, input function, 1432
tracer feasibility, monitoring tumor radiotherapy, 2118
Fluorine-18 fluorodopa
PET, reproducibility of striatal uptake, 1246
stability of 6-[^{18}F]fluorodopa preparations, 894(le)
uptake for melanogenesis, murine metastatic melanoma, 95
Fluorine-18 6-fluorodopamine, PET, dosimetric estimates, 102
16α-Fluorine-18 fluoro-17β-estradiol, PET, uptake, metastatic breast carcinoma, 1526
16β-Fluorine-18 fluoroestradiols, novel PET imaging agents, estrogen receptors, 995(ab)
21-Fluorine-18 fluoro-16α-ethyl-19-norprogesterone, PET, progestin receptor detection, breast carcinoma, 1532
ω-Fluorine-18 fluoro long chain fatty acid, cytochrome P-450 mediated defluorination, 975(ab)
Fluorine-18 6-fluoro-MDL-72394, optimal probe for dopamine nerve terminals, metabolism, rats and monkeys, 1096(ab)
20-Fluorine-18 fluoromibolerone, androgen receptors, synthesis, tissue distribution studies, 81
Fluorine-18 fluoromisonidazole
hypoxia imaging, 955(ab)
PET, demonstration of hypoxia, human gliomas, 955(ab)
Fluorine-18 fluoropropylepidepride
early kinetic behavior, first pass PET data, 1063(ab)
primate and human studies, ligand, dopamine D2 receptor, 1070(ab)
14(*R,S*)-Fluorine-18 fluoro-6-thia-heptadecanoic acid
myocardial utilization
long chain fatty acids, evaluation in mouse :1888
long chain fatty acids, measurement, 937(ab)
4-Fluorine-18 fluorotropapride, D2 receptor ligand for PET, 935(ab)
4-Fluorine-18 fluoro-L-tyrosine, asymmetric synthesis, aromatic fluorination, 935(ab)
L-(2-Fluorine-18) fluorotyrosine, PET, increased amino acid transport, brain tumors, 1338
Fluorine-18 fluorouridine, tracer feasibility, monitoring tumor radiotherapy, 2118
Fluorine-18 FTCP, PET, excitatory amino acid neurotransmission, 1008(ab)
Fluorine-18 GBR, drug effects on *in vivo* brain binding, mouse, 1097(ab)
Fluorine-18 halothane, isoflurane and, pharmacokinetics, PET, 1072(ab)
Fluorine-18 ion
FDG and, PET total body imaging, breast cancer, 981(ab)
PET and, total body skeletal imaging, 1025(ab)
Fluorine-18 N-methylspiroperidol, binding, endogenous dopamine, 1071(ab)
Fluorine-18 NMS, C-11 cocaine and, robotic assay, metabolites in plasma, 1088(ab)
Fluorine-18 SFBS, method for labeling antibodies, 984(ab)
Fluorine-19, magnetic resonance imaging agents, drug targeting, 1081(ab)
Fluorodeoxyglucose, *see also* Fluorine-18 fluorordeoxyglucose
cardiac clinical utility, 892(le)
C-11 methionine and, non-Hodgkin's lymphoma, PET, 1211
factors influencing myocardial image quality, 1039(ab)
F-18 ion and, PET total body imaging, breast cancer, 981(ab)
gated PET, parameter estimation, cardiac geometry, 927(ab)
glucose and, transport and metabolic rate constants, brain, 911(ab)
labeled water and, PET evaluation, musculoskeletal neoplasms, 962(ab)
myocardial uptake
cell membrane integrity, Rb-82, 1
treadmill stress, PET, 1039(ab)
PET
cancer evaluations, 1555
chemohormonotherapy assessment, breast cancer, 982(ab)
choroidal melanomas, 1050(ab)
decreased I-123 BMIPP uptake, enhanced glucose utilization, 1034(ab)
glucose loading, hypertrophic cardiomyopathy, 1039(ab)
head trauma, 1016(ab)
imaging of ovarian cancer, 982(ab)
insulin substitution, quality of myocardial tissue viability studies, 988(ab)
murine lymphoma, 1043(ab)
myocardial glucose metabolism, coronary artery occlusion, 909(ab)
non-oxidative glycolysis, brain tumors, 931(ab)
perfusion imaging, nuclear cardiology, 579
preliminary evaluation, brain metastases from non-CNS neoplasms, 954(ab)
primary CNS tumors, 932(ab)
primary extracranial head and neck tumors, 920(ab)
prognosis of low-grade gliomas, 932(ab)
recurrent colorectal tumors, radiotherapy, 1485
regional heterogeneity, myocardial glucose metabolism, 938(ab)
staging of axilla, breast carcinoma, 981(ab)
suspicious pulmonary and mediastinal masses, 961(ab)
Tl-201 SPECT with reinjection, previous myocardial infarction, 949(ab)
total body imaging, tumors of abdomen and pelvis, 982(ab)
typical scan pattern, Alzheimer's disease, 942(ab)

prognostic significance of augmented uptake, areas of myocardial infarction, 1039(ab)
Rb-82 kinetics and uptake, previous myocardial infarction, 1012(ab)
uptake
estrogen receptor stimulation, feasibility, 1011(ab)
metastatic melanoma, quantitative analysis, 1838(ab)
neuropsychological test performance, memory-impaired patients, 942(ab)
Fluorodeoxyglucose-6-phosphate, dephosphorylation, glucose phosphorylation, FDG and PET, 692
6-Fluorodopa, interpretation of kinetics, 3-*O*-methyl-6-fluorodopa, PET, 1007(ab)
β-Fluoromethylene-m-tyrosine, PET, striatal dopamine nerve terminals, primates, 1070(ab)
Fluoxetine, radioiodinated analogs, serotonin reuptake sites, SPECT, 964(ab)
Food and Drug Administration (FDA)
approval to market Persantine, 19N(5)
approves 2 new technetium-labeled cardiac agents, alternative to exercise, stress-thallium studies, 11N(5)
Blue Ribbon Commission, 12N(9)
David A. Kessler as Commissioner, 12N(2)
HHS advisory committee, 12N(2)
hurdles to technology diffusion, PET, 660
PET pharmaceuticals, 12N(2)
PET radiopharmaceuticals, 52N(4)
physician role in drug promotion, 18N(9)
reorganization, 13N(2)
Safe Medical Devices Act, 1990, combination products, 21N(12)
user fees, 13N(2)
Foot, diabetic, osteomyelitis, In-111 leukocytes, 1003(ab)
Forearm, bone mineral measurement, dual-energy X-ray absorptiometry, 2101
Fourier imaging
four-dimensional, image reconstruction, 1135(ab)
left ventricular regional wall motion, radionuclide ventriculography, 777
radionuclide ventriculography, 782
Fractures, talar dome, role, bone scintigraphy, 2241
Free Trade Agreement (FTA), United States and Canada, 14N(2)
Fullerenes, high hopes for Technegas, 24N(11)
Furosemide, renal radionuclide study, quantitative correction, output efficiency, 973(ab)

G

Gadolinium, gallium-67/stable gadolinium antagonism, 1830(le)
Gadolinium-153, shortage averted, 23N(7)
Galactose, -bound human serum albumin, suppression of uptake by hepatocytes and renal cells, radiolabeled antibody, 1054(ab)
Gallbladder
abnormal motor function, chronic acalculous gallbladder disease, cholecystokinin cholescintigraphy, 1695
clinical significance of non-visualization, cholescintigraphy, choledochal cyst, 976(ab)
contraction of, erythromycin, 1836(ab)
delay in visualization on hepatobiliary scintigraphy, bone marrow transplantation, absence of acute cholecystitis, 1047(ab)
ejection fraction, various infusion rates, cholecystokinin, 975(ab)
prompt filling but no bowel filling, during cholescintigraphy, necessity of CCK, 976(ab)
scintigraphic evaluation, vagotomy, Tc-99m DISIDA, 1131(ab)
visualization, post-therapy I-131 imaging, thyroid carcinoma, 2275
Gallium
-avid mobile mesenteric mass, inflammatory pseudotumor, 1614
-SPECT, prosthetic valve endocarditis, aortic ring abscess, 1791
Gallium-67
AIDS, 16N(7)
binding to human ferritin, influence of conditions, 1100(ab)
chronic prosthetic vascular graft infection, 1427
computed lung index, cellular basis, rheumatoid lung patient, 2288
immunoradiometric assay, metallic radionuclides, 825
inflammatory lung disease, 989(ab)
In-111 leukocyte and, relative efficacy, HIV patients, 1003(ab)
lymphoma grade characterization, 917(ab)
muscular sarcoidosis, fever of unknown origin, 319
retroperitoneal fibrosis, significance of negative result, 521
scintigraphy
detection of mediastinitis, after heart transplantation, 860
management of patients, malignant lymphoma, 2299
predictor of response, lymphoma treatment, 1084(ab)
stable gadolinium antagonism, 1830(le)
Tc-99m DTPA aerosol and, pulmonary complications, HIV infection, 990(ab)
tracer feasibility, monitoring tumor radiotherapy, 2118
uptake in eosinophilia myalgia syndrome, 2026(le)
uptake in tryptophan-related pulmonary disease, 328
Gallium-67 DF-dialdehyde starch-IgG, sensitive immunoradiometic assay, 978(ab)
Gallium-67 polyclonal IgG, localization, acute focal inflammatory lesions, 2126
Gallium-68 BAT-TECH, myocardial perfusion agent for PET, 974(ab)
Gallium-68 low-density lipoprotein, metabolic imaging, 300
Gallium (N_2S_2) complexes, myocardial imaging agents, 1094(ab)
Gallium-PAT, synthesis and investigation, potential myocardial agents, 1090(ab)
Gallium-transferrin complex, effect of bicarbonate on stability, 1439
Gallium tris(salicylaldimine) complexes, derivation from functionalized tripodal triamines, 944(ab)
Gallstones, common bile duct, hepatobiliary imaging, 1261
Gamma camera
accuracy and reproducibility of VEST measurements, left ventricular ejection fraction, 796
cardiac function and ST-segment, miniature nuclear probe system, 37
clinical, imaging therapeutic doses, I-131, 923(ab)
determination of Tc-99m MAG_3 clearance, renal transplant patients, 953(ab)
estimation of Tc-99m MAG_3 clearance, 954(ab)
3-head rotating, ultra-high-resolution SPECT, brain perfusion, 1079(ab)
high energy parallel-hole collimators, I-131 scattering and septal penetration, 1058(ab)
planar imaging at 511keV, high-energy collimator, 986(ab)
single crystal, accuracy, list mode ECG-gated first pass LVEF, 939(ab)
SPECT, cardiac phantom comparison, table position and collimator selection, 1136(ab)
triple head, volume 3-D display, Tc-99m HMDP, 913(ab)
two, Tc-99m MAG_3 renal clearance, children, 1704
whole body, localized and retention measurements, I-131, 1042
Gangliosides, GD2, radioimmunolocalization, anti-ganglioside antibody, 970(ab)
Gastric emptying
accurate measuring, 881
blood glucose control and, long-term oral erythromycin, gastric emptying, 931(ab)
calculation of time, two imaging protocols, 1046(ab)
confirmation of short solid-food lag phase, continuous monitoring, 1349
determining rate, 2024(le)
fat, measurement with Tc-99m(V)thiocyanate, 878
fat pre-load, normal healthy male subjects, 1046(ab)
gastrointestinal peptide motilin, diabetic gastroparesis, 931(ab)
half emptying time and lag time, geometric mean *vs.* left anterior oblique attenuation correction, 931(ab)
imaging, metoclopramide-induced akathisia, 1644(le)
left anterior oblique and geometric mean, 2176
linear, hyperosmolar glucose solutions, 377
solids in cats, MK-329 effects, 547(le)
"ultimate" test, 1836(ab)
Gastritis, quantification of *Helicobacter pylori*, C-14 urea breath test, 1192
Gastrointestinal system
activity selection and dosimetry, Er-171 and Sm-153 labeled hydrogel beads, 997(ab)
acute hemorrhage, selective scintigraphic angiography, 1601
bleeding, intra-arterial injection, Tc-99m sulfur colloid, 1047(ab)
delayed positive bleeding, Tc-99m red blood cells, utility of second injection, 330
inflammatory bowel disease, management, role of scintigraphy, 856
self-study test, 685, 1337
significance of intensity of delayed activity, Tc-99m RBC gastrointestinal bleeding study, 2249
small bowel transit time, fasting and postprandial states, 923(ab)
Gastroparesis
diabetic
gastrointestinal peptide motilin, 931(ab)
long-term oral erythromycin, blood glucose control, 931(ab)
Gastroplasty, weight reduction surgery, 1104(ab)
Gated blood-pool studies, *in vitro* RBC labeling, Ultra Tag RBC kit, *in vivo* labeling, 242
Gene, HPRT, radionuclide angiography, Tc-99m erythrocytes, 814
Generator
-ion exchange system, Re-188 perrhenic acid, 945(ab)
therapeutic radionuclides, 174
Tungsten-178/Tantalum-178, 2158

W-11/Re-188, preparation, Re-188 monoclonal antibodies, 1098(ab)
Germ cell neoplasms
Tc-99m anti-AFP monoclonal antibody fragment, 1053(ab)
Tc-99m anti-AFP monoclonal antibody, 22N(11)
Gleason scores, histologic, prostate carcinoma, serum PSA and PAP measurements, 977(ab)
Glioblastoma
C-11 PK 11195 binding, peripheral type benzodiazepine sites, 1608
metastatic, Tl-201 chloride, Tc-99m HMPAO SPECT, 322
total and specific *in vivo* binding, C-11 PK 11195, 1078(ab)
Glioma
demonstration of hypoxia, F-18 fluoromisonidazole PET, 955(ab)
direct intralesional injection, radiolabeled monoclonal antibody, 922(ab)
I-124 3F8 monoclonal antibody PET, 1021(ab)
localization, I-131 anti-tenascin monoclonal antibody, 970(ab)
low-grade, prognosis, fluorodeoxyglucose PET, 932(ab)
recurrence after radiotherapy, quantitative estimation, 933(ab)
Gliomatosis cerebri, diagnosis of, C-11 L-methionine PET, 726
γ-Globulin, high-dose, Tc-99m HMPAO-labeled white blood cells, Kawasaki disease, 944(ab)
Glomerular filtration rate (GFR)
convection-diffusion-uptake model, renal studies, 1104(ab)
estimation in infants and children, single-plasma sample method, 1294
radionuclide, endogenous creatinine clearance, non-insulin dependent diabetes mellitus, 1105(ab)
Glucose
attenuation of flow-glucose metabolism coupling, PET, 910(ab)
blood, long-term oral erythromycin, gastric emptying, 931(ab)
cortical and subcortical metabolism, alterations, Parkinson's disease and Parkinson plus syndromes, 960(ab)
enhanced utilization, decreased I-123 BMIPP uptake, FDG-PET, 1034(ab)
euglycemic hyperinsulinemic clamp method, myocardial glucose utilization, PET, 988(ab)
-fatty acid cycle, human heart, PET, 938(ab)
fluorodeoxyglucose and, transport and metabolic rate constants, brain, 911(ab)
global cerebral metabolism, influence, specific cerebral regions, 1077(ab)
hyperosmolar solutions, linear gastric emptying, 377
loading, FDG-PET, hypertrophic cardiomyopathy, 1039(ab)
metabolic rate, lumped constant and PET, normal and malignant brain, 1837(ab)
metabolism, cerebral blood flow, brain tumors, 1077(ab)
myocardial metabolism
coronary artery occlusion, FDG-PET, 909(ab)
normal humans, dynamic FDG-PET, 938(ab)
normal metabolism, increased striatal dopamine uptake, idiopathic dystonia, 1015(ab)
parametric images of myocardial metabolic rate, dynamic cardiac PET, 732
phosphorylation with FDG and PET, dephosphorylation, FDG-6-phosphate, 692
regional metabolism, benzodiazepine receptor binding, refractory temporal lobe epilepsy, 912(ab)
regional wall thickening, left ventricle, gated PET, 679
transport in brain, F-18 carbohydrate analogs of glucose, 1093(ab)
uptake
myocardial blood flow, region of interest size and PET, 1027(ab)
perfusion and cell proliferation, head and neck tumors, 1548
tumor proliferation, F-18 deoxyglucose PET, 1083(ab)
uptake in resting myocardial perfusion defects, wall motion abnormality, Tc-99m MIBI SPECT/F-18 DOG PET, 1037(ab)
utilization, C-11 PT studies, primate model of Huntington's disease, 981(ab)
utilization in tissues, thoracic and abdominal organs, 1432
Glutathione
content, Tc-99m HMPAO, brain tumors, 1675
Tc-99m HMPAO retention, 1681
GnRH-agonists, bone mineral density, lumbar spine, femoral neck, 1026(ab)
Goiter, thyroid nodules and, endocrine imaging, 1455
Granulocytes
localization of florid granulocytic inflammatory foci, immunoscintigraphy, 1002(ab)
Tc-99m monoclonal antibodies
detection of infection, postoperative orthopedic patients, 2209
"hot appendix", 1049(ab)
Graves' disease, optimal I-131 dose, 2359(le)
elimination of hyperthyroidism, 411

H

Haemophilus aphrophilus, detection of mediastinitis, Ga-67 scintigraphy, after heart transplantation, 860
Hand, skeletal angiomatosis, radiography, scintigraphy, 1912
Hazardous Materials Transportation Act, passed by Congress, 14N(2)
Head
patterns of movement, simulated brain imaging, normal subjects, 1064(ab)
position change, vertebrovasilar insufficiency, Tc-99m HMPAO SPECT, 1075(ab)
Head and neck cancer
advanced, PET and F-18 deoxyglucose, 920(ab)
glucose uptake and cell proliferation, 1548
imaging for follow-up, 1137(ab)
primary extracranial, fluorodeoxyglucose PET, 920(ab)
Head injury
acute closed, cerebral blood flow, Tc-99m HMPAO SPECT and CT, 1684
closed, regional hyperemia, SPECT, 1022(ab)
Head trauma, FDG PET, 1016(ab)
Health and Human Services (HHS)
appropriations for allied health grants and contracts, 14N(2)
FDA advisory committee, 12N(2)
Medicare reimbursement, 11N(9)
Health Care Financing Administration (HCFA)
government relations update, SNM/ACNP, 11N(2)
ICP recommends ICD-9 codes for PET, 56N(4)
Medicare fee schedule and RBRVS, 11N(9)
SNM and ACNP propose revisions to CLIA, 28N(1)
Health Insurance Association of America (HIAA), assessment of rates for PET, 56N(4)
Heart
adenosine coronary hyperemia, SPECT, remote Q-wave myocardial infarction, 979(ab)
adenosine-induced coronary hyperemia, teboroxime SPECT, 1036(ab)
autonomic nerve abnormality, animal models of diabetes, iodinated MIBG, 928(ab)
beta adrenergic receptors, CGP12177 *vs.* I-125 CYP, 1028(ab)
biological background subtraction, improved scintigraphy, subsequent antigen injection, 2318
blood-pool scintigraphy, rats and hamsters, 851
blood-pool tracers, 480
cardiac contractile reserve in man, peak power during exercise, 939(ab)
cardiac function and ST-segment
miniature nuclear probe system, 37
radionuclide monitoring, characteristics, 2194(le)
cholinergic innervation, mapping, chiral C-11 benzovesamicols, 974(ab)
clinical role of PET
cardiology in 1990s and beyond, 606
metabolic imaging, 565
clinical utility of fluorinated deoxyglucose, 892(le)
congenital disease, right ventricular overload, Tl-201 SPECT, 2215
coronary and systemic hemodynamic determinants, blood Tc-99m teboroxime clearance, 1028(ab)
coronary flow reserve
hypertrophic cardiomyopathy, dipyridamole N-13 ammonia PET, 1040(ab)
myocardial viability after infarction, PET, 1013(ab)
coronary occlusion and reperfusion, necrosis, Tc-99m sestamibi, 957(ab)
coronary reserve, O-15 water PET, compared to intracoronary Doppler study, 998(ab)
correction of PET/SPECT, resolution and wall motion effects, gated NMR imaging, 938(ab)
critically ischemic zone at risk, acute coronary occlusion, PET, 1581
dynamic cardiac PET, myocardial metabolic rate, glucose, 732
effect of flow on Tc-99m teboroxime, Tl-201 extraction and retention, 1979
effect of flow on Tc-99m TEBO, Tl-201 extraction and retention, 1979
F-18 deoxyglucose and N-13 ammonia, effect of metabolic milieu, PET, 1518
geometry, parameter estimation, gated PET FDG, 927(ab)
glucose-fatty acid cycle, PET, 938(ab)
gradual or abrupt motion, algorithm for correction, Tl-201 SPECT, 947(ab)
4-I-125 iododexetimide binding, muscarinic cholinergic receptors, 76
incubation of red blood cells, reduced extraction, Tc-99m TEBO, 910(ab)
isolated perfused, extraction and metabolism, Tc-99m teboroxime, 948(ab)
left bundle branch block
coronary artery disease, 1033(ab)
exercise Tl-201 SPECT, 1033(ab)
Tl-201 SPECT, 1034(ab)
left-to-right cardiac shunts, improved method, quantification, 1808
left ventricular function, continuous

radionuclide monitoring, 44
localization of atherosclerotic lesion, monoclonal antibody Z2D3, 1005(ab)
metabolic studies, Tc-99m N_2S_2 derivatized fatty acid analogs, 1016(ab)
molecular medicine, from science to service, 17N(8)
motion in dogs, ungated SPECT Tc-99m MIBI, 958(ab)
normal Tc-99m MIBI stress tomographic images, necessity of rest images, 930(ab)
nuclear cardiology, PET perfusion imaging, 579
orthotopic transplant, arteriopathy, exercise SPECT Tl-201, 1041(ab)
pericardial fistula, hepatobiliary scintigraphy, 518
PET studies, 17N(11)
phantom comparison of gamma camera SPECT systems, table position, collimator selection, 1136(ab)
pharmacologic cardiac stress, dobutamine for Tl-201 myocardial perfusion studies, 1130(ab)
quo vadis cardiac PET, qualitative or quantitative studies, 1311(le)
retention of Tc-99m sestamibi, relationship to mitochondrial viability, 957(ab)
review of cardiac imaging, sestamibi and teboroxime, 2012
scintigraphic portrayal, beta receptors, 1399
serial measurements of volumes by count-based methods, influencing factors, 940(ab)
sounds, multigated blood-pool imaging, 1513
SPECT, reconstruction with attenuation, geometric point response correction, 916(ab)
straight line cone-beam tomography, SPECT cardiac imaging, 956(ab)
sympathetic neurons, neuronal marker, C-11 epinine, 994(ab)
Tc-99m, SPECT reconstruction error, self-attenuation, 958(ab)
Tc-99m teboroxime SPECT, 919(ab)
three-minute acquisition, single-head detector, 929(ab)
technetium-labeled cardiac agents, approval by FDA, alternative to exercise in stress-thallium, 11N(5)
tissue kinetics of I-125 heat binding, *alpha*-1 adrenoceptors, 927(ab)
transplantation
cyclosporine radioimmunoassay, nephrotoxicity prediction, 977(ab)
detection of mediastinitis, Ga-67 scintigraphy, 860
exercise SPECT Tl-201 scintigraphy, myocardial hypoperfusion, 1041(ab)
non-invasive monitoring, In-111 antimyosin scintigraphy, 971(ab)
risk of rejection-related complications, antimyosin antibody, 1019(ab)
uptake and metabolism, 6-F-18 FDA and FNE, effect of desipramine, 993(ab)
vasodilatory action of IV adenosine and dipyridamole, PET scan, 969(ab)
ventricular myosin light chain-specific radioimmunoassay, acute myocardial infarction, 977(ab)
volume determination, SPECT images, 946(ab)
***Helicobacter pylori*,** quantification in gastritis and ulcer disease, C-14 urea breath test, 1192
Helium-3, high current, low energy, RFQ, production of PET radionuclides, 1140(ab)
Hemangioma, small cavernous, improved detection, high-resolution three-headed SPECT, 2086
Hematochezia, visual blood loss estimate, Tc-99m red blood cells, 923(ab)
Hematoma, bilateral subdural, Tc-99m HMPAO brain SPECT, 1915
Hematopoietic malignancies, In-111 *vs.* Y-90 T101 biodistribution, 970(ab)
Hemodialyzers, cellulose acetate, comparative loss, In-111 PMN granulocyte, 1048(ab)
Hemodynamics, coronary and systemic, blood Tc-99m TEBO clearance, 1028(ab)
Hemorrhage, acute gastrointestinal, selective scinitgraphic angiography, 1601
Heparin, cardiopulmonary bypass, quantitation, platelet thrombus, 1048(ab)
Hepatitis, CA 15-3 serum levels, 1088(ab)
Hepatobiliary imaging
common bile duct gallstones, 1261
correlation of Tc-99m DISIDA, biopsies, liver transplant, 1545
diagnosis of common bile duct stone, impact on management, 1046(ab)
obstruction of distal common bile duct, reversal of pattern of obstruction, naloxone, 1270
probabilistic image segmentation, 1060(ab)
quantitative scintigraphy, papillary stenosis, S/P cholecystectomy, 1046(ab)
scintigraphy
after surgical treatment, congenital biliary atresia, 1047(ab)
papillary stenosis, 1131(ab)
Tc-99m mebrofenin, 48
Hepatocytes, galactose-bound human serum albumin, suppression of uptake, radiolabeled antibody, 1054(ab)
Hepatoma, CA 15-3 serum levels, 1088(ab)
Hepatotoxicity, mild-moderate, rheumatoid arthritis, methotrexate, 1048(ab)
Hevesy Nuclear Medicine Pioneer Award, Alfred P. Wolf, 22N(5)
Hexakis (2-methyoxyisobutylisonitrile)technetium(I), increased accumulation, osteosarcoma and metastatic lymph nodes, 1977
High-Level Radioactive Waste (HLRW) Disposal Program
nuclear medicine's perspective, 18N(1)
restructuring recommended by National Research Council Board, 15N(1)
suitability of Yucca Mountain site, support by geologic study, 31N(3)
Hip
-head necrosis, bone SPECT, pedicled pelvic bone graft, 1027(ab)
porous-coated endoprostheses, quantitative analysis, radiophosphate uptake, 1391
Hippuric acid, radioiodinated, Tc-99m MAG_3 and, difference in clearance, 1642(le)
Histiocytoma, inflammatory pseudotumor, gallium-avid mobile mesenteric mass, 1614
Histone, In-111 labeled mRNA probes, 1089(ab)
HMPAO
brain uptake, test-retest results, 991(ab)
SPECT, Kleffner-Landau syndrome, 1015(ab)
Hodgkin's disease
differentiation of fibrosis, semiquantitative method, SPECT, 918(ab)
lymphoma grade characterization, thallium and gallium, 917(ab)
radioimmunodetection, degranulated human eosinophils, 89
Holmium-166 poly L-lactic acid, microspheres, radiation therapy, hepatic tumors, 2139
Hormone, therapy, bone marrow regeneration, bone metastases from prostatic carcinoma, 1025(ab)
Human antimouse antibodies (HAMA)
concentration, contribution and effective KA, changes in serum levels, 978(ab)
detection and staging of breast cancer, In-111 B72.3 monoclonal antibody, 1326
false positive TSH values, 977(ab)
Human immunodeficiency virus-1, asymptomatic seropositive patients, metabolic asymmetries, disease onset and MRI findings, 1725
Human immunodeficiency virus (HIV)
encephalopathy, SPECT, 1471, 1475
I-123 IMP images, 992(ab)
pulmonary complications, Tc-99m DTPA aerosol and Ga-67, 990(ab)
relative efficacy, In-111 leukocyte and Ga-67 imaging, 1003(ab)
Hürthle cell tumor, malignant transformation, 1266
Hydrogen-3 FMISO, F-18 FDG and, low-flow ischemia, 1028(ab)
Hydrogen-3 thymidine, tracer feasibility, monitoring tumor radiotherapy, 2118
Hydrogen-3 WIN-35,428, binding to dopamine release sites, endogenous dopamine, 1069(ab)
Hydronephrosis
evaluation in newborns, diuresis renography, 943(ab)
pelvic, antenatal diagnosis, 1649
standardized protocol for diuretic renography, neonates, 943(ab)
Hydrothorax, peritoneal-pleural communication, radionuclides, 924(ab)
Hydroxamamide, chelating moiety, preparation, Tc-99m radiopharmaceuticals, 1102(ab)
3α-Hydroxy bile acids, selenium-75 homocholic acid taurine test reevaluated, 1219
Hypercapnia, cerebrovascular responsiveness, senile dementia of Alzheimer type, vascular dementia of Binswanger type and PET, 1079(ab)
Hyperemia
adenosine-induced coronary
critical stenosis, Tl-201 and Tc-99m sestamibi, 947(ab)
teboroxime SPECT, 1036(ab)
post-stenotic myocardial Tc-99m teboroximine clearance kinetics, experimental ischemia, 2000
regional, closed head injury, SPECT, 1022(ab)
Hyperparathyroidism
bone metabolism, *in vivo* SPECT quantitation, 1157
bone turnover and loss, quantitative bone scintigraphy, 982(ab)
Hypertension
endocrine imaging, 1627
renovascular
ACE-inhibited scintigraphy, 1104(ab)
enalaprilat-MAG_3 scintigraphy, 934(ab)
renal effects, DuP753, 1103(ab)
Hyperthermia, -induced suppression of protein synthesis, tumors, PET, 1587
Hyperthyroidism
elimination, 1641(le)
optimal I-131 dose, Graves' disease, 411
enhancement of radioiodine therapy, dosimetric methodology, 1017(ab)
I-131 administration, radiation dosimetry, adult female and fetus, 808
Hyperventilation, improvement of abnormal wall motion, coronary artery disease, 939(ab)
Hypoxemia, severe, secondary to acute sternal

infarction, sickle cell anemia, 1617
Hypoxia
human gliomas, F-18 fluoromisonidazole PET, 955(ab)
imaging with F-18 fluoromisonidazole, 955(ab)
tissue, radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole, 1764
tumors, F-18 fluoroazomycin acyclonucleoside PET, 1095(ab)

I

ICD-9-CM, nuclear medicine services, 12N(2)
Iio, Masahiro, *In Memoriam*, 905
Image reconstruction, direct four-dimensional Fourier transform techniques, 1135(ab)
Immune response, I-131 chimeric mouse/human IgG1,k 17-1A, pharmacokinetics, 1162
Immunoconjugates
CDTA-linker/spacer, uptake and excretion, In-111 antibodies, 984(ab)
fast growth in U.S. market, 35N(11)
4-isothiocyanato- and 4-bromo-acetamido cyclohexyl EDTA, bifunctional chelating agents, 1023(ab)
Immunoglobulin G
accumulation at focal sites, inflammation, 1057(ab)
binding of CC49 to TAG-72, CX-1 tumor model, 1098(ab)
Fab′ and, directly labeled Tc-99m, 1101(ab)
immunoradiometric assay, metallic radionuclides, 825
In-111 DTPA and HYNIC, sequential injections, rats, 1050(ab)
In-111 exchange, lactoferrin, transferrin and ferritin, 1099(ab)
metallic radionuclide label, sensitive immunoradiometric assay, 978(ab)
Immunophoresis, treatment of B cell malignancies, I-131 Lym-1, 921(ab)
Immunoradioassay
circulating c-*erb*B-2 protooncogene products, advanced cancer patients, 1087(ab)
thyroid carcinoma, serum human thyroglobulin, 1088(ab)
Immunoscintigraphy
anti-CEA, primary and recurrent colorectal carcinoma, 1319
biological background subtraction, subsequent injection of antigen, 2318
bone marrow, superiority to scintigraphy, skeletal metastases in prostatic and renal carcinoma, 1052(ab)
false-positives, 2194(le)
induction of anti-idiotypic antibodies, improved survival, advanced ovarian carcinoma, 1051(ab)
In-111 OC 125, Bayesian analysis, diagnosis of ovarian cancer, 941(ab)
localization of florid granulocytic inflammatory foci, 1002(ab)
lung cancer detection, 2069
monoclonal Tc-99m anti-granulocyte antibody, suspected subacute bacterial endocarditis, 1019(ab)
pharmacokinetics, In-111 CYT-356, prostate cancer, 1054(ab)
prospective, chimeric I-123 anti/CEA monoclonal antibody, serum CEA, 941(ab)
reproducibility of image interpretation, In-111 and I-131 OC125 $F(ab')_2$ antibody, 221
Tc-99m monoclonal antigranulocyte antibody, suspected inflammatory disease, 1002(ab)
Tc-99m OV-TL 3 Fab′, suspicion of ovarian cancer, 941(ab)
thrombi, 2321
Immunotherapy
^{111}Ag labeling of monoclonal antibodies, 1099(ab)
scientific highlights of EANM Congress 1991, 16N(11)
IMP, SPECT, neuropsychological performance, dementia, 942(ab)
Indium, -labeled biotin, tumor imaging, 750(le)
Indium-111
anti-colorectal carcinoma monoclonal antibody, advanced colorectal carcinoma, 1054(ab)
chemotactic peptide analogs, imaging focal sites, bacterial infection, 483
comparison of DOTA and DTPA analogs, bifunctional antibody delivery, 915(ab)
exchange between IgG and lactoferrin, transferrin and ferritin, 1099(ab)
intraoperative probe, technical and clinical aspects, 987(ab)
low molecular weight bivalent hapten, dual specificity monoclonal antibody conjugate, colorectal carcinoma, 940(ab)
mRNA probes, conjugation of DTPAisothiocyanate with anti-sense oligonucleotides, 1089(ab)
quantitation of activity in SPECT, 986(ab)
recombinant tissue plasminogen activator, rapid localization, rabbit thrombosis model, 461
Tc-99m anti-CEA antibody and comparison, 1053(ab)
prospective staging of bladder carcinoma, SPECT, 970(ab)
vs. Y-90 T101 biodistribution, hematopoietic malignancies, 970(ab)
Indium-111 antibodies
SPECT, liver, beagle dogs, 1442
targeted long-lived liposomes, 992(ab)
uptake and excretion, CDTA-linker/spacer immunoconjugates, 984(ab)
Indium-111 anti-CEA $F(ab')_2$, CDTA immunoconjugates, improved biodistribution, nude tumor mice, 1023(ab)
Indium-111 anti-CEA monoclonal antibody, scintigraphy, suspected primary lung cancer, 2064
Indium-111 antifibrin monoclonal antibody
rapid imaging, 791
venous thrombotic disease, 785
Indium-111 antimyosin
scintigraphy, non-invasive monitoring, heart transplantation, 971(ab)
sustained uptake, infarcted canine myocardium, 1029(ab)
Tl-201 dual isotope imaging, reperfused myocardial infarction, 1034(ab)
Tl-201 SPECT, right ventricular infarction, function, 1018(ab)
Indium-111 antimyosin Fab
myocardial accumulation, hypertrophic cardiomyopathy, postpartum cardiomyopathy, 2291
myocardial distribution, acute inferior and right ventricular infarction, 865
myocardial scintigraphy, damage assessment, dilated-phase hypertrophic cardiomyopathy, 1333
negatively charge-modified monoclonal antibody, gamma imaging, synthetic polymers, 1742
Indium-111 B72.3
detection and staging of breast cancer, 1326
Y-90 and, chimeric conjugates, colon carcinoma, 1842(ab)
Indium-111 chloride, three-phase bone scintigraphy, osteomyelitis, 67
Indium-111 cyclodextrin, inclusion and photoaffinity labeling, antimelanoma Mab TP41.2, 984(ab)
Indium-111 CYT-103, suspected recurrent colorectal cancer, 1053(ab)
Indium-111 CYT-356, immunoscintigraphy and pharmacokinetics, prostate cancer, 1054(ab)
Indium-111 DTPA
HYNIC and, human polyclonal IgG, sequential injections, 1050(ab)
I-131 cellulose and, comparison, colon transit scintigraphy, 1668
Indium-111 DTPA-D-PHE octreotide
radiation dosimetry, somatostatin receptor-positive tumors, 1043(ab)
somatostatin receptor-positive tumors, 1084(ab)
Indium-111 Fab′2 antigranulocyte antibody, focal sites of infection, 1051(ab)
Indium-111 immunoglobulin G, scintigraphy, infected joint arthroplasty, 963(ab)
Indium-111 leukocytes
Ga-67 and, relative efficacy, HIV patients, 1003(ab)
imaging in acute cholecystitis, 803
In-111 human nonspecific IgG and, subacute infectious foci, 1854
In-111 nonspecific polyclonal IgG comparison, canine osteomyelitis model, 1394
localization, acute focal inflammatory lesions, 2126
osteomyelitis in diabetic feet, 1003(ab)
synthetic vascular graft infection, antibiotic treatment, 13
Tc-99m HMPAO leukocytes and, inflammatory component, lung cancer, 1132(ab)
Tc-99m MDP and, bone scintigraphy, vertebral osteomyelitis, 1861
Tc-99m sulfur colloid imaging and, improved diagnostic accuracy, osteomyelitis, 962(ab)
Indium-111 low-density lipoprotein
binding to liver, 2132
metabolic imaging, 300
radiopharmaceutical for metabolic imaging, 925(ab)
Indium-111 lymphocytes, scintigraphy, non-Hodgkin lymphoma, 917(ab)
Indium-111 monoclonal antibodies
biodistribution, effect, EDTA administration, 1100(ab)
biodistribution of intracolonic injection, 997(ab)
detection of hepatic metastasis, colorectal carcinoma, 940(ab)
DTPA effects on metabolism, 1055(ab)
I-125 monoclonal antibodies and, pharmacokinetic changes, interferon, 993(ab)
metabolism by liver, methods to reduce non-specific accumulation, 1058
Indium-111 nonspecific human IgG
diagnosing inflammations/infections, new scintigraphic method, 2227
In-111 autologous leukocytes and, subacute infectious foci, 1854
Indium-111 nonspecific polyclonal IgG, compared to In-111 leukocytes, canine osteomylitis model, 1394
Indium-111 OC 125
dosimetric estimations, uptake and retention kinetics, ovarian carcinoma, 997(ab)
immunoscintigraphy, Bayesian analysis, diagnosis of ovarian cancer, 941(ab)
Indium-111 OC 125 $F(ab')_2$, reproducibility of image interpretation, immunoscintigraphy,

221
Indium-111 oxime, -labeled autologous leukocytes, functional asplenia, 524
Indium-111 phospholipid vesicles, primary lung cancer, 1085(ab)
Indium-111 platelets
deposition following coronary artery injury, porcine restenosis model, 1029(ab)
intratumoral deposition, thrombocytopenia, metastatic angiosarcoma, 2278
oxine and tropolone methods for labeling, 62
splenic dynamics, steroid therapy evaluation, idiopathic thrombocytopenic purpura, 1048(ab)
Indium-111 PMN granulocyte, comparative loss, cellulose acetate hemodialyzers, 1048(ab)
Indium-111 polyclonal IgG
biodistribution, normal female subjects, 1836(ab)
infectious imaging, 2079
Indium-111 proteins, extravascular compartment, normal muscle, 1101(ab)
Indium-111 transferrin, scintigraphy, colorectal cancer, 1084(ab)
Indium-111 white blood cells
AIDS, 16N(7)
diagnostic efficacy, diabetic pedal osteomyelitis, 963(ab)
diffuse lung uptake, premature leukocytes, 1049(ab)
infection localization scintigraphy, clinical experience, Tc-99m HMPAO-WBC, 1049(ab)
labeled and unlabeled white blood cells, adherence characteristics, quality control, 1049(ab)
Tc-99m HMPAO and, inflammatory bowel disease, 924(ab)
Indium-111 ZCE025, alternation of biodistribution, iron, iron-chelating agent, 1056(ab)
Indium-114m, long-term biodistributions, 1100(ab)
Infants, estimation of glomerular filtration rate, single-plasma sample method, 1294
Infarction, acute sternal, severe hypoxemia, sickle cell anemia, 1617
Infection
bacterial, imaging focal sites, In-111 chemotactic peptide analogs, 483
chemotactic peptides for imaging, 491
chronic prosthetic vascular graft
Ga-67, 1427
Tc-99m HMPAO leukocytes, 1425
diagnosis, In-111 nonspecific human IgG, new scintigraphic method, 2227
focal sites, In-111 Fab'2 antigranulocyte antibody, 1051(ab)
molecular medicine, from science to service, 23N(8)
postoperative orthopedic patients, Tc-99m monoclonal antibodies, granulocytes, 2209
prosthetic joint, diagnosis, 2195(le)
sternal wound, diagnosis, Tc-99m leukocyte imaging, 1002(ab)
subacute, In-111 autologous leukocytes, In-111 human nonspecific IgG, 1854
Inflammation
abdominal, fast diagnosis, Tc-99m HMPAO labeled leukocytes, 2029
acute focal lesions, localization, In-111 leukocytes and Ga-67 polyclonal IgG, 2126
diagnosis, In-111 nonspecific human IgG, new scintigraphic method, 2227
focal sites, accumulation of IgG, 1057(ab)
imaging of sites in the 1990s, new horizons, 2034
imaging with neutrophil-specific Tc-99m monoclonal antibody, 1836(ab)
improved localization, streptavidin, 1014(ab)
Tc-99m human unspecific immunoglobulin, rheumatoid arthritis, 983(ab)
Inflammatory bowel disease
Tc-99m HMPAO and In-111 white cell scans, 924(ab)
Tc-99m leukocytes, 1131(ab)
Inflammatory disease
diagnostic accuracy, Tc-99m granulocyte antibody scan, 1002(ab)
lack of increase, pulmonary granulocyte margination, 1014(ab)
suspected, immunoscintigraphy, Tc-99m monoclonal antigranulocyte antibody, 1002(ab)
In Memoriam, Masahiro Iio, 905
Institute for Clinical PET (ICP), recommendation of ICD-9 codes to HCFA, 56N(4)
Insulin
kinetics, 20N(11)
substitution, quality of myocardial tissue viability studies, FDG-PET, 988(ab)
Interferon, I-125 and In-111 monoclonal antibodies, pharmacokinetic changes, 993(ab)
Interleukin 2, enhancement of tumor uptake, monoclonal antibody, 992(ab)
International Atomic Energy Agency (IAEA), radiation effects in Chernobyl, 11N(3)
International Commission on Radiation Protection (ICRP), NRC and, lower radiation exposure limits, 28N(5)
Intestine
bypass, weight reduction surgery, 1104(ab)
radionuclide cisternography, cerebrospinal fluid leak, 151
transit, calcium channel blockade, 923(ab)
Iodination, Fc region of monoclonal antibodies, 985(ab)
Iodine, antigen-binding site protection during radiolabeling, higher immunoreactive fraction, 116
Iodine-123
radioiodinated somatostatin analogue, somatostatin receptor-positive tumors, 1184
quantitative SPECT reconstruction of data, 527
SPECT, alcohol dependence, 1075(ab)
SPECT IMP, semi-quantitative, late onset before and after treatment, 952(ab)
Iodine-123 ANF, atrial natriuretic factor receptor imaging, 973(ab)
Iodine-123 anti/CEA monoclonal antibody, chimeric, prospective immunoscintigraphy, serum CEA, 941(ab)
Iodine-123 BMIPP
enhanced glucose utilization, FDG-PET, 1034(ab)
stunned myocardium, perfusion, ventricular function, 1012(ab)
Tl-201 and, discrepancies, myocardial infarction, 1034(ab)
Iodine-123 estradiol, clinical results of breast cancer detection, 1138(ab)
Iodine-123 IBF, D2 dopamine receptor imaging agent, 1008(ab)
Iodine-123 IBZM
binding competition, amphetamine-induced dopamine release, 1007(ab)
hemi-Parkinsonism, dopamine D2 receptors, 1070(ab)
kit formulation for preparation, 339
SPECT
dopamine D2 receptors, normals, 1078(ab)
dopamine D2 receptors, Parkinsonian syndromes, 1014(ab)
whole body distribution, 1018(ab)
Iodine-123 IDDE, potential radiotracer, dopaminergic function, 1092(ab)
Iodine-123 IDEX, binding of muscarinic cholinergic receptors, 1097(ab)
Iodine-123 ILIS, SPECT, increase of striatal dopaminergic D2 receptor, Rett syndrome, 1015(ab)
Iodine-123 IMP
abnormalities, temporal lobe SPECT, bipolar disorder, 1076(ab)
blood-brain permeability measurement, compartment analysis and dynamic SPECT, 911(ab)
brain SPECT, severe carotid artery stenosis, transient ischemic attacks, 972(ab)
distribution and clearance, brain, asymptomatic crack abuse subjects, 1022(ab)
effect of HIV treatment on images, 992(ab)
portosystemic shunting, inferior and mesenteric veins, 1047(ab)
quantitative localization and clearance properties, Tc-99m HMPAO, crack users and normals, 1840(ab)
SPECT
cerebral blood flow, global extraction between artery and internal jugular vein, 1080(ab)
hepatic encephalopathy, 1074(ab)
redistribution in brain, visual stimulation, 1866
shunt fraction estimation, chronic biliary cirrhosis, 124
Tc-99m ECD and, cerebrovascular disease, SPECT, 1073(ab)
Tc-99m HMPAO and
brain SPECT, dementia/stroke, 1073(ab)
simultaneous dual-tracer brain SPECT, 956(ab)
vs. Tc-99m ECD, early and delayed brain SPECT, subacute stroke, 971(ab)
Iodine-123 4-iododexetimide, brain SPECT, quantification, muscarinic cholinergic receptors, 980(ab)
L-3-Iodine-123 iodo-α-methyl tyrosine, brain uptake, competition, natural L-amino acids, 1225
2-Iodine-123 ketanserin, 5-HT2 receptor imaging, depression, 952(ab)
Iodine-123 L-AMT, study of transport, 819
Iodine-123 α-methyl-tyrosine, brain tumor uptake, 2193(le)
Iodine-123 MIBG
animal models of diabetes, cardiac autonomic nerve abnormality, 928(ab)
First Impressions, 1325
Tl-201 chloride and, myocardial uptake rate in scintigraphy, hypertrophic cardiomyopathy, 1040(ab)
Iodine-123 MPDA, Tl-201 chloride and, myocardial imaging, exercise-induced ischemia, 447
Iodine-123 OIH, *vs.* Tc-99m MAG_3, renal clearance, distribution volume, 2057
15-(ortho-Iodine-123-phenyl)-pentadecanoic acid, 2-^{18}F-2-deoxyglucose and, Tl-201 tomography, myocardial infarction, 1353
Iodine-123 Ro 16-0154
"free" concentration, non-human primate plasma, HPLC and microdialysis, 1071(ab)
SPECT, benzodiazepine receptor ligand,

1043(ab)
Iodine-123 SK&F 106528, *in vivo* disposition in rats, 1050(ab)
Iodine-123 SP-4, imaging of atherosclerotic lesions, 1842(ab)
Iodine-123 TISCH, dopamine D1 receptor imaging agent, 1069(ab)
Iodine-123 Tyr-3-octreotide
dosimetry, 1018(ab)
scintigraphy, neuroendocrine tumors, 981(ab)
Iodine-124 3F8 monoclonal antibody, PET, glioma, 1021(ab)
Iodine-125
heat binding to α-1 adrenoceptors, tissue kinetics, rat heart, 927(ab)
radiopharmaceuticals, malignant melanoma, 1573
3-Iodine-125 BP, mapping cholinergic function, 1093(ab)
Iodine-125 CYP, *vs.* CGP12177, beta adrenergic receptors, heart, 1028(ab)
Iodine-125 IgG, CX-1 tumor model, immunohistochemical localization, TAG-72 antigen, 1020(ab)
5-Iodine-125 iodo-2′-deoxyuridine, intratumoral injection, colon cancer, 1082(ab)
Iodine-125 iododexetimide, binding to muscarinic cholinergic receptors, heart, 76
Iodine-125 iodo-DSPA, probe for central noradrenergic neurons, 964(ab)
2′′-Iodine-125 iodoparoxetine, synthesis and preliminary evaluation, presynaptic serotonin ligand, 965(ab)
Iodine-125 iodovinylazomycin acyclonucleosides, tumor uptake, low *in vivo* deiodination, 1091(ab)
Iodine-125 IPPE, mapping of vesamicol receptor, 1092(ab)
Iodine-125 MIBG, therapy for neuroblastoma, 361(le)
Iodine-125 monoclonal antibodies, In-111 monoclonal antibodies and, pharmacokinetic changes, interferon, 993(ab)
Iodine-125 monoclonal antibody, pharmacokinetics, whole-body radiography, 1837(ab)
Iodine-125 NGA, Tc-99m NGA and, differences in processing, 506
Iodine-125 NP59, cellular internalization, transport and esterification, MA-10 Leydig tumor cells, 495
Iodine-125 quinuclidinyl esters, ligands for SPECT studies, muscarinic receptors, 1093(ab)
Iodine-131
ablation dose, postoperative remnant, 1640(le)
affirmation of safety, Swedish epidemiological study, 28N(10)
chimeric mouse/human IgG1,k 17-1A monoclonal antibody, pharmacokinetics, immune response, 1162
chronic ambulatory peritoneal dialysis, radioiodide dosage, papillary thyroid carcinoma, 1010(ab)
hyperthyroid therapy, radiation safety considerations, 169
hyperthyroidism, radiation dosimetry, adult female and fetus, 808
imaging therapeutic doses, clinical gamma camera, 923(ab)
localization, insular carcinoma, 1358
localized and retention measurements, whole body gamma camera, 1042(ab)
1073 MBq and 3700 MBq, postoperative ablation, differentiated thyroid cancer, 252
optimal dose, Graves' disease, 2359(le)
optimal dose for eliminating hyperthyroidism, Graves' disease, 411
post-therapy imaging of thyroid carcinoma, gallbladder visualization, 2275
scattering and septal penetration, clinical gamma camera high energy parallel hole collimators, 1058(ab)
standard 5-millicurie dose, thyroid absorbed dose, thyrotoxicosis, 364(le)
therapeutic radionuclides, 174
toxic solitary autonomous thyroid nodules, long-term follow-up, 27
whole blood doses, thyroid cancer, dosimetric model, 1045(ab)
whole-body scan
post-surgical follow-up, differentiated thyroid carcinoma, 1826
serum thyroglobulin, differentiated thyroid carcinoma, 1645(le)
Iodine-131 anti-CEA antibody, uptake by human colon carcinoma xenograft, vascular and immunologic factors, 1055(ab)
Iodine-131 antiglioma monoclonal antibody, therapeutic efficacy, *N*-succinimidyl-3-(tri-*n*-butylstannyl)benzoate, 922(ab)
Iodine-131 anti-tenascin monoclonal antibody, localization of glioma, 970(ab)
Iodine-131 B72.3
alteration of biodistribution and dosimetry, 1052(ab)
radiation absorbed dose, peritoneal carcinomatoses, 1661
Iodine-131 cellulose, In-111 DTPA and, comparison, colon transit scintigraphy, 1668
Iodine-131 chimeric monoclonal antibody
advanced metastatic breast cancer, 922(ab)
determination of stability, antigen affinity column, 1057(ab)
Iodine-131 iodocholesterol, radiation injury from interstitial injection, 892(le)
Iodine-131 iodohippurate, single-dose subcutaneous, determination, renal plasma flow, 1452
Iodine-131 Lym-1, treatment of B cell malignancies, immunophoresis, 921(ab)
Iodine-131 MIBG
long-term survival, neuroblastoma, 1086(ab)
preoperative therapy, neuroblastoma management, 921(ab)
scintigraphy, response to chemotherapy, malignant pheochromocytoma, 1044(ab)
standard diagnostic modalities and, radioimmunodetection, neuroblastoma, 769
Iodine-131 monoclonal antibody CC49, radioimmunotherapy, metastatic colorectal carcinoma, 1051(ab)
Iodine-131 NP59, compared to anatomic imaging, 1044(ab)
Iodine-131 OIH, Tc-99m MAG_3 and, simultaneous clearance, renal disease, 1108(ab)
Iodine-131 MIBG, extraskeletal and skeletal deposits, neuroblastoma, 943(ab)
Iodine-131 OC 125 F(ab′)$_2$, reproducibility of image interpretation, immunoscintigraphy, 221
Iodoazomycin arabinoside:1AZA, marker of tissue hypoxia, 1764
Iodobenzamide compound, insulin kinetics, 20N(11)
5-Iodobenzovesamicol, cholinergic neuron marker, preclinical studies, 1096(ab)
1-(5-Iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole, marker of tissue hypoxia, 1764
17α-Iodovinylestradiols, polyunsaturated, estrogen responsive tumors, synthesis and evaluation, 965(ab)
Iridium-194, radioimmunotherapy, osmium-194/iridium-194 generator system, 1089(ab)
Iron, -chelating agent, alternation of biodistribution, In-111 ZCE025, 1056(ab)
Iron oxide, antibody particles, target-specific nuclear magnetic resonance imaging, 1082(ab)
Irradiation, molten targets, vertical beam facility, 1091(ab)
Ischemia
abnormal cortical appearances, pediatric renal allografts, 1542
focal cerebral, cerebral blood flow, Tc-99m ECD, 1070(ab)
***N*-Isopropyl-p-iodoamphetamine,** kinetic analysis in human brain, 991(ab)
Isotopes
supply lines tenuous, 13N(12)

J

Joint, prosthetic, diagnosing infection, 2195(le)

K

Kawasaki disease, Tc-99m HMPAO-labeled white blood cells, high-dose γ-globulin, 944(ab)
Kearfott, Kimberlee, Tetalman Memorial Award, 22N(7)
Kessler, David
Commissioner, 12N(9)
physician role in drug promotion, 18N(9)
Kidney
ACEI renography, verapamil, 933(ab)
association of renovascular disease, asymmetric renal uptake, adenosine thallium scintigraphy, 1104(ab)
captopril renal scintigraphy, simple visual criteria, 933(ab)
chronic renal osteodystrophy, long-term bone scintigraphy, parathyroidectomy, 983(ab)
clearance and distribution volume, Tc-99m MAG_3 *vs.* I-123 OIH, 2057
clearance of Tc-99m MAG_3 and I-131 OIH, renal disease, 1108(ab)
continuous measurement of function, portable renal monitor, 953(ab)
convection-diffusion-uptake model, glomerular filtration rate, 1104(ab)
discrepancy of uptake, Tc-99m DMSA and creatinine clearance, drug-induced nephrotoxicity, 1106(ab)
diuresis renography, evaluation of hydronephrosis, newborns, 943(ab)
effects of DuP753, renovascular hypertension, 1103(ab)
function, indicator of, Tc-99m MAG_3, 1843(ab)
imaging agents, Tc-99m labeled cationic complexes, 1105(ab)
measurement of clearance, portable detector system, 1106(ab)
measuring renal tubular function, Tc-99m DTPA, renal insufficiency, 972(ab)
noninvasive method for renal blood flow measurement, N-13 ammonia, dynamic PET and 2-compartment model, 953(ab)
output efficiency, quantitative correction, response to furosemide, 973(ab)
pediatric allografts, abnormal cortical appearances, 1542
pelvic hydronephrosis, antenatal diagnosis, 1649

photopenic transplants, perinephric rim of increased activity, Tc-99m DTPA, 1107(ab)
plasma flow, single-dose subcutaneous I-131 iodohippurate, 1452
poor Tc-99m DMSA uptake, near normal Tc-99m DTPA uptake, tubulointerstitial renal disease, 2273
potential imaging agents, active tubular cationic mechanism, 1102(ab)
predictors for recovery of function, Tc-99m O4 and Tc-99m MAG_3, acute renal failure, 973(ab)
procedures of choice in nuclear medicine, 1301
pseudohorseshoe, myelomeningocele, 1140(ab)
quantitation of function, use of MAG_3, 2061
scintigraphy
ACE inhibition, 1104(ab)
angiotensin-converting enzyme inhibition, Tc-99m MAG_3, 424
simplified methods for renal clearance in children, scaling for patient size, 1821
single, Tc-99m DMSA uptake, *in vivo* SPECT, 766
suspicion of congenital or acquired disease, clinical experience, MAG_3, 1085(ab)
Tc-99m DTPA renal clearance, background correction, 362(le)
Tc-99m MAG_3 clearance, proteinuria, lowered serum albumin levels, 1709
Tc-99m MAG_3 clearance in children, two gamma camera techniques, multiple plasma samples, 1704
transplant
gamma camera method, Tc-99m MAG_3 clearance, 953(ab)
renal blood flow, vascular mean transit time, 1103(ab)
transplant scintigraphy, Tc-99m MAG_3, children, 1107(ab)
Kimura's disease, microvascular right-to-left pulmonary shunt, radionuclide method, 139
Kleffner-Landau syndrome, HMPAO SPECT, 1015(ab)
Krypton-81m, particle size of Tc-99m gas, hot spot formation, 1087(ab)

L

Lactoferrin, exchange of In-111, IgG, transferrin and ferritin, 1099(ab)
Language disorders, Kleffner-Landau syndrome, HMPAO SPECT, 1015(ab)
Lead sulfate, scintillator, high-rate high-resolution PET, 995(ab)
Leukemia
cancer findings hotly disputed, Oak Ridge National Laboratory, 11N(7)
improved treatment, tyramine-cellobiose radioiodination of antibody, 1843(ab)
no increase at Canadian nuclear sites, 26N(10)
Leukemia virus, Rauscher, CHX-DTPA synthesis, α-particle radioimmunotherapy, 1056(ab)
Leukocytes
In-111 oxime-labeled autologous, functional asplenia, 524
premature, diffuse lung uptake, In-111 WBC, 1049(ab)
Tc-99m HMPAO
fast diagnosis, abdominal infections and inflammations, 2029
inflammatory component, lung cancer, 1132(ab)
Leydig tumor cells, cellular internalization, transport and esterification, I-125 NP59, 495
Ligands
cationic N_2S_2 system, preparation and characterization, 924(ab)
cleavable N_3S-hydroxyl ester, improved targeting, Re-186 antibodies, 1020(ab)
delivery and binding, differentiation, C-11 flumazenil kinetics, 980(ab)
dopamine D1 receptor, C-11 NNC756, PET, 934(ab)
hexachelating $N_2O_2P_2$, metal-based radiopharmaceutical applications, 1103(ab)
high affinity binding, stable simplified model, 1064(ab)
labeling of antibodies with cobalt for PET, 1842(ab)
N,S, Tc-99m complexes, chelate ring systems, 1016(ab)
neuroreceptor, diffusion into synapse, binding kinetics, 1008(ab)
N3S, Tc-99m complexes, comparison to OIH, 1016(ab)
photoaffinity, X-ray affinity labeling, dopamine transporter, 1839(ab)
presynaptic serotonin, synthesis and preliminary evaluation, 2''-I-125 iodoparoxetine, 965(ab)
-receptor binding, 1182
equilibrium dissociation constants, 1004(ab)
Schiff base, radiopharmaceutical imaging agents, 1101(ab)
serotonin receptors, radioiodinated N1-alkyl-2-iodo-LSD, 964(ab)
triamenedithiol, bifunctional chelating agents, Tc-99m and Re-186, 985(ab)
Lipophilic dyes, synthesis and evaluation, radioiodinated lipophilic probe, cell tracking, 1092(ab)
Lipoprotein, low-density, biodistribution, nuclear imaging analysis, 1239
Liposomes, long-lived, In-111 antibody, 992(ab)
Lipoxygenase inhibitors, application of (methyl-^{11}C)-methionine, multicellular spheroid system, 2258
Lithotripsy, extracorporeal shock wave, regional hepatic change, hepatobiliary SPECT imaging, 1000(ab)
Liver
arterial blood flow, N-13 ammonia, dynamic PET, 2199
arterial perfusion, temporary segmental hepatic venous occlusion, 1000(ab)
blood flow, validation of techniques, animal model, 999(ab)
blood flow and receptor binding, Tc-99m DTPA-galactosyl-HSA, 2233
chronic biliary cirrhosis, shunt fraction estimation, I-123 IMP and Tc-99m pertechnetate, 124
cirrhosis without hypoxemia, Tc-99m HMPAO and Tc-99m DTPA radioaerosol clearance measurements, 990(ab)
detection of hepatic metastasis, In-111 monoclonal antibody, colorectal carcinoma, 940(ab)
differences in processing, I-125 NGA and Tc-99m NGA, 506
duodenogastroesophageal reflux, modified scintigraphic method, 436
hepatobiliary scintigraphy, cystic disease, 944(ab)
indium-111-low-density lipoprotein binding, 2132
metabolism of In-111 monoclonal antibodies, methods to reduce non-specific accumulation, 1058(ab)
parenchymal disease, evaluation, F-18 FDG PET, 1000(ab)
quantitative SPECT, In-111 antibodies, 1442
regional hepatic change, ESWL, hepatobiliary SPECT imaging, 1000(ab)
small cavernous hemangiomas, improved detection, high-resolution three-headed SPECT, 2086
transplantation
complications
Tc-99m mebrofenin hepatobiliary scintigraphy, 999(ab)
correlation of Tc-99m-DISIDA hepatobiliary studies, biopsies, 1545
reversal of intrapulmonary shunting, cirrhosis, 862
uptake
modification of Tc-99m monoclonal antibody, highly polar and branched compound, 1055(ab)
phytate colloid, normals and patients with cirrhosis, 1467(le)
Liver cancer, *see also* Carcinoma, hepatocellular
radiation therapy, neutron-activated Ho-166 poly L-lactic acid, 2139
Tc-99m anti-AFP monoclonal antibody fragment, 1053(ab)
Tc-99m anti-AFP monoclonal antibody, 22N(11)
Lower extremity, deep venous thrombosis, Tc-99m RBC venography, 2324
Low-Level Radioactive Waste Policy Amendments Act (LLRWPAA)
state of Michigan, 20N(9)
state of New York, 20N(9)
state sovereign immunity, 34N(11)
Lung
actinomycosis, Tc-99m MIBI and Tl-201 uptake, 1429
altered pulmonary permeability, detection, improved radionuclide technique, 1945
biological background subtraction, improved scintigraphy, subsequent antigen injection, 2318
contusion, radioaerosol clearance, 990(ab)
C-11 serotonin extraction in man, noninvasive measurement, 729
diagnosis of pulmonary embolism, ventilation/perfusion scans, observer agreement, 951(ab)
diffuse uptake of In-111 WBC, increased premature leukocytes, 1049(ab)
granulocyte margination, lack of increase, inflammatory disease, 1014(ab)
high hopes for Technegas, 24N(11)
increased thallium uptake, dipyridamole infusion, significance, 1031(ab)
increased uptake, adenosine thallium-201 scintigraphy, coronary artery disease, 979(ab)
increased uptake of thallium, absence of myocardial perfusion abnormalities, 959(ab)
inflammatory disease, Tc-99m DTPA aerosol and Ga-67, 989(ab)
lobar distribution of pulmonary emboli, PIOPED study, 950(ab)
MR imaging, contrast enhancement, 1081(ab)
neutrophil margination, platelet activating factor, cigarette smoke, 990(ab)
perfusion scintigraphy, transbronchial biopsy after lung transplant, 1841(ab)
radiation effect on respiratory functions, mitochondrial DNA, rat, 1043(ab)
referrals for pulmonary angiography, before and

after ventilation perfusion lung scan, 1139(ab)
regional ventilation pulmonary gas volume, theory and error analysis, PET, 1937
reversal of intrapulmonary shunting, cirrhosis, after liver transplantation, 862
rheumatoid, cellular basis, Ga-67 computed lung index, 2288
scan perfusion defects, matching pleural effusions, 950(ab)
scan, suspected pulmonary embolism, 2050, 2056
suspicious and mediastinal masses, FDG-PET evaluation, 961(ab)
Tl-201 uptake
exercise emission computed tomography, 417
left ventricular dilation, adenosine and exercise scintigraphy, 1030(ab)
tryptophan-related pulmonary disease, gallium uptake, 328
uptake in dipyridamole Tl-201 imaging, ejection fraction, peripheral vascular disease, 967(ab)
uptake of radiolabeled monoclonal antibody, reduction by endotoxin, angiotensin-converting enzyme, 453
ventilation-perfusion scan, "false-positive", tuberculous mediastinal adenopathy, 512
water measurements with PET, 719
Lung cancer, *see also* Carcinoma, lung
immunoscintigraphy, 2069
inflammatory component, Tc-99m HMPAO leukocytes, 1132(ab)
preoperative assessment, mediastinal involvement, Tl-201 SPECT, 961(ab)
primary, In-111 phospholipid vesicles, 1085(ab)
radiologically occult, detection, Tl-201 SPECT, 2284
risk overestimated for radon, 24N(7)
small cell
detection of bone metastases, scintigram/MRI/biopsy, 962(ab)
radioiodinated somatostatin analog scintigraphy, 1845
suspected primary, In-111 anti-CEA monoclonal antibody, scintigraphy, 2064
Lymphadenopathy, retroperitoneal fibrosis, Ga-67 imaging, significance of negative result, 521
Lymph node
detection and staging of breast cancer, In-111 B72.3 monoclonal antibody, 1326
metastasis, Tl-201 scintigraphy, parathyroid carcinoma, 1044(ab)
metastatic from osteosarcoma, increased accumulation, hexakis (2-methoxyisobutylisonitrile)technetium(I), 1977
Lymphoma
B cell, Cu-67 BAT-Lym-1 monoclonal antibody, 984(ab)
grade characterization, thallium and gallium, 917(ab)
initial targeting studies, Tc-99m monoclonal antibody kit, 1054(ab)
malignant
FDG-PET, 686
management of patients, Ga-67 scintigraphy, 2299
radiation or chemotherapy effects, F-18 FDG PET, 918(ab)
murine, FDG PET, 1043(ab)
non-Hodgkin
C-11 methionine and fluorodeoxyglucose, PET, 1211
In-111 labeled lymphocyte scintigraphy, 917(ab)
predictor of response to treatment, Ga-67 scintigraphy, 1084(ab)
spectrum of presentations, bone scintigraphy, 1129(ab)
Lymphoscintigraphy, abnormalities in venous thrombosis, 2144

M

Macromolecules, small coordination complexes, tumor imaging, 849
MAG_3
clinical experience, suspicion of congenital or acquired renal disease, children, 1085(ab)
enalaprilat, scintigraphy, renovascular hypertension, 934(ab)
quantitation of renal function, 2061
volume of distribution, 900(le)
Magnetic resonance tomography, presurgical epileptic diagnosis, compared to HMPAO SPECT, 1076(ab)
Malignancy, Tc-99m MDP uptake, sympathetic effusion, 325
Mallinckrodt fellowship, Gregory A. Wiseman, 17N(6)
Mallinckrodt Medical Inc., drops party to fund education efforts, 24N(8)
Mammary gland, F-18 fluorine labeled high affinity progestin, receptor-mediated uptake, 975(ab)
Mammillary systems, temporal behavior, peripheral organ distribution volume, 896(le)
Marijuana, increases in cerebellar metabolism, 980(ab)
Mastocytosis, systemic, serial bone scanning, 1026(ab)
Mathematical models
constraints on sensitivity and specificity, "logically" merged test results, 1646
development and application, nuclear medicine, 2206
maximium-likelihood and hotelling observers, complex detection task, 988(ab)
maximum-likelihood estimation, quantitation in nuclear medicine, 898(le)
three-dimensional physical brain phantom, 3-D SPECT, 1923
Meckel's diverticulum, visualization, cimetidine-enhanced Tc-99m pertechnetate, 1422
Mediastinitis, detection after heart transplantation, Ga-67 scintigraphy, 860
Medicaid, Physician Payment Review Commission contacts, 11N(9)
Medicare
fee schedule and RBRVS, 11N(9)
government relations update, SNM/ACNP, 12N(2)
Medicare and Medicaid, Clinical Laboratory Amendments of 1988, revisions, SNM and ACNP proposals, 28N(1)
Melanoma
-associated antigens, epitopes, human malignant melanoma, 1056(ab)
biologic characterization, antigen-specific targeting, radiolabeled anti-tumor antibodies, 287
malignant
I-125 radiopharmaceuticals, 1573
xenografts, radiolabeled monoclonal antibody targeting, 1056(ab)
metastatic
FDG uptake, quantitative analysis, 1838(ab)
2-18-F-fluorodopa uptake, 95
Memory
circuits in man, F-18 FDG PET, 1022(ab)
-impaired patients, relationship of neuropsychological test performance, FDG uptake, 942(ab)
Meningitis, human neoplastic, intrathecal astatine-211 monoclonal antibody, 922(ab)
Mesentery, gallium-avid mobile mass, inflammatory pseudotumor, 1614
Metal
-based radiopharmacetuical applications, hexachelating $N_2O_2P_2$, 1103(ab)
-based tracers, structural features, brain imaging, 1139(ab)
Metal ions
comparison of DOTA and DTPA analogs, bifunctional antibody delivery, 915(ab)
small coordination complexes, tumor imaging, 849
Metastasis
bone
prostate carcinoma, bone marrow regeneration, 2295
Re-186 HEDP for pain, metastatic prostate or breast cancer, 1082(ab)
bone cancer, pharmacokinetics, Re-186 and Re-186 HEDP, 1083(ab)
bone disease, palliation of pain, Re-186 HEDP, 1088(ab)
brain, non-CNS neoplasms, preliminary FDG-PET evaluation, 954(ab)
breast carcinoma, 16α-[^{18}F]-fluoro-17β-estradiol PET, 1526
detection and staging of breast cancer, In-111 B72.3 monoclonal antibody, 1326
differentiation of recurrent disease from post-therapy complication, Tl-201 SPECT, 962(ab)
distant, hepatocellular carcinoma, hepatobiliary scintigraphic agent, 1137(ab)
endocrine imaging, 1455
melanoma, 2-18-F-fluorodopa uptake, melanogenesis, 95
occult, colorectal cancer, Tc-99m anti-CEA Fab′ fragments, 1052(ab)
osseous
pain palliation, tin-111m(4^+)DTPA, 1840(ab)
Re-186(Sn)HEDP treatment, 1877
osteosarcoma, increased accumulation, hexakis (2-methoxyisobutylisonitrile)technetium(I), 1977
skeletal
bone marrow scan identification, "diffuse" metastases, 1083(ab)
bone scan results, prostate-specific antigen, 1082(ab)
treatment for pain, Re-186 HEDP, 963(ab)
stage IV renal cell carcinoma, Tc-99m MDP bone scan 983(ab)
thyroid, improved localization, 1131(ab)
L-Methionine, uptake by human cerebral cortex, maturation, infancy to old age, 16
Methotrexate, mild-moderate hepatotoxicity, rheumatoid arthritis, 1048(ab)
Methoxyphenylisocyanate, new conjugation technique, radioiodination, oligonucleotides, 1092(ab)
3-*O*-Methyl-6-fluorodopa, interpretation of 6-fluorodopa kinetics, PET, 1007(ab)
Metoclopramide, -induced akathisia, gastric emptying imaging, 1644(le)
MIBG, radiolabelled, cerebral uptake, adrenergic receptors, 992(ab)
Microspheres
Ho-166 poly L-lactic acid, radiation therapy, hepatic tumors, 2139

human serum albumin labeled by specific linker technology, use, radiation synovectomy, 964(ab)
Mitochondria
ophthalmoplegia plus, Tc-99m HMPAO SPECT, 1075(ab)
viability, cardiac retention, Tc-99m SESTAMIBI, 957(ab)
MK-329, gastric emptying of solids, 547(le)
Molecular medicine, from science to service, 11N(8)
Molybdenum-99
domestic production, 32N(6)
federal funding, industry support for domestic supplier, 13N(12)
supply of, 14N(9)
-Tc-99m, generated eluate contaminants, N_2S_2 chelation, 1102(ab)
Monoamine oxidase, mapping of activity, radioiodinated analogs of clorgyline, brain SPECT, 1091(ab)
Monoclonal antibodies
advantage of protecting antigen-binding site, antibody labeling, 122
^{111}Ag label, radioimmunotherapy, 1099(ab)
anti-CEA
autoradiography, tumor uptake, 1052(ab)
three-step tumor targeting, medullary thyroid carcinoma, 1010(ab)
antifibrin
deep vein thrombosis, 1132(ab)
uptake, coronary thrombus scintigraphy, 1005(ab)
antigen-binding site protection, radiolabeling, higher immunoreactive fraction, 116
anti-idiotypic
immunoscintigraphy, advanced ovarian carcinoma, 1051(ab)
modification, CC49 biodistribution, 1058(ab)
purification, chromatography, 993(ab)
anti-melanoma, tumor uptake, para-iodobenzoyl conjugate, 279
antimelanoma TP41.2, In-111 cyclodextrin inclusion, photoaffinity labeling, 984(ab)
antimyosin, doxorubicin, severity of myocardial damage, 1019(ab)
autoradiographic evaluation, 2-deoxyglucose distribution in xenografts, human ovarian carcinoma, 993(ab)
CC49, CX-1 tumor model, 1098(ab)
circulating c-*erb*B-2 protooncogene products, advanced cancer patients, 1087(ab)
Cu-67-Lym-1, B cell lymphoma, 984(ab)
direct labeling with Tc-99m, biodistribution in mice, 1099(ab)
discrimination between geometric isomers, Rh-BA-2,3,2-TET, 914(ab)
distribution and radiation dose in tumors, heterogeneity, 1055(ab)
dual specificity conjugate, In-111 low molecular weight bivalent hapten, colorectal carcinoma, 940(ab)
enhancement of tumor uptake, nude mice, PEG IL-2, 992(ab)
fibrin-specific, localization, pulmonary emboli, 1254
human antimouse antibodies, false positive TSH values, 977(ab)
I-131 chimeric mouse/human IgG1,k 17-1A, pharmacokinetics, immune response, 1162
immunoconjugates, fast growth in U.S. market, 35N(11)
immunotherapy for improved survival, 16N(11)
improved imaging of tumors, clearance of unbound antibodies from plasma, 970(ab)
In-111 B72.3, detection and staging, breast cancer, 1326
labeled, simple method, affinity purification, 1057(ab)
labeling with F-18 using SFBS, 984(ab)
ligands for labeling with cobalt for PET, 1842(ab)
long-term biodistribution of In-114m, 1100(ab)
-metallothionein, Tc-99m, radioimmunoimaging, 915(ab)
negatively charge-modified, gamma imaging, synthetic polymers, 1742
optimization, use in nuclear medicine, 1751
preferential iodination of Fc region, 985(ab)
preservation of immunoreactivity, selective iodination, Fc fragment, 1100(ab)
procedures, organ dosimetry, 1130(ab)
radioiodinated
bone marrow dosimetry, direct tissue counting, 1414
influence of protein dose, tumor distribution, 1058(ab)
radiolabeled
direct intralesional injection, brain glioma, 922(ab)
pondering of regulations, NRC, 24N(8)
pulmonary uptake reduction by endotoxin, angiotensin-converting enzyme, 453
targeting, multiple xenografts of human malignant melanoma, 1056(ab)
radiolabeled anti-tumor, biologic characterization, melanoma tumors, 287
synthesis and radiolabeling of "tyrosyl-ETAC", 915(ab)
T101
change in isoelectric point, normal tissue uptake, 1057(ab)
chemical modification, isoelectric point, 1101(ab)
Tc-99m anti-activated platelet, rapid imaging, arterial thrombi, 1005(ab)
Tc-99m anti-granulocyte, immunoscintigraphy, suspected subacute bacterial endocarditis, 1019(ab)
Tc-99m N_2S_2-Fab, metabolite analysis, mice and rats, 915(ab)
Z2D3, localization, atherosclerotic lesion, 1005(ab)
Monte Carlo
attenuation and scatter correction, sources in nonhomogenous object, SPECT, 1278
estimation of scatter component, simultaneous data acquisition, two radionuclides, 1059(ab)
model of non-uniform attenuating phantoms, irregular-shaped regions, SPECT, 1065(ab)
Morphine
-augmented cholescintigraphy, detection, acute cholecystitis, 1231
scintigraphic detection, acute cholecystitis, 1233
Motilin, gastric emptying, diabetic gastroparesis, 931(ab)
Movement disorders, basal ganglia hypometabolism, 1015(ab)
Multiple myeloma, without amyloidosis, pentavalent Tc-99m DMSA uptake, 1785
Muscle
normal, extravascular compartment, In-111 proteins, 1101(ab)
perfusion with Tc-99m MIBI, lower extremity peripheral arterial disease, 1700
radiocesium levels in humans, four-year period, 1491
Musculoskeletal neoplasms
noninvasive grading, PET, 1508
PET evaluation, FDG and labeled water, 962(ab)
Myelomeningocele, pseudohorseshoe kidney, 1140(ab)
Myocardial infarction
acute
rapid imaging, Tc-99m antimyosin sFv fragment, 1005(ab)
sympathetic neuronal function, C-11 HED, 1040(ab)
Tc-99m glucarate and Tl-201, 1029(ab)
assessment with three radiotracers, 2360(le)
blood flow and oxygen consumption, rate pressure product, 989(ab)
cardiac ventricular myosin light chain, single monoclonal synthetic peptide, radioimmunoassay, 977(ab)
detection with infarct-avid imaging, 269
discrepancies, I-123 BMIPP and Tl-201, 1034(ab)
early scintigraphic detection, Tc-99m glucaric acid, 263
non-Q wave, transient silent left ventricular dysfunction, unstable angina, 938(ab)
previous, Rb-82 kinetics and FDG uptake, 1012(ab)
prognostic significance, augmented FDG uptake, 1039(ab)
remote Q-wave, adenosine coronary hyperemia, SPECT thallium, 979(ab)
reperfused, Tl-201/In-111 antimyosin antibody dual isotope imaging, 1034(ab)
right ventricular
dual-isotope In-111 antimyosin/Tl-201 SPECT, gated blood pool scintigraphy, 1018(ab)
Tc-99m sestamibi SPECT, 929(ab)
simulation by myocarditis, 312
thrombolysis, anterograde flow, tissue viability, 1039(ab)
Tl-201 tomography, 2-^{18}F-2-deoxyglucose, 15-(ortho)^{123}I-phenyl)-pentadecanoic acid, 1353
Tl-201 with reinjection, FDG PET, 949(ab)
viability, coronary flow reserve, PET, 1013(ab)
Myocardial ischemia
acute anterior, prediction of functional improvement, PET, 1012(ab)
cocaine-induced global and regional, 1569
coronary occlusion, myocardial viability, Tc-99m sestamibi, 292
critically ischemic zone at risk, acute coronary occlusion, PET, 1581
differential tracer washout, SPECT acquisition, 2253
dysfunction, artifactual perfusion defects, Tc-99m sestamibi, 909(ab)
exercise-induced, I-123 MPDA and Tl-201 chloride, 447
improved detection, wash-in rate changes, Rb-82 PET, 998(ab)
inadequate exercise, suboptimal imaging, Tl-201 myocardial perfusion, 2071
isotopic findings in anomalous origin, left coronary artery from pulmonary artery, 1788
known or suspected, Tc-99m TEBO washout, myocardial images, 930(ab)
low-flow, F-18 FDG and H-3 FMISO, 1028(ab)
planar acquisitions, Tl-201 SPECT, 958(ab)
post-stenotic Tc-99m TEBO clearance kinetics, hyperemic stress, 2000
region size using an extension of bullseye methodology, short axis edge detection, 1027(ab)

Tc-99m teboroxime clearance, regional systolic dysfunction, 948(ab)
Tl-201 reinjection *vs.* PET viability, 1835(ab)
uridine and deoxyglucose uptake, 928(ab)
Myocarditis
antimyosin scintigraphy, 1019(ab)
simulation of myocardial infarction, 312
Myocardium
absence of perfusion abnormalities, increased lung uptake, thallium, 959(ab)
accumulation of monoclonal antimyosin Fab, hypertrophic cardiomyopathy, postpartum cardiomyopathy, 2291
adenosine thallium scintigraphy, compared to dipyridamole, 969(ab)
adenosine Tl-201 imaging, safety in the elderly, 978(ab)
adenosine Tl-201 scintigraphy, risk reduction, severe arrhythmia, 978(ab)
assessment of damage, dilated-phase hypertrophic cardiomyopathy, In-111 antimyosin Fab myocardial scintigraphy, 1333
at risk, rest/stress Tl-201 or Tl-201 reinjection, 949(ab)
automatic reorientation, Tl-201 SPECT, 1067(ab)
beta receptors, C-11 CGP 12177 PET, 927(ab)
blood flow
estimation and optimal SPECT collimator resolution, side information effects, 946(ab)
retention of Tc-99m teboroxime, 947(ab)
simplified method for quantification, N-13 ammonia and dynamic PET, 926(ab)
simultaneous measurement in same animal, Tc-96 sestamibi and Tl-201, 947(ab)
blood flow and glucose uptake, region of interest size, PET, 1027(ab)
canine, kinetic properties, C-11 threo-MHED, 928(ab)
changes in scar size, rats, acute LAD ligation, 1029(ab)
chick cells, tetraphenylborate, Tc-99m MIBI uptake kinetics, 1992
clearance
C-11-derived radiolabel, oxidative metabolism, 1957
Fourier phase analysis, Tc-99m TEBO, 1029(ab)
coronary artery disease, ribose facilitation, Tl-201 redistribution, 193
defect detection in Tl-201 SPECT, various collimators, 946(ab)
defect size at rest and exercise, Tl-201 and Tc-99m MIBI SPECT, 1037(ab)
detection of validity, 2024(le)
differential washout, Tc-99m TEBO, mechanism and significance, 2009
distribution of In-111 antimyosin Fab, acute inferior and right ventricular infarction, 865
dynamic imaging, Tl-201, Tc-99m TEBO, 1036(ab)
effect of exercise type, kinetics, dipyridamole and exercise stress imaging, 1031(ab)
false-negative dipyridamole-Tl-201 imaging, caffeine infusion, 1538
fatty acid utilization, 14(*R,S*)-[F-18]fluoro-6-thia-heptadecanoic acid, 937(ab)
FDA approval of new technetium-labeled cardiac agents, alternative to exercise, stress-thallium studies, 11N(5)
FDG uptake, treadmill stress, PET, 1039(ab)
flow tracer, Cu-62 PTSM, 1028(ab)
Ga-68 BAT-TECH perfusion agent for PET, 974(ab)
gated imaging, left ventricular function, Tc-99m MIBI, 1035(ab)
glucose metabolism
coronary artery occlusion, FDG-PET, 909(ab)
euglycemic hyperinsulinemic clamp method, PET, 988(ab)
image quality, factors, FDG, 1039(ab)
imaging agents based on Ga (N_2S_2) complexes, 1094(ab)
I-123 MPDA and Tl-201 chloride, exercise-induced ischemia, 447
infants and children with disease, prognosis, ventricular function, 1086(ab)
infarcted canine, sustained uptake, In-111 antimyosin, 1029(ab)
jeopardized, single vessel coronary artery disease, adenosine and exercise Tl-201 SPECT, 969(ab)
kinetics of Tc-99m teboroxime, canine stenosis model, dipyridamole, 948(ab)
left ventricular mass, myocardial perfusion, PET with dipyridamole stress, 2221
maximal blood flow during adenosine infusion, intravenous dipyridamole, 969(ab)
metabolic rate of glucose, parametric images, PET, 732
metabolism of fluorodeoxyglucose, cell membrane integrity, Rb-82, 1
neutral imaging agents, Tc-99m dithiocarbamates, 925(ab)
non-uniform attenuation compensation, bulls-eye SPECT, 1839(ab)
nonuniformity in accumulation, F-18 FDG, normal fasted humans, 1832(le)
oxidative and contractile reserve, dobutamine, 989(ab)
oxidative metabolism, C-11 acetate as tracer, 910(ab)
oxidative reserve, PET assessment, 988(ab)
oxygen consumption, C-11 acetate recirculation, PET, 1950
parametric images of metabolic rate, glucose, dynamic cardiac PET, 733
perfusion
agent Q12, 1007(ab)
arterial switch operation, 237
dipyridamole, exercise supplementation, 1564
effects of moderate aging, noninvasive delineation, 2037
enhanced processing and quantification, Tc-99m sestamibi, 1035(ab)
Rb-82 PET or Tl-201 SPECT, 1133(ab)
scintigraphy, markedly positive exercise tests, 1035(ab)
SPECT, rest Tl-201/stress Tc-99m sestamibi, 1006(ab)
Tc-99m MIBI, intravenous adenosine and dipyridamole, 1027(ab)
Tl-201 suboptimal imaging, inadequate exercise, 2071
Tc-99m sestamibi, coronary artery disease detection, 1961, 1966
PET studies, reducing resolution distortions, region of interest strategies, 926(ab)
photon attenuation, ventricular ejection fraction, radionuclide ventriculography, 939(ab)
post-stenotic Tc-99m TEBO clearance kinetics experimental ischemia, hyperemic stress, 2000
non-exercise cardiac stress, 947(ab)
protein synthesis, PET, C-14 leucine, 1835(ab)
quantification of blood flow, N-13 ammonia and O-15 water, 926(ab)
quantification of perfusion, Cu-62 PTSM PET, 937(ab)
quantitative stress Tl-201 perfusion SPECT, normalcy rate, 959(ab)
reduced perfusion reserve, dysfunctional collateral-dependent myocardium, 998(ab)
regional heterogeneity of glucose metabolism, normal humans, dynamic FDG-PET, 938(ab)
regional perfusion, C-11 acetate, 665
regional thickening, ECG-gated imaging, Tc-99m sestamibi, 957(ab)
regional uptake, F-18 deoxyglucose, fasting condition, 2152
regional wall thickening, left ventricle, gated PET, 679
resting perfusion defects and glucose uptake, wall motion abnormality, Tc-99m MIBI SPECT/F-18 DOG PET, 1037(ab)
retention of Tc-99m sestamibi, necrosis, coronary occlusion and reperfusion, 957(ab)
reversibility of perfusion defects, reproducibility, quantitative planar Tl-201 scintigraphy, 759
scatter and attenuation correction, Tc-99m sestamibi SPECT, 1067(ab)
sequential tomographic perfusion imaging, Tc-99m teboroxime, compared to Tl-201 and arteriography, 919(ab)
SPECT
LV long axis orientation, reconstruction arc, 946(ab)
reduction of image artifacts and distortions, 946(ab)
stress Tl-201 perfusion scintigraphy, role of 24 hour imaging, Tl-201 re-injection, 1129(ab)
stunned, I-123 BMIPP, myocardial perfusion, 1012(ab)
stunned/ischemic, thrombolytic therapy, adenosine/metabolic imaging, 1012(ab)
synthesis and investigation of Ga-PAT, 1090(ab)
Tc-99m diphosphine Phase I study, 967(ab)
Tc-99m perfusion agents, optimized imaging properties, 925(ab)
Tc-99m sestamibi perfusion studies, optimal method for sampling and displaying, 1006(ab)
Tc-99m SQ30217
clearance rate, coronary artery stenosis, 1037(ab)
three-headed SPECT, 1273
Tc-99m teboroxime clearance, regional systolic dysfunction, acute ischemia and pharmacologic stress, 948(ab)
thallium scintigraphy, congenitally-corrected transposition, great arteries, 1611
thickening
sestamibi, count-based method, 1006(ab)
Tc-99m sestamibi SPECT, count-based method, 1068(ab)
tissue fraction, correction for partial volume effects, tissue viability, 2169
tissue glucose utilization, input function, noninvasive method, 1432
tissue viability studies, insulin substitution, FDG-PET, 988(ab)
tomographic perfusion imaging, at rest and after dipyridamole, 1968
tomographic SPECT, Tc-99m teboroxime and Tl-201, 920(ab)
tomography, symbiotic developments, SPECT and PET, 166
transaxial tomograms, reorientation, left ventricular long-axis, 1794

transient perfusion defects, dipyridamole infusion thallium scan, 1030(ab)
uptake of C-11 acetate, indirect estimate, regional myocardial blood flow, 245
uptake of copper pyruvaldehyde thiosemicarbazone, N-13 ammonia, PET, 999(ab)
uptake rate in scintigraphy, I-123 MIBG and Tl-201 chloride, hypertrophic cardiomyopathy, 1040(ab)
utilization of long chain fatty acids, 14(*R,S*)-F-18 fluoro-6-thia-heptadecanoic acid, 1888
viability, 10, 1315(le)
coronary occlusion, Tc-99m SESTAMIBI, 292
detection, Tl-201 chloride, 200
immediate or delayed imaging, Tl-201 reinjection, 949(ab)
ischemic cardiomyopathy, PET, 130
Rb-82 and F-18 FDG PET, 968(ab)
semiquantitative assessment, cardiac PET polar maps, 926(ab)
severe asynergic regions, rest-injected Tl-201, 1718
Tc-99m SESTAMIBI, 298
Tl-201 defect severity, stress and late redistribution, 950(ab)
washout characteristics, additional useful information, teboroxime, 1988
water transport, convectin-diffusion and compartment model, 926(ab)

N

Naloxone, reversal of pattern of obstruction, distal common bile duct, hepatobiliary imaging, 1270
Narcotics, pattern of obstruction of distal common bile duct, reversal by naloxone, hepatobiliary imaging, 1270
National Biomedical Tracer Facility (NBTF), feasibility study approved by DOE, 17N(3)
National Council on Radiation Protection and Measurements (NCRP), study of misadministrations/QA rule, 13N(2)
National Emissions Standards for Hazardous Air Pollutants (NESHAPS), EPA postponement of rule, 29N(6)
National Health Service Corps (NHSC), revitalization with appropriation, 14N(2)
National Research Council, release of updated monograph, F-18 labeling, 28N(1)
National Research Council (NRC)
publication of PE monographs, 48N(4)
restructuring of U.S. HLRW Disposal Program, 15N(1)
Nebraska, low-level radioactive waste lawsuits, 14N(2)
Neck
femoral, bone mineral density, GnRH-agonists, 1026(ab)
input function, brain PET using O-15 water, 1003(ab)
Necrosis
myocardial retention of Tc-99m sestamibi, canine model, coronary occlusion and reperfusion, 957(ab)
segmental, pancreas transplant, Tl-201 perfusion scintigraphy, 1605
Neogalactosyl albumin, I-125- and Tc-99m-, differences in processing, liver, 506
Neonates, diuretic renography, standardized protocol, hydronephrosis, 943(ab)
Neoplasms, non-CNS, brain metastases, preliminary FDG-PET evaluation, 954(ab)
Nephrotoxicity
cyclosporine radioimmunoassay, heart transplant, 977(ab)
drug-induced, discrepancy of renal uptake, Tc-99m DMSA and creatinine clearance, 1106(ab)
NESHAPS, Environmental Protection Agency, 20N(9)
Neuroblastoma
endocrine imaging, 1627
extraskeletal and skeletal deposits, Tc-99m MDP and I-131 MIBG, 943(ab)
I-125 MIBG therapy, 361(le)
long-term survival, I-131 MIBG, 1086(ab)
management, preoperative I-131 MIBG therapy, 921(ab)
radioimmunodetection, I-131 MIBG, standard diagnostic modalities, 769
Neurocardiology, molecular medicine, from science to service, 19N(8)
Neuroendocrine tumors, I-123 Tyr^3-octreotide scintigraphy, 981(ab)
Neurological disorders, acute, regional cerebral perfusion, childhood, 943(ab)
Neurons
activation, optimum scanning regimen, bolus O-15 water, 1064(ab)
cardiac adrenergic, Adriamycin cardiomyopathy, 1029(ab)
central noradrenergic, probe, I-125 iodo-DSPA, 964(ab)
cholinergic, preclinical studies, 5-iodobenzovesamicol, 1096(ab)
marker for central cholinergic presynaptic sites, 4-F-18 fluorobenzyl-ABV, 994(ab)
myocardial sympathetic, C-11 HED, acute myocardial infarction, 1040(ab)
sympathetic, heart, C-11 epinine, 994(ab)
Neuropsychological test
AIDS, 1078(ab)
dementia, SPECT/IMP, 942(ab)
relationship of performance on test to FDG uptake, memory-impaired patients, 942(ab)
Neuroreceptors
epilepsy, 651
molecular medicine, from science to service, 17N(8)
Neutrophils
margination in the lung, platelet activating factor, cigarette smoke, 990(ab)
-specific Tc-99m monoclonal antibody, imaging inflammatory diseases, 1836
Newborns, evaluation of hydronephrosis, diuresis renography, 943(ab)
Newsline
Commentary
clinical PET, 42N(4), 46N(4)
Lines from the President, 25N(3), 24N(6), 16N(9)
PET radiopharmaceutical research, 44N(4)
New York, low-level radioactive waste lawsuits, 14N(2)
Nicol, Philip D., Berson-Yalow Award, radioimmunoassay research, 22N(6)
Nitrogen, losses, malnutrition in AIDS, depletion of body cell mass, 1050(ab)
Nitrogen-13 ammonia
compared to O-15 water, quantification, myocardial blood flow, 926(ab)
dipyridamole PET, coronary flow reserve, hypertrophic cardiomyopathy, 1040(ab)
dynamic PET and, simplified method for quantification, myocardial blood flow, 926(ab)
F-18 deoxyglucose and, effect of metabolic milieu, cardiac PET imaging, 1518
noninvasive method for renal blood flow measurement, dynamic PET, 2-compartment model, 953(ab)
PET
hepatic arterial blood flow, 2199
myocardial uptake, copper pyruvaldehyde thiosemicarbazone, 999(ab)
regional myocardial blood flow, reoriented dynamic PET, 909(ab)
NMSP, high affinity binding ligands, stable simplified model, 1064(ab)
Noise
improvements, resolution dependence, maximum likelihood reconstruction, 966(ab)
suppression in image sequences, filters, 987(ab)
Nordion International, main medical radionuclide reactor shuts down, 30N(3)
Nuclear magnetic resonance
AIDS, 1078(ab)
computer-assisted superimposition of MRI, brain SPECT, 1478
correction of cardiac PET/SPECT, resolution and wall motion effects, 938(ab)
detection of bone metastases, small cell lung cancer, 962(ab)
deuterium measurement of blood flow, wash-in technique, murine tumors, 1081(ab)
development of negative oral contrast agent, 1081(ab)
disease onset and, metabolic asymmetries, asymptomatic seropositive HIV-1 patients, 1725
follow-up of differentiated thyroid carcinoma, Tl-201 and Tc-MIBI, 921(ab)
gated PET FDG imaging, parameter estimation, cardiac geometry, 927(ab)
HMPAO-SPECT and, acute disseminated encephalomyelitis, 1897
MRI for detection of recurrent thyroid cancer, ultrasonography, radioiodine scintigraphy, 1011(ab)
MRI T2 increased signal, PET interictal hypometabolism, temporal lobe epilepsy, 912(ab)
multidetector time-of-flight positron coincidence detector, 1063(ab)
proton and sodium MRI, modulation transfer functions, associated frequency descriptions, 1133(ab)
SPET/radioimmunoscintigraphy and PET/FDG studies, choroidal melanomas, 1050(ab)
target-specific, antibody-iron-oxide particles, 1082(ab)
three-dimensional brain surface MR image, planar mapping, 1002(ab)
three-dimensional display, 534
Tl-201 chloride, planar and SPECT, malignant ENT-tumors, 920(ab)
use of MR images, finite resolution effects in SPECT, cerebral cortex, 985(ab)
Nuclear medicine
algorithms to improve diagnostic role, AIDS, 1138(ab)
clinical practice guidelines, 13N(6)
department, source of toxic gas leakage, 1641(le)
future of, SNM's role, 25N(3)
network design, 1133(ab)
optimizing antibodies, 1751
perspective on HLRW disposal, 18N(1)
practice guidelines, SNM office of health care policy, 24N(12)
renal, procedures of choice, 1301
strategic planning, 22N(12)
three-dimensional display, 534

Nuclear power industry, large-scale cancer study, 17N(9)
Nuclear Regulatory Commission (NRC)
advisory committee calls for narrowed QA rule, better response, radiopharmacy petition, 21N(3)
"below regulatory concern" policy, 35N(11)
enforcement legislation, 14N(9)
halt on below regulatory concern, 26N(8)
human factors research, 25N(12)
ICRP and, lower radiation exposure limits, 29N(5)
increased user fees, 35N(11)
interim final rule, petition, rulemaking change, 13N(2)
interim rule on medical radionuclides, 14N(9)
misadministration data released, 34N(11)
new chairman, 14N(9)
quality assurance, 14N(9)
quality assurance meetings, 13N(2)
quality management rule, consideration of appeal by SNM/ACNP, 20N(10)
radiation safety standards, 14N(9)
regulations for radiolabeled monoclonal antibodies, 24N(8)
response to SNM queries, radiopharmacy petition, 28N(5)
user fees, 14N(9), 23N(7)
user fees and appropriations, 14N(2)

O

Oak Ridge National Laboratory (ORNL)
cancer findings hotly disputed, 11N(7)
nuclear medicine axed, 29N(6)
Obesity, weight reduction surgery, extracellular and intracellular water, intestinal bypass *vs.* gastroplasty, 1104(ab)
Obsessive-compulsive disorders, cerebral blood flow, Xe-133, 1076(ab)
Office of Health Technology Assessment (OHTA)
dual-photon absorptiometry, single-photon absorptiometry, assessment, 12N(2)
PET assessment, 12N(9)
reassessment of DPA/SPA, 11N(9)
Oligonucleotides, radioiodination, new conjugation technique, activated methoxy phenylisothiocyanate, 1092(ab)
Oncology
clinical, PET applications, 623, 649
nuclear, molecular medicine, from science to service, 19N(8)
PET cancer evaluations with FDG, 1555
Ophthalmoplegia plus, brain, Tc-99m HMPAO SPECT, 1075(ab)
Opioids, epilepsy, 651
Oropharyngeal emptying, bolus viscosity, 1045(ab)
Orthopedics, postoperative patients, detection of infection, Tc-99m monoclonal antibodies against granulocytes, 2209
Osmium-194, -iridium-194 generator system, radioimmunotherapy, iridium-194, 1089(ab)
Osteomyelitis
canine model, In-111 nonspecific polyclonal IgG, In-111 leukocytes, 1394
diabetic feet, value, In-111 leukocytes, 1003(ab)
diabetic pedal, diagnostic efficacy, In-111 WBC imaging, 963(ab)
improved diagnostic accuracy, combined In-111 leukocyte and Tc-99m sulfur colloid imaging, 962(ab)
In-111 chloride, three-phase bone scintigraphy, 67
vertebral, In-111 leukocyte and Tc-99m MDP, bone scintigraphy, 1861
Osteomyelofibrosis, typical bone and bone marrow scan pattern, 1085(ab)
Osteoporosis, measurement of response to nonhormonal therapy, dual photon absorptiometry, 982(ab)
Osteosarcoma, metastatic lymph nodes and, increased accumulation, hexakis (2-methoxyisobutylisonitrile)technetium(I), 1977
Oxine, labeling of In-111 platelets, 62
Oxygen
C-11-derived radiolabel, myocardial clearance rates, 1957
cerebral oxygen extraction fraction, brief inhalation method, PET, 1738
hyperbaric, brain injury, SPECT, 1840(ab)
Oxygen consumption
blood flow and, rate pressure product, myocardial infarction, 989(ab)
myocardium, C-11 acetate recirculation, PET, 1950
Oxygen-15 butanol, O-15 water and, radiation dosimetry, normal volunteers, 1043(ab)
Oxygen-15 water
antisaccade task, normal and schizophrenic patients, 952(ab)
bolus, optimum scanning regimen, neuronal activation, 1064(ab)
FDG and, PET evaluation, musculoskeletal neoplasms, 962(ab)
handheld automated injector, 1063(ab)
myocardial oxidative reserve, PET, 988(ab)
N-13 ammonia and, quantification, myocardial blood flow, 926(ab)
O-15 butanol and, radiation dosimetry, normal volunteers, 1043(ab)
optimal scan time, cerebral blood flow, 1931
PET
brain activation, 58
coronary reserve, compared to intracoronary Doppler study, 998(ab)
input function, dynamic neck scan, 1003(ab)
residual effect of physiological stimulation, cerebral blood flow, 1072(ab)
Oxygen-18, -F-18 gas target system, spectroscopic identification, electrophilic F-18, 1010(ab)
supply shortage, 0-18 water, 13N(12)

P

Pachydermoperiostosis, Tc-99m MDP scintigraphic pattern, 1907
Pain
osseous metastases, Re-186(Sn)HEDP treatment, 1877
palliation, osseous metastases, tin-111m(4$^+$)DTPA, 1840(ab)
scientific highlights of EANM Congress 1991, 16N(11)
study of I-123 L-AMT transport, 819
Palilalia, brain mapping, Tc-99m HMPAO SPECT, 1619
Pancreas
endocrine imaging, 1627
neoplasms
radiotherapy response, F-18 FDG PET, 1084(ab)
tumor markers, 1088(ab)
transplant, segmental necrosis, Tl-201 perfusion scintigraphy, 1605
Papillary stenosis, quantitative hepatobiliary scintigraphy, 1131(ab)
Pap smear, histologic Gleason scores, prostate carcinoma, 977(ab)
Para-iodobenzoyl conjugate, anti-melanoma monoclonal antibodies, tumor uptake, 279
Parathyroid, imaging, 887, 1627
change detection and movement correction, Tc-99m MIBI, 1011(ab)
Parathyroidectomy, long-term bone scintigraphy, chronic renal osteodystrophy, 983(ab)
Parkinsonian syndromes, dopamine D2 receptors, I-123 IBZM SPECT, 1014(ab)
Parkinson's disease, alterations, cortical and subcortical glucose metabolism, 960(ab)
Pediatric patients
acute neurological disorders, evaluation, regional cerebral perfusion, 943(ab)
clinical trial of Tc-99m MAG_3, 1085(ab)
estimation of glomerular filtration rate, single-plasma sample method, 1294
FDG PET in head trauma, 1016(ab)
glomerular filtration rate, 1297
infants and children, prognosis in myocardial disease, ventricular function, 1086(ab)
Kleffner-Landau syndrome, HMPAO SPECT, 1015(ab)
lumbar spine bone mineral content, 216
radiation dose estimated, Tc-99m mercaptoacetyltriglycine, 1017(ab)
regional cerebral blood flow
childhood autism, SPECT, 1086(ab)
Tc-99m HMPAO SPECT, 1080(ab)
values measured on predetermined ROIs, Xe-133, 1841(ab)
renal transplant scintigraphy, Tc-99m MAG_3, 1107(ab)
right ventricular overload, Tl-201 SPECT, congenital heart disease, 2215
simplified methods for renal clearance, scaling for patient size, 1821
suspicion of congenital or acquired renal disease, clinical experience, MAG_3, 1085(ab)
Tc-99m MAG_3 renal clearance, two gamma camera techniques, multiple plasma samples, 1704
Pelvis
hydronephrosis, antenatal diagnosis, 1649
tumors, PET total body imaging, FDG, 982(ab)
volume 3-D display of Tc-99m HMDP, triple head gamma camera, 913(ab)
Penis, plethysmography and Xe washout, corpora cavernosal inflow and outflow, early tumescence, 404
Periostitis, spectrum of scintigraphic findings, 1129(ab)
Peripheral organ distribution volume, temporal behavior, mammillary systems, 896(le)
Peripheral vascular disease, ejection fraction, lung uptake, dipyridamole Tl-201, 967(ab)
Peristalsis, ureteric imaging, 973(ab)
Persantine
approval from FDA to market, 19N(5)
intravenous, packaging of, 2023(le)
pH, chemical identity, pentavalent Tc-99m DMSA, 845
Pharmacy, nuclear, compounding of radioactive drugs, 548(le)
L-Phenylalanine, postinjection, basal ganglia contrast in PET, 6-^{18}F-DOPA, 1408
Pheochromocytoma
endocrine imaging, 1627
malignant, chemotherapy response, I-131 MIBG scintigraphy, 1044(ab)
Phosphatidylinositol, turnover, 1,2-C-11 diacylglycerol PET, 1097(ab)
Phosphorus trihydrazide complex, Technetium-99m, 1102(ab)
Photoaffinity, ligands, X-ray affinity labeling, dopamine transporter, 1839(ab)

Photon, attenuation by myocardium, ventricular ejection fraction, radionuclide ventriculography, 939(ab)
Physician Payment Review Commission (PPRC), Medicaid, 11N(9)
Phytate colloid, liver uptake, normals and patients with cirrhosis, 1467(le)
Pindolol, radioiodinated, animal brain and whole body distribution, 1140(ab)
Pituitary, adenoma, clinical evaluation, PET, 610
Planar imaging
attenuation measurements, optimization of transmission source collimation, SPECT, 986(ab)
511KeV with gamma camera, high-energy collimator, 986(ab)
mapping of three-dimensional brain surface MR image, 1002(ab)
Plasma
C-11 cocaine and F-18 NMS metabolites, robotic assay, 1088(ab)
clearance of Tc-99m MAG_3, single blood sample, 1105(ab)
renal flow, single-dose subcutaneous I-131 iodohippurate, 1452
separator and dynamic PET, cerebral oxygen metabolic rate, 1062(ab)
Plasma cell pseudotumor, inflammatory pseudotumor, gallium-avid mobile mesenteric mass, 1614
Plasminogen activator, tissue, In-111, rabbit thrombosis model, 461
Platelet activating factor, neutrophil margination in the lung, cigarette smoke, 990(ab)
Platelets
activated, *in vivo* thrombus labeling, Annexin-V, 928(ab)
thrombus quantitation on oxygenator and arterial filter, cardiopulmonary bypass, heparinized surface and iloprost infusion, 1048(ab)
Polylysine, Bolton-Hunter and biotin derivatized, pre-targeting, streptavidin conjugates, 993(ab)
Polymers, thermally structured conductivity, method, radiation dosimetry, 1130(ab)
Positron emission tomography (PET)
β-adrenergic receptor concentration, 989(ab)
advanced coron.. , artery disease, clinical outcome, 1011(ab)
AIDS, 1078(ab)
AIDS and nuclear medicine, 16N(7)
alteration of arterial input function, dipyridamole, 1040(ab)
animal studies, performance characteristics, 1064(ab)
anterograde flow on tissue viability, myocardial infarction, thrombolysis, 1039(ab)
applications in clinical oncology, 623, 649
ART acronym, 1833(le)
assessment of rates by HIAA, 56N(4)
attenuation of flow-glucose metabolism coupling, 910(ab)
brain, C-11 nicotine preparation, metabolite studies, 1095(ab)
C-11 acetate recirculation, myocardial oxygen consumption, 1950
C-11 alprazolam, cerebral uptake and retention, 1009(ab)
C-11 carfentanil, opiate *mu* receptor binding, Alzheimer's disease, 1079(ab)
C-11 CGP 12177, myocardial *beta* receptors, 927(ab)
1,2-C-11 diacylglycerols, phosphatidylinositol turnover, 1097(ab)
C-11 fentanil, opiate *mu* receptors, depression, 1078(ab)
C-11 flumazenil, benzodiazepine receptor binding parameters, 1062(ab)
C-11 L-methionine, diagnosis, gliomatosis cerebri, 726
C-11 methionine and fluorodeoxyglucose, non-Hodgkin's lymphoma, 1211
C-11 NN756, dopamine D1 receptor ligands, 934(ab)
C-11 pergolide, dopamine D3 receptor agonist, 934(ab)
C-11 PK 11195 binding, peripheral type benzodiazepine sites, gliobiastoma, 1608
C-11 pyrilamine, factor analysis, histamine H-1 receptors, 1071(ab)
C-11 raclopride, quantitation in striatum, 1838(ab)
L-[1-^{11}C]tyrosine, transport into human brain, 2043
C-11 YM-09151-2, D2 dopamine receptor-specific binding, brain, 713
C-14 leucine, myocardial protein synthesis, 1835(ab)
cancer evaluations with FDG, 1555
cardiac, 17N(11)
effect of metabolic milieu, F-18 deoxyglucose and N-13 ammonia, 1518
cardiac β-adrenergic receptor density, 739
cardiac blood-pool tracers, 480
cardiac polar maps, myocardial viability, semiquantitative assessment, 927(ab)
cerebral oxygen extraction fraction, brief inhalation method, 1738
cerebrovascular responsiveness to hypercapnia, Alzheimer's and Binswanger dementia, 1079(ab)
clinical, 561, 2351
Creighton University, 1134(ab)
clinical application, evaluation, brain tumors, 616
clinical aspects, 42N(4), 46N(4), 52N(4)
clinical evaluation of pituitary adenoma, 610
clinical role
cardiology, 606
metabolic imaging of heart, 565
compared to Tl-201 reinjection, metabolic activity, new fill-in, 673
computer-based interactive educational technique, 1134(ab)
copper blood-pool agents, 475
correction for resolution and wall motion effects, gated NMR imaging, 938(ab)
correction method, variation in axial recovery coefficient, 966(ab)
critically ischemic zone at risk, acute coronary occlusion, 1581
Cu-62 PTSM, quantification, myocardial perfusion, 937(ab)
3-D, conventional multi-slice tomograph without septa, 1062(ab)
data acquisition, algorithm, depth-of-interaction measurement information, 995(ab)
design and use of tomographs, slice spacing, 551(le)
dipyridamole N-13 ammonia, coronary flow reserve, hypertrophic cardiomyopathy, 1040(ab)
dipyridamole stress, left ventricular mass, myocardial perfusion, 2221
disease onset and MRI findings, metabolic asymmetries, asymptomatic seropositive HIV-1 patients, 1725
distribution of scattered coincidences, estimation, 996(ab)
dopamine D-2 receptors, modeling approach, *in vivo* concentration, 1004(ab)
dynamic
cerebral oxygen metabolic rate, on-line plasma separator, 1062(ab)
N-13 ammonia, myocardial blood flow, 926(ab)
registration of individual frames, reduction of head motion artifact, 966(ab)
dynamic cardiac, myocardial metabolic rate, glucose, 732
epilepsy, 651
evolution of, 15N(4)
extratemporal epilepsy, 912(ab)
F-18 altanserin
radiolabeling, *in vivo* biologic behavior in rats, 2266
serotonin S2 receptor imaging, 980(ab)
F-18 antimyosin antibody, myocardial imaging, 1030(ab)
F-18 deoxyglucose
advanced head and neck cancer, 920(ab)
glucose uptake, tumor proliferation, 1083(ab)
F-18 DOG, glucose uptake, resting myocardial perfusion defects, 1037(ab)
FDG
chemohormonotherapy assessment, breast cancer, 982(ab)
choroidal melanomas, 1050(ab)
decreased I-123 BMIPP uptake, enhanced glucose utilization, 1034(ab)
glucose loading, hypertrophic cardiomyopathy, 1039(ab)
head trauma, 1016(ab)
insulin substitution, quality of myocardial tissue viability studies, 988(ab)
malignant lymphoma, 686
murine lymphoma, 1043(ab)
myocardial glucose metabolism, coronary artery occlusion, 909(ab)
non-oxidative glycolysis, brain tumors, 931(ab)
ovarian cancer, 982(ab)
preliminary evaluation, brain metastases from non-CNS neoplasms, 954(ab)
primary CNS tumors, 932(ab)
prognosis, low-grade gliomas, 932(ab)
prognostic significance of augmented uptake, areas of myocardial infarction, 1039(ab)
recurrent colorectal tumors, radiotherapy, 1485
regional heterogeneity, myocardial glucose metabolism, 938(ab)
staging of axilla, breast carcinoma, 981(ab)
suspicious pulmonary and mediastinal masses, 961(ab)
Tl-201 SPECT with reinjection, previous myocardial infarction, 949(ab)
total body imaging, tumors of abdomen and pelvis, 982(ab)
typical scan pattern, Alzheimer's disease, 942(ab)
uptake in metastatic melanoma, quantitative analysis, 1838(ab)
F-18 FDG
coma and brain death, 1077(ab)
evaluation, parenchymal liver disease, 1000(ab)
histologic findings, recurrent brain tumors, 932(ab)
memory circuits in man, 1022(ab)
neurologic sequelae, decompression accidents, 1079(ab)
preoperative evaluation, intractable focal epilepsy, 912(ab)

radiotherapy response, pancreatic cancer, 1084(ab)
Rb-82, identification of viable myocardium, 968(ab)
F-18 fluconazole, candidal infections, rabbits, 1014(ab)
F-18 fluoride ion, bone metabolic rates, 1004(ab)
F-18 fluoroacylated biotin, fast localization of tumors, 1009(ab)
F-18 fluoroazomycin acyclonucleoside, hypoxic tumors, 1095(ab)
4-F-18 fluorobenzyl-ABV, marker, central cholinergic presynaptic sites, 994(ab)
F-18 6-(4′-fluorobenzylamino)-3-ethocycarbonyl-β-carboline, 1094(ab)
F-18 fluorodeoxyglucose
absorbed doses in humans, 699
response to cancer therapy, 1655
F-18 L-6-fluorodopa, reproducibility of striatal uptake, 1246
F-18 6-fluorodopamine, dosimetric estimates, 102
16α-[^{18}F]-fluoro-17β-estradiol, uptake, metastatic breast carcinoma, 1526
16β-F-18 fluoroestradiols, estrogen receptors, 995(ab)
21-[^{18}F]-fluoro-16α-ethyl-19-norprogesterone, progestin receptor detection, breast carcinoma, 1532
F-18 fluoromisonidazole, demonstration of hypoxia, human gliomas, 955(ab)
4-F-18-fluorotropapride
D2 receptor ligand, 935(ab)
specific D2 receptor ligand, 935(ab)
F-18 FTCP, excitatory amino acid neurotransmission, 1008(ab)
F-18 halothane and isoflurane, pharmacokinetics, 1072(ab)
F-18 ion, total body skeletal imaging, 1025(ab)
failure of compartmental models, high-affinity receptors, diffusion gradients, 1060(ab)
F-DOPA, various graphical analyses, estimation of influx constant, 1004(ab)
first comprehensive cost study, 56N(4)
first pass, early kinetic behavior, F-18 fluoropropylepidepride, 1063(ab)
6-fluorodopa, kinetics, 3-*O*-methyl-6-fluorodopa, 1007(ab)
β-fluoromethylene-m-tyrosine, striatal dopamine nerve terminals, primates, 1070(ab)
Ga-68 BAT-TECH, myocardial perfusion agent, 974(ab)
gated, regional wall thickening, left ventricle, 679
gated FDG, parameter estimation, cardiac geometry, 927(ab)
gated transmission source, 1134(ab)
glucose phosphorylation with FDG and PET, 692
glucose uptake and cell proliferation, 1548
high-rate high-resolution, lead sulfate, scintillator, 995(ab)
human heart, glucose-fatty acid cycle, 938(ab)
hurdles to technology diffusion, 660
hyperthermia-induced suppression, protein synthesis, tumors, 1587
I-124 3F8 monoclonal antibody, glioma, 1021(ab)
image reconstruction, incorporation, correlated structural images, 865(ab)
imaging human brain development, 23
influence of positioning, accuracy and precision, 1252
input function, tissue glucose utilization, thoracic and abdominal organs, 1432
interative image reconstruction algorithms, multigrid implementation, 1061(ab)
intercommissural line for stereotactic registration, automated detection, 966(ab)
interictal hypometabolism, MRI T2 increased signal, temporal lobe epilepsy, 912(ab)
inter-image comparison, scattergram technique, 1061(ab)
international, 26N(7)
international state, 28N(4)
in vivo imaging of sigma receptors, primate brain, 1071(ab)
labeled water and FDG, evaluation, musculoskeletal neoplasms, 962(ab)
L-(2^{18}F)fluorotyrosine, increased amino acid transport, brain tumors, 1338
ligands for labeling antibodies with cobalt, 1842(ab)
Lines from the President, post-anatomic imaging era, 16N(9)
lumped constant and glucose metabolic rate, normal and malignant brain, 1837(ab)
mapping heart cholinergic innervation, chiral C-11 benzovesamicols, 974(ab)
metabolic focal deficits, interindividual differences, image resolution, 1063(ab)
molecular medicine, from science to service, 14N(8)
monographs, surge in, 46N(4)
multiple 3-D volume realignment, measurement and presentation of images, 1065(ab)
multiple radiotracers, intracranial mass lesions, 954(ab)
multiprobe, multidetector time-of-flight positron coincidence detector, 1063(ab)
multi-slice scanners, fully 3-D reconstruction algorithms, 966(ab)
myocardial, reducing resolution distortions, region of interest strategies, 926(ab)
myocardial FDG uptake, treadmill stress, 1039(ab)
myocardial glucose utilization, euglycemic hyperinsulinemic clamp method, 988(ab)
myocardial metabolism of fluorodeoxyglucose, cell membrane integrity, Rb-82, 1
myocardial oxidative reserve, 988(ab)
myocardial viability, ischemic cardiomyopathy, 130
N-13 ammonia
hepatic arterial blood flow, 2199
myocardial uptake, copper pyruvaldehyde thiosemicarbazone, 999(ab)
neural network subserving picture comprehension, 1072(ab)
3-N-ω-[F-18]fluoroalkylated benperidol, mapping CNS dopaminergic receptors, 935(ab)
noninvasive grading, musculoskeletal tumors, 1508
noninvasive method for renal blood flow measurement, N-13 ammonia, 2-compartment model, 953(ab)
non-steady state conditions, regional cerebral blood flow, 910(ab)
OHTA assessment, 12N(9)
optimal efficiency in coronary disease detection, 1130(ab)
optimization of regional cerebral blood flow, 1934
O-15 water
brain activation, 58
coronary reserve, compared to intracoronary Doppler study, 998(ab)
input function, dynamic neck scan, 1003(ab)
parameter estimation method, stagewise maximization, input function noise, 1003(ab)
PCT-3600W, design and performance, 1061(ab)
performance and design features, animal studies, 1134(ab)
performance standards, 2342
perfusion imaging
nuclear cardiology and, 579
simple, one image arterial input function, 938(ab)
pharmaceuticals, FDA regulation, 12N(2)
photographic quality in literature, 1464(le)
planning and financing, 34N(4)
polar maps, perfusion defect extent, left ventricular function, 999(ab)
prediction of functional improvement, acute anterior ischemia, 1012(ab)
present and future directions, Tenth Annual SNM Mid-Winter Meeting, 24N(1)
primary extracranial head and neck tumors, fluorodeoxyglucose, 920(ab)
production of radionuclides, high current electrostatic accelerator, 1096(ab)
quadruple-tracer study, radiotherapy monitoring, 1083(ab)
quo vadis cardic, qualitative or quantitative studies, 1311(le)
radiation or chemotherapy effects, malignant lymphoma, 918(ab)
radionuclides, RFQ, high current, low energy He-3, 1140(ab)
radiopharmaceuticals, 52N(4)
radiopharmaceuticals research, 44N(4)
Rb-82
improved detection of myocardial ischemia, 998(ab)
Tl-201 SPECT or, myocardial perfusion imaging, 1133(ab)
recovery coefficient, 1062(ab)
regional and global tumor cerebral blood flow, adenosine, 932(ab)
regional lung water measurements, 719
regional ventilation pulmonary gas volume, theory and error analysis, 1937
regional water content, effective pH, Binswanger type encephalopathy, 1079(ab)
region of interest size, myocardial blood flow, glucose uptake, 1027(ab)
regulation of radiopharmaceuticals, 34N(4)
reimbursement, 12N(2)
reoriented dynamic, regional myocardial blood flow, N-13 ammonia, 909(ab)
reproducibility, 998(ab)
research, 23N(5)
segmented attenuation correction, 161
simultaneous emission and transmission scans, 154
SPECT and
sensitivity and specificity, Alzheimer's disease, 942(ab)
symbiotic developments, myocardial tomography, 166
super PET 3000-E, design parameters, dynamic cardiac imaging, 1838(ab)
synthesis of F-18 5-HT subtype 3 receptor antagonist, 1841(ab)
Tc-94m flow agents, 925(ab)
Tetalman Memorial Award, Kimberlee Kearfott, 22N(7)
therapy management in oncologic patients, 1084(ab)
thoracic oncology, 1138(ab)
three-dimensional registration, tomographic

whole body imaging, 1061(ab)
time to chart the brain, 17N(9)
total body imaging, FDG and F-18 ion, breast cancer, 981(ab)
tracer feasibility, monitoring tumor radiotherapy, 2118
variance improvement of attenuation coefficients, reconstruction-reprojection, 1060(ab)
variance of region-of-interest values, approximation formula, 996(ab)
viability, Tl-201 reinjection, ischemic/viable myocardium, 1835(ab)
which radiopharmaceutical for brain tumors, 1346
Posture, body, esophageal emptying, semi-solid bolus test meal, 930(ab)
Potassium, losses, malnutrition in AIDS, depletion of body cell mass, 1050(ab)
Pregnancy, adult female and fetus, radiation dosimetry, I-131 administration, 808
Probe
intraoperative, technical and clinical aspects, 987(ab)
non-imaging miniature, serial on-line left ventricular ejection fraction, 1038(ab)
Progesterone, F-18 fluorine labeled high affinity progestin, receptor-mediated uptake, uterine and mammary tumor tissue, 975(ab)
Progestin, -rhenium complexes, metal-based imaging agents, steroid receptors, 925(ab)
Prostate, -specific antigen and bone scan results, skeletal metastases, prostate cancer, 1082(ab)
Prostate serum antigen, correlation, histologic Gleason scores, prostate carcinoma, 977(ab)
Prostate-specific antigen
bone scintigraphy and, clinical utility, prostate cancer follow-up, 1387
utilization of bone scans, recurrence of adenocarcinoma, radical prostatectomy, 1713
Prostatic cancer, *see also* Carcinoma, prostatic
immunoscintigraphy and pharmacokinetics, In-111 CYT-356, 1054(ab)
metastatic, painful bone metastases, Re-186 HEDP, 1082(ab)
Prosthesis
joint, diagnosing infection, 2195(le)
vascular graft infection, Tc-99m HMPAO leukocytes, 1425
Protein
differential potassium and nitrogen losses, malnutrition in AIDS, depletion of body cell mass, 1050(ab)
hyperthermia-induced suppression of synthesis, tumors, PET, 1587
radiolabeling, phenylenediamine Schiff base bifunctional chelating agents, 1023(ab)
synthesis in myocardium, PET, C-14 leucine, 1835(ab)
Protein-losing enteropathy, abdominal scintigraphy, Tc-99m human serum albumin, 924(ab)
Proteinuria, lowered serum albumin levels and, Tc-99m MAG_3 clearance, effective renal plasma flow, 1709
Protooncogenes, c-*erb*B-2, advanced cancer patients, 1087(ab)
Pseudotumor, inflammatory, gallium-avid mobile mesenteric mass, 1614
Psychiatry
correlation of CERETEC SPECT findings, beam and clinical findings, 1137(ab)
refractory unipolar depression, regional cerebral blood flow, Tc-99m HMPAO SPECT, 951(ab)
unipolar depression, regional cerebral blood flow alterations, 951(ab)
Pulmonary embolism
clinical management, lower extremity radionuclide venography, 1087(ab)
computer-assisted diagnosis, ventilation-perfusion lung imaging, 1837(ab)
decision analysis approach, 2050, 2056
high hopes for Technegas, 25N(11)
likelihood, increasing size of pleural effusions, 950(ab)
lobar distribution, PIOPED study, 950(ab)
localization and visualization, radiolabeled fibrin-specific monoclonal antibody, 1254
lung MR imaging, contrast enhancement, 1081(ab)
matching pleural effusions, lung scan perfusion defects, 950(ab)
suspected
decision analysis approach, intermediate probability lung scan, 950(ab)
normal chest radiograph, ventilation/perfusion scans, 950(ab)
Pump, Novacor left ventricular assist device, blood-pool radionuclide angiography, 255
4-Pyridylsulfide, thiol protecting group of MAG_3, labeling antibody-MAG_3 conjugate with Tc-99m, 1024(ab)

R

Race, body composition, 1105(ab)
Raclopride
low specific activity, receptor density calculation, dopamine receptors in living human brain, 961(ab)
6-O-F-18 fluoroalkylated analogues, mapping cerebral D2 receptors, PET, 1095(ab)
Radiation
cancer findings hotly disputed, Oak Ridge National Laboratory, 11N(7)
effects
Chernobyl, assessment by U.S. and IAEA delegations, 11N(3)
malignant lymphoma, F-18 FDG PET, 918(ab)
respiratory functions, mitochondrial DNA, 1043(ab)
environmental, ash from firewood, 28N(10)
exposure four years after Chernobyl, physical and biological evidence, 1018(ab)
hormesis, 350
injury from interstitial injection, I-131 iodocholesterol, 892(le)
ionizing, BERT unit, 26N(1)
lower exposure limits, NRC and ICRP, 28N(5)
media coverage, bias against negative findings, 25N(12)
necrosis, Tl-201 and Tc-99m DTPA brain SPECT, 1137(ab)
protection, radiobiology, 57
safety considerations, post-iodine-131 hyperthyroid therapy, 169
synovectomy
evaluation of new radiopharmaceuticals, 963(ab)
glass Sm-153 microspheres, 945(ab)
specific linker technology, microspheres labeled with albumin, 964(ab)
therapy for hepatic tumors, neutron-activated Ho-166 poly L-lactic acid, 2139
therapy response, F-18 FDG PET, pancreatic cancer, 1084(ab)
workers, relation of economic status, death risk, 22N(2)
Radiation dose
absorbed dose calculations, Sm-153 EDTMP, bone, 840
adult female and fetus, I-131 administration, hyperthyroidism, 808
biodistribution, Tc-99m T2G1s antifibrin, 1042(ab)
bladder wall, 2-[^{18}F]FDG, adult humans, 707
distribution of monoclonal antibodies, tumors, heterogeneity, 1055(ab)
estimates of Tc-99m mercaptoacetyltriglycine, children, 1017(ab)
In-111 DTPA-D-PHE octreotide, somatostatin receptor-positive tumors, 1043(ab)
intraperitoneally administered I-131 B72.3, peritoneal carcinomatoses, 1661
normal human biodistribution, Tc-99m polyclonal human IgG, 1099(ab)
O-15 butanol and O-15 water, PET, normal volunteers, 1043(ab)
thermally stimulated conductivity in polymers, 1130(ab)
Radioactive drugs, compounding, nuclear pharmacist's role, 548(le)
Radioactivity, discharges and cancer, 1827(le)
Radioaerosol
clearance, experimental pulmonary contusion, 990(ab)
release during ventilation studies, 1133(ab)
Radioassay
circulating c-*erb*B-2 protooncogene products, advanced cancer patients, 1087(ab)
receptor-ligand binding, 1182
validation of *in vivo* receptor measurements, Tc-99m galactosyl-neoglycoalbumin, 1177
Radiocesium, levels in humans over four-year period, 1491
Radiochemistry, Canadian program to train chemists, radiopharmacy techniques, 23N(2)
Radiography, skeletal angiomatosis limited to hand, 1912
Radioimmunity, bone marrow, 549(le)
Radioimmunoassay
Berson-Yalow Award to Dr. Philip D. Nicol, 22N(6)
CA 15-3, scintigraphic radiologic and clinical correlation, breast cancer, 1132(ab)
cyclosporine, prediction of nephrotoxicity, heart transplant, 977(ab)
single monoclonal synthetic peptide, cardiac ventricular myosin light chain, 977(ab)
Radioimmunoconjugates, Re-186 radiolabeled small molecule metabolites, 915(ab)
Radioimmunodetection
degranulated eosinophils, Hodgkin's disease, 89
neuroblastoma, I-131 MIBG, standard diagnostic modalities, 769
Radioimmunoimaging, recombinant antibody-metallothionein, labeling with Tc-99m, 915(ab)
Radioimmunolocalization, anti-ganglioside antibody, GD2 ganglioside, imaging considerations, 970(ab)
Radioimmunoscintigraphy, choroidal melanomas, 1050(ab)
Radioimmunotherapy
advantage of protecting antigen-binding site, antibody labeling, 122
canine xenografts, Mallinckrodt fellowship, 17N(6)
dosimetry, body activity correction method, 997(ab)
higher immunoreactive fraction, antigen-binding site protection, radiolabeling, 116

I-131 chimeric monoclonal antibody, advanced metastatic breast cancer, 922(ab)
I-131 monoclonal antibody CC49, metastatic colorectal carcinoma, 1051(ab)
iridium-194, osmium-194/iridium-194 generator system, 1089(ab)
α-particle, CHX-DTPA synthesis, Rauscher leukemia virus, 1056(ab)
tumor dosimetry, terminal portion, tumor time-activity curve, 1314(le)
Radioiodide, therapy of benign thyroid disease, optimized dose planning, 1044(ab)
Radioiodination
highly specific sigma receptor ligand, SPECT imaging agent, 1841(ab)
lipophilic probe, synthesis and evaluation, cell tracking, 1092(ab)
monoclonal antibodies, influence of protein dose, tumor distribution, 1058(ab)
oligonucleotides, new conjugation technique, activated methoxy phenylisothiocyanate, 1092(ab)
pindolol, animal brain and whole body distribution, 1140(ab)
synthesis and radiolabeling of "tyrosyl-ETAC", 915(ab)
tyramine-cellobiose, improved treatment, leukemia, 1843(ab)
Radioiodine, enhancement of therapy, hyperthyroidism, dosimetric methodology, 1017(ab)
Radiolabeling, anti-retroviral probes, 28N(7)
Radioligands, high affinity dopamine D2 receptor, iodinated benzamides, 1593
Radiolysis, sensitivity of Tc-99m D,L-HMPAO, aqueous solutions, 111
Radionuclide angiography, Tc-99m erythrocytes, no mutations, HPRT gene of human T-cells, 814
Radionuclides
confirmation of short solid-food lag phase, continuous monitoring, gastric emptying, 1349
α-cyclohextrin, 1091(ab)
determination of peritoneal-pleural communication, hydrothorax, 924(ab)
diagnosis of vertebral osteomyelitis, In-111 leukocyte and Tc-99m MDP, bone scintigraphy, 1861
esophageal transit, usefulness, 1310(le)
evolution of positron emission tomography, 15N(4)
first-pass and gated, systolic left ventricular function, 1801
glomerular filtration rate, endogenous creatinine clearance, non-insulin dependent diabetes mellitus, 1105(ab)
improved technique, detection, altered pulmonary permeability, 1945
internally deposited, absorbed dose calculations, blood and blood vessels, 830
main medical reactor shuts down, Nordion International, 30N(3)
microvascular right-to-left pulmonary shunt, 139
monitoring of cardiac function and ST-segment, characteristics, 2194(le)
PET
production of, high current electrostatic accelerator, 1096(ab)
RFQ, high current, low energy He-3, 1140(ab)
positron-emitting, nuclear cardiology, PET perfusion imaging, 579
probabilistic image segmentation, 1060(ab)
scintigraphy, receptors on tumors, 1189
simultaneous data acquisition, Monte Carlo estimation, scatter component, 1059(ab)
small tissue volumes, estimates, beta absorbed fractions, 835
therapeutic, production and decay property considerations, 174
venography, 1129(ab)
Radiopharmaceuticals
cardiac blood-pool scintigraphy, rats and hamsters, 851
clinical role of metabolic imaging of heart, PET, 565
copper blood-pool agents, 475
design of, applications, computational chemistry, 1139(ab)
development of, 2361(le)
evaluation for radiation synovectomy, 963(ab)
I-123 ANF, atrial natriuretic factor receptor imaging, 973(ab)
imaging of venous thrombosis, 791
Lines from the President, post-anatomic imaging era, 16N(9)
metal-based, hexachelating $N_2O_2P_2$, 1103(ab)
PET
brain tumors, 1346
FDA and, 52N(4)
regulation of, 34N(4)
research in, 44N(4)
pilot research grant, anti-tumor, anti-viral agents, 29N(6)
review, 12N(9)
Schiff base ligands, 1101(ab)
single, left ventricular perfusion, one camera, 929(ab)
study of I-123 L-AMT transport, 819
swifter regulatory approval, 21N(12)
Tc-99m- and In-111 low-density lipoproteins, metabolic imaging, 925(ab)
Tc-99m-labeled, estimation, weighted effective dose, 1835(ab)
use of radioiodinated somatostatin analogue, 1184
Radiopharmacy
petition
NRC advisory committee, narrowed QA rule, 21N(3)
NRC response to SNM queries, 28N(5)
Radiophosphate, uptake, asymptomatic porous-coated hip endoprostheses, 1391
Radiosensitizers, 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole, marker of tissue hypoxia, 1764
Radiotherapy
fluorodeoxyglucose PET, recurrent colorectal tumors, 1485
local external beam, Strontium-89 as adjuvant, 918(ab)
malignant glioma recurrence, quantitative estimation, 933(ab)
monitoring, quadruple-tracer study, 1083(ab)
pre-operative, renal cell carcinoma, Sm-153 activatable glass microspheres, 1089(ab)
strontium-89, dose estimation, metastasized prostatic carcinoma, 997(ab)
tumor, tracer feasibility, 2118
tumor monitoring, 2124
Radiotracers
design of, computational aids, vesamicol receptor, 1089(ab)
I-123 IDDE, dopaminergic function, 1092(ab)
multiple, intracranial mass lesions, PET, 954(ab)
three, assessment, myocardial infarction, 2360(le)
Radon
easing fears, 22N(7)
household, lung cancer risk overestimated, 24N(7)
Receptors
adrenergic
Adriamycin cardiomyopathy, adrenergic neuron damage, 1029(ab)
cerebral uptake, radiolabelled MIBG, 992(ab)
β-adrenergic
C-11 carazolol, 1097(ab)
concentration in humans, PET, 989(ab)
androgen, 20-F-18 fluoromibolene, synthesis and tissue distribution, 81
atrial natriuretic factor, imaging with I-123 ANF, 973(ab)
benzodiazepine
binding parameters, C-11 flumazenil PET, 1062(ab)
C-11 PK 11195 PET, glioblastoma, 1608
I-123 RO 16-0154 SPECT, 1043(ab)
potency, SPECT application, 1762
regional glucose metabolism, refractory temporal lobe epilepsy, 912(ab)
SPECT, potency measurement, 979(ab)
stepwise displacement curves, SPECT, 1754
beta
myocardium, C-11 CGP 12177 PET, 927(ab)
scintigraphic portrayal, heart, 1399
beta adrenergic, CGP12177 *vs.* I-125 CYP, heart, 1028(ab)
binding ligands, equilibrium dissociation constants, 1004(ab)
cardiac β-adrenergic, density, PET/CGP 12177 and new method, 739
concentration and forward-binding rate constant, radiopharmacokinetic modeling, Tc-99m galactosyl-neoglycoalbumin, 1169
density calculation, raclopride effects, dopamine receptors in living human brain, 961(ab)
dopamine
agonist C-11 pergolide, PET, 934(ab)
fenoldopam, renal artery stenosis, 933(ab)
X-ray affinity labeling, photoaffinity ligands, 1839(ab)
dopamine D1, I-123 TISCH, 1069(ab)
dopamine D2
amphetamine-induced dopamine release, I-123 IBZM binding competitions, 1007(ab)
C-11 YM-09151-2 binding in brain, PET, 713
dynamic I-123 IBZM SPECT, normals, 1078(ab)
F-18 and C-11 labeled amphetamine, 994(ab)
F-18 fluoropropylepidepride, primate and human studies, 1070(ab)
I-123 IBF, 1008(ab)
I-123 IBZM, hemi-Parkinsonism, 1070(ab)
I-123 IBZM SPECT, Parkinsonian syndromes, 1014(ab)
ligand for PET, 4-F-18 fluorotropapride, 935(ab)
modeling approach, *in vivo* concentration, 1004(ab)
6-O-F-18 fluoroalkylated analogues, raclopride, 1095(ab)
radioligands, iodinated benzamides, 1593
Rett syndrome, I-123 ILIS SPECT, 1015(ab)
dopaminergic, mapping, 3-N-ω-[F-18]fluoroalkylated benperidol, 935(ab)
estrogen
16α-[^{18}F]-fluoro-17β-estradiol PET, metastatic breast carcinoma, 1526
fluorodeoxyglucose uptake, before and after stimulation, 1011(ab)
novel PET imaging agents, 16β-F-18 fluoroestradiols, 995(ab)
extrastriatal dopamine D2, post-mortem studies, 961(ab)

hepatic, hepatic blood flow, Tc-99m DTPA-galactosyl-HSA, 2233
high-affinity, failure of compartmental models, diffusion gradients, 1060(ab)
histamine H1
C-11 pyrilamine, imaging in living brain, 308
factor analysis of C-11 pyrilamine, PET, 1071(ab)
mapping in brain, C-11 pyrilamine, 1069(ab)
5-HT2, 2-I-123 ketanserin, depression, 952(ab)
5-HT subtype 3, synthesis of antagonist, 1841(ab)
-ligand binding, *in vivo* assay, 1182
measurements via *in vitro* radioassay, Tc-99m galactosyl-neoglycoalbumin, 1177
muscarinic, I-125 quinuclidinyl esters, SPECT, 1093(ab)
muscarinic cholinergic
binding, I-123 IDEX, 1097(ab)
4-I-125 iododexetimide, heart, 76
quantification, aging and Alzheimer's disease, 942(ab)
quantification in brain, I-123 4-iododexetimide SPECT, 980(ab)
opiate *mu*
depression, PET and C-11 carfentanil, 1078(ab)
reduced binding in amygdala, Alzheimer's disease, 1079(ab)
progesterone, F-18 fluorine high affinity progestin, uterine and mammary tumor tissue, 975(ab)
progestin, 21-[^{18}F]-fluoro-16α-ethyl-19-norprogesterone PET, breast carcinoma, 1532
serotonin
F-18 altanserin PET, 2266
radioiodinated N1-alkyl-2-iodo-LSD, 964(ab)
serotonin S2, F-18 altanserin PET, 980(ab)
sigma
in vivo imaging, primate brain, 1071(ab)
radioiodination of ligand, SPECT agent, 1841(ab)
somatostatin
endocrine imaging, 1627
In-111 DTPA-D-Phe-Octreotide, tumors, 1084(ab)
tumors, radiation dosimetry of In-111 DTPA-D-PHE octreotide, 1043(ab)
use of radioiodinated analogue, 1184
steroid, metal-based imaging agents, progestin-rhenium complexes, 925(ab)
tumors, radionuclide scintigraphy, 1189
vesamicol
computational aids, radiotracer design, 1089(ab)
mapping, I-125 IPPE, 1092(ab)
Red blood cells
denatured, residual spleen, negative colloid scans, 2286
incubation, extraction of Tc-99m TEBO, rabbit heart, 910(ab)
in vitro labeling, Ultra Tag RBC kit, *in vivo* labeling, 242
novel *in vivo* label, 2025(le)
survival times, reference values, 2245
Reference range, determination, problem of small sample sizes, 2306
Reflex sympathetic dystrophy syndrome, staging, vascular tracers *vs.* bone tracers, 1026(ab)
Reflux, duodenogastroesophageal, modified scintigraphic method, 436
Regional wall motion
abnormal in patients with coronary disease, improvement with hyperventilation, 939(ab)
abnormality, glucose uptake and resting myocardial perfusion defects, Tc-99m MIBI SPECT/F-18 DOG PET, 1037(ab)
bullseye polar map display, gated cardiac pool SPECT, LV regional asynergy, 1037(ab)
correction of cardiac PET/SPECT for resolution, gated NMR imaging, 938(ab)
discrepancies, stress images, Tl-201 and Tc-99m sestamibi, 1036(ab)
left ventricular, radionuclide ventriculography, 777
myocardial tissue fraction, correction for partial volume effects, measure of tissue viability, 2169
relationship to 4 hour reinjection thallium uptake, 1032(ab)
Renal artery
stenosis
captopril-enhanced renal scintigraphy, Tc-99m MAG_3, 934(ab)
fenoldopam, 933(ab)
Renal cells, galactose-bound human serum albumin, suppression of uptake, radiolabeled antibody, 1054(ab)
Renin, plasma activity, pre post captopril, Tc-99m MAG_3 renography, 934(ab)
Renin-angiotensin system, positron-labeled ACE inhibitor, F-18 fluorocaptopril, 1730
Renography
ACEI, verapamil effect, 933(ab)
captopril, noninvasive screening test, hypertension secondary to renal artery stenosis, 1107(ab)
diuresis
evaluation of hydronephrosis, newborns, 943(ab)
standardized protocol in neonates, hydronephrosis, 943(ab)
Tc-99m MAG_3, pre post captopril, renal angiography and plasma renin activity, 934(ab)
Resource-Based Relative Value Scale (RBRVS)
government relations update, SNM/ACNP, 11N(2)
Medicare fee schedule and, 11N(9)
specialties united against rules, 24N(8)
Resource Conservation and Recovery Act (RCRA), consideration for reauthorization, 14N(2)
Restenosis, porcine model, In-111 platelet deposition, coronary artery injury, 1029(ab)
Retroperitoneal fibrosis, Ga-67, significance of negative result, 521
Rett syndrome, increase of striatal dopaminergic D2 receptor, I-123 ILIS SPECT, 1015(ab)
Rhabdomyosarcoma, hyperthermia-induced suppression, protein synthesis, PET, 1587
Rhenium, -progestin complexes, metal-based imaging agents, steroid receptors, 925(ab)
Rhenium-186
pharmacokinetics, after Re-186 HEDP, metastatic bone cancer, 1083(ab)
radiolabeled small molecule metabolites, radioimmunoconjugates, 915(ab)
triamenedithiol ligands, bifunctional chelating agents, 985(ab)
Rhenium-186 antibodies, improved targeting, cleavable N_3S-hydroxyl ester, 1020(ab)
Rhenium-186 HEDP
EXAPS and WAXS structural characterization, palliation of pain, metastatic bone disease, 1089(ab)
treatment of painful bone metastases, metastatic prostate or breast cancer, 1082(ab)
Rhenium-186 monoclonal antibodies, preparation and evaluation, 1098(ab)
Rhenium-186(Sn)HEDP
treatment of painful osseous metastases, double-blind crossover with placebo, 1877
treatment of painful skeletal metastases, double-blind crossover comparison with placebo, 963(ab)
Rhenium-188
in-house W-188/Re-188 generator, preparation, monoclonal antibodies, 1098(ab)
-W-188 gel generator, potential for production, natural tungsten target, 1090(ab)
Rhenium-188 perrhenic acid, tandem generator/ion exchange system, 945(ab)
Rheumatic fever, Tc-99m HMPAO labeled WBC scan, 1041(ab)
Rheumatoid arthritis
mild-moderate hepatotoxicity, methotrexate, 1048(ab)
Tc-99m human unspecific immunoglobulin, 983(ab)
Rhinoplasty, early assessment of nasal bone graft viability, bone scan, 33
Rhodium-BA-2,3,2-TET, discrimination between geometric isomers, monoclonal antibodies, 914(ab)
Ribose
detection of reversible Tl-201 defects, 2027(le)
facilitation of Tl-201 redistribution, coronary artery disease, 193
RNA, messenger, In-111 labeled probes, conjugation of DTPAisothiocyanate with anti-sense oligonucleotides, 1089(ab)
Robotics, automated synthesis, 23N(4)
ROC analysis, tumor detect ability, Tc-99m MIBI and Tl-201, bronchial carcinoma, 961(ab)
Rubidium-82
cell membrane integrity, myocardial metabolism, fluorodeoxyglucose, 1
F-18 FDG PET and, identification, viable myocardium, 968(ab)
kinetics and FDG uptake, previous myocardial infarction, 1012(ab)
PET
improved detection of myocardial ischemia, 998(ab)
perfusion imaging, nuclear cardiology, 579
Tl-201 SPECT or, myocardial perfusion imaging, 1133(ab)

S

Safe Medical Device Act of 1990
FDA enforcement, combination products, 21N(12)
reporting requirements, 12N(9)
signed into law, 13N(2)
Salinity, Tl-201 distribution in American lobsters, 1105(ab)
Samarium-153
activatable glass microspheres, pre-operative radiotherapy, renal cell carcinoma, 1089(ab)
glass microspheres for radiation synovectomy, 945(ab)
labeled hydrogel beads, activity selection and dosimetry, gastrointestinal transit, 997(ab)
Samarium-153 EDTMP
bone imaging agent, therapeutic trial, 918(ab)
radiation absorbed dose calculations, bone, 840
Sample size, small, reference range determination, 2306
Sarcoidosis
muscular
fever of unknown origin, Ga-67 imaging, 319
three-phase bone scan, 1829(le)
Scandium-47, carrier-free, preparation of, 945(ab)
Scatter correction

attenuation and, SPECT, sources in nonhomogenous object, 1278
attenuation correction and, Tc-99m sestamibi SPECT, myocardial distributions, 1067(ab)
Compton
position-dependent energy spectrum acquisition, 1069(ab)
regularized energy-spectral fitting-deconvolution method, 916(ab)
dual photopeak window, 917(ab)
experimental evaluation of cross-plane scattering, 995(ab)
Klein-Nishina based energy factors, Compton free imaging, 1000(ab)
Monte Carlo estimation, simultaneous data acquisition, two radionuclides, 1059(ab)
multiplier, region of interest selection, dual-window Compton correction, 186
PET performance standards, 2342
response function in SPECT, infinite slab and object geometry, 1065(ab)
Schiff base
complexes, tetradentate thioiminato, 1843(ab)
ligands, radiopharmaceutical imaging agents, 1101(ab)
Schizophrenia
antisaccade task, O-15 water assessment, 952(ab)
sustained attention, brain SPECT, 1076(ab)
Scintigraphy
abdominal, protein-losing enteropathy, Tc-99m human serum albumin, 924(ab)
adenosine and exercise, lung Tl-201 uptake, CAD, 1030(ab)
adenosine thallium myocardial, compared to IV dipyridamole, 969(ab)
adenosine Tl-201
asymmetric renal uptake, renovascular disease, 1104(ab)
increased lung uptake, coronary artery disease, 979(ab)
risk reduction, severe arrhythmia, 978(ab)
adherence of Tc-99m sucralfate to oral microlesions, 1465(le)
aerosol, therapy for cystic fibrosis, 1139(ab)
angiography, acute gastrointestinal hemorrhage, 1601
antimyosin
myocarditis, 1019(ab)
myocarditis simulating MI, 312
benefit of tomography, cerebrospinal fluid leak, 2149
bone
art of, technical aspects, 2332
chronic low back pain, SPECT, 913(ab)
evaluation, talar dome fractures, 2241
In-111 leukocytes and Tc-99m MDP, vertebral osteomyelitis, 1861
metastases detection, small cell lung cancer, 962(ab)
prostate-specific antigen, prostate cancer follow-up, 1387
spectrum of lymphoma presentations, 1129(ab)
cardiac blood-pool, pinhole collimator, rats and hamsters, 851
colon transit, comparison, I-131 cellulose and In-111 DTPA, 1668
coronary thrombus, uptake, antifibrin monoclonal antibody, 1005(ab)
diagnosing inflammations/infections, In-111 nonspecific human IgG, 2227
esophageal, 1371
manometry, multiple swallow investigations, 931(ab)
motility disorders, multiple swallow test, 1365
exercise SPECT Tl-201, cardiac transplantation, myocardial hypoperfusion, 1041(ab)
Ga-67
detection of mediastinitis, after heart transplantation, 860
management of patients, malignant lymphoma, 2299
predictor of response, lymphoma treatment, 1084(ab)
gallbladder function, vagotomy, Tc-99m DISIDA, 1131(ab)
gated blood pool, left ventricular function curve, atrial fibrillation, 1042(ab)
hepatobiliary
after surgical treatment, congenital biliary atresia, 1047(ab)
cystic disease, 944(ab)
papillary stenosis, 1131(ab)
pericardial fistula, 518
Tc-99m mebrofenin, liver transplantation, 999(ab)
I-123 Tyr^3-octreotide, neuroendocrine tumors, 981(ab)
I-131 MIBG, response to chemotherapy, malignant pheochromocytoma, 1044(ab)
In-111 anti-CEA monoclonal antibody, suspected primary lung cancer, 2064
In-111 antimyosin, non-invasive monitoring, heart transplantation, 971(ab)
In-111 IgG, infected joint arthroplasty, 963(ab)
In-111 labeled lymphocyte, non-Hodgkin lymphoma, 917(ab)
In-111 transferrin, colorectal cancer, 1084(ab)
In-111 WBC infection localization, clinical experience, Tc-99m HMPAO-WBC, 1049(ab)
long-term bone, parathyroidectomy, chronic renal osteodystrophy, 983(ab)
lung perfusion, transbronchial biopsy after lung transplant, 1841(ab)
management of inflammatory bowel disease, 856
modified method, duodenogastroesophageal reflux, 436, 2027(le)
morphine injection, acute cholecystitis, 1233
myocardial perfusion, markedly positive exercise tests, 1035(ab)
myocardial uptake, I-123 MIBG and Tl-201 chloride, hypertrophic cardiomyopathy, 1040(ab)
noninvasive assessment of colonic transit, nondigestible solids, man, 1375
portrayal of beta receptors in the heart, 1399
postoperative complications, laparoscopic cholecystectomy, 1910
quantitative bone, bone turnover and loss, hyperparathyroidism, 982(ab)
radioiodide, recurrent thyroid cancer, MRI detection, 1011(ab)
radioiodinated somatostatin analog, small cell lung cancer, 1845
radiologic and clinical correlation, CA 15-3 RIA values, breast cancer, 1132(ab)
radionuclide, receptors on tumors, 1189
renal
captopril, simple visual criteria, 933(ab)
captopril, Tc-99m MAG_3, 934(ab)
right ejection fraction, 429
serial bone, duration, etidronate effect, 1782
skeletal, detection, urinary tract abnormalities, 11409ab)
skeletal angiomatosis limited to hand, 1912
spectrum of findings, periostitis, 1129(ab)
stress redistribution Tl-201, ambulatory electrocardiography, patient population factors, 958(ab)
superiority of bone marrow immunoscintigraphy, skeletal metastases, prostatic and renal carcinoma, 1052(ab)
systematic bone reactions to fracture, 914(ab)
Tc-99m antifibrin
acute deep venous thrombosis, 1020(ab)
diagnosis, acute recurrent deep venous thrombosis, 967(ab)
Tc-99m glucaric acid, myocardial infarction, 263
Tc-99m MDP, pachydermoperiostosis, 1907
Tc-99m MIBI, localization, recurrent medullary thyroid carcinoma, 2281
Tc-99m pertechnetate, columnar-lined esophagus, 930(ab)
thallium myocardial, congenitally-corrected transposition, great arteries, 1611
thallium technetium, endocrine imaging, 1627
three-phase bone, In-111 chloride, osteomyelitis, 67
thyroid cancer, 1463(le)
Tl-201
lymph node metastasis, parathyroid carcinoma, 1044(ab)
myocardial perfusion, arterial switch operation, 237
prediction of restenosis, coronary angioplasty, 959(ab)
radionuclide scintigraphy comparison, serum thyroglobulin, 441
serum thyroglobulin and, follow-up of thyroid cancer, 2098
whole body, peripheral vascular disease, contrast arteriography, 1041(ab)
Scintillation camera, left ventricular perfusion, single radiopharmaceutical, one camera, 929(ab)
Scintillator, lead sulfate, high-rate high-resolution PET, 995(ab)
Sclerosis, systemic, left ventricular diastolic function, 1042(ab)
Seizures
generalized absence, C-11 diprenorphine, 960(ab)
investigation, 17N(11)
Selenium-75 homocholic acid, taurine test reevaluated, 1219
Serotonin
dopamine BMAX, C-11 NMSP, unified estimation procedure, 1008(ab)
ligand, synthesis and preliminary evaluation, 2′′-I-125 iodoparoxetine, 965(ab)
receptor study with PET, F-18 altanserin, 2266
reuptake sites, radioiodinated analogs of fluoxetine, SPECT, 964(ab)
Sestamibi, teboroxime and, review of cardiac imaging, 2012
Sex, body composition, 1105(ab)
Shunt
fraction estimation, transcolonic I-123 IMP and Tc-99m pertechnetate, chronic biliary cirrhosis, 124
left-to-right cardiac, improved method, quantification, 1808
microvascular right-to-left pulmonary, radionuclide method, 139
portosystemic, inferior and superior mesenteric veins, I-123 IMP, 1047(ab)
Single photon emission computed tomography (SPECT)
acetazolamide-enhanced, cerebral perfusion, carotid endarterectomy, 971(ab)
acquisition, effect, differential tracer washout, 2253
adenosine

exercise SPECT Tl-201 imaging, multi-center trial, 968(ab)
Tl-201 and, reinjection technique, 979(ab)
adenosine and exercise Tl-201, single vessel CAD, jeopardized myocardium, 969(ab)
AIDS and nuclear medicine, 16N(7)
algorithms, energy-distance principle, 916(ab)
application to *in vivo* measurement, benzodiazepine potency, 1762
artifacts and, in search of imaginary lesion, 875
artificial neural network for lesion detection, 986(ab)
benzodiazepine receptor
potency measurement, stepwise displacement curves, 979(ab)
stepwise displacement curves, 1754
benzodiazepine receptor ligand I-123 RO 16-0154, *in vivo* distribution in man, 1043(ab)
body contour orbit, negative effect, spatial resolution, 1067(ab)
bone
evaluation of femoral allograft, spine, 913(ab)
hip-head-necrosis, pedicled pelvic bone graft, 1027(ab)
bone scintigraphy, chronic low back pain, 913(ab)
brain
chronic vestibular dysfunction, 1075(ab)
radioiodinated analogs of clorgyline, mapping MAO-A activity, 1091(ab)
simultaneous dual-tracer, Tc-99m HMPAO and I-123 IMP, 956(ab)
simultaneous emission data acquisition, 1066(ab)
sustained attention, schizophrenia, 1076(ab)
brain injury, hyperbaric oxygen therapy, 1840(ab)
brain perfusion reserve, acetazolamide test, Tc-99m HMPAO, 1074(ab)
bulls-eye analysis, non-uniform attenuation compensation, myocardium, 1839(ab)
bullseye technology, ischemic region size, short axis edge detection, 1027(ab)
cardiac
gated NMR imaging, resolution and wall motion effects, 938(ab)
reconstruction with attenuation, geometric point response correction, 916(ab)
causes of count loss artifacts, 1771
CERETEC
beam and clinical findings, psychiatric patients, 1137(ab)
complex visual reasoning stimulus, cerebral blood flow, 1137(ab)
circular harmonic transform algorithm, 141
combined cone beam, parallel hole collimation, 956(ab)
Compton scatter correction, position-dependent energy spectrum acquisition, 1069(ab)
delayed Tl-201 myocardial, normalization of stress, normal reference area, 1901
depth-weighted maximum projection, computational aspects, 1462(le)
determination of cardiac volumes, 946(ab)
dual-isotope, resting rCBF, cerebrovascular reserve, 972(ab)
dynamic
blood-brain permeability measurement, I-123 IMP/Tc-99m HMPAO/Tc-99m ECD, 911(ab)
feasibility studies, 955(ab)
dynamic brain, intracerebral kinetics, Tc-99m ECD, 991(ab)
early and delayed, Tc-99m ECD *vs.* I-123 IMP, subacute stroke, 971(ab)
energy-weighted acquisition, determination, weighting functions, 343
exercise Tl-201, arteriopathy, orthotopic heart transplant, 1041(ab)
exercise Tl-201 scintigraphy, cardiac transplantation, myocardial hypoperfusion, 1041(ab)
finite resolution effects, use of MR images, cerebral cortex, 985(ab)
fusion with structural CT/MRI images, 1135(ab)
gallium-, prosthetic valve endocarditis, aortic ring abscess, 1791
gated, three-dimensional motion, perfusion quantification, 2311
gated cardiac pool, bullseye polar map display, wall motion, 1037(ab)
Gibbs prior distributions, different count densities, maximum a posteriori reconstruction, 1066(ab)
hepatobiliary, ESWL, regional hepatic change, 1000(ab)
high-resolution three-headed, improved detection, small cavernous hemangiomas, 2086
HMPAO
Kleffner-Landau syndrome, 1015(ab)
MRI and, acute disseminated encephalomyelitis, 1897
HMPAO brain uptake, test-retest results, 991(ab)
human immunodeficiency virus encephalopathy, 1471
I-123
alcohol dependence, 1075(ab)
severe carotid artery stenosis, transient ischemic attacks, 972(ab)
I-123 IBZM, dopamine D2 receptors, normals, 1078(ab)
I-123 IBZM, dopamine D2 receptors, Parkinsonian syndromes, 1014(ab)
I-123 ILIS, increase of striatal dopaminergic D2 receptor, Rett syndrome, 1015(ab)
I-123 IMP
cerebral blood flow, global extraction between artery and internal jugular vein, 1080(ab)
hepatic encephalopathy, 1074(ab)
semi-quantitative, late onset before and after treatment, 952(ab)
I-123 IMP and Tc-99m HMPAO, brain, dementia/stroke, 1073(ab)
I-123 IMP redistribution in brain, effects of visual stimulation, 1866
I-123 4-iododexetimide, quantification, muscarinic cholinergic receptors, 980(ab)
I-123 TISCH, dopamine D1 receptor imaging, 1069(ab)
I-125 quinuclidinyl esters, muscarinic receptors, 1093(ab)
image reconstruction, 3D model, compensation of attenuation and collimation divergence, 917(ab)
IMP, neuropsychological performance, dementia, 942(ab)
improved display data, 360(le)
In-111 activity quantitation, 986(ab)
In-111 and Tc-99m anti-CEA antibody, prospective staging, bladder carcinoma, 970(ab)
In-111 antibodies, liver, beagle dogs, 1442
influence of positioning, accuracy and precision, 1252
interictal, Tc-99m HMPAO, temporal lobe epilepsy, 1688
iterative reconstruction methods, 937(ab)
iterative reconstruction techniques, visual and quantitative studies, 1135(ab)
Lines from the President, post-anatomic imaging era, 16N(9)
maximum A posteriori reconstruction, new Gibbs prior, 936(ab)
maximum-likelihood estimation, mathematical model, quantitation in nuclear medicine, 898(le)
maximum likelihood reconstruction, 2D blurring model, 936(ab)
molecular medicine, from science to service, 14N(8)
Monte Carlo model, non-uniform attenuating phantoms, 1065(ab)
multidetector point-focusing, three-dimensional simulations, 333
multi-detector system, simultaneous transmission and emission converging tomography, 955(ab)
multiheaded dedicated, quality control program, 1136(ab)
myocardial
LV long axis orientation, reconstruction arc, 946(ab)
reduction of image artifacts and distortions, 946(ab)
new reconstruction algorithm, tilted cone beam tomography, 1066(ab)
non-uniform attenuation compensation
acquired transmission data, 1067(ab)
cone-beam transmission computed tomography, 1813
transmission and CT data, 1839(ab)
optimal collimator resolution, side information effects, myocardial blood flow, 946(ab)
optimization of transmission source collimation, planar imaging attenuation measurements, 986(ab)
PET and
perfusion imaging, nuclear cardiology, 579
sensitivity and specificity, Alzheimer's disease, 942(ab)
symbiotic developments, myocardial tomography, 166
photographic quality in literature, 1464(le)
preconditioned iterative algorithms, improved convergence rates, 1065(ab)
present and future directions, Tenth Annual SNM Mid-Winter Meeting, 24N(1)
prototype system, imaging performances, 1838(ab)
quantitation of bone metabolism, hyperparathyroidism, thyrotoxicosis, 1157
quantitative reconstruction, neural network, 936(ab)
quantitative simultaneous iterative reconstruction technique, 1066(ab)
quantitative stress Tl-201 myocardial perfusion, normalcy rate, 959(ab)
radioactivity in conjugate counting, quantitative measurements, 1136(ab)
radioiodinated analogs of fluoxetine, serotonin reuptake sites, 964(ab)
radioiodination of specific sigma receptor ligand, 1841(ab)
rCBF study in childhood autism, 1086(ab)
reconstruction error due to self-attenuation, Tc-99m myocardial imaging, 958(ab)
reconstruction images, 3-D photon detection kernels, 1068(ab)
reconstruction of I-123 data, 527
regional brain blood flow, before and after cerebral angioplasty, 971(ab)
regional cerebral blood flow, brain infarction, outcome prediction, 382
regional hyperemia, closed head injury, 1022(ab)

reimbursement, 11N(2), 11N(9)
rest/stress Tl-201 or Tl-201 reinjection, myocardium at risk, 949(ab)
rest Tl-201/stress Tc-99m sestamibi, dual isotope myocardial perfusion, 1006(ab)
rest-treadmill exercise Tc-sestamibi, first pass ejection fraction, 929(ab)
saturation of amino acid uptake, human brain tumor, 1229
scatter and attenuation correction method, 916(ab)
semiquantitative method, differentiation, fibrosis from viable mediastinal Hodgkin's disease, 918(ab)
simultaneous segmentation and reconstruction, Gibbs distributions, 937(ab)
spatially variant scatter response function, infinite slab and object geometry, 1065(ab)
stationary 3D, brain imaging system, 1135(ab)
straight line cone-beam tomography, cardiac imaging, feasibility study, 956(ab)
system resolution, quantitative measurements, cerebral cortex and cerebellum, 1080(ab)
Tc-99m DMSA, uptake in single kidney, 766
Tc-99m ECD and I-123 IMP, cerebrovascular disease, 1073(ab)
Tc-94m flow agents, 925(ab)
Tc-99m HMPAO
abnormal brain perfusion, cocaine-dependent polydrug users, 1022(ab)
acetazolamide, vascular reserve in brain diseases, 1074(ab)
arterial input curve, 1501
bilateral subdural hematomas, brain, 1915
brain, opthalmoplegia plus, 1075(ab)
brain mapping, echolalia and palilalia, 1619
brain perfusion, double injection, 1073(ab)
brain perfusion abnormality, cocaine-dependent polydrug users, 1206
cerebral activation changes, Stroop test, 991(ab)
cerebral blood flow, acute closed-head injury, 1684
cerebrovascular disease, acetazolamide, 1073(ab)
convulsions and fever, brain, 1086(ab)
EEG localization of foci, childhood-onset epilepsy, 912(ab)
generalized anxiety and panic disorders, 1136(ab)
kinetic behavior, cerebral blood flow, 1069(ab)
localization, childhood epileptogenetic foci, 913(ab)
magnetic resonance tomography, presurgical epileptic diagnosis, 1076(ab)
medically intractable temporal lobe epilepsy, 388
regional cerebral blood flow, refractory unipolar depression, 951(ab)
regional distribution of CBF, childhood, 1080(ab)
scattered focal cortical defects, 1840(ab)
Tl-201 chloride, metastatic glioblastoma, 322
vertebrobasilar insufficiency, change in head position, 1075(ab)
Xe-133 CBF profiles, Alzheimer's disease, 941(ab)
Tc-99m MIBI
glucose uptake, resting myocardial perfusion defects, 1037(ab)
Tl-201 and, myocardial defect size at rest and exercise, 1037(ab)
Tc-99m MRP20, brain perfusion agent, 399, 500
Tc-99m sestamibi
prone and supine, normal distributions, 1036(ab)
right ventricular involvement, acute myocardial infarction, 929(ab)
right ventricular regional perfusion, 1199
scatter and attenuation correction, myocardial distributions, 1067(ab)
Tc-99m TEBO
heart, 919(ab)
heart, three-minute acquisition with single-head detector, 929(ab)
teboroxime, adenosine-induced coronary hyperemia, 1036(ab)
temporal lobe, rapid cycling bipolar disorder, 1076(ab)
thallium index and brain tumors, 1138(ab)
three-dimensional, mathematical brain model, 3-D physical brain phantom, 1923
three-headed, application to Tc-99m SQ30217 myocardial imaging, 1273
Tl-201
adenosine coronary hyperemia, remote Q-wave myocardial infarction, 979(ab)
adenosine *vs.* exercise, CAD in the elderly, 968(ab)
algorithm, gradual or abrupt heart motion, 947(ab)
automatic reorientation, myocardium, 1067(ab)
"black hole" sign, left ventricular aneurysms, 959(ab)
bullseye subtraction polar map, perfusion after coronary bypass grafting, 1035(ab)
bullseye subtraction polar map, visual analysis, 1035(ab)
computer-assisted superimposition of MRI, brain, 1478
detection, radiologically occult lung cancer, 2284
differentiation, recurrent metastatic disease from post-therapy complication, 962(ab)
dipyridamole, left bundle branch block, 1033(ab)
In-111 antimyosin, right ventricular infarction, 1018(ab)
left bundle branch block, 1034(ab)
left ventricular long-axis reorientation, myocardial transaxial tomograms, 1794
motion correction algorithm, 1007(ab)
myocardial defect detection, various collimators, 946(ab)
orbit-related variation, spatial resolution, 871
planar acquisitions, ischemic heart disease, 958(ab)
preoperative assessment, mediastinal involvement of lung cancer, 961(ab)
Rb-82 PET or, myocardial perfusion imaging, 1133(ab)
reinjection and FDG PET imaging, previous myocardial infarction, 949(ab)
right ventricular overload, children, 2215
use of energy-weighted acquisition, 805
Tl-201 and Tc-99m DTPA, radiation necrosis, 1137(ab)
Tl-201 chloride, malignant ENT-tumors, comparison with MRI, 920(ab)
Tl-201 ECG-gated, systolic thickening, left ventricular function, 1496
Tl-201 exercise, reproducibility, 1033(ab)
tomographic, myocardial imaging, Tc-99m teboroxime and Tl-201, 920(ab)
transmission computed tomographic brain scans and, accurate correlation, 1080(ab)
treatment of Compton scattering, maximum-likelihood, expectation-maximization reconstructions, 1285
ultra-high-resolution, brain perfusion, 3-head rotating gamma camera, 1079(ab)
ungated Tc-99m MIBI bullseyes, cardiac motion, Tl-201 in dogs, 958(ab)
volume rendering, display of cold lesions, 985(ab)
Xe-133 and Tc-99m HMPAO, stroke and dementia, 972(ab)
Skeleton
acute sternal infarction, severe hypoxemia, sickle cell anemia, 1617
angiomatosis, limitation to hand, radiography and scintigraphy, 1912
bone marrow scan identification, "diffuse" metastases, equivocal super bone scan, 1083(ab)
deposits of Tc-99m MDP and I-131 MIBG, neuroblastoma, 943(ab)
metastases, bone scan results, prostate-specific antigen, 1082(ab)
painful osseous metastases, Re-186(Sn)HEDP treatment, 1877
scintigraphy, detection, urinary tract abnormalities, 1140(ab)
total body imaging with F-18 and PET, 1025(ab)
treatment of painful metastases, Re-186 HEDP, 963(ab)
Skull, volume 3-D display of Tc-99m HMDP, triple head gamma camera, 913(ab)
Sleep, total deprivation, changes in regional brain perfusion, major depression, 952(ab)
Society of Nuclear Medicine (SNM)
ACNP and, government relations update, 11N(2)
Administrator's Day program, 30N(3)
American College of Nuclear Physicians and government relations update, 11N(9)
revisions to CLIA, 28N(1)
Benedict Cassen Memorial Fund, receipt of $1.25 million bequest, 20N(6)
consideration of appeal, NRC quality management rule, 20N(10)
future of nuclear medicine, 25N(3)
Lines from the President, 24N(6)
petition in federal court, NRC's increased user fees, 35N(11)
practice guidelines, commentary, 24N(12)
strategic planning, Lines from the President, 22N(12)
strategic task force leader chosen, 26N(10)
Tenth Annual Mid-Winter Meeting Symposium, present and future directions, SPECT/PET/computers, 24N(1)
38th Annual Meeting, 20N(5)
Somatostatin
radioiodinated, analog scintigraphy, small-cell lung cancer, 1845
radioiodinated analogue, 1184
receptor-positive tumors
In-111 DTPA-D-Phe-Octreotide, 1084(ab)
radiation dosimetry, In-111 DTPA-D-PHE octreotide, 1043(ab)
Spectroscopy, identification and chemical reactivity, electrophilic F-18 species, O-18/F-18 gas target system, 1010(ab)
Spheres, energy deposition patterns, estimates, beta absorbed fractions, 835
Spheroids, multicellular, application of (methyl-^{11}C)-methionine, 2258
Sphincter of Oddi
dysfunction
combined visual and quantitative method, CCK-cholescintigraphy, 1046(ab)
delayed cholescintigraphic kinetics, 976(ab)
radionuclide injection, common bile duct

clearance, 975(ab)
pattern of obstruction of distal common bile duct, reversal by naloxone, hepatobiliary imaging, 1270
Spinal cord, injury, bone density, 1026(ab)
Spine
evaluation of femoral allograft, bone SPECT, 913(ab)
lumbar
bone mineral content, children, 216
bone mineral density, GnRH-agonists, 1026(ab)
volume 3-D display of Tc-99m HMDP, triple head gamma camera, 913(ab)
Spleen
compensatory growth, 207, 1827(le)
dynamics of In-111 autologous platelets, steroid therapy evaluation, idiopathic thrombocytopenic purpura, 1048(ab)
functional asplenia, In-111 oxime-labeled autologous leukocytes, 524
heterotopic autotransplantation, traumatic splenic rupture, long-term follow-up, 204
residual, denatured red blood cell scan, negative colloid scans, 2286
Staphylococcus aureus, detection of infection in mice, Tc-99m polyclonal human immunoglobulin, 468
Stenosis
critical, adenosine-induced hyperemia, Tl-201 and Tc-99m sestamibi, 947(ab)
papillary, quantitative hepatobiliary scintigraphy, 1046(ab)
Stereotaxy, intercommissual line for PET images, automated detection, 966(ab)
Sternotomy, sternal viability, with and without mammary artery bypass, 1025(ab)
Sternum, acute infarction, severe hypoxemia, sickle cell anemia, 1617
Streptavidin
improved localization of inflammation, 1014(ab)
pre-targeting of conjugates, Bolton-Hunter and biotin derivatized polylysine, 993(ab)
quantitation, pharmacokinetics and analysis, 1098(ab)
Striatum, quantitation, C-11 raclopride, PET, 1838(ab)
Stroke
acute, ROER and RCBF/RCBV ratio, 960(ab)
brain infarction, regional cerebral blood flow, outcome prediction with SPECT, 382
dementia and, Xe-133 rCBF SPECT, Tc-99m HMPAO SPECT, 972(ab)
I-123 IMP and Tc-99m HMPAO, brain SPECT, 1073(ab)
subacute, early and delayed brain SPECT, Tc-99m ECD *vs.* I-123 IMP, 971(ab)
Strontium, environmental radiation, fallout in firewood, 28N(10)
Strontium-85, use of Tc-96 in biological studies, 1001(ab)
Strontium-89, adjuvant to local external beam radiotherapy, 918(ab)
***N*-Succinimidyl-3-(tri-*n*-butylstannyl)benzoate,** therapeutic efficacy, I-131 antiglioma monoclonal antibody, 922(ab)
Sulfhydryl, synthesis and radiolabeling, "tyrosyl-ETAC", 915(ab)
Summit on Manpower, release of job satisfaction study, 30N(1)
Sweden, epidemiological study, affirmation, I-131 therapy, 28N(10)
Synovectomy
radiation
evaluation of new radiopharmaceuticals, 963(ab)
glass Sm-153 microspheres, 945(ab)
specific linker technology, microspheres labeled with albumin, 964(ab)

T

TAG-72
binding of IgG and Fab forms of CC49, CX-1 tumor model, 1098(ab)
detection and staging of breast cancer, In-111 B72.3 monoclonal antibody, 1326
immunohistochemical localization, CX-1 tumor model, I-125 IgG, 1020(ab)
Tamoxifen, halogenated, synthesis and evaluation, 1093(ab)
T-cells, radionuclide angiography, Tc-99m erythrocytes, HPRT gene, 814
Teboroxime
additional useful information, myocardial washout characteristics, 1988
sestamibi and, review of cardiac imaging, 2012
SPECT, adenosine-induced coronary hyperemia, 1036(ab)
Technegas
altered pulmonary permeability, 1945
high hopes, 24N(11)
Technetium, thallium scintigraphy, endocrine imaging, 1627
Technetium complexes, tetradentate thioiminato Schiff base complexes, 1843(ab)
Technetium-94m, flow agents, bridging PET and SPECT, 925(ab)
Technetium-96, use in biological studies, cross-over corrections, 1001(ab)
Technetium-96 sestamibi, Tl-201 and, simultaneous measurement in same animal, myocardial blood flow, 947(ab)
Technetium-99m
amide thiolate-Fab conjugates, β-amido alkyl succinate cleavable linkers, 1017(ab)
anti-activated platelet monoclonal antibody, rapid imaging, arterial thrombi, 1005(ab)
antibody-metallothionein, radioimmunoimaging, 915(ab)
autoradiography of labeled compounds, quantitation of radioactivity, computed radiography, 1060(ab)
cationic samples, renal imaging agents, 1105(ab)
complexes of N3S ligands, comparison to OIH, 1016(ab)
direct labeling of monoclonal antibodies, biodistribution in mice, 1099(ab)
directly labeled IMMU-4 IgG and Fab', 1101(ab)
directly labeled to antibodies, stability of, 1099(ab)
dual isotope Tl-201, enhanced spill correction techniques, pure Tl-201 image, 1059(ab)
-labeled cardiac agents, approval by FDA, alternative to exercise in stress-thallium, 11N(5)
-Mo-99, generated eluate contaminants, N_2S_2 chelation, 1102(ab)
multidentate-N,S ligands, 1016(ab)
myocardial imaging, SPECT reconstruction error, self-attenuation, 958(ab)
myocardial perfusion agents, optimized imaging properties, 925(ab)
N_2S_2 derivatized fatty acid analogs, cardiac metabolic studies, 1016(ab)
N_2S_2 preformed chelate labeled anti-melanoma monoclonal antibody Fab fragment, metabolite analysis, mice and rats, 915(ab)
perfusion agents, list mode ECG-gated first pass LVEF, single crystal gamma camera, 939(ab)
phosphorus trihydrazide complex, 1102(ab)
potential renal imaging agents, active tubular cationic mechanism, 1102(ab)
preformed chelate, kit development, antibody Fab fragment, 1445
preparation of radiopharmaceuticals, chelating moiety, hydroxamamide, 1102(ab)
Q12, myocardial perfusion agent, humans, 1007(ab)
radiopharmaceuticals, estimation, weighted effective dose, 1835(ab)
Tl-201 and, multiple regression analysis, 1059(ab)
-Tl-201 dual isotope imaging, energy weighted acquisition, 1001(ab)
triamenedithiol ligands, bifunctional chelating agents, 985(ab)
unspecific immunoglobulin, rheumatoid arthritis, 983(ab)
use of Tc-96 in biological studies, 1001(ab)
Technetium-99m anti-activated platelet monoclonal antibody, uptake and thrombus age, 1013(ab)
Technetium-99m anti-AFP monoclonal antibody, germ cell and liver tumors, 22N(11), 1053(ab)
Technetium-99m antibody fragment, CEA immunoscintigraphy, colorectal cancer, 1051(ab)
Technetium-99m anti-CEA antibody
In-111 and
comparison, 1053(ab)
prospective staging of bladder carcinoma, SPECT, 970(ab)
Technetium-99m anti-CEA Fab' fragments, occult metastases, colorectal cancer, 1052(ab)
Technetium-99m anti-CEA-MAK, bladder carcinoma, 1053(ab)
Technetium-99m antifibrin
scintigraphy
acute deep venous thrombosis, 1020(ab)
diagnosis, acute recurrent deep venous thrombosis, 967(ab)
Technetium-99m antigranulocyte antibody
bone marrow regeneration, bone metastases, prostate carcinoma, 2295
immunoscintigraphy, suspected subacute bacterial endocarditis, 1019(ab)
Technetium-99m antigranulocyte monoclonal antibody, bone marrow regeneration after hormone therapy, bone metastases, prostatic carcinoma, 1025(ab)
Technetium-99m antimyosin sFv fragment, rapid imaging, acute myocardial infarction, dogs, 1005(ab)
Technetium-99m desferoximine, aerosol and intravenous administration, 1017(ab)
Technetium-99m diphosphine, myocardial imaging, Phase I study, 967(ab)
Technetium-99m DISIDA
hepatobiliary studies, correlation with biopsies, liver transplant, 1545
scintigraphic evaluation, gallbladder function, 1131(ab)
Technetium-99m dithiocarbamates, neutral myocardial imaging agents, 925(ab)
Technetium-99m DMSA
creatinine clearance and, discrepancy of renal uptake, drug-induced nephrotoxicity, 1106(ab)
pentavalent-
chemical identity, 845
multiple myeloma without amyloidosis, 1785
poor renal uptake, near normal Tc-99m DTPA uptake, tubulointerstitial renal disease, 2273

uptake in single kidney, *in vivo* SPECT, 766
Technetium-99m DTPA
measuring renal tubular function, renal insufficiency, 972(ab)
near normal uptake, poor Tc-99m DMSA renal uptake, tubulointerstitial renal disease, 2273
photopenic renal transplants, 1107(ab)
renal clearance, background correction, 362(le)
Tc-99m HMPAO and, evaluation of brain death, 1839(ab)
Tl-201 and, SPECT, radiation necrosis, 1137(ab)
Technetium-99m DTPA aerosol
AIDS, 16N(7)
Ga-67 and, pulmonary complications, HIV infection, 990(ab)
inflammatory lung disease, 989(ab)
Technetium-99m DTPA-galactosyl-HSA, quantitative model, hepatic blood flow, hepatic binding receptor, 2233
Technetium-99m DTPA radioaerosol
clearance in experimental pulmonary contusion, 990(ab)
clearance measurements, liver cirrhosis without hypoxemia, 990(ab)
Technetium-99m ECD
blood-brain permeability measurement, compartment analysis and dynamic SPECT, 911(ab)
cerebral blood flow, focal cerebral ischemia, 1070(ab)
I-123 IMP and, cerebrovascular disease, SPECT, 1073(ab)
intracerebral kinetics, dynamic brain SPECT, 991(ab)
vs. I-123 IMP, early and delayed brain SPECT, subacute stroke, 971(ab)
Technetium-99m erythrocytes, no mutations in HPRT gene of human T-cells, radionuclide angiography, 814
Technetium-99m galactosyl-neoglycoalbumin
radiopharmacokinetic modeling, receptor concentration, forward-binding rate constant, 1169
validation of *in vivo* receptor measurements, radioassay, 1177
Technetium-99m gas, particle size, hot spot formation and, 1087(ab)
Technetium-99m glucarate
localization in zones of acute cerebral injury, 272
Tl-201 and, acute myocardial infarction, 1029(ab)
Technetium-99m glucaric acid, myocardial infarction, early scintigraphic detection, 263
Technetium-99m granulocyte antibody, diagnostic accuracy in scan, inflammatory or infectious diseases, 1002(ab)
Technetium-99m HMDP, volume 3-D display, triple head gamma camera, 913(ab)
Technetium-99m HMPAO
acetazolamide, carotid artery disease, 1074(ab)
blood-brain permeability measurement, compartment analysis and dynamic SPECT, 911(ab)
brain clearance compared with cCBF, 1844(ab)
brain imaging, brain death, apallic syndrome and agonal cerebral dysfunction, 1077(ab)
brain perfusion
long-term cocaine abuse, 1021(ab)
medically intractable temporal lobe epilepsy, 388
brain SPECT
bilateral subdural hematomas, 1915
convulsions and fever, 1086(ab)
ophthalmoplegia plus, 1075(ab)
changes in cerebral blood flow reserve, carotid endarterectomy, 1382
clearance measurements, liver cirrhosis without hypoxemia, 990(ab)
computer-assisted superimposition of MRI, brain SPECT, 1478
I-123 IMP and
brain SPECT, dementia/stroke, 1073(ab)
simultaneous dual-tracer brain SPECT, 956(ab)
increase in distribution, visual stimulation, human visual cortex, 210
interictal SPECT and, temporal lobe epilepsy, 1688
in vivo quality control, 1316(le)
In-111 white cell scans and, inflammatory bowel disease, 924(ab)
kinetic behavior in human brain, cerebral blood flow, dynamic SPECT, 1069(ab)
labeled leukocytes
fast diagnosis, abdominal infections and inflammations, 2029
inflammatory component, lung cancer, 1132(ab)
-labeled white blood cells, high-dose γ-globulin, Kawasaki disease, 944(ab)
labeling efficiency, standard and multiple elution method, 1103(ab)
perfusion patterns, severity and onset, dementia in Alzheimer's disease, 1076(ab)
quantitative localization and clearance properties, I-123 IMP, crack users and normals, 1840(ab)
retention and uptake, role of glutathione, 1681
SPECT
abnormal brain perfusion, cocaine-dependent polydrug users, 1022(ab)
acetazolamide test, brain perfusion reserve, 1074(ab)
arterial input curve, 1501
brain mapping, echolalia and palilalia, 1619
brain perfusion, double injection, 1073(ab)
brain perfusion abnormality, cocaine-dependent polydrug users, 1206
cerebral activation changes, Stroop test, 991(ab)
cerebral blood flow, acute closed-head injury, 1684
cerebrovascular disease, acetazolamide, 1073(ab)
EEG localization of foci, childhood-onset epilepsy, 912(ab)
generalized anxiety and panic disorders, 1136(ab)
localization, childhood epileptogenetic foci, 913(ab)
magnetic resonance tomography, presurgical epileptic diagnosis, 1076(ab)
regional cerebral blood flow, refractory unipolar depression, 951(ab)
regional distribution of CBF, childhood, 1080(ab)
scattered focal cortical defects, 1840(ab)
Tl-201 chloride, metastatic glioblastoma, 322
vertebrobasilar insufficiency, change in head position, 1075(ab)
Xe-133 CBF profiles, Alzheimer's disease, 941(ab)
Xe-133 rCBF SPECT and, stroke and dementia, 972(ab)
Tc-99m DTPA and, evaluation of brain death, 1834(ab)
uptake and glutathione content, brain tumors, 1675
WBC scan, carditis, rheumatic fever, 1041(ab)
Technetium-99m D,L-HMPAO
energy-dependent accumulation, rat brain slices, 1071(ab)
sensitivity to radiolysis, aqueous solutions, 111
Technetium-99m HMPAO leukocytes, chronic prosthetic vascular graft infection, 1425
Technetium-99m HMPAO-WBC, clinical experience, comparison, In-WBC infection localization scintigraphy, 1049(ab)
Technetium-99m HYNIC, In-111 DTPA and, sequential injections, rats, 1050(ab)
Technetium-99m IgG, direct-labeled, 1024(ab)
Technetium-99m LDL, biodistribution, nuclear imaging analysis, 1239
Technetium-99m leukocytes
diagnosis of sternal wound infection, 1002(ab)
inflammatory bowel disease, 1131(ab)
Technetium-99m $(L\text{-}L)_3^+$ complexes, ether analogs of DMPE, 1102(ab)
Technetium-99m low-density lipoprotein, radiopharmaceutical for metabolic imaging, 925(ab)
Technetium-99m MAG_3
captopril-enhanced renal scintigraphy, renal artery stenosis, renovascular hypertension, 934(ab)
clearance
calculation, camera-based method, 953(ab)
gamma camera method, renal transplant patients, 953(ab)
clinical trial in children, 1085(ab)
estimation of clearance, two gamma techniques, 954(ab)
fast preparation and quality control method, 1843(ab)
GEM-dimethyl derivatives, comparative evaluation, 1016(ab)
I-131 OIH and, simultaneous clearance, renal disease, 1108(ab)
plasma clearance, single blood sample, 1105(ab)
4-pyridylsulfide, thiol protecting group of MAG_3, 1024(ab)
radioiodinated hippuric acid and, difference in clearance, 1642(le)
reliability as indicator of renal function, 1843(ab)
renal clearance, proteinuria, lowered serum albumin levels, 1709
renal clearance in children, two gamma camera techniques, multiple plasma samples, 1704
renal scintigraphy, angiotensin-converting enzyme inhibition, 424
renography, pre post captopril, renal angiography and plasma renin activity, 934(ab)
Tc-99m O4 and, recovery of renal function, acute renal failure, 973(ab)
volume of distribution, 900(le)
vs. I-123 OIH, renal clearance, distribution volume, 2057
Technetium-99m MDP
bone scan, stage IV renal cell carcinoma, 983(ab)
extraskeletal and skeletal deposits, neuroblastoma, 943(ab)
four-phase bone scan, electric burns, 1026(ab)
In-111 leukocytes and, bone scintigraphy, vertebral osteomyelitis, 1861
scintigraphic pattern, pachydermoperiostosis, 1907
uptake in sympathetic effusion, index of malignancy, 325
Technetium-99m mebrofenin
hepatobiliary function, 48
hepatobiliary scintigraphy, complications, liver transplantation, 999(ab)

scintigraphy reliability, diagnosis, intrahepatic cholestasis, 976(ab)
Technetium-99m MIBI
dipyridamole Tc-99m-2-MIBI compared to Tl-201 stress-rest, tomoscintigraphic imaging, diseased coronary vessels, 369
follow-up of differentiated thyroid carcinoma, 921(ab)
gated myocardial imaging, left ventricular function, 1035(ab)
muscle perfusion, lower extremity peripheral arterial disease, 1700
myocardial perfusion, intravenous adenosine, dipyridamole, 1027(ab)
normal stress tomographic imaging, necessity of rest images, 930(ab)
parathyroid imaging, change detection and movement correction, 1011(ab)
scintigraphy, localization, recurrent medullary thyroid carcinoma, 2281
SPECT
glucose uptake, resting myocardial perfusion defects, 1037(ab)
Tl-201 and, myocardial defect size at rest and exercise, 1037(ab)
Tl-201 and, ROC analysis of tumor detect ability, bronchial carcinoma, 961(ab)
Tl-201 reinjection and, detection of viable myocardium, chronic coronary artery disease, 949(ab)
Tl-201 uptake and, pulmonary actinomycosis, 1429
ungated SPECT bullseyes, cardiac motion, Tl-201 in dogs, 958(ab)
uptake kinetics and accumulation, tetraphenylborate, chick myocardial cells, 1992
Technetium-99m monoclonal antibody
anti-CEA immunoscintigraphy, primary and recurrent colorectal carcinoma, 1319
granulocytes
detection of infection, postoperative orthopedic patients, 2209
"hot appendix", 1049(ab)
kit, initial targeting studies, lymphoma, 1054(ab)
modification, highly polar and branched compound, hepatic uptake, 1055(ab)
neutrophil-specific, imaging inflammatory diseases, 1836
routine application, colorectal cancer, 940(ab)
Technetium-99m monoclonal antigranulocyte antibody, immunoscintigraphy, suspected inflammatory disease, 1002(ab)
Technetium-99m MRP20, brain perfusion agent, 500
SPECT, 399
Technetium-99m NGA, I-125 NGA and, differences in processing, liver, 506
Technetium-99m NR-LU-10 monoclonal antibody, fusion with chest CT, non-small cell lung carcinoma, 1132(ab)
Technetium-99m O4, Tc-99m MAG_3 and, recovery of renal function, acute renal failure, 973(ab)
Technetium-99m OV-TL 3 Fab', immunoscintigraphy, suspicion of ovarian cancer, 941(ab)
Technetium-99m pertechnetate
cimetidine-enhanced, visualization, Meckel's diverticulum, 1422
scintigraphy, columnar-lined esophagus, 930(ab)
shunt fraction estimation, chronic biliary cirrhosis, 124
Technetium-99m phytate, extrahepatic uptake, 186
Technetium-99m PMT
evaluation of distant metastases, hepatocellular carcinoma, 1137(ab)
uptake, relationship to prognosis, hepatocellular carcinoma, 228
Technetium-99m polyclonal human IgG, normal human biodistribution, radiation dosimetry, 1099(ab)
Technetium-99m polyclonal human immunoglobulin, detection of local staphylococcal infection, 468
Technetium-99m pyrophosphate, myocardial distribution of In-111 antimyosin Fab, acute inferior and right ventricular infarction, 865
Technetium-99m red blood cells
delayed positive gastrointestinal bleeding, utility of second injection, 330
gastrointestinal bleeding study, significance, intensity of delayed activity, 2249
heterotopic splenic autotransplantation, traumatic splenic rupture, long-term follow-up, 204
high-resolution three-headed SPECT, improved detection, small cavernous hemangiomas, 2086
penile plethsymography and Xe washout, corpora cavernosal inflow and outflow, early tumescence, 404
venography, deep venous thrombosis, lower extremity, 2324
visual blood loss estimate, hematochezia, 923(ab)
Technetium-99m serum albumin, protein-losing enteropathy, abdominal scintigraphy, 924(ab)
Technetium-99m sestamibi
artifactual perfusion defects, ischemic myocardial dysfunction, 909(ab)
cardiac retention, relationship to mitochondrial viability, 957(ab)
detection of coronary artery disease, 919(ab)
ECG-gated imaging, regional myocardial thickening, 957(ab)
enhanced processing and quantification, myocardial perfusion images, 1035(ab)
myocardial perfusion
coronary artery disease detection, 1961, 1966
optimal method for sampling and displaying, 1006(ab)
myocardial retention, necrosis, coronary occlusion and reperfusion, 957(ab)
myocardial viability, coronary occlusion, 292
prone and supine myocardial SPECT, normal distributions, 1036(ab)
quantitative myocardial thickening, count-based method, 1006(ab)
rapid preparation and quality control method, 2162
rapid quality control method, 1835(ab)
rest Tl-201-, dual isotope myocardial perfusion SPECT, 1006(ab)
rest/treadmill exercise, first pass ejection fraction, normal limits, 929(ab)
SPECT
count-based method, myocardial thickening, 1068(ab)
right ventricular involvement, acute myocardial infarction, 929(ab)
right ventricular regional perfusion, 1199
scatter and attenuation correction, myocardial distributions, 1067(ab)
Tl-201 and
critical stenosis, adenosine-induced hyperemia, 957(ab)
discrepancies in stress images, wall motion, 1036(ab)
tomograms, automatic determination, processing parameters, 1001(ab)
window on myocardial viability, 298
Technetium-99m SQ30217
myocardial imaging, three-headed SPECT, 1273
regional myocardial clearance rate, detection, coronary artery stenosis, 1037(ab)
Technetium-99m sucralfate, adherence to oral microlesions, scintigraphic demonstration, 1465(le)
Technetium-99m sulfur colloid
granulocyte colony-stimulating factor, autologous bone marrow, 1013(ab)
In-111 leukocyte and, improved diagnostic accuracy, osteomyelitis, 962(ab)
intra-arterial injection, gastrointestinal bleeding, 1047(ab)
Technetium-99m T101 antibody, metabolic studies, 1056(ab)
Technetium-99m teboroxime
blood clearance, coronary and systemic hemodynamic determinants, 1028(ab)
cardiac SPECT, 919(ab)
three-minute acquisition, single-head detector, 929(ab)
detection of coronary artery disease, 919(ab)
differential myocardial washout, mechanism and significance, 2009
differential post-stenotic myocardial clearance, non-exercise cardiac stress, 947(ab)
differential tracer washout, SPECT acquisition, 2253
effect of flow, Tl-201 extraction and retention, heart, 1979
extraction and metabolism, isolated perfused rat heart, 948(ab)
Fourier phase analysis, myocardial clearance, 1029(ab)
myocardial clearance, regional systolic dysfunction, acute ischemia and pharmacologic stress, 948(ab)
myocardial kinetics, canine stenosis model, dipyridamole, 948(ab)
reduced extraction, incubation of red blood cells, rabbit heart, 910(ab)
retention and myocardial blood flow, 947(ab)
sequential tomographic myocardial perfusion imaging, compared to Tl-201 and arteriography, 919(ab)
single radiopharmaceutical and one camera, left ventricular perfusion, 929(ab)
Tl-201 and dynamic myocardial imaging, 1036(ab)
Tl-201 dipyridamole and, detection, coronary artery disease, 919(ab)
Tl-201 planar myocardial perfusion and, detection, coronary artery disease, 919(ab)
tomographic myocardial perfusion imaging, at rest and after dipyridamole, 1968
tomographic SPECT myocardial imaging, 920(ab)
washout in myocardial images, known or suspected ischemic heart disease, 930(ab)
Technetium-99m T2G1s antifibrin, radiation dosimetry and biodistribution, 1042(ab)
Technetium-99m tumor necrosis factor, imaging tumors, biologic response modifiers, 1021(ab)
Technetium-99m (V)dimercaptosuccinic acid, pharmacokinetics and biodistribution, animal tumor model, 1235
Technetium-99m(V)thiocyanate, measurement of gastric emptying of fat, 878
Technical Corrections Act (TCA), Medicare reimburesement, 11N(9)
Testicles, procedures of choice in nuclear medicine, 1301
Tetalman Memorial Award, Kimberlee Kearfott,

22N(7)
Tetradentate thioiminato, Schiff base complexes of technetium, 1843(ab)
Tetraphenylborate, Tc-99m MIBI uptake kinetics and accumulation, chick myocardial cells, 1992
Thallium, technetium scintigraphy, endocrine imaging, 1627
Thallium-201
adenosine myocardial imaging, safety in the elderly, 978(ab)
adenosine scintigraphy
asymmetric renal uptake, renovascular disease, 1104(ab)
increased lung uptake, coronary artery disease, 979(ab)
risk reduction, severe arrhythmia, 978(ab)
adenosine SPECT, reinjection technique, 979(ab)
bullseye subtraction polar map, perfusion after coronary bypass grafting, 1035(ab)
defect severity at stress and late redistribution, predictor, myocardial viability, 950(ab)
detection of coronary artery disease, 919(ab)
detection of reversible defects, ribose, 2027(le)
-dipyridamole
false-negative myocardial imaging, caffeine infusion, 1538
image quality, exercise supplementation, 1559
lung uptake, ejection fraction in peripheral vascular disease, 967(ab)
mechanisms, transient myocardial perfusion defects, 1030(ab)
safety in high risk patients, coronary artery disease, 2107, 2115
distribution, salinity effect, American lobsters, 1105(ab)
dynamic myocardial imaging and, Tc-99m TEBO, 1036(ab)
ECG-gated SPECT, systolic thickening, left ventricular function, 1496
exercise imaging, adenosine, moderate coronary stenosis, 1031(ab)
exercise SPECT
arteriopathy, orthotopic heart transplant, 1041(ab)
left bundle branch block, 1033(ab)
reproducibility, 1033(ab)
extraction and retention, Tc-99m TEBO, heart, 1979
FDA approval of new technetium-labeled cardiac agents, alternative to exercise, stress-thallium studies, 11N(5)
F-18 deoxyglucose and, detection, recurrent brain tumor, 955(ab)
follow-up of differentiated thyroid carcinoma, 921(ab)
4 hour reinjection uptake, relationship to regional wall motion, 1032(ab)
I-123 BMIPP and, discrepancies, myocardial infarction, 1034(ab)
In-111 antimyosin antibody dual isotope imaging, reperfused myocardial infarction, 1034(ab)
increased lung uptake
absence of myocardial perfusion abnormalities, 959(ab)
dipyridamole infusion, significance, 1031(ab)
late redistribution, prospective evaluation, 1032(ab)
late reverse redistribution, 1032(ab)
lymphoma grade characterization, 917(ab)
myocardial and plasma kinetics, exercise type, dipyridamole and exercise stress imaging, 1031(ab)
myocardial perfusion
pharmacologic cardiac stress, dobutamine, 1130(ab)
suboptimal imaging, inadequate exercise, 2071
myocardial scintigraphy, congenitally-corrected transposition, great arteries, 1611
myocardial SPECT, normalization of stress, normal reference area, 1901
nuclear cardiology, PET perfusion imaging, 579
perfusion scintigraphy, segmental necrosis, pancreas transplant, 1605
planar myocardial perfusion, detection, coronary artery disease, 919(ab)
pulmonary uptake, exercise emission computed tomography, 417
pure image, enhanced spill correction techniques, dual isotope, 1059(ab)
quantitative planar scintigraphy, reproducibility, reversibility of myocardial perfusion defects, 759
quantitative stress, myocardial perfusion SPECT, normalcy rate, 959(ab)
redistribution
after 4 hours reinjection, 1032(ab)
bullseye subtraction polar map, visual analysis, 1035(ab)
facilitated by ribose, coronary artery disease, 193
reinjection
compared to 4-hour redistribution images, 948(ab)
immediate or delayed imaging, myocardial viability, 949(ab)
metabolic activity, new fill-in, 673
role of 24 hour imaging, oral dipyridamole stress Tl-201 myocardial perfusion scintigraphy, 1129(ab)
Tc-99m MIBI and, viable myocardium in CAD, 949(ab)
vs. PET viability, ischemic/viable myocardium, 1835(ab)
rest-injected, viability, severe asynergic regions, 1718
rest/stress SPECT, Tl-201 reinjection or, myocardium at risk, 949(ab)
rest/stress Tc-99m sestamibi, dual isotope myocardial perfusion SPECT, 1006(ab)
scintigraphy
adenosine compared to dipyridamole, myocardium, 969(ab)
cardiac transplantation, myocardial hypoperfusion, 1041(ab)
lymph node metastasis, parathyroid carcinoma, 1044(ab)
myocardial perfusion, arterial switch operation, 237
prediction of restenosis, coronary angioplasty, 959(ab)
scintigraphy and serum thyroglobulin, postoperative follow-up, thyroid cancer, 2098
scintigraphy in differentiated thyroid cancer, compared to radionuclide scintigraphy, serum thyroglobulin, 441
sequential tomographic myocardial perfusion imaging, Tc-99m teboroxime, 919(ab)
SPECT
adenosine *vs.* exercise, CAD in the elderly, 968(ab)
algorithm, gradual or abrupt heart motion, 947(ab)
automatic reorientation, myocardium, 1067(ab)
"black hole" sign, left ventricular aneurysms, 959(ab)
computer-assisted superimposition of MRI, 1478
detection, radiologically occult lung cancer, 2284
differentiation, recurrent metastatic disease from post-therapy complication, 962(ab)
dipyridamole, left bundle branch block, 1033(ab)
In-111 antimyosin, right ventricular infarction, 1018(ab)
index, brain tumors, 1138(ab)
left bundle branch block, 1034(ab)
motion correction algorithm, 1007(ab)
myocardial defect detection, various collimators, 946(ab)
orbit-related variation, spatial resolution, 871
planar acquisitions, ischemic heart disease, 958(ab)
preoperative assessment, mediastinal involvement of lung cancer, 961(ab)
Rb-82 PET or, myocardial perfusion imaging, 1133(ab)
reinjection and FDG PET imaging, previous myocardial infarction, 949(ab)
right ventricular overload, children, 2215
use of energy-weighted acquisition, 805
stress/delayed, accuracy, quantitative analysis, 749(le)
stress/redistribution scans, 1313(le)
stress/redistribution scintigraphy, ambulatory electrocardiography, patient population factors, 958(ab)
stress/rest study compared to dipyridamole Tc-99m-2-MIBI, tomoscintigraphic imaging, diseased coronary vessels, 369
stress tomograms, visual assessment, 3-D displays, 1006(ab)
Tc-96, use in biological studies, 1001(ab)
Tc-96 sestamibi and, simultaneous measurement in same animal, myocardial blood flow, 947(ab)
Tc-99m and, multiple regression analysis, 1059(ab)
Tc-99m DTPA and, radiation necrosis, brain SPECT, 1137(ab)
-Tc-99m dual isotope imaging, energy weighted acquisition, 1001(ab)
Tc-99m glucarate and, acute myocardial infarction, 1029(ab)
Tc-99m MIBI and, ROC analysis of tumor detect ability, bronchial carcinoma, 961(ab)
Tc-99m MIBI SPECT and, myocardial defect size, rest and exercise, 1037(ab)
Tc-99m MIBI uptake and, pulmonary actinomycosis, 1429
Tc-99m sestamibi and
critical stenosis, adenosine-induced hyperemia, 957(ab)
discrepancies in stress images, wall motion, 1036(ab)
tomographic SPECT myocardial imaging, 920(ab)
tomography, dobutamine, suspected coronary artery disease, 979(ab)
tomography in myocardial infarction, 2-^{18}F-2-deoxyglucose, 15-(ortho-^{123}I-phenyl)-pentadecanoic acid, 1353
uptake in lung and left ventricular dilation, adenosine and exercise scintigraphy, CAD, 1030(ab)
Thallium-201 chloride
detection of viable myocardium, 200
I-123 MIBG and, myocardial uptake rate in scintigraphy, hypertrophic cardiomyopathy,

1040(ab)
I-123 MPDA and, myocardial imaging, exercise-induced ischemia, 447
planar and SPECT, malignant ENT-tumors, comparison with MRI, 920(ab)
Tc-99m SPECT and, metastatic glioblastoma, 322
uptake in evaluation of "cold" thyroid nodules, early and late lesion-to-non-lesion ratio, 1045(ab), 1873
Thallium-201 dipyridamole, Tc-99m teboroxime and, detection, coronary artery disease, 919(ab)
Therapeutic nuclear medicine
palliation of pain
osseous metastases, tin-111m(4+)DTPA, 1840(ab)
Re-186 HEDP, metastatic bone disease, 1082(ab), 1088(ab)
Re-186(Sn)HEDP, osseous metastases, 1877
Thorax, tissue glucose utilization, noninvasive method, input function, 1432
Thrombi
age, uptake of Tc-99m anti-activated platelet monoclonal antibody, 1013(ab)
arterial, rapid imaging, Tc-99m anti-activated platelet monoclonal antibody, 1005(ab)
biological background subtraction, improved immunoscintigraphy, subsequent antigen injection, 2318
coronary, scintigraphy, antifibrin monoclonal antibody, 1005(ab)
immunoscintigraphy, 2321
in vivo labeling with Annexin-V, activated platelets, 928(ab)
quantitation on oxygenator and arterial filter, cardiopulmonary bypass, heparinized surface and iloprost infusion, 1048(ab)
Thrombocytopenia, intratumoral In-111 platelet deposition, metastatic angiosarcoma, 2278
Thrombocytopenic purpura, idiopathic, splenic dynamics, In-111 autologous platelets, 1048(ab)
Thrombolysis
detection of ischemic/stunned myocardium, adenosine/metabolic imaging, 1012(ab)
myocardial infarction, anterograde flow, tissue viability, 1039(ab)
Thrombosis
acute deep venous, Tc-99m antifibrin scintigraphy, 1020(ab)
acute recurrent deep venous, diagnosis, Tc-99m antifibrin scintigraphy, 967(ab)
deep venous
antifibrin monoclonal antibody, 1132(ab)
diagnostic accuracy, biostatistician's perspectives, 2328
In-111 antifibrin monoclonal antibody, 785
radiopharmaceutical for rapid imaging, 785
rabbit model, In-111 recombinant tissue plasminogen activator, 461
venous, lymphoscintigraphic abnormalities, 2144
Thymidine kinase, bone marrow transplant patients, marker, effect of transplantation, 1087(ab)
Thyroglobulin
constraints on sensitivity and specificity, "logically" merged test results, 1646
predictive factor of tumoral recurrence, differentiated thyroid cancer, 395
serum
new IRMA, thyroid carcinoma, 1088(ab)
Tl-201 scintigraphy, differentiated thyroid cancer, 441
whole-body I-131 scan, differentiated thyroid carcinoma, 1645(le)
Thyroid
absorbed dose from 5-millicurie I-131 dose, thyrotoxicosis, 364(le)
autonomously functioning nodule, 30
benign disease, radioiodide therapy, optimized dose planning, 1044(ab)
cold nodule evaluation and Tl-201 chloride uptake, early and late lesion to non-lesion ratio, 1045(ab)
elimination of hyperthyroidism, optimal I-131 dose, Graves' disease, 411
evaluation of "cold" nodules, Tl-201 chloride uptake, 1873
metastases, improved localization, 1131(ab)
nodule evaluation, 2181
nodules, goiter and, endocrine imaging, 1455
post-I-131 hyperthyroid therapy, radiation safety considerations, 169
scan, fine needle aspiration in solitary nodule, preoperative diagnosis, 1045(ab)
toxic solitary autonomous nodules, radioactive iodine, long-term follow-up, 27
Thyroid cancer, *see also* Carcinoma, thyroid
differentiated, postoperative ablation, 1073 MBq and 3700 MBq I-131, 252
postoperative follow-up, Tl-201 scintigraphy, serum thyroglobulin, 2098
recurrent, MRI, ultrasonography and radioiodine scintigraphy, 1011(ab)
scinitgraphic assessment, 1463(le)
thyroglobulin, predictive factor of tumoral recurrence, 395
whole blood doses from I-131, dosimetric model, 1045(ab)
Thyrotoxicosis, bone metabolism, *in vivo* SPECT quantitation, 1157
Tin-111m(4+)DTPA, pain palliation, osseous metastases, 1840(ab)
Tomography, dobutamine Tl-201, suspected coronary artery disease, 979(ab)
Transferrin
exchange of In-111 between IgG and lactoferrin, ferritin, 1099(ab)
-gallium complex, stability of, effect of bicarbonate, 1439
Transplantation
autologous bone marrow, Tc-99m sulfur colloid, granulocyte colony-stimulating factor, 1013(ab)
bone marrow, serum thymidine kinase, marker for effect of transplant, 1087(ab)
cardiac
cyclosporine radioimmunoassay, nephrotoxicity prediction, 977(ab)
detection of mediastinitis, Ga-67 scintigraphy, 860
non-invasive monitoring, In-111 antimyosin scintigraphy, 971(ab)
risk of rejection-related complications, antimyosin antibody, 1019(ab)
liver
correlation of Tc-99m-DISIDA hepatobiliary studies, biopsies, 1545
reversal of intrapulmonary shunting, cirrhosis, 862
pancreas, segmental necrosis, Tl-201 perfusion scintigraphy, 1605
photopenic renal, perinephrenic rim of increased activity, Tc-99m DTPA, 1107(ab)
renal
blood flow, vascular mean transit time, 1103(ab)
gamma camera method, Tc-99m MAG_3 clearance, 953(ab)
Tc-99m MAG_3 scintigraphy, children, 1107(ab)
Trauma, scintimetric evaluation, physiologic and pathophysiologic factors, bone remodeling, 914(ab)
Triamenedithiol, ligands, bifunctional chelating agents, Tc-99m and Re-186, 985(ab)
Triamines, functionalized tripodal, gallium tris(salicylaldimine) complexes, 944(ab)
Trimethylanilinium F-18 fluoride salts, formation and thermal decomposition, 1010
Tropolone, labeling of In-111 platelets, 62
Tryptophan, -related pulmonary disease, Ga-67 scan, 328
TSH, false positive values, human mouse antimouse antibodies, 977(ab)
Tuberculous mediastinal adenopathy, "false-positive" ventilation-perfusion lung scan, 512
Tumors, *see also* specific type
imaging with indium-labeled biotin, 750(le)
Tungsten-188
-Re-188 gel generator, potential for production, natural tungsten target, 1090(ab)
-Re-188 generator, preparation, Re-188 monoclonal antibodies, 1098(ab)
Tyramine, -cellobiose radioiodination of antibody, improved treatment, leukemia, 1843(ab)
Tyrosine, transport into human brain, L-[1-^{11}C] tyrosine and PET, 2043
L-m-Tyrosine, electrophilic fluorination, structural effect, acyl hypofluorites, 935(ab)
Tyrosyl-ETAC, synthesis and radiolabeling, radioiodination, 915(ab)

U

Ulcers, quantification of *Helicobacter pylori*, C-14 urea breath test, 1192
Ultrasonography, recurrent thyroid cancer, MRI detection, 1011(ab)
Ureter, peristalsis imaging, 973(ab)
Uridine, deoxyglucose uptake and, ischemic myocardium, 928(ab)
Urinary tract, detection of abnormalities, skeletal scintigraphy, 1140(ab)
Uterus
F-18 fluorine labeled high affinity progestin, receptor-mediated uptake, 975(ab)
normal female subjects, biodistribution, In-111 polyclonal IgG, 1836(ab)

V

Vagotomy, scintigraphic evaluation, gallbladder function, Tc-99m DISIDA, 1131(ab)
Varicella, functional asplenia, In-111 oxime-labeled autologous leukocytes, 524
Varicocele, grading of, 2092
Vascular system
peripheral vascular disease, whole body scintigraphy, contrast arteriography, 1041(ab)
synthetic graft infection, antibiotic treatment, In-111 leukocyte scan, 13
Vein, inferior and mesenteric, portosystemic shunting, I-123 IMP, 1047(ab)
Venography, radionuclide
comparison of various techniques, 1129(ab)
lower extremity
clinical management, suspected pulmonary embolism, 1087(ab)
Tc-99m red blood cells, deep venous thrombosis, 2324
Ventilation
pulmonary gas volume, theory and error analysis,

PET, 1937
quantitation of radioaerosol release, 1133(ab)
Ventilation-perfusion scans
diagnosis of pulmonary embolism, observer agreement, anatomical lung segment chart, 951(ab)
"false-positive", tuberculous mediastinal adenopathy, 512
lung imaging, computer-assisted diagnosis, pulmonary embolism, 1837(ab)
normal chest radiograph, suspected pulmonary embolism, 950(ab)
Ventricle
left
Novacor device, blood-pool radionuclide angiography, 255
regional wall thickening, gated PET, 679
Ventricular function
left
bicycle and treadmill radionuclide angiocardiography, 1918
"black hole" sign and aneurysms, Tl-201 SPECT, 959(ab)
bullseye polar map display, wall motion and gated cardiac pool SPECT, 1037(ab)
continuous radionuclide monitoring, 44
diastolic function, systemic sclerosis, 1042(ab)
effect of anger, 1038(ab)
gated blood pool scintigraphy, atrial fibrillation, 1042(ab)
gated myocardial imaging, Tc-99m MIBI, 1035(ab)
perfusion defect extent, PET polar maps, 999(ab)
regional wall motion, radionuclide ventriculography, 777
single radiopharmaceutical, one camera, 929(ab)
surface detector, expected errors, 1068(ab)
systolic thickening, Tl-201 ECG-gated SPECT, 1496
volume, count-based ratios, 1312(le)
left diastolic, contrast ventriculography, equilibrium radionuclide angiography, 1849
left ROI, validity, blood pool signal, 954(ab)
prognosis of infants and children, myocardial disease, 1086(ab)
right
ejection fraction, scintigraphy, 429
overload assessment, Tl-201 SPECT in children, 2215
regional perfusion, Tc-99m sestamibi SPECT, 1199
stunned myocardium, I-123 BMIPP, perfusion, 1012(ab)
systolic left, first-pass and gated equilibrium methods, 1801
transient silent left ventricular dysfunction, non-Q wave myocardial infarction, unstable angina, 938(ab)
Ventricular volume, left, geometric methods of determination, 552(le)
Ventriculography
contrast, equilibrium radionuclide angiography and, left ventricular diastolic function, 1849
first-pass and multigated radionuclide, right aortic arch, 1904
radionuclide
cardiomyoplasty, 1038(ab)
Fourier analysis, 782
left ventricular regional wall motion, 777
photon attenuation by myocardium, ventricular ejection fraction, 939(ab)
Verapamil, ACEI renography, 933(ab)
VEST system
accuracy and reproducibility of measurements, left ventricular ejection fraction, 796
transient silent left ventricular dysfunction, non-Q wave myocardial infarction, unstable angina, 938(ab)
Visual cortex, Tc-99m HMPAO distribution, visual stimulation, 210
Visual stimulation, redistribution of I-123 IMP, brain SPECT, 1866

W

Wagner, Henry N., Jr., practical matters, 11N(10)
Waste, low-level radioactive waste lawsuits, 14N(2)
Water
extracelluular and intracellular, weight reduction surgery, intestinal bypass *vs.* gastroplasty, 1104(ab)
lung, measurements with PET, 719
transport in myocardium, convection-diffusion and compartment model, 926(ab)
White blood cells
Tc-99m HMPAO, high-dose γ-globulin, Kawasaki disease, 944(ab)
unlabeled and In-111 WBC, adherence characteristics, quality control, 1049(ab)
Wiseman, Gregory A., Mallinckrodt fellowship, 17N(6)
Wolf, Alfred P., to receive Hevesy Nuclear Medicine Pioneer Award, 22N(5)
Wood ash, environmental radiation, 28N(10)

X

Xenografts
canine, Mallinckrodt fellowships, 17N(6)
human colon carcinoma, anti-CEA antibody uptake, vascular and immunologic factors, 1055(ab)
human malignant melanoma, radiolabeled monoclonal antibody targeting, dogs, 1056(ab)
Xenon, washout and Tc-99m RBC penile plethysmography, corpora cavernosal inflow and outflow, early tumescence, 404
Xenon-127, cost considerations, 1642(le)
Xenon-133
brain perfusion, long-term cocaine abuse, 1021(ab)
CBF profiles, compared to Tc-99m HMPAO SPECT, Alzheimer's disease, 941(ab)
cerebral blood low, obsessive-compulsive disorders, 1076(ab)
regional cerebral blood flow SPECT, Tc-99m HMPAO SPECT and, stroke and dementia, 972(ab)
values measured on predetermined ROIs, rCBF, children, 1841(ab)
X-ray, affinity labeling, dopamine transporter, photoaffinity ligands, 1839(ab)

Y

Yalow, Rosalyn S.
honored at symposium, 25N(12)
Yttrium-90
cancer therapy studies, government and commercial suppliers, 16N(2)
comparison of DOTA and DTPA analogs, bifunctional antibody delivery, 915(ab)
hapten-chelate constructs, improved stability through modification, linker, 1023(ab)
In-111 macrocycle chimeric B72.3 conjugates and, comparative biodistributions, colon carcinoma, 1842(ab)
production at Hanford, 1090(ab)
Yttrium-90 B72.3 monoclonal antibody, refractory adenocarcinoma, pharmacokinetics, 1021(ab)
Yttrium-90 CYT-103 monoclonal antibody, Phase I trial, refractory colorectal carcinoma, 1052(ab)
Yttrium-90 T101, *vs.* In-111 biodistribution, hematopoietic malignancies, 970(ab)
Yucca Mountain, Nevada
legal wrangles, 19N(1)
restructuring of U.S. HLRW Disposal Program, 15N(1)
suitability of site for HLRW, geologic study, 31N(3)

Z

Zidovudine, human immunodeficiency virus encephalopathy, SPECT, 1471